0001050007-16-000004.txt : 20160428 0001050007-16-000004.hdr.sgml : 20160428 20160428133908 ACCESSION NUMBER: 0001050007-16-000004 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 47 CONFORMED PERIOD OF REPORT: 20160331 FILED AS OF DATE: 20160428 DATE AS OF CHANGE: 20160428 FILER: COMPANY DATA: COMPANY CONFORMED NAME: NUTRACEUTICAL INTERNATIONAL CORP CENTRAL INDEX KEY: 0001050007 STANDARD INDUSTRIAL CLASSIFICATION: MEDICINAL CHEMICALS & BOTANICAL PRODUCTS [2833] IRS NUMBER: 870515089 STATE OF INCORPORATION: DE FISCAL YEAR END: 0930 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-23731 FILM NUMBER: 161598853 BUSINESS ADDRESS: STREET 1: 1400 KEARNS BOULEVARD STREET 2: 2ND FLOOR CITY: PARK CITY STATE: UT ZIP: 84060 BUSINESS PHONE: 4356556000 MAIL ADDRESS: STREET 1: 1400 KEARNS BOULEVARD STREET 2: 2ND FLOOR CITY: PARK CITY STATE: UT ZIP: 84060 10-Q 1 nutr-033116x10q.htm 10-Q 10-Q
 
 
 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 10-Q
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
for the Quarterly Period Ended March 31, 2016
Commission file number 000-23731
NUTRACEUTICAL INTERNATIONAL CORPORATION
(Exact name of registrant as specified in its charter)
Delaware
(State of incorporation)
 
87-0515089
(IRS Employer Identification No.)
 
 
 
1400 Kearns Boulevard, 2nd Floor, Park City, Utah
(Address of principal executive offices)
 
84060
(Zip code)
 
 
 
(435) 655-6106
(Registrant's telephone number, including area code)
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. YES x    NO o
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). YES x    NO o
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See the definitions of "large accelerated filer," "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act:
Large accelerated filer o
 
Accelerated filer x
 
Non-accelerated filer o
 (Do not check if a
smaller reporting company)
 
Smaller reporting company o
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). YES o    NO x
At April 26, 2016, the registrant had 9,339,532 shares of common stock outstanding.

 
 
 


NUTRACEUTICAL INTERNATIONAL CORPORATION 

INDEX
Description
 
 
Page
 
 
 
 
 
Item 1.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Item 2.
 
 
 
 
 
Item 3.
 
 
 
 
 
Item 4.
 
 
 
 
 
 
 
 
 
Item 1.
 
 
 
 
 
Item 1A.
 
 
 
 
 
Item 2.
 
 
 
 
 
Item 6.

2


PART I—FINANCIAL INFORMATION
Item 1.    Financial Statements
NUTRACEUTICAL INTERNATIONAL CORPORATION 
CONDENSED CONSOLIDATED BALANCE SHEETS
(unaudited)
(dollars in thousands)
 
March 31,
2016
 
September 30,
2015
 (1)
ASSETS
 

 
 

Current assets:
 

 
 

Cash
$
4,162

 
$
4,615

Accounts receivable, net
19,277

 
16,798

Inventories
61,491

 
59,440

Prepaid expenses and other current assets
3,715

 
4,195

Deferred income taxes
1,169

 
1,167

Total current assets
89,814

 
86,215

 
 
 
 
Property, plant and equipment, net
83,460

 
77,645

Goodwill
30,925

 
24,384

Intangible assets, net
24,148

 
17,605

Deferred income taxes
4,555

 
4,932

Other non-current assets
1,613

 
1,668

Total assets
$
234,515

 
$
212,449

LIABILITIES AND STOCKHOLDERS' EQUITY
 

 
 

Current liabilities:
 

 
 

Accounts payable
$
13,915

 
$
14,023

Accrued expenses
6,797

 
6,505

Total current liabilities
20,712

 
20,528

 
 
 
 
Long-term debt
47,500

 
31,500

Other non-current liabilities
184

 
174

Total liabilities
68,396

 
52,202

Stockholders' equity:
 

 
 

Common stock
94

 
95

Additional paid-in capital
4,026

 
6,961

Retained earnings
162,477

 
153,618

Accumulated other comprehensive income
(396
)
 
(379
)
Treasury stock
(82
)
 
(48
)
Total stockholders' equity
166,119

 
160,247

Total liabilities and stockholders' equity
$
234,515

 
$
212,449


(1)
The condensed consolidated balance sheet as of September 30, 2015 has been prepared using information from the audited financial statements at that date.
The accompanying notes are an integral part of these condensed consolidated financial statements.

3


NUTRACEUTICAL INTERNATIONAL CORPORATION 
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
(unaudited)
(dollars in thousands, except per share data)

 
Three Months Ended
March 31,
 
Six Months Ended
March 31,
 
2016
 
2015
 
2016
 
2015
Net sales
$
59,492

 
$
55,404

 
$
115,451

 
$
108,448

Cost of sales
29,163

 
28,149

 
57,014

 
55,338

Gross profit
30,329

 
27,255

 
58,437

 
53,110

Operating expenses
 

 
 

 
 
 
 
Selling, general and administrative
21,779

 
19,789

 
42,121

 
39,343

Amortization of intangible assets
999

 
728

 
1,980

 
1,460

Income from operations
7,551

 
6,738

 
14,336

 
12,307

Interest and other expense, net
322

 
273

 
596

 
570

Income before provision for income taxes
7,229

 
6,465

 
13,740

 
11,737

Provision for income taxes
2,611

 
2,369

 
4,881

 
4,290

Net income
$
4,618

 
$
4,096

 
$
8,859

 
$
7,447

Other comprehensive income (loss):
 

 
 

 
 
 
 
Foreign currency translation adjustment, net of tax
62

 
(109
)
 
(17
)
 
(330
)
Comprehensive income
$
4,680

 
$
3,987

 
$
8,842

 
$
7,117

Net income per common share
 

 
 

 
 
 
 
Basic
$
0.49

 
$
0.43

 
$
0.94

 
$
0.77

Diluted
0.49

 
0.43

 
0.94

 
0.77

Weighted average common shares outstanding
 

 
 

 
 
 
 
Basic
9,401,972

 
9,622,051

 
9,430,878

 
9,637,753

Dilutive effect of stock options

 
4,874

 

 
5,884

Diluted
9,401,972

 
9,626,925

 
9,430,878

 
9,643,637



The accompanying notes are an integral part of these condensed consolidated financial statements.

4


NUTRACEUTICAL INTERNATIONAL CORPORATION 
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(unaudited)
(dollars in thousands)
 
Six Months Ended
March 31,
 
2016
 
2015
Cash flows from operating activities:
 

 
 

Net income
$
8,859

 
$
7,447

Adjustments to reconcile net income to net cash provided by operating activities:
 

 
 

Depreciation and amortization
7,020

 
6,507

Amortization of deferred financing fees
63

 
67

Losses on disposals of property, plant and equipment
4

 
7

Tax benefit from stock option exercises

 
(1
)
Deferred income taxes
375

 
(77
)
Changes in assets and liabilities, net of effects of acquisitions:
 

 
 

Accounts receivable, net
(1,139
)
 
(1,706
)
Inventories
771

 
1,137

Prepaid expenses and other current assets
894

 
517

Other non-current assets
(61
)
 
81

Accounts payable
(296
)
 
(1,136
)
Accrued expenses
804

 
(1,685
)
Other non-current liabilities
10

 
10

Net cash provided by operating activities
17,304

 
11,168

Cash flows from investing activities:
 

 
 

Purchases of property, plant and equipment
(4,023
)
 
(4,217
)
Acquisitions of businesses
(26,235
)
 
(81
)
Net cash used in investing activities
(30,258
)
 
(4,298
)
Cash flows from financing activities:
 

 
 

Proceeds from debt
25,500

 
2,000

Payments on debt
(9,500
)
 
(7,000
)
Payments of deferred financing fees

 
(420
)
Proceeds from issuances of common stock
40

 
64

Purchases of common stock for treasury
(3,566
)
 
(2,352
)
Tax benefit from stock option exercises

 
1

Net cash provided by (used in) financing activities
12,474

 
(7,707
)
Effect of exchange rate changes on cash
27

 
(179
)
Net decrease in cash
(453
)
 
(1,016
)
Cash at beginning of period
4,615

 
6,232

Cash at end of period
$
4,162

 
$
5,216

   
The accompanying notes are an integral part of these condensed consolidated financial statements.

5


NUTRACEUTICAL INTERNATIONAL CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(unaudited)
(dollars in thousands, except per share data)



1. BASIS OF PRESENTATION
Nutraceutical International Corporation and its subsidiaries (the "Company") is an integrated manufacturer, marketer, distributor and retailer of branded nutritional supplements and other natural products sold primarily to and through domestic health and natural food stores. Internationally, the Company markets and distributes branded nutritional supplements and other natural products to and through health and natural product distributors and retailers. The Company's core business strategy is to acquire, integrate and operate businesses in the natural products industry that manufacture, market and distribute branded nutritional supplements. The Company believes that the consolidation and integration of these acquired businesses provide ongoing financial synergies through increased scale and market penetration, as well as strengthened customer relationships.
The Company manufactures and sells nutritional supplements and other natural products under numerous brands, including Solaray®, KAL®, Dynamic Health™, Nature's Life®, LifeTime®, Natural Balance®, NaturalCare®, Health from the Sun®, Pioneer®, Nutra BioGenesis™, Life-flo®, Organix South®, Heritage Store® and Monarch Nutraceuticals™.
The Company owns neighborhood natural food markets, which operate under the trade names The Real Food Company™, Thom's Natural Foods™, Cornucopia Community Market™ and Granola's™. The Company also owns health food stores, which operate under various trade names, including Fresh Vitamins™ and Peachtree Natural Foods®.
In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all necessary adjustments, consisting of normal recurring adjustments, to state fairly the consolidated financial position of the Company as of March 31, 2016, the results of its operations for the three and six months ended March 31, 2016 and 2015 and its cash flows for the six months ended March 31, 2016 and 2015, in conformity with accounting principles generally accepted in the United States of America ("US GAAP") for interim financial information applied on a consistent basis. Results for the three and six months ended March 31, 2016 are not necessarily indicative of the results to be expected for the full fiscal year.
Certain information and footnote disclosures normally included in the annual financial statements prepared in accordance with US GAAP have been omitted. Accordingly, these financial statements should be read in conjunction with the Company's Form 10-K for the fiscal year ended September 30, 2015, which was filed with the Securities and Exchange Commission on November 19, 2015.
Use of Estimates
The preparation of these financial statements in conformity with US GAAP required management to make estimates and assumptions that affected the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements and the reported amounts of net sales and expenses during the reported periods. Significant estimates included values and lives assigned to acquired intangible assets, reserves for customer returns and allowances, uncollectible accounts receivable, valuation adjustments for slow-moving, obsolete and/or damaged inventory and valuation and recoverability of long-lived assets. Actual results may differ from these estimates.
New Accounting Standards
In February 2016, the Financial Accounting Standards Board ("FASB") issued authoritative guidance, which is included in Accounting Standards Codification ("ASC") 842, "Leases." This guidance requires lessees to recognize most leases on the balance sheet by recording a right-of-use asset and a lease liability. This guidance is effective

6


NUTRACEUTICAL INTERNATIONAL CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(unaudited)
(dollars in thousands, except per share data)


for the Company as of October 1, 2019. The Company is currently evaluating the impact this standard may have on its consolidated financial statements.
In November 2015, the FASB issued authoritative guidance, which is included in ASC 740, "Income Taxes." This guidance simplifies the presentation of deferred income taxes and requires that deferred tax assets and liabilities be classified as noncurrent in the classified statement of financial position. This guidance is effective for the Company as of October 1, 2017 and is not expected to have a material impact on the consolidated financial statements as the guidance only changes the classification of deferred income taxes.
In September 2015, the FASB issued authoritative guidance, which is included in ASC 805, "Business Combinations." This guidance simplifies the accounting for measurement-period adjustments and is effective for the Company as of October 1, 2016. The Company does not expect this guidance to have a material impact on its consolidated financial statements.
In July 2015, the FASB issued authoritative guidance, which is included in ASC 330, "Inventory." This guidance simplifies the accounting for measuring inventory at the lower of cost and net realizable value and is effective for the Company as of October 1, 2017. The Company does not expect this guidance to have a material impact on its consolidated financial statements.
In May 2014, the FASB issued authoritative guidance, which is included in ASC 606, "Revenue from Contracts with Customers." This guidance provides a single, comprehensive revenue recognition model for all contracts with customers and requires that a company recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. In July 2015, the FASB delayed the effective date of this guidance by one year. As a result, this guidance is effective for the Company as of October 1, 2018 and shall be applied either retrospectively to each period presented or as a cumulative-effect adjustment as of the date of adoption. The Company is currently evaluating the impact this standard may have on its consolidated financial statements.
The Company periodically reviews new accounting standards that are issued. Although some of these accounting standards may be applicable to the Company, the Company has not identified any other new standards that it believes merit further discussion, and the Company expects that none would have a significant impact on its consolidated financial statements.
2. ACCOUNTS RECEIVABLE
Accounts receivable, net of allowances for sales returns and doubtful accounts, consisted of the following:
 
March 31,
2016
 
September 30,
2015
Accounts receivable
$
20,344

 
$
17,882

Less allowances
(1,067
)
 
(1,084
)
 
$
19,277

 
$
16,798


7


NUTRACEUTICAL INTERNATIONAL CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(unaudited)
(dollars in thousands, except per share data)


3. INVENTORIES
Inventories were comprised of the following:
 
March 31,
2016
 
September 30,
2015
Raw materials
$
26,508

 
$
23,106

Work-in-process
11,576

 
9,755

Finished goods
23,407

 
26,579

 
$
61,491

 
$
59,440

4. ACQUISITIONS
During the six months ended March 31, 2016, the Company made two acquisitions of businesses. On October 6, 2015, the Company acquired certain operating assets of Dynamic Health Laboratories, Inc. ("Dynamic Health"). On February 18, 2016, the Company acquired certain operating assets of Aubrey Organics, Inc. ("Aubrey Organics"). The aggregate purchase price of these acquisitions was $26,235 in cash.
During the six months ended March 31, 2015, the Company made one acquisition of a business. On November 18, 2014, the Company acquired certain operating assets of Agape Health Products for $81 in cash.
These acquisitions are in keeping with the Company's business strategy of consolidating the fragmented industry in which it competes. These acquisitions were accounted for using the acquisition method of accounting. Accordingly, the purchase price was assigned to the assets acquired based on their fair values at their respective dates of acquisition. The excess of purchase price over the fair values of the assets acquired was classified as goodwill. The goodwill relates to expected synergies from these acquisitions. The following reflects the preliminary allocation of the purchase prices for the fiscal 2016 acquisitions and the final allocation of the purchase price for the fiscal 2015 acquisition to the assets acquired:
 
Fiscal 2016 Acquisition - Dynamic Health
 
Fiscal 2016 Acquisition - Aubrey Organics
 
Fiscal 2015 Acquisition
Assets acquired:
 

 
 

 
 

Current assets
$
3,821

 
$
755

 
$
41

Property, plant and equipment
644

 
6,004

 

Goodwill
6,541

 

 

Intangible assets
8,020

 
450

 
40

 
$
19,026

 
$
7,209

 
$
81

The fiscal 2016 and fiscal 2015 acquired intangible assets totaling $8,470 and $40, respectively, related to trademarks, tradenames and customer relationships, and are being amortized over periods of six to fifteen years for financial statement purposes. The fiscal 2016 and fiscal 2015 acquired intangible assets are expected to be deductible for tax purposes over fifteen years. Goodwill of $6,541 for fiscal 2016 is not subject to amortization for financial statement purposes and is expected to be deductible for tax purposes over fifteen years.
The Condensed Consolidated Statements of Comprehensive Income and the Condensed Consolidated Statements of Cash Flows presented herein include the activities of these acquired businesses from their respective dates of acquisition. The expected long-term sales and expense synergies of acquired businesses generally are not realized immediately following acquisition, as certain transition and integration matters must be completed.

8


NUTRACEUTICAL INTERNATIONAL CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(unaudited)
(dollars in thousands, except per share data)


Since the date of acquisition (October 6, 2015), net sales of $8,355 and gross profit of $3,207 for Dynamic Health were included in the Condensed Consolidated Statements of Comprehensive Income for the six months ended March 31, 2016. The Company tracks selling, general and administrative expenses on a consolidated basis, not on a brand-by-brand basis. As a result, the disclosure of any results after gross profit is impracticable. The following table provides unaudited pro forma information for the three and six months ended March 31, 2015, as if the acquisition of Dynamic Health had been completed on October 1, 2014. Pro forma information was not provided for the three and six months ended March 31, 2016 since the acquisition was completed near the beginning of these periods and the pro forma results are not materially different than actual results. The information has been provided for illustrative purposes only and is not necessarily indicative of the actual results that would have been achieved by the Company for the periods presented or that will be achieved in the future. The pro forma information has been adjusted to give effect to items directly attributable to the Dynamic Health acquisition. These adjustments include acquisition costs, amortization expense associated with acquired intangible assets, interest expense associated with borrowings on the Company's revolving credit facility to fund the acquisition, application of the Company's depreciable lives policy for property, plant and equipment, elimination of intercompany transactions and any consequential tax effects.
 
Three Months Ended
March 31, 2015
 
Six Months Ended
March 31, 2015
Net sales
$
59,970

 
$
117,591

Net income
$
4,161

 
$
7,580

This information has not been adjusted to reflect any changes in the operations of the business subsequent to acquisition. Changes in the operations of the acquired business may include, but are not limited to, discontinuation of certain customers and/or products, application of the Company's pricing and credit policies, integration of systems and personnel, changes in manufacturing processes, relocation of facilities, potential cost synergies and changes in marketing and sales programs. Due to these changes, future results could be materially different than the pro forma information provided.
The actual and pro forma net sales and earnings related to the Aubrey Organics acquisition were not material.
5. GOODWILL AND INTANGIBLE ASSETS
The change in the carrying amount of goodwill from September 30, 2015 to March 31, 2016 was as follows:
 
Goodwill
 
Accumulated
Impairment
 
Net
Balance as of September 30, 2015
$
64,778

 
$
(40,394
)
 
$
24,384

Goodwill attributable to fiscal 2016 acquisitions
6,541

 

 
6,541

Balance as of March 31, 2016
$
71,319

 
$
(40,394
)
 
$
30,925


9


NUTRACEUTICAL INTERNATIONAL CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(unaudited)
(dollars in thousands, except per share data)


The carrying amounts of intangible assets at March 31, 2016 and September 30, 2015 were as follows:
 
March 31, 2016
 
September 30, 2015
 
Weighted-
Average
Amortization
Period
(Years)
 
Gross
Carrying
Amount (1)
 
Accumulated
Amortization (1)
 
Net
Carrying
Amount
 
Gross
Carrying
Amount (1)
 
Accumulated
Amortization (1)
 
Net
Carrying
Amount
 
Intangible assets subject to amortization:
 

 
 

 
 

 
 

 
 

 
 

 
 
Trademarks/tradenames/licenses
$
13,893

 
$
(2,587
)
 
$
11,306

 
$
12,470

 
$
(1,966
)
 
$
10,504

 
11
Customer relationships/non-compete agreements
23,975

 
(11,133
)
 
12,842

 
16,836

 
(9,773
)
 
7,063

 
7
Developed software and technology
772

 
(772
)
 

 
772

 
(772
)
 

 
5
 
38,640

 
(14,492
)
 
24,148

 
30,078

 
(12,511
)
 
17,567

 
 
Intangible assets not subject to amortization:
 

 
 

 
 

 
 

 
 

 
 

 
 
Trademarks/tradenames/licenses

 

 

 
38

 

 
38

 
 
 
$
38,640

 
$
(14,492
)
 
$
24,148

 
$
30,116

 
$
(12,511
)
 
$
17,605

 
 
(1) Amounts include the impact of foreign currency translation adjustments.
Estimated future amortization expense related to the March 31, 2016 net carrying amount of $24,148 for intangible assets subject to amortization is as follows:
Year Ending September 30,
Estimated
Amortization
Expense
2016(1)
$
1,944

2017
3,582

2018
3,391

2019
2,964

2020
2,875

Thereafter
9,392

 
$
24,148

(1)
Estimated amortization expense for the year ending September 30, 2016 includes only amortization to be recorded after March 31, 2016.
General and economic conditions may impact retail and consumer demand, as well as the market price of the Company's common stock, and could negatively impact the Company's future operating performance, cash flow and/or stock price and could result in goodwill and/or intangible asset impairment charges being recorded in future periods. Also, the Company periodically reviews its brands to achieve marketing, sales and operational synergies. These reviews could result in brands being consolidated or discontinued and could result in intangible asset impairment charges being recorded in future periods. Goodwill and/or intangible asset impairment charges could materially impact the Company's consolidated financial statements. The valuation of goodwill and intangible assets is subject to a high degree of judgment, uncertainty and complexity.

10


NUTRACEUTICAL INTERNATIONAL CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(unaudited)
(dollars in thousands, except per share data)


6. DEBT
Debt was comprised of the following:
 
March 31,
2016
 
September 30,
2015
Long-term debt—revolving credit facility
$
47,500

 
$
31,500

The carrying value of the Company's debt approximates fair value at March 31, 2016 and September 30, 2015. Estimated fair values for debt have been determined based on borrowing rates currently available to the Company for bank loans with similar terms and maturities and are classified as Level 2 (significant observable inputs other than quoted prices) in the FASB's fair value hierarchy.
On November 4, 2014, the Company amended its revolving credit facility (the "Credit Agreement"). The Credit Agreement extends the term of the credit facility to November 2019, increases the available credit borrowings to $100,000 with no automatic reductions and provides an accordion feature that can increase the available credit borrowings to $130,000, subject to approval by the lenders and compliance with certain covenants and conditions. The lenders under the Credit Agreement continue to be Rabobank International and Wells Fargo. To date, the Company has not experienced any difficulties in accessing the available funds under the Credit Agreement. Deferred financing fees of $420 related to the Credit Agreement are being amortized over the term of the Credit Agreement.
At March 31, 2016, the Company had outstanding revolving credit borrowings of $47,500 under the Credit Agreement. Borrowings under the Credit Agreement are collateralized by substantially all assets of the Company. At the Company's election, borrowings bear interest at the applicable Eurodollar Rate plus a variable margin or at a Base Rate plus a variable margin. Base Rate is the higher of: (i) the Prime Lending Rate, (ii) the Federal Funds Rate plus 0.5% or (iii) the one-month Eurodollar Rate multiplied by the Statutory Reserve Rate plus 1.0% (capitalized terms are defined in the Credit Agreement, a copy of which was filed with the Securities and Exchange Commission on November 5, 2014). At March 31, 2016, the applicable weighted-average interest rate for outstanding borrowings was 2.12%. The Company is also required to pay a variable quarterly fee on the unused balance under the Credit Agreement. At March 31, 2016, the applicable rate was 0.25%. Accrued interest on Eurodollar Rate borrowings is payable based on elected intervals of one, two or three months. Accrued interest on Base Rate borrowings is payable quarterly. The Credit Agreement matures on November 4, 2019, and the Company is required to repay all principal and interest outstanding under the Credit Agreement on such date.
The Credit Agreement contains restrictive covenants, including limitations on incurring other indebtedness and requirements that the Company maintain certain financial ratios. As of March 31, 2016, the Company was in compliance with the restrictive covenants. Upon the occurrence of a default, the lender has various remedies or rights, which may include proceeding against the collateral or requiring the Company to repay all amounts outstanding under the Credit Agreement.
7. SHARE PURCHASES
During the three and six months ended March 31, 2016, the Company purchased 80,529 and 145,940 shares of common stock for an aggregate price of $1,962 and $3,566, respectively. During the three and six months ended March 31, 2015, the Company purchased 68,463 and 117,025 shares of common stock for an aggregate price of $1,278 and $2,352, respectively. All of these shares of common stock held in treasury were retired prior to March 31 in the respective quarter of purchase, except at March 31, 2016 and 2015, the Company held 3,354 and 2,000 shares of common stock in treasury. As of March 31, 2016, the Company was permitted to purchase up to 335,321

11


NUTRACEUTICAL INTERNATIONAL CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(unaudited)
(dollars in thousands, except per share data)


additional shares under its approved purchase plan, with no expiration date or restrictions. The Company accounts for treasury shares using the cost method.
8. STOCK OPTIONS AND OTHER EQUITY AWARDS
As of March 31, 2016, the Company had no outstanding options to purchase shares of common stock, as all previously issued options were exercised or expired prior to September 30, 2015.
During the six months ended March 31, 2015, the Company received proceeds of $9 related to the exercise of stock options. During this same period, the Company recorded a tax benefit of $1and optionees realized an aggregate pre-tax gain of $3 from these stock option exercises.
No options to purchase shares of common stock for the three and six months ended March 31, 2015 were excluded from the computation of diluted earnings per share because none of the stock options were anti-dilutive.
On January 28, 2013, stockholders approved the Nutraceutical International Corporation 2013 Long-Term Equity Incentive Plan (the "2013 Plan") and the reservation of 800,000 shares of the Company's common stock for issuance under the 2013 Plan. Equity awards available under the 2013 Plan include stock options, stock appreciation rights and stock awards. In conjunction with the Company's fiscal 2015 and fiscal 2014 incentive compensation (bonus) payments, 22,664 and 24,827 shares of the Company's common stock were issued, respectively. These non-cash stock awards were granted on December 11, 2015 and December 11, 2014 at an aggregate fair value of $556 and $504, respectively, with fair value being determined by the closing price of the Company's common stock on the grant date. These stock awards were registered, unrestricted and fully vested on the grant date. As of March 31, 2016, 720,721 shares of the Company's common stock were available for issuance under the 2013 Plan.
9. SEGMENTS
Segment identification and selection is consistent with the management structure used by the Company's chief operating decision maker to evaluate performance and make decisions regarding resource allocation, as well as the materiality of financial results consistent with that structure. Based on the Company's management structure and method of internal reporting, the Company has one operating segment. The Company's chief operating decision maker does not review operating results on a disaggregated basis; rather, the chief operating decision maker reviews operating results on an aggregate basis.
Net sales attributed to customers in the United States and foreign countries for the three and six months ended March 31, 2016 and 2015 were as follows:
 
Three Months Ended
March 31,
 
Six Months Ended
March 31,
 
2016
 
2015
 
2016
 
2015
United States
$
52,350

 
$
48,807

 
$
102,400

 
$
95,532

Foreign countries
7,142

 
6,597

 
13,051

 
12,916

 
$
59,492

 
$
55,404

 
$
115,451

 
$
108,448

Certain net sales attributed to customers in the United States are sold to customers who in turn may sell such products to customers in foreign countries, while certain net sales attributed to customers in foreign countries are sold to customers who in turn may sell such products to customers in the United States.

12


NUTRACEUTICAL INTERNATIONAL CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(unaudited)
(dollars in thousands, except per share data)


The Company's net sales by product group for the three and six months ended March 31, 2016 and 2015 were as follows:
 
Three Months Ended
March 31,
 
Six Months Ended
March 31,
 
2016
 
2015
 
2016
 
2015
Branded nutritional supplements and other natural products
$
53,687

 
$
49,102

 
$
104,186

 
$
96,190

Other(1)
5,805

 
6,302

 
11,265

 
12,258

 
$
59,492

 
$
55,404

 
$
115,451

 
$
108,448

(1)
Net sales for any other product or group of similar products are less than 10% of consolidated net sales.
In October 2015, the Company made a decision to classify certain net sales in the other product group that were previously included in the branded nutritional supplements and other natural products group. As a result of this decision, the other product group net sales amount for the three and six months ended March 31, 2015 has been increased by $781 and $1,570, respectively, from the prior year's presentation.

13


Item 2.    Management's Discussion and Analysis of Financial Condition and Results of Operations
General
The following discussion and analysis should be read in conjunction with the other sections of this report on Form 10-Q, including Part I, Item 1.
We are an integrated manufacturer, marketer, distributor and retailer of branded nutritional supplements and other natural products sold primarily to and through domestic health and natural food stores. Internationally, we market and distribute branded nutritional supplements and other natural products to and through health and natural product distributors and retailers. Our core business strategy is to acquire, integrate and operate businesses in the natural products industry that manufacture, market and distribute branded nutritional supplements. We believe that the consolidation and integration of these acquired businesses provide ongoing financial synergies through increased scale and market penetration, as well as strengthened customer relationships.
We manufacture and sell nutritional supplements and other natural products under numerous brands, including Solaray®, KAL®, Dynamic Health™, Nature's Life®, LifeTime®, Natural Balance®, NaturalCare®, Health from the Sun®, Pioneer®, Nutra BioGenesis™, Life-flo®, Organix South®, Heritage Store® and Monarch Nutraceuticals™.
We own neighborhood natural food markets, which operate under the trade names The Real Food Company™, Thom's Natural Foods™, Cornucopia Community Market™ and Granola's™. We also own health food stores, which operate under various trade names, including Fresh Vitamins™ and Peachtree Natural Foods®.
We were formed in 1993 to effect a consolidation strategy in the fragmented vitamin, mineral, herbal and other nutritional supplements industry (the "VMS Industry"). Since our formation, we have completed numerous acquisitions of businesses in the VMS Industry. As a result of acquisitions, internal growth and cost management, we believe that we are well positioned to continue to capitalize on acquisition opportunities that arise in the VMS Industry.
Critical Accounting Policies
The preparation of our financial statements in conformity with accounting principles generally accepted in the United States of America required us to make estimates and assumptions that affected the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements and the reported amounts of net sales and expenses during the reported periods. Significant estimates included values and lives assigned to acquired intangible assets, reserves for customer returns and allowances, uncollectible accounts receivable, valuation adjustments for slow-moving, obsolete and/or damaged inventory and valuation and recoverability of long-lived assets. Actual results may differ from these estimates. Our critical accounting policies include the following:
Accounts Receivable—Provision is made for estimated bad debts based on periodic analysis of individual customer balances, including an evaluation of days sales outstanding, payment history, recent payment trends and perceived creditworthiness. If general economic conditions and/or customer financial conditions were to change, additional provisions for bad debts may be required, which could have a material impact on the consolidated financial statements.
Inventories—Valuation adjustments are made for slow-moving, obsolete and/or damaged inventory based on a periodic analysis of individual inventory items, including an evaluation of historical usage and/or movement, age, expiration date and general condition. If market demand and/or consumer preferences are less favorable than historical trends or future expectations, additional valuation adjustments for slow-moving, obsolete and/or damaged inventory may be required, which could have a material impact on the consolidated financial statements.
Property, Plant and Equipment—Depreciation and amortization expense is impacted by our judgments regarding the estimated useful lives of assets placed in service. If the estimated lives of assets are significantly less than expected, depreciation and amortization expense would be accelerated, which could have a material impact on the consolidated financial statements.

14


We evaluate the recoverability of property, plant and equipment whenever events or circumstances indicate that the carrying amount of an asset group may not be recoverable. We measure recoverability of an asset group by comparison of its carrying amount to the future undiscounted cash flows the asset group is expected to generate. If an asset group is considered to be impaired, the difference between the carrying amount and the fair value of the impaired asset group is recognized as an impairment charge.
Goodwill and Intangible Assets—Goodwill and intangible assets require estimates and judgments in determining the initial recognition and measurement, including factors and assumptions used in determining fair values and useful lives. Intangible assets with finite useful lives are amortized and are reviewed for impairment when events or changes in circumstances indicate the carrying value may not be recoverable. Goodwill is tested annually for impairment and when events or changes in circumstances indicate the carrying value may not be recoverable. We perform our annual impairment testing as of September 30 each year, which is the last day of our fiscal year.
A two-step process is used to test for goodwill impairment. The first step is to determine if there is an indication of impairment by comparing the estimated fair value of each reporting unit to its carrying value, including existing goodwill. Reporting unit fair values are estimated using market data as well as other factors. Goodwill is considered impaired if the carrying value of a reporting unit exceeds the estimated fair value. Upon an indication of impairment, a second step is performed to measure the amount of the impairment by comparing the implied fair value of the reporting unit's goodwill with its carrying value.
Amortizable intangible assets are reviewed for recoverability by comparing an asset group's carrying amount to the future undiscounted cash flows the asset group is expected to generate. If an asset group is considered to be impaired, the difference between the carrying amount and the fair value of the impaired asset group is recorded.
General and economic conditions may impact retail and consumer demand, as well as the market price of our common stock, and could negatively impact our future operating performance, cash flow and/or stock price and could result in goodwill and/or intangible asset impairment charges being recorded in future periods. Also, we periodically review our brands to achieve marketing, sales and operational synergies. These reviews could result in brands being consolidated or discontinued and could result in intangible asset impairment charges being recorded in future periods. Such goodwill and/or intangible asset impairment charges could materially impact our consolidated financial statements. The valuation of goodwill and intangible assets is subject to a high degree of judgment, uncertainty and complexity.
Revenue Recognition—Revenue is recognized when the following criteria are met: (1) persuasive evidence of an arrangement exists; (2) the product has been shipped and the customer takes ownership and assumes the risk of loss; (3) the selling price is fixed or determinable; and (4) collection of the resulting receivable is reasonably assured. We believe that these criteria are satisfied upon shipment from our facilities or, in the case of our neighborhood natural food markets and health food stores, at the point of sale within these stores. Revenue is reduced by provisions for estimated customer returns and allowances, which are based on historical averages that have not varied significantly for the periods presented, as well as specific known claims, if any. No other significant deductions from revenue must be estimated at the point in time that revenue is recognized.
Our estimates and judgments related to our critical accounting policies, including factors and assumptions considered in making these estimates and judgments, did not vary significantly for the periods presented and had no material impact on the consolidated financial statements as reported.
New Accounting Standards
See Note 1 to the Condensed Consolidated Financial Statements for information regarding new accounting standards.

15


Results of Operations
The following table sets forth certain Consolidated Statements of Comprehensive Income data as a percentage of net sales for the periods indicated:
 
Three Months Ended
March 31,
 
Six Months Ended
March 31,
 
2016
 
2015
 
2016
 
2015
Net sales
100.0
%
 
100.0
%
 
100.0
%
 
100.0
%
Cost of sales
49.0
%
 
50.8
%
 
49.4
%
 
51.0
%
Gross profit
51.0
%
 
49.2
%
 
50.6
%
 
49.0
%
Selling, general and administrative
36.6
%
 
35.7
%
 
36.5
%
 
36.3
%
Amortization of intangible assets
1.7
%
 
1.3
%
 
1.7
%
 
1.3
%
Income from operations
12.7
%
 
12.2
%
 
12.4
%
 
11.4
%
Interest and other expense, net
0.5
%
 
0.5
%
 
0.5
%
 
0.5
%
Income before provision for income taxes
12.2
%
 
11.7
%
 
11.9
%
 
10.9
%
Provision for income taxes
4.4
%
 
4.3
%
 
4.2
%
 
4.0
%
Net income
7.8
%
 
7.4
%
 
7.7
%
 
6.9
%
Adjusted EBITDA(1)
18.6
%
 
18.1
%
 
18.5
%
 
17.3
%
(1) See "—Adjusted EBITDA."
Comparison of the Three Months Ended March 31, 2016 to the Three Months Ended March 31, 2015
Net Sales.    Net sales increased by $4.1 million, or 7.4%, to $59.5 million for the three months ended March 31, 2016 (the "second quarter of fiscal 2016") from $55.4 million for the three months ended March 31, 2015 (the "second quarter of fiscal 2015"). Net sales of branded nutritional supplements and other natural products increased by $4.6 million, or 9.3%, to $53.7 million for the second quarter of fiscal 2016, compared to $49.1 million for the second quarter of fiscal 2015. The increase in net sales of branded nutritional supplements and other natural products was primarily related to the net sales contributions of the fiscal 2015 and fiscal 2016 acquisitions and, to a lesser extent, price increases of $1.0 million, partially offset by a decrease in sales volume of branded products to certain customers. Other net sales were $5.8 million for the second quarter of fiscal 2016 and $6.3 million for the second quarter of fiscal 2015.
Gross Profit.    Gross profit increased by $3.0 million, or 11.3%, to $30.3 million for the second quarter of fiscal 2016 from $27.3 million for the second quarter of fiscal 2015. As a percentage of net sales, gross profit increased to 51.0% for the second quarter of fiscal 2016 from 49.2% for the second quarter of fiscal 2015. This increase in gross profit was primarily related to the increase in net sales and, to a lesser extent, a decrease in certain manufacturing overhead costs.
Selling, General and Administrative.    Selling, general and administrative expenses increased by $2.0 million, or 10.1%, to $21.8 million for the second quarter of fiscal 2016 from $19.8 million for the second quarter of fiscal 2015. As a percentage of net sales, selling, general and administrative expenses increased to 36.6% for the second quarter of fiscal 2016, compared to 35.7% for the second quarter of fiscal 2015. This increase in selling, general and administrative expenses was primarily attributable to operational and transition costs related to the fiscal 2015 and fiscal 2016 acquisitions.
Amortization of Intangible Assets.    Amortization of intangible assets was $1.0 million for second quarter of fiscal 2016 and $0.7 million for the second quarter of fiscal 2015. For each period, amortization expense was primarily related to intangible assets recorded in connection with acquisitions.
Interest and Other Expense, Net.    Net interest and other expense was $0.3 million for both the second quarter of fiscal 2016 and fiscal 2015 and primarily consisted of interest expense on indebtedness under our revolving credit facility.

16


Provision for Income Taxes.    Our effective tax rate was 36.1% for the second quarter of fiscal 2016 and 36.6% for the second quarter of fiscal 2015. In each period, our effective tax rate was higher than the federal statutory rate primarily due to state taxes.
Comparison of the Six Months Ended March 31, 2016 to the Six Months Ended March 31, 2015
Net Sales.    Net sales increased by $7.1 million, or 6.5%, to $115.5 million for the six months ended March 31, 2016 from $108.4 million for the six months ended March 31, 2015. Net sales of branded nutritional supplements and other natural products increased by $8.0 million, or 8.3%, to $104.2 million for the six months ended March 31, 2016 from $96.2 million for the six months ended March 31, 2015. The increase in net sales of branded nutritional supplements and other natural products was primarily related to the net sales contributions of the fiscal 2015 and fiscal 2016 acquisitions and, to a lesser extent, price increases of $2.6 million, partially offset by a decrease in sales volume of branded products to certain customers. Other net sales were $11.3 million for the six months ended March 31, 2016 and $12.2 million for the six months ended March 31, 2015.
Gross Profit.    Gross profit increased by $5.3 million, or 10.0%, to $58.4 million for the six months ended March 31, 2016 from $53.1 million for the six months ended March 31, 2015. As a percentage of net sales, gross profit increased to 50.6% for the six months ended March 31, 2016 from 49.0% for the six months ended March 31, 2015. This increase in gross profit was primarily related to the increase in net sales and, to a lesser extent, a decrease in certain manufacturing overhead costs.
Selling, General and Administrative.    Selling, general and administrative expenses increased by $2.8 million, or 7.1%, to $42.1 million for the six months ended March 31, 2016 from $39.3 million for the six months ended March 31, 2015. This increase in selling, general and administrative expenses was primarily attributable to operational and transition costs related to the fiscal 2015 and fiscal 2016 acquisitions. As a percentage of net sales, selling, general and administrative expenses were 36.5% for the six months ended March 31, 2016 and 36.3% for the six months ended March 31, 2015.
Amortization of Intangible Assets.    Amortization of intangible assets was $2.0 million for six months ended March 31, 2016 and $1.5 million for the six months ended March 31, 2015. For each period, amortization expense was primarily related to intangible assets recorded in connection with acquisitions.
Interest and Other Expense, Net.    Net interest and other expense was $0.6 million for both the six months ended March 31, 2016 and 2015 and primarily consisted of interest expense on indebtedness under our revolving credit facility.
Provision for Income Taxes.    Our effective tax rate was 35.5% for the six months ended March 31, 2016 and 36.6% for the six months ended March 31, 2015. In each period, our effective tax rate was higher than the federal statutory rate primarily due to state taxes.
Adjusted EBITDA
Adjusted EBITDA (a non-GAAP measure) is defined in our performance measures as earnings before net interest and other expense, taxes, depreciation, amortization and goodwill and intangible asset impairments. Adjusted EBITDA has some inherent limitations in measuring operating performance due to the exclusion of certain financial elements such as depreciation and amortization and is not necessarily comparable to other similarly-titled captions of other companies due to potential inconsistencies in the method of calculation. Furthermore, Adjusted EBITDA is not intended to be a substitute for cash flows from operating activities, as a measure of liquidity, or an alternative to net income in determining our operating performance in accordance with generally accepted accounting principles. Our use of an EBITDA-based metric should be considered within the following context:
We acknowledge that plant and equipment (while less important in our line of business due to outsourcing alternatives) are necessary to earn revenue based on our current business model.
Our use of an EBITDA-based measure of operating performance is not based on any belief about the reasonableness of excluding depreciation and amortization when measuring financial performance.
Our use of an EBITDA-based measure is supported by its importance to the following key stakeholders:

17


Analysts—who estimate our projected Adjusted EBITDA and other EBITDA-based metrics in their independently-developed financial models for investors;
Creditors—who evaluate our operating performance based on compliance with certain EBITDA-based debt covenants;
Investment Bankers—who use EBITDA-based metrics in their written evaluations and comparisons of companies within our industry; and
Board of Directors and Executive Management—who use EBITDA-based metrics for evaluating management performance relative to our operating budget and bank covenant compliance, as well as our ability to service debt and raise capital for growth opportunities, including acquisitions, which are a critical component of our stated strategy. Generally, we have recorded a monthly accrual for incentive compensation as a percentage of Adjusted EBITDA, which has been paid out to executive management, as well as other employees, upon completion of our annual audit.
The following table sets forth a reconciliation of net income to Adjusted EBITDA for each period included herein:
 
Three Months Ended
March 31,
 
Six Months Ended
March 31,
 
2016
 
2015
 
2016
 
2015
 
(dollars in thousands)
Net income
$
4,618

 
$
4,096

 
$
8,859

 
$
7,447

Provision for income taxes
2,611

 
2,369

 
4,881

 
4,290

Interest and other expense, net(1)
322

 
273

 
596

 
570

Depreciation and amortization
3,538

 
3,268

 
7,020

 
6,507

Adjusted EBITDA
$
11,089

 
$
10,006

 
$
21,356

 
$
18,814

(1)
Includes amortization of deferred financing fees.
Our Adjusted EBITDA increased to $11.1 million for the second quarter of fiscal 2016 from $10.0 million for the second quarter of fiscal 2015. Adjusted EBITDA as a percentage of net sales increased to 18.6% for the second quarter of fiscal 2016 from 18.1% for the second quarter of fiscal 2015.
Our Adjusted EBITDA increased to $21.4 million for the six months ended March 31, 2016 from $18.8 million for the six months ended March 31, 2015. Adjusted EBITDA as a percentage of net sales increased to 18.5% for the six months ended March 31, 2016 from 17.3% for the six months ended March 31, 2015.
Seasonality
We believe that our business is characterized by minor seasonality. However, sales to any particular customer or of any particular product can vary substantially from one quarter to the next based on such factors as industry trends, timing of promotional discounts, domestic and international economic conditions and acquisition-related activities. Excluding the effect of acquisitions, we have historically recorded higher branded product sales volume during the second fiscal quarter (January through March) due to increased interest in health-related products among consumers following the holiday season.
Liquidity and Capital Resources
We had working capital of $69.1 million as of March 31, 2016, compared to $65.7 million as of September 30, 2015. The increase in working capital was primarily the result of increases in accounts receivable and inventories.
Net cash provided by operating activities for the six months ended March 31, 2016 was $17.3 million, compared to $11.2 million for the comparable period in fiscal 2015. This increase in net cash provided by operating activities for the six months ended March 31, 2016 was primarily attributable to an increase in net income as well as changes in operating assets and liabilities.

18


Net cash used in investing activities was $30.3 million for the six months ended March 31, 2016, compared to $4.3 million for the comparable period in fiscal 2015. Our investing activities consisted of acquisitions of businesses and capital expenditures. The capital expenditures primarily related to buildings, building improvements, distribution and manufacturing equipment and information systems.
During the six months ended March 31, 2016, we made two acquisitions of businesses. On October 6, 2015, we acquired certain operating assets of Dynamic Health Laboratories, Inc. On February 18, 2016, we acquired certain operating assets of Aubrey Organics, Inc. The aggregate purchase price of these acquisitions was $26.2 million in cash.
During the six months ended March 31, 2015, we made one acquisition of a business. On November 18, 2014, we acquired certain operating assets of Agape Health Products for $0.1 million in cash.
Net cash provided by financing activities was $12.5 million for the six months ended March 31, 2016 and net cash used in financing activities was $7.7 million for the comparable period in fiscal 2015. During these periods, financing activities primarily related to borrowings and repayments under our revolving credit facility, payments of deferred financing fees, purchases of common stock for treasury and proceeds from the issuance of common stock related to stock option exercises and the direct stock purchase plan. During the six months ended March 31, 2016, net borrowings under our revolving credit facility were $16.0 million and primarily related to the acquisition of certain operating assets of Dynamic Health Laboratories, Inc. and Aubrey Organics, Inc.
In October 2007, we registered a direct stock purchase plan with the Securities and Exchange Commission. The purpose of this direct stock purchase plan is to provide a convenient way for existing stockholders, as well as new investors, to purchase shares of our common stock. A total of 1,500,000 shares of our common stock were registered under the plan, with 1,665 shares purchased during the six months ended March 31, 2016. As of March 31, 2016, there were 1,375,779 shares of common stock available for purchase.
On November 4, 2014, we amended our revolving credit facility (the "Credit Agreement"). The Credit Agreement extends the term of the credit facility to November 2019, increases the available credit borrowings to $100.0 million with no automatic reductions and provides an accordion feature that can increase the available credit borrowings to $130.0 million, subject to approval by the lenders and compliance with certain covenants and conditions. The lenders under the Credit Agreement continue to be Rabobank International and Wells Fargo. To date, we have not experienced any difficulties in accessing the available funds under the Credit Agreement. Deferred financing fees of $0.4 million related to the Credit Agreement are being amortized over the term of the Credit Agreement.
At March 31, 2016, we had outstanding revolving credit borrowings of $47.5 million under the Credit Agreement. Borrowings under the Credit Agreement are collateralized by substantially all of our assets. At our election, borrowings bear interest at the applicable Eurodollar Rate plus a variable margin or at a Base Rate plus a variable margin. Base Rate is the higher of: (i) the Prime Lending Rate, (ii) the Federal Funds Rate plus 0.5% or (iii) the one-month Eurodollar Rate multiplied by the Statutory Reserve Rate plus 1.0% (capitalized terms are defined in the Credit Agreement, a copy of which was filed with the Securities and Exchange Commission on November 5, 2014). At March 31, 2016, the applicable weighted-average interest rate for outstanding borrowings was 2.12%. We are also required to pay a quarterly fee on the unused balance under the Credit Agreement. At March 31, 2016, the applicable rate was 0.25%. Accrued interest on Eurodollar Rate borrowings is payable based on elected intervals of one, two or three months. Accrued interest on base rate borrowings is payable quarterly. The Credit Agreement matures on November 4, 2019, and we are required to repay all principal and interest outstanding under the Credit Agreement on such date.
The Credit Agreement contains restrictive covenants, including limitations on incurring certain other indebtedness and requirements that we maintain certain financial ratios. As of March 31, 2016, we were in compliance with the restrictive covenants. Upon the occurrence of a default, the lender has various remedies or rights, which may include proceeding against the collateral or requiring us to repay all amounts outstanding under the Credit Agreement.

19


A key component of our business strategy is to seek to make additional acquisitions, which may require that we obtain additional financing, which could include the incurrence of substantial additional indebtedness or the issuance of additional stock. We believe that borrowings under our current revolving credit facility or a replacement credit facility, together with cash flows from operations, will be sufficient to make required payments under the current credit facility or any such replacement facility, and to make anticipated capital expenditures and fund working capital needs for the next twelve months.
Contractual Obligations and Other Commitments
Our significant non-cancelable contractual obligations and other commitments as of March 31, 2016 were as follows:
 
Payments Due By Period
Contractual Obligations and Other Commitments
Total
 
Less Than
1 Year
 
1 - 3 Years
 
4 - 5 Years
 
After
5 Years
 
(dollars in thousands)
Revolving credit facility
$
47,500

 
$

 
$

 
$
47,500

 
$

Interest on revolving credit facility(a)
4,209

 
1,170

 
2,340

 
699

 

Operating leases
6,274

 
3,917

 
2,040

 
297

 
20

Total
$
57,983

 
$
5,087

 
$
4,380

 
$
48,496

 
$
20

(a)
Represents estimated interest obligations associated with our outstanding revolving credit facility balance of $47.5 million at March 31, 2016, assuming no principal payments are made before maturity, a weighted-average interest rate of 2.12% and an underutilization fee rate of 0.25%.
Off-Balance Sheet Arrangements
Our operating lease commitments are disclosed in the Contractual Obligations and Other Commitments table above. As of March 31, 2016, we had no other off-balance sheet arrangements that have had, or are reasonably likely to have, a material effect on our consolidated financial statements.
Inflation
Inflation affects the cost of raw materials, goods and services we use. In recent years, inflation has been modest. The competitive environment somewhat limits our ability to recover higher costs resulting from inflation by raising prices. We seek to mitigate the adverse effects of inflation primarily through improved productivity and cost containment programs. We do not believe that inflation has had a material impact on our results of operations for the periods presented, except with respect to increased costs in manufacturing, packaging and distribution resulting from increased fuel and other petrochemical costs, as well as payroll-related costs, insurance premiums and other costs arising from or related to government imposed regulations.
Forward-Looking Statements
This Form 10-Q contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 with respect to our financial condition, results of operations and business. These forward-looking statements can be identified by the use of terms such as "believe," "expects," "plan," "intend," "may," "will," "should," "can," or "anticipates," or the negative thereof, or variations thereon, or comparable terminology, or by discussions of strategy. These statements involve known and unknown risks, uncertainties and other factors that may cause industry trends or our actual results to be materially different from any future results expressed or implied by these statements. Important factors that may cause our results to differ from these forward-looking statements include, but are not limited to: (i) changes in or new government regulations or increased enforcement of the same including adverse determinations by regulators; (ii) unavailability of desirable acquisitions, inability to complete them or inability to integrate them; (iii) increased costs, including from increased raw material or energy prices; (iv) changes in general worldwide economic or political conditions; (v) adverse publicity or negative consumer perception regarding nutritional supplements; (vi) issues with obtaining raw materials of adequate quality or quantity; (vii) litigation and claims, including product liability, intellectual property and other types;

20


(viii) disruptions from or following acquisitions including the loss of customers; (ix) increased competition; (x) slow or negative growth in the nutritional supplement industry or the healthy foods channel; (xi) the loss of key personnel or the inability to manage our operations efficiently; (xii) problems with information management systems, manufacturing efficiencies and operations, including system interruptions and security/cybersecurity breaches; (xiii) insurance coverage issues; (xiv) the volatility of the stock market generally and of our stock specifically; (xv) increases in the cost of borrowings or unavailability of additional debt or equity capital, or both, or fluctuations in foreign currencies; and (xvi) interruption of business or negative impact on sales and earnings due to acts of God, acts of war, terrorism, bio-terrorism, civil unrest and other factors outside of our control.
We undertake no obligation to update or revise publicly any forward-looking statements to reflect new information, events or circumstances occurring after the date of this Form 10-Q.
Item 3.    Quantitative and Qualitative Disclosures about Market Risk
At our election, borrowings bear interest at the applicable Eurodollar Rate plus a variable margin or at a Base Rate plus a variable margin. Base Rate is the higher of: (i) the Prime Lending Rate, (ii) the Federal Funds Rate plus 0.5% or (iii) the one-month Eurodollar Rate multiplied by the Statutory Reserve Rate plus 1.0%. At March 31, 2016, the applicable weighted-average interest rate for borrowings was 2.12% and we had total borrowings outstanding of $47.5 million. A hypothetical 100 basis point change in interest rates would not have had a material impact on our reported net income or cash flows for the six months ended March 31, 2016 and 2015.
With respect to our international operations, we are subject to currency fluctuations; however, we do not believe that these fluctuations would have a material adverse impact on our financial position or results of operations because the majority of our net sales to foreign customers are transacted in U.S. dollars. Net sales to foreign customers not transacted in U.S. dollars include sales to customers in Barbados, Canada, Dominica, Japan, the Netherlands, Norway, St. Kitts, St. Lucia, St. Vincent, Sweden and the United Kingdom. To date, we have not hedged any of our potential foreign currency exposures.
Item 4.    Controls and Procedures
Evaluation of Disclosure Controls and Procedures.    We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our Exchange Act reports is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission's rules and forms and that such information is accumulated and communicated to our management, including our principal executive and principal financial officers, as appropriate, to allow for timely decisions regarding required disclosure.
In designing and evaluating the disclosure controls and procedures, we recognize that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and we are required to apply our judgment in evaluating the cost-benefit relationship of possible controls and procedures.
As required by SEC Rule 13a-15(b), we carried out an evaluation, under the supervision of and with the participation of our management, including our principal executive and principal financial officers, of the effectiveness of the design and operation of our disclosure controls and procedures as of March 31, 2016. Based on the foregoing, our principal executive and principal financial officers have concluded that our disclosure controls and procedures were effective at the reasonable assurance level as of March 31, 2016.
Changes in Internal Control Over Financial Reporting.    There were no changes in our internal control over financial reporting that occurred during the last fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

21


PART II—OTHER INFORMATION
Item 1.    Legal Proceedings
As discussed in our other filings, we are subject to regulation by a number of federal, state and foreign agencies and are involved in various legal matters arising in the ordinary course of business.
We carry insurance coverage in the types and amounts that we consider reasonably adequate to cover the risks we face in the industry in which we compete.
In the opinion of management, the losses related to individual regulatory and legal matters in which we are presently involved are not probable and no estimate can be made of the range of potential gains or losses. While incapable of estimation, in the opinion of management, none of the regulatory and legal matters in which we are involved are individually expected to have a material adverse effect on our consolidated financial position, results of operations or cash flows. However, our aggregate liability arising from regulatory and legal proceedings related to these matters or future matters could have a material effect on our financial position, results of operations or cash flows.
Item 1A.    Risk Factors
There have been no material changes in our risk factors from those disclosed in our 2015 Annual Report on Form 10-K.
Item 2.    Unregistered Sales of Equity Securities and Use of Proceeds
We did not sell any unregistered equity securities during the quarterly period ended March 31, 2016.
Prior to fiscal 2016, our Board of Directors approved a share purchase program authorizing us to buy up to 4,500,000 shares of our common stock. As of March 31, 2016, there were 335,321 shares available for purchase under this program. The shares available for purchase under this program have no expiration date. Purchases under this program during the three months ended March 31, 2016 occurred in January, February and March as follows:
Period
 
Total Number
of Shares
Purchased
 
Average Price
Paid Per
Share
 
Total Number
of Shares
Purchased as
Part of
Publicly
Announced
Plan
 
Maximum
Number of
Shares that
May Yet Be
Purchased Under
the Plan
January 1-31, 2016
 
33,500

 
$
24.34

 
33,500

 
 

February 1-29, 2016
 
24,076

 
24.15

 
24,076

 
 

March 1-31, 2016
 
22,953

 
24.61

 
22,953

 
 

 
 
80,529

 
24.36

 
80,529

 
335,321


22


Item 6.    Exhibits
31.1

Certifications Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
 
 
32.1

Certifications Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
 
 
101.INS

XBRL Instance Document(1)
 
 
101.SCH

XBRL Taxonomy Extension Schema Document(1)
 
 
101.CAL

XBRL Taxonomy Extension Calculation Linkbase Document(1)
 
 
101.DEF

XBRL Taxonomy Extension Definition Linkbase Document(1)
 
 
101.LAB

XBRL Taxonomy Extension Labels Linkbase Document(1)
 
 
101.PRE

XBRL Taxonomy Extension Presentation Linkbase Document(1)
(1)
Filed herewith.

23


SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 
NUTRACEUTICAL INTERNATIONAL CORPORATION
(Registrant)
Date: April 28, 2016
By:
 
/s/ CORY J. MCQUEEN
 
 
 
Cory J. McQueen
 Vice President and Chief Financial Officer
(Principal Financial and Accounting Officer
and Duly Authorized Officer)

24
EX-31.1 2 nutr-ex311x033116.htm EXHIBIT 31.1 Exhibit


Exhibit 31.1
CERTIFICATIONS
I, Frank W. Gay II, certify that:
1.
I have reviewed this report on Form 10-Q of Nutraceutical International Corporation;
2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Registrant as of, and for, the periods presented in this report;
4.
The Registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Registrant and have:
a)
designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this quarterly report is being prepared;
b)
designed such internal controls over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c)
evaluated the effectiveness of the Registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d)
disclosed in this report any change in the Registrant's internal control over financial reporting that occurred during the Registrant's most recent fiscal quarter (the Registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the Registrant's internal control over financial reporting; and
5.
The Registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Registrant's auditors and the audit committee of the Registrant's board of directors (or persons performing the equivalent functions):
a)
all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Registrant's ability to record, process, summarize and report financial information; and
b)
any fraud, whether or not material, that involves management or other employees who have a significant role in the Registrant's internal control over financial reporting.

Date: April 28, 2016
 
/s/ FRANK W. GAY II
 
 
Frank W. Gay II
Chairman of the Board and Chief Executive Officer
(Principal Executive Officer)












CERTIFICATIONS
I, Cory J. McQueen, certify that:
1.
I have reviewed this report on Form 10-Q of Nutraceutical International Corporation;
2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Registrant as of, and for, the periods presented in this report;
4.
The Registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Registrant and have:
a)
designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this quarterly report is being prepared;
b)
designed such internal controls over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c)
evaluated the effectiveness of the Registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d)
disclosed in this report any change in the Registrant's internal control over financial reporting that occurred during the Registrant's most recent fiscal quarter (the Registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the Registrant's internal control over financial reporting; and
5.
The Registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Registrant's auditors and the audit committee of the Registrant's board of directors (or persons performing the equivalent functions):
a)
all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Registrant's ability to record, process, summarize and report financial information; and
b)
any fraud, whether or not material, that involves management or other employees who have a significant role in the Registrant's internal control over financial reporting.

Date: April 28, 2016
 
/s/ CORY J. MCQUEEN
 
 
Cory J. McQueen
Vice President and Chief Financial Officer
(Principal Financial and Accounting Officer)



EX-32.1 3 nutr-ex321x033116.htm EXHIBIT 32.1 Exhibit


Exhibit 32.1
CERTIFICATION PURSUANT TO SECTION 906
OF THE SARBANES-OXLEY ACT OF 2002

In connection with the quarterly report on Form 10-Q of Nutraceutical International Corporation ("Nutraceutical") for the period ended March 31, 2016 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Frank W. Gay II, Chairman of the Board and Chief Executive Officer of Nutraceutical, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:
(1)
the Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)
the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of Nutraceutical.

/s/ FRANK W. GAY II
 
Frank W. Gay II
Chairman of the Board and Chief Executive Officer
 
Date: April 28, 2016
 

CERTIFICATION PURSUANT TO SECTION 906
OF THE SARBANES-OXLEY ACT OF 2002

In connection with the quarterly report on Form 10-Q of Nutraceutical International Corporation ("Nutraceutical") for the period ended March 31, 2016 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Cory J. McQueen, Vice President and Chief Financial Officer of Nutraceutical, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:
(1)
the Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)
the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of Nutraceutical.

/s/ CORY J. MCQUEEN
 
Cory J. McQueen
Vice President and Chief Financial Officer
 
Date: April 28, 2016
 
Signed originals of these written statements required by Section 906 have been provided to Nutraceutical and will be retained by Nutraceutical and furnished to the Securities and Exchange Commission or its staff upon request.



EX-101.INS 4 nutr-20160331.xml XBRL INSTANCE DOCUMENT 0001050007 2015-10-01 2016-03-31 0001050007 2016-04-26 0001050007 2016-03-31 0001050007 2015-09-30 0001050007 2014-10-01 2015-03-31 0001050007 2016-01-01 2016-03-31 0001050007 2015-01-01 2015-03-31 0001050007 2015-03-31 0001050007 2014-09-30 0001050007 us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember 2015-09-30 0001050007 nutr:AubreyOrganicsMember 2016-03-31 0001050007 nutr:DynamicHealthLaboratoriesIncMember 2016-03-31 0001050007 nutr:DynamicHealthLaboratoriesIncMember 2014-10-01 2015-03-31 0001050007 nutr:DynamicHealthLaboratoriesIncMember 2015-01-01 2015-03-31 0001050007 us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember 2014-11-18 2014-11-18 0001050007 nutr:DynamicHealthLaboratoriesIncMember 2015-10-01 2016-03-31 0001050007 us-gaap:MaximumMember 2015-10-01 2016-03-31 0001050007 us-gaap:MinimumMember 2015-10-01 2016-03-31 0001050007 us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember 2015-10-01 2016-03-31 0001050007 us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember 2016-03-31 0001050007 us-gaap:MaximumMember 2014-10-01 2015-09-30 0001050007 us-gaap:MinimumMember 2014-10-01 2015-09-30 0001050007 us-gaap:DevelopedTechnologyRightsMember 2016-03-31 0001050007 nutr:TrademarksTradeNamesAndPatentsMember 2015-09-30 0001050007 nutr:CustomerRelationshipsDistributionRightsAndNoncompeteAgreementMember 2016-03-31 0001050007 nutr:TrademarksTradeNamesAndPatentsMember 2016-03-31 0001050007 nutr:CustomerRelationshipsDistributionRightsAndNoncompeteAgreementMember 2015-10-01 2016-03-31 0001050007 us-gaap:DevelopedTechnologyRightsMember 2015-09-30 0001050007 nutr:CustomerRelationshipsDistributionRightsAndNoncompeteAgreementMember 2015-09-30 0001050007 us-gaap:DevelopedTechnologyRightsMember 2015-10-01 2016-03-31 0001050007 nutr:TrademarksTradeNamesAndLicensesMember 2015-09-30 0001050007 nutr:TrademarksTradeNamesAndLicensesMember 2016-03-31 0001050007 nutr:TrademarksTradeNamesAndPatentsMember 2015-10-01 2016-03-31 0001050007 us-gaap:RevolvingCreditFacilityMember 2015-10-01 2016-03-31 0001050007 us-gaap:RevolvingCreditFacilityMember 2014-11-04 0001050007 nutr:StatutoryReserveRateMember 2015-10-01 2016-03-31 0001050007 us-gaap:RevolvingCreditFacilityMember us-gaap:EurodollarMember 2015-10-01 2016-03-31 0001050007 us-gaap:RevolvingCreditFacilityMember nutr:FederalFundsRateMember 2015-10-01 2016-03-31 0001050007 us-gaap:RevolvingCreditFacilityMember 2016-03-31 0001050007 us-gaap:RevolvingCreditFacilityMember us-gaap:PrimeRateMember 2015-10-01 2016-03-31 0001050007 nutr:RevolvingCreditFacilityAccordionFeatureMember 2014-11-04 0001050007 us-gaap:CommonStockMember 2014-10-01 2015-03-31 0001050007 us-gaap:CommonStockMember 2016-03-31 0001050007 us-gaap:CommonStockMember 2015-10-01 2016-03-31 0001050007 us-gaap:CommonStockMember 2015-03-31 0001050007 us-gaap:CommonStockMember 2015-01-01 2015-03-31 0001050007 us-gaap:CommonStockMember 2016-01-01 2016-03-31 0001050007 nutr:LongTermEquityIncentivePlan2013Member 2013-01-28 0001050007 nutr:LongTermEquityIncentivePlan2013Member 2016-03-31 0001050007 nutr:LongTermEquityIncentivePlan2013Member 2014-10-01 2015-09-30 0001050007 nutr:LongTermEquityIncentivePlan2013Member 2015-12-11 2015-12-11 0001050007 nutr:EmployeeAndNonEmployeeStockOptionsMember 2015-01-01 2015-03-31 0001050007 nutr:EmployeeAndNonEmployeeStockOptionsMember 2016-03-31 0001050007 nutr:LongTermEquityIncentivePlan2013Member 2013-10-01 2014-09-30 0001050007 nutr:LongTermEquityIncentivePlan2013Member 2014-12-11 2014-12-11 0001050007 nutr:EmployeeAndNonEmployeeStockOptionsMember 2014-10-01 2015-03-31 0001050007 nutr:OtherProductsMember 2016-01-01 2016-03-31 0001050007 nutr:OtherProductsMember 2015-01-01 2015-03-31 0001050007 nutr:BrandedNutritionalSupplementsAndOtherNaturalProductsMember 2015-01-01 2015-03-31 0001050007 nutr:BrandedNutritionalSupplementsAndOtherNaturalProductsMember 2015-10-01 2016-03-31 0001050007 nutr:BrandedNutritionalSupplementsAndOtherNaturalProductsMember 2016-01-01 2016-03-31 0001050007 nutr:BrandedNutritionalSupplementsAndOtherNaturalProductsMember 2014-10-01 2015-03-31 0001050007 nutr:OtherProductsMember 2015-10-01 2016-03-31 0001050007 nutr:OtherProductsMember 2014-10-01 2015-03-31 0001050007 country:US 2016-01-01 2016-03-31 0001050007 country:US 2015-01-01 2015-03-31 0001050007 us-gaap:NonUsMember 2016-01-01 2016-03-31 0001050007 country:US 2014-10-01 2015-03-31 0001050007 us-gaap:NonUsMember 2015-01-01 2015-03-31 0001050007 us-gaap:NonUsMember 2014-10-01 2015-03-31 0001050007 us-gaap:NonUsMember 2015-10-01 2016-03-31 0001050007 country:US 2015-10-01 2016-03-31 xbrli:pure iso4217:USD xbrli:shares xbrli:shares nutr:acquisition iso4217:USD nutr:segment false --09-30 Q2 2016 2016-03-31 10-Q 0001050007 9339532 Accelerated Filer NUTRACEUTICAL INTERNATIONAL CORP P15Y P15Y P15Y 3000 781000 1570000 P1M P3M P2M 335321 68463 117025 80529 145940 14023000 13915000 17882000 20344000 16798000 19277000 6505000 6797000 -379000 -396000 P15Y P6Y P15Y P6Y 6961000 4026000 1084000 1067000 67000 63000 728000 1460000 999000 1980000 0 0 212449000 234515000 86215000 89814000 6541000 4161000 7580000 59970000 117591000 41000 755000 3821000 40000 450000 8020000 8470000 0 6004000 644000 81000 7209000 19026000 6232000 5216000 4615000 4162000 -1016000 -453000 95000 94000 3987000 7117000 4680000 8842000 28149000 55338000 29163000 57014000 0.005 0.01 Federal Funds Rate Eurodollar Rate Prime Lending Rate one-month Eurodollar Rate 0.0212 -77000 375000 1167000 1169000 4932000 4555000 6507000 7020000 0.43 0.77 0.49 0.94 0.43 0.77 0.49 0.94 -179000 27000 1000 1000 0 P7Y P11Y P5Y 12511000 9773000 1966000 772000 14492000 11133000 2587000 772000 9392000 1944000 2875000 2964000 3391000 3582000 30078000 16836000 12470000 772000 38640000 23975000 13893000 772000 17567000 7063000 10504000 0 24148000 12842000 11306000 0 -7000 -4000 24384000 0 30925000 0 6541000 6541000 64778000 71319000 40394000 40394000 0 27255000 53110000 30329000 58437000 3207000 6465000 11737000 7229000 13740000 2369000 4290000 2611000 4881000 -1136000 -296000 1706000 1139000 -1685000 804000 -1137000 -771000 -81000 61000 10000 10000 -517000 -894000 38000 0 30116000 38640000 17605000 24148000 273000 570000 322000 596000 26579000 23407000 59440000 61491000 23106000 26508000 9755000 11576000 52202000 68396000 212449000 234515000 20528000 20712000 47500000 130000000 100000000 0.0025 31500000 47500000 -7707000 12474000 -4298000 -30258000 11168000 17304000 4096000 7447000 4618000 8859000 1 2 1 6738000 12307000 7551000 14336000 1668000 1613000 -109000 -330000 62000 -17000 174000 184000 2352000 3566000 420000 0 81000 26235000 81000 26235000 4217000 4023000 4195000 3715000 1000 0 64000 40000 2000000 25500000 9000 77645000 83460000 7000000 9500000 153618000 162477000 55404000 49102000 6302000 48807000 6597000 108448000 96190000 12258000 95532000 12916000 59492000 53687000 5805000 52350000 7142000 115451000 8355000 104186000 11265000 102400000 13051000 19789000 39343000 21779000 42121000 504000 556000 800000 720721 0 24827 22664 160247000 166119000 2000 3354 48000 82000 1278000 2352000 1962000 3566000 420000 4874 5884 0 0 9626925 9643637 9401972 9430878 9622051 9637753 9401972 9430878 <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all necessary adjustments, consisting of normal recurring adjustments, to state fairly the consolidated financial position of the Company as of </font><font style="font-family:inherit;font-size:11pt;">March&#160;31, 2016</font><font style="font-family:inherit;font-size:11pt;">, the results of its operations for the three and six months ended </font><font style="font-family:inherit;font-size:11pt;">March&#160;31, 2016</font><font style="font-family:inherit;font-size:11pt;"> and </font><font style="font-family:inherit;font-size:11pt;">2015</font><font style="font-family:inherit;font-size:11pt;"> and its cash flows for the six months ended </font><font style="font-family:inherit;font-size:11pt;">March&#160;31, 2016</font><font style="font-family:inherit;font-size:11pt;"> and </font><font style="font-family:inherit;font-size:11pt;">2015</font><font style="font-family:inherit;font-size:11pt;">, in conformity with accounting principles generally accepted in the United States of America ("US&#160;GAAP") for interim financial information applied on a consistent basis. Results for the three and six months ended </font><font style="font-family:inherit;font-size:11pt;">March&#160;31, 2016</font><font style="font-family:inherit;font-size:11pt;"> are not necessarily indicative of the results to be expected for the full fiscal year.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Certain information and footnote disclosures normally included in the annual financial statements prepared in accordance with US&#160;GAAP have been omitted. Accordingly, these financial statements should be read in conjunction with the Company's Form&#160;10-K for the fiscal year ended </font><font style="font-family:inherit;font-size:11pt;">September&#160;30, 2015</font><font style="font-family:inherit;font-size:11pt;">, which was filed with the Securities and Exchange Commission on November&#160;19, 2015.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"></font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:95.51656920077973%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:63%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended<br clear="none"/>March 31, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Six Months Ended<br clear="none"/>March 31, 2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Net sales</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">59,970</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">117,591</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Net income</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">4,161</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">7,580</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">ACQUISITIONS</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">During the six months ended </font><font style="font-family:inherit;font-size:11pt;">March&#160;31, 2016</font><font style="font-family:inherit;font-size:11pt;">, the Company made </font><font style="font-family:inherit;font-size:11pt;">two</font><font style="font-family:inherit;font-size:11pt;"> acquisitions of businesses. On October&#160;6, 2015, the Company acquired certain operating assets of Dynamic Health Laboratories,&#160;Inc. ("Dynamic Health"). On February 18, 2016, the Company acquired certain operating assets of Aubrey Organics, Inc. ("Aubrey Organics"). The aggregate purchase price of these acquisitions was </font><font style="font-family:inherit;font-size:11pt;">$26,235</font><font style="font-family:inherit;font-size:11pt;"> in cash.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">During the six months ended </font><font style="font-family:inherit;font-size:11pt;">March&#160;31, 2015</font><font style="font-family:inherit;font-size:11pt;">, the Company made </font><font style="font-family:inherit;font-size:11pt;">one</font><font style="font-family:inherit;font-size:11pt;"> acquisition of a business. On November&#160;18, 2014, the Company acquired certain operating assets of Agape Health Products for </font><font style="font-family:inherit;font-size:11pt;">$81</font><font style="font-family:inherit;font-size:11pt;"> in cash.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">These acquisitions are in keeping with the Company's business strategy of consolidating the fragmented industry in which it competes. These acquisitions were accounted for using the acquisition method of accounting. Accordingly, the purchase price was assigned to the assets acquired based on their fair values at their respective dates of acquisition. The excess of purchase price over the fair values of the assets acquired was classified as goodwill. The goodwill relates to expected synergies from these acquisitions. The following reflects the preliminary allocation of the purchase prices for the fiscal </font><font style="font-family:inherit;font-size:11pt;">2016</font><font style="font-family:inherit;font-size:11pt;"> acquisitions and the final allocation of the purchase price for the fiscal </font><font style="font-family:inherit;font-size:11pt;">2015</font><font style="font-family:inherit;font-size:11pt;"> acquisition to the assets acquired:</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:95.32163742690058%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:62%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Fiscal 2016 Acquisition - Dynamic Health</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Fiscal 2016 Acquisition - Aubrey Organics</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Fiscal 2015 Acquisition</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Assets acquired:</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Current assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">3,821</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">755</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">41</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Property, plant and equipment</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">644</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">6,004</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Goodwill</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">6,541</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Intangible assets</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">8,020</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">450</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">40</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">19,026</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">7,209</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">81</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The fiscal </font><font style="font-family:inherit;font-size:11pt;">2016</font><font style="font-family:inherit;font-size:11pt;"> and fiscal </font><font style="font-family:inherit;font-size:11pt;">2015</font><font style="font-family:inherit;font-size:11pt;"> acquired intangible assets totaling </font><font style="font-family:inherit;font-size:11pt;">$8,470</font><font style="font-family:inherit;font-size:11pt;"> and </font><font style="font-family:inherit;font-size:11pt;">$40</font><font style="font-family:inherit;font-size:11pt;">, respectively, related to trademarks, tradenames and customer relationships, and are being amortized over periods of </font><font style="font-family:inherit;font-size:11pt;">six</font><font style="font-family:inherit;font-size:11pt;"> to </font><font style="font-family:inherit;font-size:11pt;">fifteen</font><font style="font-family:inherit;font-size:11pt;"> years for financial statement purposes. The fiscal </font><font style="font-family:inherit;font-size:11pt;">2016</font><font style="font-family:inherit;font-size:11pt;"> and fiscal </font><font style="font-family:inherit;font-size:11pt;">2015</font><font style="font-family:inherit;font-size:11pt;"> acquired intangible assets are expected to be deductible for tax purposes over </font><font style="font-family:inherit;font-size:11pt;">fifteen</font><font style="font-family:inherit;font-size:11pt;"> years. Goodwill of </font><font style="font-family:inherit;font-size:11pt;">$6,541</font><font style="font-family:inherit;font-size:11pt;"> for fiscal </font><font style="font-family:inherit;font-size:11pt;">2016</font><font style="font-family:inherit;font-size:11pt;"> is not subject to amortization for financial statement purposes and is expected to be deductible for tax purposes over </font><font style="font-family:inherit;font-size:11pt;">fifteen</font><font style="font-family:inherit;font-size:11pt;"> years.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The Condensed Consolidated Statements of Comprehensive Income and the Condensed Consolidated Statements of Cash Flows presented herein include the activities of these acquired businesses from their respective dates of acquisition. The expected long-term sales and expense synergies of acquired businesses generally are not realized immediately following acquisition, as certain transition and integration matters must be completed.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Since the date of acquisition (October 6, 2015), net sales of </font><font style="font-family:inherit;font-size:11pt;">$8,355</font><font style="font-family:inherit;font-size:11pt;"> and gross profit of </font><font style="font-family:inherit;font-size:11pt;">$3,207</font><font style="font-family:inherit;font-size:11pt;"> for Dynamic Health were included in the Condensed Consolidated Statements of Comprehensive Income for the six months ended </font><font style="font-family:inherit;font-size:11pt;">March&#160;31, 2016</font><font style="font-family:inherit;font-size:11pt;">. The Company tracks selling, general and administrative expenses on a consolidated basis, not on a brand-by-brand basis. As a result, the disclosure of any results after gross profit is impracticable. The following table provides unaudited pro forma information for the three and six months ended </font><font style="font-family:inherit;font-size:11pt;">March&#160;31, 2015</font><font style="font-family:inherit;font-size:11pt;">, as if the acquisition of Dynamic Health had been completed on October&#160;1, 2014. Pro forma information was not provided for the three and six months ended </font><font style="font-family:inherit;font-size:11pt;">March&#160;31, 2016</font><font style="font-family:inherit;font-size:11pt;"> since the acquisition was completed near the beginning of these periods and the pro forma results are not materially different than actual results. The information has been provided for illustrative purposes only and is not necessarily indicative of the actual results that would have been achieved by the Company for the periods presented or that will be achieved in the future. The pro forma information has been adjusted to give effect to items directly attributable to the Dynamic Health acquisition. These adjustments include acquisition costs, amortization expense associated with acquired intangible assets, interest expense associated with borrowings on the Company's revolving credit facility to fund the acquisition, application of the Company's depreciable lives policy for property, plant and equipment, elimination of intercompany transactions and any consequential tax effects.</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:95.51656920077973%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:63%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended<br clear="none"/>March 31, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Six Months Ended<br clear="none"/>March 31, 2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Net sales</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">59,970</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">117,591</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Net income</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">4,161</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">7,580</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">This information has not been adjusted to reflect any changes in the operations of the business subsequent to acquisition. Changes in the operations of the acquired business may include, but are not limited to, discontinuation of certain customers and/or products, application of the Company's pricing and credit policies, integration of systems and personnel, changes in manufacturing processes, relocation of facilities, potential cost synergies and changes in marketing and sales programs. Due to these changes, future results could be materially different than the pro forma information provided.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The actual and pro forma net sales and earnings related to the Aubrey Organics acquisition were not material.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">DEBT</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Debt was comprised of the following:</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:72%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">March&#160;31, <br clear="none"/>2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">September&#160;30, <br clear="none"/>2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Long-term debt&#8212;revolving credit facility</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">47,500</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">31,500</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:11pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The carrying value of the Company's debt approximates fair value at </font><font style="font-family:inherit;font-size:11pt;">March&#160;31, 2016</font><font style="font-family:inherit;font-size:11pt;"> and </font><font style="font-family:inherit;font-size:11pt;">September&#160;30, 2015</font><font style="font-family:inherit;font-size:11pt;">. Estimated fair values for debt have been determined based on borrowing rates currently available to the Company for bank loans with similar terms and maturities and are classified as Level&#160;2 (significant observable inputs other than quoted prices) in the FASB's fair value hierarchy.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">On November&#160;4, 2014, the Company amended its revolving credit facility (the "Credit Agreement"). The Credit Agreement extends the term of the credit facility to November 2019, increases the available credit borrowings to </font><font style="font-family:inherit;font-size:11pt;">$100,000</font><font style="font-family:inherit;font-size:11pt;"> with no automatic reductions and provides an accordion feature that can increase the available credit borrowings to </font><font style="font-family:inherit;font-size:11pt;">$130,000</font><font style="font-family:inherit;font-size:11pt;">, subject to approval by the lenders and compliance with certain covenants and conditions. The lenders under the Credit Agreement continue to be Rabobank International and Wells Fargo. To date, the Company has not experienced any difficulties in accessing the available funds under the Credit Agreement. Deferred financing fees of </font><font style="font-family:inherit;font-size:11pt;">$420</font><font style="font-family:inherit;font-size:11pt;"> related to the Credit Agreement are being amortized over the term of the Credit Agreement.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">At </font><font style="font-family:inherit;font-size:11pt;">March&#160;31, 2016</font><font style="font-family:inherit;font-size:11pt;">, the Company had outstanding revolving credit borrowings of </font><font style="font-family:inherit;font-size:11pt;">$47,500</font><font style="font-family:inherit;font-size:11pt;"> under the Credit Agreement. Borrowings under the Credit Agreement are collateralized by substantially all assets of the Company. At the Company's election, borrowings bear interest at the applicable </font><font style="font-family:inherit;font-size:11pt;">Eurodollar Rate</font><font style="font-family:inherit;font-size:11pt;"> plus a variable margin or at a Base Rate plus a variable margin. Base Rate is the higher of: (i)&#160;the </font><font style="font-family:inherit;font-size:11pt;">Prime Lending Rate</font><font style="font-family:inherit;font-size:11pt;">, (ii)&#160;the </font><font style="font-family:inherit;font-size:11pt;">Federal Funds Rate</font><font style="font-family:inherit;font-size:11pt;"> plus </font><font style="font-family:inherit;font-size:11pt;">0.5%</font><font style="font-family:inherit;font-size:11pt;"> or (iii)&#160;the </font><font style="font-family:inherit;font-size:11pt;">one-month Eurodollar Rate</font><font style="font-family:inherit;font-size:11pt;"> multiplied by the Statutory Reserve Rate plus </font><font style="font-family:inherit;font-size:11pt;">1.0%</font><font style="font-family:inherit;font-size:11pt;"> (capitalized terms are defined in the Credit Agreement, a copy of which was filed with the Securities and Exchange Commission on November&#160;5, 2014). At </font><font style="font-family:inherit;font-size:11pt;">March&#160;31, 2016</font><font style="font-family:inherit;font-size:11pt;">, the applicable weighted-average interest rate for outstanding borrowings was </font><font style="font-family:inherit;font-size:11pt;">2.12%</font><font style="font-family:inherit;font-size:11pt;">. The Company is also required to pay a variable quarterly fee on the unused balance under the Credit Agreement. At </font><font style="font-family:inherit;font-size:11pt;">March&#160;31, 2016</font><font style="font-family:inherit;font-size:11pt;">, the applicable rate was </font><font style="font-family:inherit;font-size:11pt;">0.25%</font><font style="font-family:inherit;font-size:11pt;">. Accrued interest on Eurodollar Rate borrowings is payable based on elected intervals of </font><font style="font-family:inherit;font-size:11pt;">one</font><font style="font-family:inherit;font-size:11pt;">, </font><font style="font-family:inherit;font-size:11pt;">two</font><font style="font-family:inherit;font-size:11pt;"> or </font><font style="font-family:inherit;font-size:11pt;">three</font><font style="font-family:inherit;font-size:11pt;"> months. Accrued interest on Base Rate borrowings is payable quarterly. The Credit Agreement matures on November&#160;4, 2019, and the Company is required to repay all principal and interest outstanding under the Credit Agreement on such date.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The Credit Agreement contains restrictive covenants, including limitations on incurring other indebtedness and requirements that the Company maintain certain financial ratios. As of </font><font style="font-family:inherit;font-size:11pt;">March&#160;31, 2016</font><font style="font-family:inherit;font-size:11pt;">, the Company was in compliance with the restrictive covenants. Upon the occurrence of a default, the lender has various remedies or rights, which may include proceeding against the collateral or requiring the Company to repay all amounts outstanding under the Credit Agreement.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">GOODWILL AND INTANGIBLE ASSETS</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The change in the carrying amount of goodwill from </font><font style="font-family:inherit;font-size:11pt;">September&#160;30, 2015</font><font style="font-family:inherit;font-size:11pt;"> to </font><font style="font-family:inherit;font-size:11pt;">March&#160;31, 2016</font><font style="font-family:inherit;font-size:11pt;"> was as follows:</font></div><div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:60%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Goodwill</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Accumulated</font></div><div style="text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Impairment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Net</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Balance as of September&#160;30, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">64,778</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(40,394</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">24,384</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Goodwill attributable to fiscal 2016 acquisitions</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">6,541</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">6,541</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Balance as of March&#160;31, 2016</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">71,319</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(40,394</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">30,925</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The carrying amounts of intangible assets at </font><font style="font-family:inherit;font-size:11pt;">March&#160;31, 2016</font><font style="font-family:inherit;font-size:11pt;"> and </font><font style="font-family:inherit;font-size:11pt;">September&#160;30, 2015</font><font style="font-family:inherit;font-size:11pt;"> were as follows:</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="26" rowspan="1"></td></tr><tr><td style="width:22%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:6%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:6%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">March 31, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">September 30, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted-</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Amortization</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Period</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(Years)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Carrying</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Amount </font><font style="font-family:inherit;font-size:6pt;font-weight:bold;">(1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Accumulated</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Amortization</font><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;</font><font style="font-family:inherit;font-size:6pt;font-weight:bold;">(1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Net</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Carrying</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Carrying</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Amount </font><font style="font-family:inherit;font-size:6pt;font-weight:bold;">(1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Accumulated</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Amortization </font><font style="font-family:inherit;font-size:6pt;font-weight:bold;">(1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Net</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Carrying</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Intangible assets subject to amortization:</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Trademarks/tradenames/licenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">13,893</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(2,587</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">11,306</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">12,470</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(1,966</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">10,504</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">11</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Customer relationships/non-compete agreements</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">23,975</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(11,133</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">12,842</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">16,836</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(9,773</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">7,063</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">7</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Developed software and technology</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">772</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(772</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">772</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(772</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">5</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">38,640</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(14,492</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">24,148</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">30,078</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(12,511</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">17,567</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Intangible assets not subject to amortization:</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#160;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#160;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#160;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#160;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#160;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#160;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Trademarks/tradenames/licenses</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">38</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">38</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">38,640</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(14,492</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">24,148</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">30,116</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(12,511</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">17,605</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(1) Amounts include the impact of foreign currency translation adjustments.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Estimated future amortization expense related to the </font><font style="font-family:inherit;font-size:11pt;">March&#160;31, 2016</font><font style="font-family:inherit;font-size:11pt;"> net carrying amount of </font><font style="font-family:inherit;font-size:11pt;">$24,148</font><font style="font-family:inherit;font-size:11pt;"> for intangible assets subject to amortization is as follows:</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.61013645224172%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:86%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Year Ending September 30,</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Estimated</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Amortization</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Expense</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">2016(1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">1,944</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">2017</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">3,582</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">2018</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">3,391</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">2019</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">2,964</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">2020</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">2,875</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Thereafter</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">9,392</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">24,148</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">(1)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Estimated amortization expense for the year ending September&#160;30, 2016 includes only amortization to be recorded after </font><font style="font-family:inherit;font-size:11pt;">March&#160;31, 2016</font><font style="font-family:inherit;font-size:11pt;">.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">General and economic conditions may impact retail and consumer demand, as well as the market price of the Company's common stock, and could negatively impact the Company's future operating performance, cash flow and/or stock price and could result in goodwill and/or intangible asset impairment charges being recorded in future periods. Also, the Company periodically reviews its brands to achieve marketing, sales and operational synergies. These reviews could result in brands being consolidated or discontinued and could result in intangible asset impairment charges being recorded in future periods. Goodwill and/or intangible asset impairment charges could materially impact the Company's consolidated financial statements. The valuation of goodwill and intangible assets is subject to a high degree of judgment, uncertainty and complexity.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">INVENTORIES</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Inventories were comprised of the following:</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:93.76218323586744%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:69%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">March&#160;31, <br clear="none"/>2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">September&#160;30, <br clear="none"/>2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Raw materials</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">26,508</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">23,106</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Work-in-process</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">11,576</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">9,755</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Finished goods</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">23,407</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">26,579</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">61,491</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">59,440</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">ACCOUNTS RECEIVABLE</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Accounts receivable, net of allowances for sales returns and doubtful accounts, consisted of the following:</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:94.15204678362574%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:70%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">March&#160;31, <br clear="none"/>2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">September&#160;30, <br clear="none"/>2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Accounts receivable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">20,344</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">17,882</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Less allowances</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(1,067</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(1,084</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">19,277</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">16,798</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">BASIS OF PRESENTATION</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Nutraceutical International Corporation and its subsidiaries (the "Company") is an integrated manufacturer, marketer, distributor and retailer of branded nutritional supplements and other natural products sold primarily to and through domestic health and natural food stores. Internationally, the Company markets and distributes branded nutritional supplements and other natural products to and through health and natural product distributors and retailers. The Company's core business strategy is to acquire, integrate and operate businesses in the natural products industry that manufacture, market and distribute branded nutritional supplements. The Company believes that the consolidation and integration of these acquired businesses provide ongoing financial synergies through increased scale and market penetration, as well as strengthened customer relationships.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The Company manufactures and sells nutritional supplements and other natural products under numerous brands, including </font><font style="font-family:inherit;font-size:11pt;font-style:italic;">Solaray</font><font style="font-family:inherit;font-size:11pt;">&#174;, </font><font style="font-family:inherit;font-size:11pt;font-style:italic;">KAL</font><font style="font-family:inherit;font-size:11pt;">&#174;, </font><font style="font-family:inherit;font-size:11pt;font-style:italic;">Dynamic Health&#8482;</font><font style="font-family:inherit;font-size:11pt;">, </font><font style="font-family:inherit;font-size:11pt;font-style:italic;">Nature's Life</font><font style="font-family:inherit;font-size:11pt;">&#174;, </font><font style="font-family:inherit;font-size:11pt;font-style:italic;">LifeTime</font><font style="font-family:inherit;font-size:11pt;">&#174;, </font><font style="font-family:inherit;font-size:11pt;font-style:italic;">Natural Balance</font><font style="font-family:inherit;font-size:11pt;">&#174;</font><font style="font-family:inherit;font-size:11pt;font-style:italic;">, NaturalCare</font><font style="font-family:inherit;font-size:11pt;">&#174;, </font><font style="font-family:inherit;font-size:11pt;font-style:italic;">Health from the Sun</font><font style="font-family:inherit;font-size:11pt;">&#174;, </font><font style="font-family:inherit;font-size:11pt;font-style:italic;">Pioneer</font><font style="font-family:inherit;font-size:11pt;">&#174;, </font><font style="font-family:inherit;font-size:11pt;font-style:italic;">Nutra BioGenesis&#8482;</font><font style="font-family:inherit;font-size:11pt;">, </font><font style="font-family:inherit;font-size:11pt;font-style:italic;">Life-flo</font><font style="font-family:inherit;font-size:11pt;">&#174;, </font><font style="font-family:inherit;font-size:11pt;font-style:italic;">Organix South</font><font style="font-family:inherit;font-size:11pt;">&#174;, </font><font style="font-family:inherit;font-size:11pt;font-style:italic;">Heritage Store</font><font style="font-family:inherit;font-size:11pt;">&#174; and </font><font style="font-family:inherit;font-size:11pt;font-style:italic;">Monarch Nutraceuticals&#8482;</font><font style="font-family:inherit;font-size:11pt;">.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The Company owns neighborhood natural food markets, which operate under the trade names </font><font style="font-family:inherit;font-size:11pt;font-style:italic;">The Real Food Company&#8482;</font><font style="font-family:inherit;font-size:11pt;">, </font><font style="font-family:inherit;font-size:11pt;font-style:italic;">Thom's Natural Foods&#8482;</font><font style="font-family:inherit;font-size:11pt;">, </font><font style="font-family:inherit;font-size:11pt;font-style:italic;">Cornucopia Community Market&#8482;</font><font style="font-family:inherit;font-size:11pt;"> and </font><font style="font-family:inherit;font-size:11pt;font-style:italic;">Granola's&#8482;</font><font style="font-family:inherit;font-size:11pt;">. The Company also owns health food stores, which operate under various trade names, including </font><font style="font-family:inherit;font-size:11pt;font-style:italic;">Fresh Vitamins&#8482;</font><font style="font-family:inherit;font-size:11pt;"> and </font><font style="font-family:inherit;font-size:11pt;font-style:italic;">Peachtree Natural Foods</font><font style="font-family:inherit;font-size:11pt;">&#174;.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all necessary adjustments, consisting of normal recurring adjustments, to state fairly the consolidated financial position of the Company as of </font><font style="font-family:inherit;font-size:11pt;">March&#160;31, 2016</font><font style="font-family:inherit;font-size:11pt;">, the results of its operations for the three and six months ended </font><font style="font-family:inherit;font-size:11pt;">March&#160;31, 2016</font><font style="font-family:inherit;font-size:11pt;"> and </font><font style="font-family:inherit;font-size:11pt;">2015</font><font style="font-family:inherit;font-size:11pt;"> and its cash flows for the six months ended </font><font style="font-family:inherit;font-size:11pt;">March&#160;31, 2016</font><font style="font-family:inherit;font-size:11pt;"> and </font><font style="font-family:inherit;font-size:11pt;">2015</font><font style="font-family:inherit;font-size:11pt;">, in conformity with accounting principles generally accepted in the United States of America ("US&#160;GAAP") for interim financial information applied on a consistent basis. Results for the three and six months ended </font><font style="font-family:inherit;font-size:11pt;">March&#160;31, 2016</font><font style="font-family:inherit;font-size:11pt;"> are not necessarily indicative of the results to be expected for the full fiscal year.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Certain information and footnote disclosures normally included in the annual financial statements prepared in accordance with US&#160;GAAP have been omitted. Accordingly, these financial statements should be read in conjunction with the Company's Form&#160;10-K for the fiscal year ended </font><font style="font-family:inherit;font-size:11pt;">September&#160;30, 2015</font><font style="font-family:inherit;font-size:11pt;">, which was filed with the Securities and Exchange Commission on November&#160;19, 2015.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The preparation of these financial statements in conformity with US&#160;GAAP required management to make estimates and assumptions that affected the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements and the reported amounts of net sales and expenses during the reported periods. Significant estimates included values and lives assigned to acquired intangible assets, reserves for customer returns and allowances, uncollectible accounts receivable, valuation adjustments for slow-moving, obsolete and/or damaged inventory and valuation and recoverability of long-lived assets. Actual results may differ from these estimates.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">New Accounting Standards</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">In February 2016, the Financial Accounting Standards Board ("FASB") issued authoritative guidance, which is included in Accounting Standards Codification ("ASC") 842, "</font><font style="font-family:inherit;font-size:11pt;font-style:italic;">Leases</font><font style="font-family:inherit;font-size:11pt;">." This guidance requires lessees to recognize most leases on the balance sheet by recording a right-of-use asset and a lease liability. This guidance is effective for the Company as of October 1, 2019. The Company is currently evaluating the impact this standard may have on its consolidated financial statements.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">In November 2015, the FASB issued authoritative guidance, which is included in ASC 740, "</font><font style="font-family:inherit;font-size:11pt;font-style:italic;">Income Taxes</font><font style="font-family:inherit;font-size:11pt;">." This guidance simplifies the presentation of deferred income taxes and requires that deferred tax assets and liabilities be classified as noncurrent in the classified statement of financial position. This guidance is effective for the Company as of October&#160;1, 2017 and is not expected to have a material impact on the consolidated financial statements as the guidance only changes the classification of deferred income taxes.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">In September 2015, the FASB issued authoritative guidance, which is included in ASC 805, "</font><font style="font-family:inherit;font-size:11pt;font-style:italic;">Business Combinations</font><font style="font-family:inherit;font-size:11pt;">." This guidance simplifies the accounting for measurement-period adjustments and is effective for the Company as of October&#160;1, 2016. The Company does not expect this guidance to have a material impact on its consolidated financial statements.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">In July 2015, the FASB issued authoritative guidance, which is included in ASC 330, "</font><font style="font-family:inherit;font-size:11pt;font-style:italic;">Inventory</font><font style="font-family:inherit;font-size:11pt;">." This guidance simplifies the accounting for measuring inventory at the lower of cost and net realizable value and is effective for the Company as of October&#160;1, 2017. The Company does not expect this guidance to have a material impact on its consolidated financial statements.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">In May 2014, the FASB issued authoritative guidance, which is included in ASC 606, "</font><font style="font-family:inherit;font-size:11pt;font-style:italic;">Revenue from Contracts with Customers</font><font style="font-family:inherit;font-size:11pt;">." This guidance provides a single, comprehensive revenue recognition model for all contracts with customers and requires that a company recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. In July 2015, the FASB delayed the effective date of this guidance by one year. As a result, this guidance is effective for the Company as of October&#160;1, 2018 and shall be applied either retrospectively to each period presented or as a cumulative-effect adjustment as of the date of adoption. The Company is currently evaluating the impact this standard may have on its consolidated financial statements.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The Company periodically reviews new accounting standards that are issued. Although some of these accounting standards may be applicable to the Company, the Company has not identified any other new standards that it believes merit further discussion, and the Company expects that none would have a significant impact on its consolidated financial statements.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">New Accounting Standards</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">In February 2016, the Financial Accounting Standards Board ("FASB") issued authoritative guidance, which is included in Accounting Standards Codification ("ASC") 842, "</font><font style="font-family:inherit;font-size:11pt;font-style:italic;">Leases</font><font style="font-family:inherit;font-size:11pt;">." This guidance requires lessees to recognize most leases on the balance sheet by recording a right-of-use asset and a lease liability. This guidance is effective for the Company as of October 1, 2019. The Company is currently evaluating the impact this standard may have on its consolidated financial statements.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">In November 2015, the FASB issued authoritative guidance, which is included in ASC 740, "</font><font style="font-family:inherit;font-size:11pt;font-style:italic;">Income Taxes</font><font style="font-family:inherit;font-size:11pt;">." This guidance simplifies the presentation of deferred income taxes and requires that deferred tax assets and liabilities be classified as noncurrent in the classified statement of financial position. This guidance is effective for the Company as of October&#160;1, 2017 and is not expected to have a material impact on the consolidated financial statements as the guidance only changes the classification of deferred income taxes.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">In September 2015, the FASB issued authoritative guidance, which is included in ASC 805, "</font><font style="font-family:inherit;font-size:11pt;font-style:italic;">Business Combinations</font><font style="font-family:inherit;font-size:11pt;">." This guidance simplifies the accounting for measurement-period adjustments and is effective for the Company as of October&#160;1, 2016. The Company does not expect this guidance to have a material impact on its consolidated financial statements.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">In July 2015, the FASB issued authoritative guidance, which is included in ASC 330, "</font><font style="font-family:inherit;font-size:11pt;font-style:italic;">Inventory</font><font style="font-family:inherit;font-size:11pt;">." This guidance simplifies the accounting for measuring inventory at the lower of cost and net realizable value and is effective for the Company as of October&#160;1, 2017. The Company does not expect this guidance to have a material impact on its consolidated financial statements.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">In May 2014, the FASB issued authoritative guidance, which is included in ASC 606, "</font><font style="font-family:inherit;font-size:11pt;font-style:italic;">Revenue from Contracts with Customers</font><font style="font-family:inherit;font-size:11pt;">." This guidance provides a single, comprehensive revenue recognition model for all contracts with customers and requires that a company recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. In July 2015, the FASB delayed the effective date of this guidance by one year. As a result, this guidance is effective for the Company as of October&#160;1, 2018 and shall be applied either retrospectively to each period presented or as a cumulative-effect adjustment as of the date of adoption. The Company is currently evaluating the impact this standard may have on its consolidated financial statements.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The Company periodically reviews new accounting standards that are issued. Although some of these accounting standards may be applicable to the Company, the Company has not identified any other new standards that it believes merit further discussion, and the Company expects that none would have a significant impact on its consolidated financial statements.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Accounts receivable, net of allowances for sales returns and doubtful accounts, consisted of the following:</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:94.15204678362574%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:70%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">March&#160;31, <br clear="none"/>2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">September&#160;30, <br clear="none"/>2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Accounts receivable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">20,344</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">17,882</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Less allowances</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(1,067</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(1,084</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">19,277</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">16,798</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The Company's net sales by product group for the three and six months ended </font><font style="font-family:inherit;font-size:11pt;">March&#160;31, 2016</font><font style="font-family:inherit;font-size:11pt;"> and </font><font style="font-family:inherit;font-size:11pt;">2015</font><font style="font-family:inherit;font-size:11pt;"> were as follows:</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:92.00779727095517%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:54%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended<br clear="none"/>March 31,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Six Months Ended<br clear="none"/>March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Branded nutritional supplements and other natural products</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">53,687</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">49,102</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">104,186</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">96,190</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Other(1)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">5,805</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">6,302</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">11,265</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">12,258</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">59,492</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">55,404</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">115,451</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">108,448</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:11pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">(1)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Net sales for any other product or group of similar products are less than </font><font style="font-family:inherit;font-size:11pt;">10%</font><font style="font-family:inherit;font-size:11pt;"> of consolidated net sales.</font></div></td></tr></table></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The change in the carrying amount of goodwill from </font><font style="font-family:inherit;font-size:11pt;">September&#160;30, 2015</font><font style="font-family:inherit;font-size:11pt;"> to </font><font style="font-family:inherit;font-size:11pt;">March&#160;31, 2016</font><font style="font-family:inherit;font-size:11pt;"> was as follows:</font></div><div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:60%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Goodwill</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Accumulated</font></div><div style="text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Impairment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Net</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Balance as of September&#160;30, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">64,778</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(40,394</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">24,384</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Goodwill attributable to fiscal 2016 acquisitions</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">6,541</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">6,541</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Balance as of March&#160;31, 2016</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">71,319</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(40,394</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">30,925</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The carrying amounts of intangible assets at </font><font style="font-family:inherit;font-size:11pt;">March&#160;31, 2016</font><font style="font-family:inherit;font-size:11pt;"> and </font><font style="font-family:inherit;font-size:11pt;">September&#160;30, 2015</font><font style="font-family:inherit;font-size:11pt;"> were as follows:</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="26" rowspan="1"></td></tr><tr><td style="width:22%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:6%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:6%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">March 31, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">September 30, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted-</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Amortization</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Period</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(Years)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Carrying</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Amount </font><font style="font-family:inherit;font-size:6pt;font-weight:bold;">(1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Accumulated</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Amortization</font><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;</font><font style="font-family:inherit;font-size:6pt;font-weight:bold;">(1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Net</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Carrying</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Carrying</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Amount </font><font style="font-family:inherit;font-size:6pt;font-weight:bold;">(1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Accumulated</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Amortization </font><font style="font-family:inherit;font-size:6pt;font-weight:bold;">(1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Net</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Carrying</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Intangible assets subject to amortization:</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Trademarks/tradenames/licenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">13,893</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(2,587</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">11,306</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">12,470</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(1,966</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">10,504</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">11</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Customer relationships/non-compete agreements</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">23,975</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(11,133</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">12,842</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">16,836</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(9,773</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">7,063</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">7</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Developed software and technology</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">772</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(772</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">772</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(772</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">5</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">38,640</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(14,492</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">24,148</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">30,078</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(12,511</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">17,567</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Intangible assets not subject to amortization:</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#160;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#160;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#160;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#160;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#160;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#160;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Trademarks/tradenames/licenses</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">38</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">38</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">38,640</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(14,492</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">24,148</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">30,116</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(12,511</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">17,605</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(1) Amounts include the impact of foreign currency translation adjustments.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Inventories were comprised of the following:</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:93.76218323586744%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:69%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">March&#160;31, <br clear="none"/>2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">September&#160;30, <br clear="none"/>2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Raw materials</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">26,508</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">23,106</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Work-in-process</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">11,576</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">9,755</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Finished goods</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">23,407</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">26,579</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">61,491</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">59,440</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Debt was comprised of the following:</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:72%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">March&#160;31, <br clear="none"/>2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">September&#160;30, <br clear="none"/>2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Long-term debt&#8212;revolving credit facility</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">47,500</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">31,500</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The following reflects the preliminary allocation of the purchase prices for the fiscal </font><font style="font-family:inherit;font-size:11pt;">2016</font><font style="font-family:inherit;font-size:11pt;"> acquisitions and the final allocation of the purchase price for the fiscal </font><font style="font-family:inherit;font-size:11pt;">2015</font><font style="font-family:inherit;font-size:11pt;"> acquisition to the assets acquired:</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:95.32163742690058%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:62%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Fiscal 2016 Acquisition - Dynamic Health</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Fiscal 2016 Acquisition - Aubrey Organics</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Fiscal 2015 Acquisition</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Assets acquired:</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Current assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">3,821</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">755</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">41</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Property, plant and equipment</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">644</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">6,004</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Goodwill</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">6,541</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Intangible assets</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">8,020</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">450</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">40</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">19,026</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">7,209</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">81</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Net sales attributed to customers in the United States and foreign countries for the three and six months ended </font><font style="font-family:inherit;font-size:11pt;">March&#160;31, 2016</font><font style="font-family:inherit;font-size:11pt;"> and </font><font style="font-family:inherit;font-size:11pt;">2015</font><font style="font-family:inherit;font-size:11pt;"> were as follows:</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:92.78752436647173%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:2%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:2%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended<br clear="none"/>March 31,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Six Months Ended<br clear="none"/>March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">United States</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">52,350</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">48,807</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">102,400</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">95,532</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Foreign countries</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">7,142</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">6,597</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">13,051</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">12,916</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">59,492</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">55,404</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">115,451</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">108,448</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Estimated future amortization expense related to the </font><font style="font-family:inherit;font-size:11pt;">March&#160;31, 2016</font><font style="font-family:inherit;font-size:11pt;"> net carrying amount of </font><font style="font-family:inherit;font-size:11pt;">$24,148</font><font style="font-family:inherit;font-size:11pt;"> for intangible assets subject to amortization is as follows:</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.61013645224172%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:86%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Year Ending September 30,</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Estimated</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Amortization</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Expense</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">2016(1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">1,944</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">2017</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">3,582</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">2018</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">3,391</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">2019</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">2,964</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">2020</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">2,875</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Thereafter</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">9,392</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">24,148</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">(1)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Estimated amortization expense for the year ending September&#160;30, 2016 includes only amortization to be recorded after </font><font style="font-family:inherit;font-size:11pt;">March&#160;31, 2016</font><font style="font-family:inherit;font-size:11pt;">.</font></div></td></tr></table></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">SEGMENTS</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Segment identification and selection is consistent with the management structure used by the Company's chief operating decision maker to evaluate performance and make decisions regarding resource allocation, as well as the materiality of financial results consistent with that structure. Based on the Company's management structure and method of internal reporting, the Company has </font><font style="font-family:inherit;font-size:11pt;">one</font><font style="font-family:inherit;font-size:11pt;"> operating segment. The Company's chief operating decision maker does not review operating results on a disaggregated basis; rather, the chief operating decision maker reviews operating results on an aggregate basis.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Net sales attributed to customers in the United States and foreign countries for the three and six months ended </font><font style="font-family:inherit;font-size:11pt;">March&#160;31, 2016</font><font style="font-family:inherit;font-size:11pt;"> and </font><font style="font-family:inherit;font-size:11pt;">2015</font><font style="font-family:inherit;font-size:11pt;"> were as follows:</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:92.78752436647173%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:2%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:2%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended<br clear="none"/>March 31,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Six Months Ended<br clear="none"/>March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">United States</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">52,350</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">48,807</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">102,400</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">95,532</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Foreign countries</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">7,142</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">6,597</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">13,051</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">12,916</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">59,492</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">55,404</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">115,451</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">108,448</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:11pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Certain net sales attributed to customers in the United States are sold to customers who in turn may sell such products to customers in foreign countries, while certain net sales attributed to customers in foreign countries are sold to customers who in turn may sell such products to customers in the United States.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The Company's net sales by product group for the three and six months ended </font><font style="font-family:inherit;font-size:11pt;">March&#160;31, 2016</font><font style="font-family:inherit;font-size:11pt;"> and </font><font style="font-family:inherit;font-size:11pt;">2015</font><font style="font-family:inherit;font-size:11pt;"> were as follows:</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:92.00779727095517%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:54%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended<br clear="none"/>March 31,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Six Months Ended<br clear="none"/>March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Branded nutritional supplements and other natural products</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">53,687</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">49,102</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">104,186</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">96,190</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Other(1)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">5,805</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">6,302</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">11,265</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">12,258</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">59,492</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">55,404</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">115,451</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">108,448</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:11pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">(1)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Net sales for any other product or group of similar products are less than </font><font style="font-family:inherit;font-size:11pt;">10%</font><font style="font-family:inherit;font-size:11pt;"> of consolidated net sales.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">In October 2015, the Company made a decision to classify certain net sales in the other product group that were previously included in the branded nutritional supplements and other natural products group. As a result of this decision, the other product group net sales amount for the three and six months ended </font><font style="font-family:inherit;font-size:11pt;">March&#160;31, 2015</font><font style="font-family:inherit;font-size:11pt;"> has been increased by </font><font style="font-family:inherit;font-size:11pt;">$781</font><font style="font-family:inherit;font-size:11pt;"> and </font><font style="font-family:inherit;font-size:11pt;">$1,570</font><font style="font-family:inherit;font-size:11pt;">, respectively, from the prior year's presentation.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">STOCK OPTIONS AND OTHER EQUITY AWARDS</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">As of </font><font style="font-family:inherit;font-size:11pt;">March&#160;31, 2016</font><font style="font-family:inherit;font-size:11pt;">, the Company had </font><font style="font-family:inherit;font-size:11pt;">no</font><font style="font-family:inherit;font-size:11pt;"> outstanding options to purchase shares of common stock, as all previously issued options were exercised or expired prior to </font><font style="font-family:inherit;font-size:11pt;">September&#160;30, 2015</font><font style="font-family:inherit;font-size:11pt;">. </font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">During the six months ended March 31, 2015, the Company received proceeds of </font><font style="font-family:inherit;font-size:11pt;">$9</font><font style="font-family:inherit;font-size:11pt;"> related to the exercise of stock options. During this same period, the Company recorded a tax benefit of </font><font style="font-family:inherit;font-size:11pt;">$1</font><font style="font-family:inherit;font-size:11pt;">and optionees realized an aggregate pre-tax gain of </font><font style="font-family:inherit;font-size:11pt;">$3</font><font style="font-family:inherit;font-size:11pt;"> from these stock option exercises.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">No</font><font style="font-family:inherit;font-size:11pt;"> options to purchase shares of common stock for the three and six months ended </font><font style="font-family:inherit;font-size:11pt;">March&#160;31, 2015</font><font style="font-family:inherit;font-size:11pt;"> were excluded from the computation of diluted earnings per share because </font><font style="font-family:inherit;font-size:11pt;">none</font><font style="font-family:inherit;font-size:11pt;"> of the stock options were anti-dilutive.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">On January&#160;28, 2013, stockholders approved the Nutraceutical International Corporation </font><font style="font-family:inherit;font-size:11pt;">2013</font><font style="font-family:inherit;font-size:11pt;"> Long-Term Equity Incentive Plan (the "2013 Plan") and the reservation of </font><font style="font-family:inherit;font-size:11pt;">800,000</font><font style="font-family:inherit;font-size:11pt;"> shares of the Company's common stock for issuance under the </font><font style="font-family:inherit;font-size:11pt;">2013</font><font style="font-family:inherit;font-size:11pt;"> Plan. Equity awards available under the </font><font style="font-family:inherit;font-size:11pt;">2013</font><font style="font-family:inherit;font-size:11pt;"> Plan include stock options, stock appreciation rights and stock awards. In conjunction with the Company's fiscal </font><font style="font-family:inherit;font-size:11pt;">2015</font><font style="font-family:inherit;font-size:11pt;"> and fiscal </font><font style="font-family:inherit;font-size:11pt;">2014</font><font style="font-family:inherit;font-size:11pt;"> incentive compensation (bonus) payments, </font><font style="font-family:inherit;font-size:11pt;">22,664</font><font style="font-family:inherit;font-size:11pt;"> and </font><font style="font-family:inherit;font-size:11pt;">24,827</font><font style="font-family:inherit;font-size:11pt;"> shares of the Company's common stock were issued, respectively. These non-cash stock awards were granted on December&#160;11, 2015 and December&#160;11, 2014 at an aggregate fair value of </font><font style="font-family:inherit;font-size:11pt;">$556</font><font style="font-family:inherit;font-size:11pt;"> and </font><font style="font-family:inherit;font-size:11pt;">$504</font><font style="font-family:inherit;font-size:11pt;">, respectively, with fair value being determined by the closing price of the Company's common stock on the grant date. These stock awards were registered, unrestricted and fully vested on the grant date. As of </font><font style="font-family:inherit;font-size:11pt;">March&#160;31, 2016</font><font style="font-family:inherit;font-size:11pt;">, </font><font style="font-family:inherit;font-size:11pt;">720,721</font><font style="font-family:inherit;font-size:11pt;"> shares of the Company's common stock were available for issuance under the </font><font style="font-family:inherit;font-size:11pt;">2013</font><font style="font-family:inherit;font-size:11pt;"> Plan.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">SHARE PURCHASES</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">During the three and six months ended </font><font style="font-family:inherit;font-size:11pt;">March&#160;31, 2016</font><font style="font-family:inherit;font-size:11pt;">, the Company purchased </font><font style="font-family:inherit;font-size:11pt;">80,529</font><font style="font-family:inherit;font-size:11pt;"> and </font><font style="font-family:inherit;font-size:11pt;">145,940</font><font style="font-family:inherit;font-size:11pt;"> shares of common stock for an aggregate price of </font><font style="font-family:inherit;font-size:11pt;">$1,962</font><font style="font-family:inherit;font-size:11pt;"> and </font><font style="font-family:inherit;font-size:11pt;">$3,566</font><font style="font-family:inherit;font-size:11pt;">, respectively. During the three and six months ended </font><font style="font-family:inherit;font-size:11pt;">March&#160;31, 2015</font><font style="font-family:inherit;font-size:11pt;">, the Company purchased </font><font style="font-family:inherit;font-size:11pt;">68,463</font><font style="font-family:inherit;font-size:11pt;"> and </font><font style="font-family:inherit;font-size:11pt;">117,025</font><font style="font-family:inherit;font-size:11pt;"> shares of common stock for an aggregate price of </font><font style="font-family:inherit;font-size:11pt;">$1,278</font><font style="font-family:inherit;font-size:11pt;"> and </font><font style="font-family:inherit;font-size:11pt;">$2,352</font><font style="font-family:inherit;font-size:11pt;">, respectively. All of these shares of common stock held in treasury were retired prior to March 31 in the respective quarter of purchase, except at </font><font style="font-family:inherit;font-size:11pt;">March&#160;31, 2016</font><font style="font-family:inherit;font-size:11pt;"> and </font><font style="font-family:inherit;font-size:11pt;">2015</font><font style="font-family:inherit;font-size:11pt;">, the Company held </font><font style="font-family:inherit;font-size:11pt;">3,354</font><font style="font-family:inherit;font-size:11pt;"> and </font><font style="font-family:inherit;font-size:11pt;">2,000</font><font style="font-family:inherit;font-size:11pt;"> shares of common stock in treasury. As of </font><font style="font-family:inherit;font-size:11pt;">March&#160;31, 2016</font><font style="font-family:inherit;font-size:11pt;">, the Company was permitted to purchase up to </font><font style="font-family:inherit;font-size:11pt;">335,321</font><font style="font-family:inherit;font-size:11pt;"> additional shares under its approved purchase plan, with no expiration date or restrictions. The Company accounts for treasury shares using the cost method.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:32px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The preparation of these financial statements in conformity with US&#160;GAAP required management to make estimates and assumptions that affected the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements and the reported amounts of net sales and expenses during the reported periods. Significant estimates included values and lives assigned to acquired intangible assets, reserves for customer returns and allowances, uncollectible accounts receivable, valuation adjustments for slow-moving, obsolete and/or damaged inventory and valuation and recoverability of long-lived assets. Actual results may differ from these estimates.</font></div></div> The condensed consolidated balance sheet as of September 30, 2015 has been prepared using information from the audited financial statements at that date. EX-101.SCH 5 nutr-20160331.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 2102100 - Disclosure - ACCOUNTS RECEIVABLE link:presentationLink link:calculationLink link:definitionLink 2402402 - Disclosure - ACCOUNTS RECEIVABLE (Details) link:presentationLink link:calculationLink link:definitionLink 2302301 - Disclosure - ACCOUNTS RECEIVABLE (Tables) link:presentationLink link:calculationLink link:definitionLink 2104100 - Disclosure - ACQUISITIONS link:presentationLink link:calculationLink link:definitionLink 2404402 - Disclosure - ACQUISITIONS (Details) link:presentationLink link:calculationLink link:definitionLink 2304301 - Disclosure - ACQUISITIONS (Tables) link:presentationLink link:calculationLink link:definitionLink 2101100 - Disclosure - BASIS OF PRESENTATION link:presentationLink link:calculationLink link:definitionLink 2201201 - Disclosure - BASIS OF PRESENTATION (Policies) link:presentationLink link:calculationLink link:definitionLink 1001000 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) link:presentationLink link:calculationLink link:definitionLink 1003000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) link:presentationLink link:calculationLink link:definitionLink 1002000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Unaudited) link:presentationLink link:calculationLink link:definitionLink 2106100 - Disclosure - DEBT link:presentationLink link:calculationLink link:definitionLink 2406402 - Disclosure - DEBT (Details) link:presentationLink link:calculationLink link:definitionLink 2306301 - Disclosure - DEBT (Tables) link:presentationLink link:calculationLink link:definitionLink 0001000 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 2105100 - Disclosure - GOODWILL AND INTANGIBLE ASSETS link:presentationLink link:calculationLink link:definitionLink 2405403 - Disclosure - GOODWILL AND INTANGIBLE ASSETS (Carrying Amounts of Intangible Assets) (Details) link:presentationLink link:calculationLink link:definitionLink 2405404 - Disclosure - GOODWILL AND INTANGIBLE ASSETS (Schedule of Estimated Future Amortization Expense) (Details) link:presentationLink link:calculationLink link:definitionLink 2405402 - Disclosure - GOODWILL AND INTANGIBLE ASSETS (Schedule of Goodwill) (Details) link:presentationLink link:calculationLink link:definitionLink 2305301 - Disclosure - GOODWILL AND INTANGIBLE ASSETS (Tables) link:presentationLink link:calculationLink link:definitionLink 2103100 - Disclosure - INVENTORIES link:presentationLink link:calculationLink link:definitionLink 2403402 - Disclosure - INVENTORIES (Details) link:presentationLink link:calculationLink link:definitionLink 2303301 - Disclosure - INVENTORIES (Tables) link:presentationLink link:calculationLink link:definitionLink 2109100 - Disclosure - SEGMENTS link:presentationLink link:calculationLink link:definitionLink 2409402 - Disclosure - SEGMENTS (Details) link:presentationLink link:calculationLink link:definitionLink 2309301 - Disclosure - SEGMENTS (Tables) link:presentationLink link:calculationLink link:definitionLink 2107100 - Disclosure - SHARE PURCHASES link:presentationLink link:calculationLink link:definitionLink 2407401 - Disclosure - SHARE PURCHASES (Details) link:presentationLink link:calculationLink link:definitionLink 2108100 - Disclosure - STOCK OPTIONS AND OTHER EQUITY AWARDS link:presentationLink link:calculationLink link:definitionLink 2408401 - Disclosure - STOCK OPTIONS AND OTHER EQUITY AWARDS (Details) link:presentationLink link:calculationLink link:definitionLink 2408402 - Disclosure - STOCK OPTIONS AND OTHER EQUITY AWARDS (Details 2) link:presentationLink link:calculationLink link:definitionLink 2408403 - Disclosure - STOCK OPTIONS AND OTHER EQUITY AWARDS (Details 3) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 6 nutr-20160331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 7 nutr-20160331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 8 nutr-20160331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Document and Entity Information Entity Registrant Name Entity Registrant Name Entity Central Index Key Entity Central Index Key Current Fiscal Year End Date Current Fiscal Year End Date Entity Filer Category Entity Filer Category Document Type Document Type Document Period End Date Document Period End Date Document Fiscal Year Focus Document Fiscal Year Focus Document Fiscal Period Focus Document Fiscal Period Focus Amendment Flag Amendment Flag Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Equity [Abstract] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Antidilutive Securities [Axis] Antidilutive Securities [Axis] Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Stock options Employee And Non Employee Stock Options [Member] An arrangement whereby an employee and non-employee is entitled to receive in the future, subject to vesting and other restrictions, a number of shares in the entity at a specified price, as defined in the agreement. Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Options outstanding (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Proceeds from Stock Options exercised Proceeds from Stock Options Exercised Tax benefit realized from exercise of stock options Employee Service Share-based Compensation, Tax Benefit Realized from Exercise of Stock Options Gain on exercise of stock options by optionees Gain (Loss) on Exercise of Stock Options by Exerciser Gain (Loss) on Exercise of Stock Options by Exerciser Statement of Cash Flows [Abstract] Cash flows from operating activities: Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract] Net income Net Income (Loss) Available to Common Stockholders, Basic Adjustments to reconcile net income to net cash provided by operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Depreciation and amortization Depreciation, Depletion and Amortization Amortization of deferred financing fees Amortization of Debt Issuance Costs Losses on disposals of property, plant and equipment Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property Tax benefit from stock option exercises Excess Tax Benefit from Share-based Compensation, Operating Activities Deferred income taxes Deferred Income Tax Expense (Benefit) Changes in assets and liabilities, net of effects of acquisitions: Increase (Decrease) in Operating Capital [Abstract] Accounts receivable, net Increase (Decrease) in Accounts Receivable Inventories Increase (Decrease) in Inventories Prepaid expenses and other current assets Increase (Decrease) in Prepaid Expense and Other Assets Other non-current assets Increase (Decrease) in Other Noncurrent Assets Accounts payable Increase (Decrease) in Accounts Payable Accrued expenses Increase (Decrease) in Accrued Liabilities Other non-current liabilities Increase (Decrease) in Other Noncurrent Liabilities Net cash provided by operating activities Net Cash Provided by (Used in) Operating Activities Cash flows from investing activities: Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract] Purchases of property, plant and equipment Payments to Acquire Property, Plant, and Equipment Acquisitions of businesses Payments to Acquire Businesses, Net of Cash Acquired Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities Cash flows from financing activities: Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract] Proceeds from debt Proceeds from Lines of Credit Payments on debt Repayments of Lines of Credit Payments of deferred financing fees Payments of Financing Costs Proceeds from issuances of common stock Proceeds from Issuance of Common Stock Purchases of common stock for treasury Payments for Repurchase of Common Stock Tax benefit from stock option exercises Proceeds and Excess Tax Benefit from Share-based Compensation Net cash provided by (used in) financing activities Net Cash Provided by (Used in) Financing Activities Effect of exchange rate changes on cash Effect of Exchange Rate on Cash and Cash Equivalents Net decrease in cash Cash and Cash Equivalents, Period Increase (Decrease) Cash at beginning of period Cash and Cash Equivalents, at Carrying Value Cash at end of period Business Combinations [Abstract] Schedule of preliminary allocation of the aggregate purchase price for the acquisitions to the aggregate assets acquired Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block] Schedule of unaudited pro forma information Business Acquisition, Pro Forma Information [Table Text Block] Organization, Consolidation and Presentation of Financial Statements [Abstract] Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Use of Estimates Use of Estimates, Policy [Policy Text Block] New Accounting Standards New Accounting Pronouncements, Policy [Policy Text Block] Goodwill and Intangible Assets Disclosure [Abstract] Schedule of changes in the carrying amount of goodwill Schedule of Goodwill [Table Text Block] Schedule of carrying amounts of intangible assets Schedule of Intangible Assets and Goodwill [Table Text Block] Schedule of estimated amortization expense related to intangible assets subject to amortization Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block] Stock Options and Other Equity Awards Shareholders' Equity and Share-based Payments [Text Block] Receivables [Abstract] Accounts receivable Accounts Receivable, Gross, Current Less allowances Allowance for Doubtful Accounts Receivable, Current Accounts receivable, net Accounts Receivable, Net, Current Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract] Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract] 2016 Finite-Lived Intangible Assets, Amortization Expense, Remainder of Fiscal Year 2017 Finite-Lived Intangible Assets, Amortization Expense, Year Two 2018 Finite-Lived Intangible Assets, Amortization Expense, Year Three 2019 Finite-Lived Intangible Assets, Amortization Expense, Year Four 2020 Finite-Lived Intangible Assets, Amortization Expense, Year Five Thereafter Finite-Lived Intangible Assets, Amortization Expense, after Year Five Net Carrying Amount Finite-Lived Intangible Assets, Net Segment Reporting [Abstract] Segments Segment Reporting Disclosure [Text Block] Debt Disclosure [Abstract] Debt Debt Disclosure [Text Block] Goodwill and Intangible Assets Goodwill and Intangible Assets Disclosure [Text Block] Schedule of accounts receivable, net of allowances for sales returns and doubtful accounts Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block] Schedule of net sales attributed to customers in the United States and foreign countries Schedule of Revenue from External Customers Attributed to Foreign Countries by Geographic Area [Table Text Block] Schedule of net sales by product group Revenue from External Customers by Products and Services [Table Text Block] Statement of Financial Position [Abstract] ASSETS Assets [Abstract] Current assets: Assets, Current [Abstract] Cash Accounts receivable, net Inventories Inventory, Net Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Deferred income taxes Deferred Tax Assets, Net, Current Total current assets Assets, Current Property, plant and equipment, net Property, Plant and Equipment, Net Goodwill Goodwill Intangible assets, net Intangible Assets, Net (Excluding Goodwill) Deferred income taxes Deferred Tax Assets, Net, Noncurrent Other non-current assets Other Assets, Noncurrent Total assets Assets LIABILITIES AND STOCKHOLDERS' EQUITY Liabilities and Equity [Abstract] Current liabilities: Liabilities, Current [Abstract] Accounts payable Accounts Payable, Current Accrued expenses Accrued Liabilities, Current Total current liabilities Liabilities, Current Long-term debt Long-term Line of Credit, Noncurrent Other non-current liabilities Other Liabilities, Noncurrent Total liabilities Liabilities Stockholders' equity: Stockholders' Equity Attributable to Parent [Abstract] Common stock Common Stock, Value, Issued Additional paid-in capital Additional Paid in Capital, Common Stock Retained earnings Retained Earnings (Accumulated Deficit) Accumulated other comprehensive income Accumulated Other Comprehensive Income (Loss), Net of Tax Treasury stock Treasury Stock, Value Total stockholders' equity Stockholders' Equity Attributable to Parent Total liabilities and stockholders' equity Liabilities and Equity Stockholders' Equity Note [Abstract] Share Purchases Stockholders' Equity Note Disclosure [Text Block] Plan Name [Axis] Plan Name [Axis] Plan Name [Domain] Plan Name [Domain] 2013 Plan Long Term Equity Incentive Plan2013 [Member] Represents information pertaining to the 2013 Long-Term Equity Incentive Plan. Shares of common stock reserved for issuance (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized Equity compensation payments (in shares) Stock Issued During Period, Shares, Share-based Compensation, Net of Forfeitures Equity compensation payments Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value Shares of common stock available for issuance (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Antidilutive securities Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Anti-dilutive stock options (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Acquisitions Business Combination Disclosure [Text Block] Schedule of Business Acquisitions, by Acquisition [Table] Schedule of Business Acquisitions, by Acquisition [Table] Business Acquisition [Axis] Business Acquisition [Axis] Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Acquisitions Series of Individually Immaterial Business Acquisitions [Member] Dynamic Health Laboratories Inc. Dynamic Health Laboratories Inc [Member] Represents the information pertaining to acquisition of Dynamic Health Laboratories Inc. Aubrey Organics Aubrey Organics [Member] Aubrey Organics [Member] Range [Axis] Range [Axis] Range [Domain] Range [Domain] Minimum Minimum [Member] Maximum Maximum [Member] ACQUISITIONS Business Acquisition [Line Items] Number of business acquisitions Number of Businesses Acquired Aggregate purchase price in cash Payments to Acquire Businesses, Gross Amortization period Acquired Finite-lived Intangible Assets, Weighted Average Useful Life Expected period for deduction of acquired intangible assets for tax purposes Business Acquisition, Purchase Price Allocation, Intangible Assets Period for Deduction of Expected Tax Deductible Amount Represents the period over which the amount of acquired intangible assets in connection with a business combination is expected to be deductible for income tax purposes. Business acquisition goodwill amount Business Acquisition, Goodwill, Expected Tax Deductible Amount Expected period for deduction of acquired goodwill for tax purposes (years) Business Acquisition, Purchase Price Allocation, Goodwill, Period for Deduction of Expected Tax Deductible Amount Represents the period over which the amount of acquired goodwill in connection with a business combination is expected to be deductible for income tax purposes. Net sales Revenue, Net Gross profit Gross Profit Assets acquired: Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net [Abstract] Current assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets Property, plant and equipment Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment Intangible assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill Aggregate purchase price Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net Unaudited pro forma information Business Acquisition, Pro Forma Information [Abstract] Net sales Business Acquisition, Pro Forma Revenue Net income Business Acquisition, Pro Forma Net Income (Loss) Schedule of Long-term Debt Instruments [Table] Schedule of Long-term Debt Instruments [Table] Credit Facility [Axis] Credit Facility [Axis] Credit Facility [Domain] Credit Facility [Domain] Restated Credit Agreement Revolving Credit Facility [Member] Credit Agreement, accordion feature Revolving Credit Facility Accordion Feature [Member] Represents information pertaining to the accordion feature of a revolving credit facility. Variable Rate [Axis] Variable Rate [Axis] Variable Rate [Domain] Variable Rate [Domain] Eurodollar Rate Eurodollar [Member] Prime Lending Rate Prime Rate [Member] Federal Funds Rate Federal Funds Rate [Member] Represents the interest rate at which depository institutions actively trade balances held at the Federal Reserve, called federal funds, with each other, usually overnight, on an uncollateralized basis. Statutory Reserve Rate Statutory Reserve Rate [Member] The amount of liquid assets that firms must hold in order to remain solvent and attain partial protection against a substantial investment loss Debt Instruments [Line Items] Debt Instrument [Line Items] Long-term debt—revolving credit facility Available credit borrowings Line of Credit Facility, Maximum Borrowing Capacity Deferred financing cost Unamortized Debt Issuance Expense Outstanding revolving credit borrowings Long-term Line of Credit Reference rate Debt Instrument, Description of Variable Rate Basis Margin over reference rate (as a percent) Debt Instrument, Basis Spread on Variable Rate Weighted-average interest rate (as a percent) Debt, Weighted Average Interest Rate Quarterly fee on the unused balance (as a percent) Line of Credit Facility, Unused Capacity, Commitment Fee Percentage Interval for payment of accrued interest under option one Line of Credit Facility, Interval for Periodic Interest Payment Option, One Represents the period of interval used as base for payment of accrued interest under the line of credit facility, under option one, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Interval for payment of accrued interest under option two Line of Credit Facility, Interval for Periodic Interest Payment Option, Two Represents the period of interval used as base for payment of accrued interest under the line of credit facility, under option two, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Interval for payment of accrued interest under option three Line of Credit Facility, Interval for Periodic Interest Payment Option, Three Represents the period of interval used as base for payment of accrued interest under the line of credit facility, under option three, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Schedule of Finite Lived and Indefinite Lived Intangible Assets [Table] Schedule of Finite Lived and Indefinite Lived Intangible Assets [Table] Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life and those that exist in perpetuity. Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Trademarks/tradenames/licenses Trademarks Trade Names And Patents [Member] Represents trademarks, trade names and patents held by the entity. Trademarks are rights acquired through registration to gain or protect exclusive use of a business name, symbol or other device or style, trade names are rights acquired through registration of a business name to gain or protect exclusive use thereof and patents are exclusive legal right granted by the government to the owner to exploit an invention or a process for a period of time specified by law. Customer relationships/non-compete agreements Customer Relationships Distribution Rights And Noncompete Agreement [Member] Represents customer relationships, distribution rights and non-compete agreements held by the entity. Customer relationship that exists between the entity and its customer, for example, but not limited to, tenant relationships, distribution rights are legal rights, generally of a limited duration, to distribute a product or products, often within specific geographic areas or supply channels and agreement in which one party agrees not to pursue a similar trade in competition with another party are non-compete agreements. Developed software and technology Developed Technology Rights [Member] Indefinite-lived Intangible Assets [Axis] Indefinite-lived Intangible Assets [Axis] Indefinite-lived Intangible Assets, Major Class Name [Domain] Indefinite-lived Intangible Assets, Major Class Name [Domain] Trademarks/tradenames/licenses Trademarks Trade Names And Licenses [Member] Represents trademarks, trade names and licenses held by the entity. Trademarks are rights acquired through registration to gain or protect exclusive use of a business name, symbol or other device or style, trade names are rights acquired through registration of a business name to gain or protect exclusive use thereof and licenses are rights, generally of limited duration, under an arrangement (for example, to sell or otherwise utilize specified products or processes in a specified territory). INTANGIBLE ASSETS Finite Lived and Indefinite Lived Assets [Line Items] Intangible assets subject to amortization: Finite-Lived Intangible Assets, Net [Abstract] Gross Carrying Amount Finite-Lived Intangible Assets, Gross Accumulated Amortization Finite-Lived Intangible Assets, Accumulated Amortization Weighted- Average Amortization Period (Years) Finite-Lived Intangible Asset, Useful Life Intangible assets not subject to amortization: Indefinite-Lived Intangible Assets (Excluding Goodwill) [Abstract] Carrying Amount Indefinite-Lived Intangible Assets (Excluding Goodwill) Total intangible assets Intangible Assets, Net (Excluding Goodwill) [Abstract] Gross Carrying Amount Intangible Assets, Gross (Excluding Goodwill) Net Carrying Amount Basis of Presentation Nature of Operations [Text Block] Inventory Disclosure [Abstract] Raw materials Inventory, Raw Materials, Net of Reserves Work-in-process Inventory, Work in Process, Net of Reserves Finished goods Inventory, Finished Goods, Net of Reserves Inventories Goodwill [Roll Forward] Goodwill [Roll Forward] Goodwill, Balance as of September 30, 2015 Goodwill, Gross Accumulated Impairment, Balance as of September 30, 2015 Goodwill, Impaired, Accumulated Impairment Loss Goodwill, net, Balance as of September 30, 2015 Goodwill attributable to fiscal 2016 acquisitions Goodwill, Acquired During Period Goodwill, Accumulated Impairment Goodwill, Impairment Loss Goodwill, Balance as of March 1, 2016 Accumulated Impairment, Balance as of March 31, 2016 Goodwill, net, Balance as of March 31, 2016 Schedule of Stock by Class [Table] Schedule of Stock by Class [Table] Class of Stock [Axis] Class of Stock [Axis] Class of Stock [Domain] Class of Stock [Domain] Common Stock Common Stock [Member] Share purchases Class of Stock [Line Items] Shares of common stock purchased (in shares) Treasury Stock Shares Acquired Cost Method The number of shares of common and preferred stock that were repurchased during the period. Recorded using the cost method. Aggregate price at which shares of common stock purchased Treasury Stock, Value, Acquired, Cost Method Treasury stock (in shares) Treasury Stock, Shares Additional number of shares authorized to be repurchased (in shares) Stock Repurchase Program, Additional, Number of Shares Authorized to be Repurchased The number of additional shares authorized to be repurchased by an entity's Board of Directors under a stock repurchase plan. Schedule of debt Schedule of Line of Credit Facilities [Table Text Block] Schedule of inventories Schedule of Inventory, Current [Table Text Block] Income Statement [Abstract] Cost of sales Cost of Goods and Services Sold Gross profit Operating expenses Operating Expenses [Abstract] Selling, general and administrative Selling, General and Administrative Expense Amortization of intangible assets Amortization of Intangible Assets Income from operations Operating Income (Loss) Interest and other expense, net Interest Expense, Debt Income before provision for income taxes Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest Provision for income taxes Income Tax Expense (Benefit) Net income Other comprehensive income (loss): Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract] Foreign currency translation adjustment, net of tax Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent Comprehensive income Comprehensive Income (Loss), Net of Tax, Attributable to Parent Net income per common share Earnings Per Share [Abstract] Basic (in dollars per share) Earnings Per Share, Basic Diluted (in dollars per share) Earnings Per Share, Diluted Weighted average common shares outstanding Weighted Average Number of Shares Outstanding, Diluted [Abstract] Basic (in shares) Weighted Average Number of Shares Outstanding, Basic Dilutive effect of stock options (in shares) Weighted Average Number Diluted Shares Outstanding Adjustment Diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted Accounts Receivable Loans, Notes, Trade and Other Receivables Disclosure [Text Block] Inventories Inventory Disclosure [Text Block] Number of operating segments Number of Operating Segments Revenue from External Customers by Products and Services [Table] Revenue from External Customers by Products and Services [Table] Geographical [Axis] Geographical [Axis] Geographical [Domain] Geographical [Domain] United States UNITED STATES Foreign countries Non-US [Member] Products and Services [Axis] Products and Services [Axis] Products and Services [Domain] Products and Services [Domain] Branded nutritional supplements and other natural products Branded Nutritional Supplements And Other Natural Products [Member] Represents the branded nutritional supplements and other natural products of the entity. Other Other Products [Member] Represents the product group other than branded nutritional supplements and other natural products. SEGMENTS Segment Reporting Information [Line Items] Increase in product group net sales from prior year due to classify certain net sales Increase in Product Group Net Sales Due to Classify Certain Net Sales Amount represents increase in net sale of product group due to classify certain net sales. EX-101.PRE 9 nutr-20160331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 10 g604248.jpg begin 644 g604248.jpg M_]C_X 02D9)1@ ! 0$!L &P #__@!*35),3%]'4D%02$E#4SI;3E544D%# M155424-!3%])3E1%4DY!5$E/3D%,74Y55%)!0T555$E#04Q?1E!/7S1#7TQ/ M1T\N15!3_]L 0P ! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_]L 0P$! 0$! 0$! 0$! M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! M 0$! 0$! 0$!_\ $0@ 8P#> P$B (1 0,1 ?_$ !\ 0 " @(# 0$ M ("0<* 08#!0L"!/_$ $ 0 $$ 00! P(#!08""@, $" P0%!@ ' M"!$2"1,A%#$B05$*%3)A<18C@9&AL4)2%Q@9&B4G*"DS-D31\/_$ !T! $$ M P$! %!@<( P0) 0+_Q P$0 " @$$ @$# P0" @, " M P$$!0 &$1('$R$(%"(C,4$5)#)1%A="87'P\?_: P# 0 "$0,1 #\ W^-- M--&C33331HTTTTT:-----&C33331HTUB_<'<-C$X[D6&&9%NOV6T,N*4E+/U M 44N+\4GR*4)+@3V.P1V1KN639!7XM16-[9OMQXE?'6ZI;I/BISKQ9;Z3\DN M.E".AT>B3W\:JTS+=QZ;93[VZF(2[(<4ZAH.D);805>VVVTH*<4AMLI0VL*) M* //M6JP_4MY:R>PL!5V_M1\+W=N,+,IERP^4L/'T26N8&)YLVV2) @/C\A!?)NB)Y&"5$Q,'Q, MN\1W:MHMJA-VZ[-@3G6R\Y_=(->75% )2A(\VDK("NAYI'7\^Y5,O-2&FWV5 MI<:=0E;;B#VE:%#L*!'W!&J7X.]5'8RDQ67RAQ]'M-K4LI'GY!1/9 *2.N@? M@@G[?'8LSV!S5O,,'92MYE4VD?56.LMNJ=<^E;2E4*2\5$J]R0A2@H@^)]L= M 'ON+?I.\F;GLY;)["WA?NWXM5WYG;]G*.-]L&J9VR-&+#9)K5FM@VUB;3Z$ M#_5 AVB'1Y6\86]JT:V9C'NI+]RZUI1+D!@6#PEW'/$?J#*BF(B.2""_*8YS MCIIIJ^&H&TTTT^WWT:-?RS9L2NC.3)S[<:,R 7'G5>*$]D)'9_4D@ #Y)/0U MA.\WOJX$U,>MA?O".E1]R7]0EMM2$J6A00@ME?GVD%(ZZ*5$_ET<);[[S(F3 M7<4HWF5P(;Y18/M/^2G9,=QE:5)+1+8;;<"VPE:NUD*) ( $3;'7B3Y=$D_ "B3^I^?TU03SG]2.Z:^X+&U_&-M%:GC#%5_/IK)N6 M;>049P^G3BT#*PU$F(K)P#!N9#(!LJX[6%V)X8M9C'U\EE:EIKK@RRMCE]X( M:Y1$K:Z%\,AC([%"YF!$9"2CM,];0,7W9Q[('FH0Y*W\AHW,1E"ZJ1VKSL83;82XE]2U$&6TM)("$]+:^22 ML'MV> OJ*S&YLFO9GD>*R\Q9ZCA,ZM T@R3Y@I*C?K!,5D6F3Q]DRL*E-^*Y M)%W0FI7D#Q!?VU3;E\>FS-6K^60I.$I=57/2(L*YCN:1[\E++9:BJ=!):*5)!4 DGOX)'SJ ]G6S;1\.S?)?@/!I) *4- M_'X4@?'CT.B"#T22.OG78MLZ^WSAVXRRS4\ZNPDN/)+B%D+4_(<=6MMQ2B?! M">DH"D@^)/7YZRZO#UI22H!#8'9*B!X]J':AY#Y^/T^W?^&N0_D_R0W=>]LS MFK;($VM%5>L4RP:=-(S%2LHHDN#$"[L@>HDYK"XGM,ST&VYC\1XPI5]L5&I= M=QP0&2NP(BQ^1<(G:.)'Y_R*$A$R4BM8K[?CQJ-2,70@A:6O%:3Y!8/X@>P? M($#X/R!\#LCL?UFQP]R.93YO)Q^5(\V,BB/M%M;2U%#U:P)45:'00EOS"G6E M!22'/@=^21J(F7;BX]0R7X5:IFSE1G7(LA(![;E!?X4=)(["6PHD$_?Y\N_C M4B>/;EY;9#C^9-8_8P:FOG$S+.*V50W64!*G6 I/:_-*UAIY)44)"@%*22!I M8\79/-XS?&TMPA0N'6HYFBRZY*FM.KC'.76ON;TF956FF]JVM.85ZV$)3,E MZWO)U>[E?'V8C,5OMZ>0Q[PI-N,2IA6UKBS2]*GD+C,GK22A6,F<]9B('YU; M3IKA)"DI4/LH C\_@CL?/YZYUURB8F(F/VF(F/\ XGYUS4TU'?D9NXK:[$4" MO*Q?7RW(=W4#'::SO;1Y,>OJ MH4B=+>7WXH9CMJ<6?@$]D)Z'Q]R._C5&6YNYMUOWO'8+J),B12-2G*^A27UN M-Q*82O)$CV $M(<4I1'7MK*NP"ZL'4(>>/(,;(V;;33MQ6S>84VM2:+.C:=: M.LW;T2)"8$"9)5\:_4F[GVJICS!(=*#_QE:EK*.NO'S\B5 MGY[/VZUT.95QWWE*F.A;O?90HDA?_, 1V4J2GL]I/R4^( "CK(>X#T3 :$1V MWV462F0I#04D/$^;23YGI12Z$N^ZZA0^&@3UU\Z[QQ(CB(Y_B(CXB/]1_&FFFFO=>:::: M:-&FFFFC1IIIIHT::::\$KWQ&D?3)2J1[+GL)7_ 7? ^ 5_(JZ[U\-/U+8SJ M9^L#/HL9(RZ#)=0&.9(RXX$8CF9F(CYG7HQV(1YB.TQ',SQ$PJ(&(UU5>-RGX,H/E];L%#+KC+KT5+WM!Q]]L!45:5C8KS"@F$V4FU:VI=*S MY*)C\&=9"VCXNW=O6_?QV$IUIL8ME8,A%N[7J#6"W+838GVE!-KE"3+VI%@\ M=..9:J#G3O?O3C.RF&3LCN9$=VR7&EHQZE4ZI#UW:L,EUN$VI"5EE*ONX\L! M*$@CLJZ&M?O,]P<[WIW&=N+IV596-Q;!4!@^Y(:JX2>@8%>VZ4I8AQV!X*:: M"&W'5J64DJ/?L\LFY3G%NJXOI "SW MU\='66=I,/C8U).0S@%3EI4(S* #[':CY+>2OKR\TG\"1\I4>R#\ZI!Y@\X6 M=YB2JJ2IX:K!3C\4+98ZW:F)&+EZ8%<"0-=N>$-O M9'+.;7W#O7(5C3%WT^M=;OQ*\?1"3:2JPE MMV>TG:D9&8 !4J)=8'CT7&<8 MJ*IAHLJCPHPE.EE#3K[O2BIV1XDGW0M92D*'RA/\70ZUB'D)NBC#,:545$A2 M[R\9:]I3*_;>B1W'E-J>#B %I7T@^*D^*C\_;OK7;'LX,=AUQ/BH,-N$J*N^ MP@=A/B?PGLJZ2>_N?$??HPTSJ.L%\<1,=8[2+"CK,#'Y M0W-A;(+([O+/[F<;J-2R[*V$N9(JM6BD6(4Z)DIE0&,&0Q^XQ\C,3QK)/$/8 M^WWLW#_?%]':F8/B]BU)RJ1+<#Z[*6[&3+A52V7 5N?7MEPN2"H%M""?D]=W MO5F.T=-41:&JJH,"GA,MQXM?'CMHC--M)2A'3?B0M8"4E3CGDXXH>2U*42=8 M1XO[35^TFT]'5,QD-V]VTSD-_(4V42I%A81VEMM2B25*7"C%N*@'H-I04A(Z MU(C77GQ/L.EM;9](+=%$Y7,55VLO[5@V1&RL"#'(A4=D24(6I3ZHBE.);+C:4("DM!IQMQQ8Q;E&^W(7+ZV)1&Y@433$=IEZU MA*9;>LW&5)4U/?26@$R5EII2DLD,)?4X\TTE8!1&H_4E@-KOW#MS>5/(JW!M MG)7J ?;H2"R&V$?!, M?-[:-NL6\V$B2^%AEOZ.,&V7RVHI_OFFVBCYC*/M@#[#H:ZA@F'4^*3Y-Y8K M-G=REJ>>EOE*R)+JB](<7V#VI3RO)#B0?GY_,Z\NZV=6%I5R,>KEK]NRC+BR M/9*FW&F'2"X'%H\2/)20 /S[^._@BCGE#R3FO*FY6&4,JT7- ([%U35QZXB MK)&>\<1$$YOY'[G$4E(Q(P%F:&W$X[;>(\7;*(J6(EZ[.YMS,2(6\Y:(P9:< MT>8ZUU<=*ZR,9%*EK&1GDCPD&+GD'O!"J(GOQ*:5:*8+T:,MQZ/$:6M+I#*=7Y[8;?4FV6&4^)4<-B*Q7QP)+C33+;LZ8KY>F M2U,-M)>DND#S<* 3T /@:ACP/V59Q?&['R0"@"E%PF[EU+Z6[)Q M$1+)KE)5H,R*#8#6B(R4IUU:E>:R=5Z9+E:B#^HU21OWQMSW: MS(K5^KJ)%AA4Q]4FDL*Q4J>U$B!30,2P0$+?A/)?=#;1>46W$!2D'VTE6J.> M??%69I6;&>P19"WM?(9"Q%=EER<5F'"4ONJJ!! FM;:*Y)BX$0:P@,9B5 ME%W_ *<][;7RJPV_G&4L7NNG3&A0RKHK52S&(4U1(H3:D@8ZY4*(D$GWDT*A MBY[+.(Q^S/KXY4H(0% E25GKH$=]?S('Z?SU[7^U"6FTD/) '0"?@>0^$D]C M[_J!T.R!]^NM80<:MV)*HC\&Q:E(("XSS+K;O9^0"VL)41U\A0!2004J.LE8 MAA,^8XN9;I=8CM.(4AE:O_E)_A2@? 6H$]E(_0]GH:J+?HU*:V'9,QZE,2F? MR<1CS^GUD>1^8@9&8Y@IGF.>(BT&X1VY@:)Y+-96NI(!!K@W*-UCF(ZA761] MF$<<<=(X_F/]QW]I]^SC@>:@T^D$% )#I[!2@?F5>7B1V /COO4EN+VT$3+L MR#H6@_Q)'R>M8KIL?6XZ? A:@E2AX%Q2?$=?,M_3CL1F]M]*R%JE$[Z6KF)AA(B0 @F) CC]N)UDU*4H2E*0$I2 E*0.@E('0 'Y ?IKG337 M4+]OVU33]_WU 'F91_3S<=RN(\ZB8F&NO>00HLEH2.VG4$#P2ZA:@E?DH*4V MI(3V 0( JR-2?(O.!*QW[@\OS[Z((^>AV#\?B!^W]+@>1F*M9)MU/?\ 86[( MI7&[1KP6A)2F-YJ6I27.T/)2E2C[)25+) 3\_!JBDXE42)!FO)4VI8\2E((3 MYD?C7XC\*%$@GPZ['8_/K7,3ZEL.G!^5LI9MUB^VW!2HY>HU:BF#:*HJ71CB M)Y,65P(Y&?W."F([1JY_A?R/MNEL^IB=PL8MV-98KH:( QDJELO4GK'!0N(: M0@9Q,#/$<\1Q'KX5K(L$E:0L,#H*=3WXI /9Z^W9Z^P'?S^FLA;:;;.;@9S6 M4ZGD):?DL*LI3K8E)BPU$I#K31!;D2/<"$^TZ/ITD]N+!2!KU,6#'B1PRPV4 M,- D )(4OQ_B(6H ]=]#[#[]'O5BO&7;9C&J%S*YB&7+2X:#$%;22MN+4** M9*$LO@ /?5J6AYUQ(Z"PIL'X5ID>&]EL\A>0L7B5U>F&JLC)9HR$AC^F5"4Q ME3#"%.+ 3T3*W6CGZP5YN!L=ZOS6[O'6E=@;E8+MO@&\3BL=JUO?6N8 MAC-M.RRZR"O@!M5'01MB\%.9FW?.?CWB>]F"O M,0;.2RW3[AX47R[9X!GD2,RY=8W/2XE#KL;MUNQHK((,>WHYD&:PXI2GT-2= MO'QZ6"VYM7=F*.U;PV?Q-*Q>^X)++&)R=J'$%>Q]NM0C5M H_L7F$2TD/ Y$ MX )C#9WD16?W)NG:6257I9G 92Y7I>GW#7S&-J2D&VJLOF9*S5:T(O5P,_0# MZY#)C)G&0]].5_'#C,O&T;_;S8#M(K+_ *\8Q_;B\9I!>JJS%38HK5/H*9*X M9G0_?0A7FCZAHE/2P=9\ARXT^)%G0WD28)!.MCN,A+,9AM/PAMAE">_P DH;0D?/\ 1(TV\K@:M#:VT\XI M]AEKX'3+?;,<,"8".LQ.G)B=P6P!,EU@LO1?;=#A+A8^@E"*_7SV$^2F"B8U_1IH"#\@]C]1KCL'L M@D?<=_;^OZ::NG7KG7C=::?;6T\VAUIQ*D.-.)"VW$*'2D+0H%*TJ!(*5 @@ M]=:PKOQR'VJXWXO297NKD;-'"R?-L/VZQ>"V$2+C),RSG(*_':"DI*[W&W9\ MER78(E32@AN!5QYEA)6VRP2K-H4%=]'[$C\ONDE)_P!1K*==X(588AHU[!-6 MAQK,5/-'K]XJ9,0+)5[5PV!F>DF,%Q,\:Q!823VH6]96*\*-R@8,M1#>TI)@ M#/9?L]9RN2B.T#,CS$ M7TY[)W9F6YI9V<)8N-EN27CUJE5MASRUH"SXK.;,R1FL2&2GMT_>)WK-_)6H M7#LC=9ZQ$1]KV.ZB/^(A[B/IUCX'IQU_>(YYF8M[#;%2L&2C),J3) ;D* 4J2@I0EU?2NG L)41T3*37'8_G_@#U_H.M<@@_8@_T M^=2SM#9V!V/AD8+;]2*M-,]S(I[OLOF(@[%ALQ$L8+8+-<2N94[#Z^RR#'I:P0I7P219^2 .R0!^I^!KCL'X/V/Q^($ _R^1\ M]_E^OY:C?R/XPV]Y+Q]:KF(97MT&$S'Y.L(3:J]Y"6K_ #B18EOK'NLOCF.P MR,\S)),Z$*VL5V_\EE(SS_$_ZG_[\QJL'9+8?,^@++K_ (-N-'M!*N@.[\S>/FZNZ-#MW3[53+1FLQ)^ M Z_5U&2BD)=JLCQNS<;D5TJTI:VPAWN(5N386M]ZR6]6*R)MY$%Z,N4_&L(T M!!'8((_4?(UN>*O'N"\21[\ H+64 M2*9UJ7:D9"BRA9L624T8$C%Q V."@OP..>OS'$MI/U*XRG4E:%)<5D#7 M'8[Z['?Z=_/^6L;;O[O;=[#[<97NSNMD]=B&!855NVU_>V;R6F([""EMB.P@ MGSEV$^4MF#6P& N3.FR&(S"%.. :D(0=;L""5$U]ET"I*0(S8UQ\ I2Q[&1$ M90( /8IF8B.9G60V)IUR:YH)KUDR;7O8( I*0Y-KFG,"(@ R1F4Q$1$E,Q'. MLE::]/CUY!R:BI$"^J*VZ@IDM^Q*$.UA,6$42&/)19?#$AOW6BHEM?D MGL]=FL_ECR-YW;9BEQ)E/$?-I&F@_G_/\ W^/]-<>0_7OH]'KL]'^?7?7^.DO2IKG3 M37'8_G_@"?\ 8:-&N=0@W]]1GA[QKS0[;;I;O5L3<5F,W.L,$QNKNLQRNEKG MH\63'L;ZFQN#8R:2%+:G0S#?L1'$OZA'TZ7 %E,W@01\$$']/D'6F%ZO]3$K M/57MK"L:;KY5]Q>Q>=L0,QSS#%\@ M[FR&U,-4R&.13>ZQEZ6/.+L.)8*LB\B8(H8HB9$J$1@C$.#F9GXB)F7NK#B6 M/[27LU7SXS$V!/V!M8,Z%*:;D19D*9LON!&EPY<=T*:D1I4=UQB0P\A33S+B MVW$+2H@X&W$Q_+O0=YZP]W<,J;:U]/\ Y/VXI\FQZNDRGX>W[S\M$R73(BOK M6V,AV]5(FW^ N.+^HR/"7;?%6GU2X #,@-R0#^TL[']**C_T%3RH$ !LIV>S MH!(4#VLK2LJZ4/CH]? U?)RHXT;<0EZ&Z3'E.I,B9#E_$."ANG;_E M#L@2VS$FD-4=^O-EF.9UMKZ>69X M==5^28KE7)C&;[';^IDIE5EQ46=55RZ^PA2&SXNQY,=U#J2?Q([*'$I<2I(L ME]6S.MPMK?3SY!;G[69]E.VN=8!08OD5'E.'V2:NYCN#,<=JY<1$E4:4"Q,@ MV4AIQCVNGEAM*E!'F%::&^%YR/XUY)M1Z/$>DNK7A M>5SX;"%T*WB8TO!LDZ7D54VDA[';B5;T"@D0UH3N#>M(ZC_LN.67?\+F#XDV M".^P7]Q\);2H$?\ *5I5V>D@ E1">SK?SVVD[>M^$L/]Q4S6+=N7).HW %;J MN6PV2W-AW5&L4<$N)LTGA%BNSF ,C7/8(@R3=M;C;N,/->8FK;PV25M[$HR% M$B:FUB\QCMLY6O=0IP=3G[6_79%>RJ8)@"M@Q'/&L^^G7;YUD/"'C5DNY>=9 M!N5G>4[84F49-FV42VIMW>6&1.R+?W)LAEB,TKZ2/+8@,)0R@-QXS:#Y*25& MK/TWM[=]\[]4[U$-H]P=\MTL]VTV<-LC;S",JR%F?CF.IN-R'(Z?I8#5>P?. MJ@)3652UOJ7&@ LJ]PJ*DV6>F!?U^2^GQQ%M:R0),8[)XA6N.I3XA,^B9U-%7V.J@?2KE,3?6,]5N5%?8D1UOOM)>CO-OMN+C;I/, M+\'&U*0KVUI6VX$%00ZE2">T_+.Q].K/_=0.I5_90HO*I!U4\T&AO+'U9BM$ MAS4.$-8B(3 2*I-?P/QIZ7;MCV^%B3=L2G(60&S(V6_WZYVA,5\*DAT^R\EG-,# MA*S+$$(CE5KEFKE2*$XO04J_?MQ):1/^I\F0B*P&&6SY:I=]>=2 MXW);TMK L'V8W(:I\I3B$AA)&Y&UZUMK><*&DEID.2EH4M)]II;GR&SK9G0? M@CY_B7]P1_QJ_,CH_P"'Y?/VUYN_+W/^M_&-,9JPBSBMPJL1%"A[2BGN(H1 M68K3820@M7M)+5,>78K,M)AD?NS\35CR)Y.N%%B7HRVWS3,W[T@/W.VJC&R5 M:;'H,28UOK]BC!<1ZTP J$1UJ>=^YG-]WU=MG>,W&#E#?[1T^\>R=9?2*O)8 M\7*=NL7?CJS2NR#(*S"GX:$VEVFLH&+&OC/6<5MR\Z?>>1&"FU70<6>.VY7' M7:O*,1S#D=N7R1SG([ZYRAK/=WI$=Z35S[&JBQ(M+61:YL"OQJ).B?7MP&BX MIA4J2ACI ;0*>N1G?_>)N'/RKH<:IOB$]@=E>[0=+A"@#VDMI2D@]?) /EJY M;FUR$G<5.*&^/(.JH6LGM]L<%FWE)0R%2$0[*]?D1:JE8GN1DJ>:KA96$9ZP M<04*3$;= <;4I*ACW4-EV,\;;=Q-+&K/-[8PS6>C&XY-S(91^9RE2L=G(Q6& MV?QZ5<'8AQ*?70U7O(/=K*.6G%WD/ MG:=Y,@XOYRQ78[O$](A2+3*:*VR3+:#Z"PEP6FF+9B(_C";"IM'/%G&Q_U*^-F ?=V1N;87]LK9;!=P;?:78W#*^'1<(RJ\GO%4EUGIOLN*C3Z#N'XU@'-/U1,#PVM;H<4Q'*\ M3QO&J.,\]*8I:.KS_=2'4PX\J0\^\\U&AMLI9<5(>4MM*5./+="E%S74A;VK MY.QVQ&%W4>8)OW>XLADK68IEMRSDJA9+'.;X^=Y:Y/E M5HPK:23;PYU+C3-9:5MC%L+N9%DR7?W=+=]I<1^*T[F7:/TT-Z]D^0NV.\M) MZA')S,9+19Q2V6-W%[3S>&;H9EN[<95C%7?OO0I61W.-9#E+5Q2UC M4A)CNV$G&;2GS"O8^J,RWJYTF5"9D-PY*T;6CKK:&U*6M+:2 GS6+#[>+FGA7IH<3L]&SV M22,07N5R)Y!PZJ#D&2;=X2Q'8GIQ3;^MFMRZN/F5U7RH*OWO:LG]V/6M:F.T M")"U1]YH\1>3W"#9#+.7?&CGMRGRS-]GH\#,L^PG?++(6XN$;E8W&MVDWYFT M!I8T2')CLS42U0(346O=A1I9;^GDI9<$"]X-G-M;WU]]W]N.2V;;C;68?OGC M-1:;;Y7MWNE<;3V-I>VF"8C!Q.MDY/CCT:::V[L,[H\S+NFM8KD*TI[CE?NE:5%C$="$O1I]9/E/PI3#H M;1[K3[#C:_!/DD^(Z=5BFQB46/+8?EU.Z6Y<&TCLJ\W:^ M8]+K+-N-+0D=M.K@S8TIOL!+C#[:T%0/>F<].';L7?-[%5.M,-_81>+=90J; MU7$6:VXC16-\]V*[BJI#U@V1-J@B9.8&9>26Y5.]MC4\K<[W&;%S19-==[1I M6\M6=MX'V01RL&P!MMR@S5V!;2X@.9B,=V>^&_T#]H$HN.QWOW+7L%=[9/9T MG:07[:<-8M8VS4^R+7[O$'WUUZ[Z!^]_I3+\3-<42KVDI;UT;]I9PC*'^+&! M;H(W/RF'B&);D4=,O9Z#%K8^(9#D5W77DB+F]_/:8%[8V^.,UXCT%<]+--"5 M*F3DQ#8*;D(]3?V,.9^TT8*PS)CNO0./ME#=2RZAXM2#LMD$EUB24 _32TH= M;4(BS[Y:'OJ\4*2DYF_:3%.I].]A38!_\ZL)"@I*U(/E09'1'DX4A/9 M"2OH$_.GWAP31\B^$"JUJM4K>U=J,L]*E8?>ZS8RBFV6C"_RM. 0YM%Q:_$2 MAL2(E#&S)-O^-O- VGV;45]U;L56[V;40JO6''$FLHH9$Q621'$('^WY[\A( MS/,PN"W$[=_;>'M7O!F'.7DOO;CMWM%C[XVAW'>P=> PG\GQ6AF0Y$84^-UU MT',;!6Q4%V>I1;453U2GO)Q<,/47WSWVPCU5O3FV9V_WKW+P';+=V7CQW%PS M%;QJ)092U W,=AOQ[&O?A2 I-O5@U-HMIYI3D(I+8;>;#ANMXY+"^/NQ1'R# MLWM>H*3^)"O+!J)7:7$]MJ3T00I"BE7?X2=4!^IP4CUJ/2<\_E'O0_( CS*C MNBZEKH?'X?<5^(GL$=CX[[TT-FV)S>^?K7.-QZJXE4PF4;69 M%9%55?WI;$,!\JET,$3EG88F'=O-/]%V1BPQ;KE/V;@V;!F-^Z;B&WG<17LK M^X988^$N21*- LA,@9!TB"F)L_\ 4WY[M<#ME*2^QK%QGN].[&4(V\V4PEY3 MK==:97(:;=D6MV\RI#PI*)J1%6_&BK$RQGS*ZM8+:9+LAB,"?3&Y;[VXK295 MR3]3+E%2[KVL1J[OL3V0D8I@>T.&7\U"7E4N,44&J;MIM;3I+PM\"VJWDDN752VQ[M8S>PK;%LQ@-REK1[ M")F35>.6=9!9=K64TU+J1-TEJ@&W#L$QA&JNF RIFONK>^\L#G MG..I@:F!'%88+EFDMM;(5)MV\PR*=E)W#.Y(TUL/D*8H@!$66#DL-\=-H]X= MFN,F,[29QO'(WCWDHK5K:62XC58D7TF.14^F3E6Y?JM\Q)6ZS421-D7F,7]/CVW57;-N29<( MQLZW7U\JT9L[",%L2)42,J(RXT]*96*VN)7$AS MU#.-NU/)3F[R%W>WPL-UJZ9EK^TN"[BVFU_'W%J^39SJMW"FL,VYVQ>HRFWL7F;,38R"TALJ7K;=?FZ.)RN[6Y2EB,5?S@4+%F-OX[+WKV5^W? MD#JT*;ZL5JE4$O)M@)M8^J7= +!Y)%:MO<*L-;R>,VHG&6+BPB@NU>MIL'8L/.Q7!*3&I?M#U$[P>J%A.'0(M1B M6)<@,.QO%:>*ZMYNMQRB?W+K*>(R\XIQQ^*Q!88;8D.//N/ *===6M94J$_K M$D+]4[Q"FTA/%+'PLN.%L!?]KZ]02"GY)*%@]$?K\@ =ROM^I3H^;-SIQ]95 M2I.V&6EH17"HL"NX3"W'R%5)$JM[+%AK9KI*4IDY6O@!B(C'+V;ESP]M-N1L M,MW!W(NNU[[!W&%%/*9JJH2M,$66/4E*U"Y@PQ@!!LY*2YDME8*_VBW%[];C MZK6+%IL(^=2AXZB(;OS MB(CG?V8*>(XY(J>,DBGC]R*?DIGYF?F9G6K]^T=;;8/8IXBY]+QZ*K,EY;F. M*.9$R],BV3V.5[6.9# J'G8LE@/1(5T^_814NI6IA]]_VEI0\XA6POE>%8IN M_L!:X-N7103%D);D M1'F'VFW$--9,[9L1L+Q@<6'0=6WN?[8_:SM7ZY=9CZ"["$2CYB M)C6P==$[_P#)RI0F56JFV9LKE82NQ)X=BSEX=>K9,)D"ED%V"9&>8GC7SO,4 MWXWQVHW7L^,>VN\^[.#[%7FYKE#/V^QO<;,:N"BI7>F*]#K;6-<6I9V"/2)V]P_9WU/>6F"[<5!QS%8^WDVH;JA8VML/H*C M**B7 0[,O)UG8/OM2GGI#LU^6Y.EO//.3)+ZG7"IIJQWE:(K[?R8UXA Y+8X MWLB*8A49"[&0PA10GX_ M&^TR9_3Z$X[,#-*EWDOM*DBL(FLCUIF ".G QQ/+U[]KL#SG@Q89;E&/M6>2 M[99SCMY@ETF;9P)^-VEPM=/9RH3U;-A^Y];7+,=YB6)$8E#3P9$AAEUN&7[. M/EV;;HTF_P!G.Y>X&XVX62XTUA^!8]+S;GN1D^SIIJ'\41-^G_<U;;K0A$#%EU:+*Z[;$#Q#F5US M()-G8E!,BN1B>->GY/6MDS^T(\=[!J?+;E5<;:7#X"TON!N/C5_CV4RKFI3' M"OIU,6$BRFNOK<:7(*GSX/)"&PC94W:V_P ,W5VPSK;GIG0'4R8;Y8<9?;"_%*D/1WF9##J$/,.M.H0M+334WXPUT/&;5F8- M5LO&RM@%(L7(7;3 D#&8() RDQD9B1.9*.)F9TZ_'HB[(>3U.$6J9OK(K8MD M0:S \9CP,# HD2 @_$A*)@A_&8F/C7SGMKLNSS!.67_5KP?V2B9)?22-;!_HM89 MC>U?J \Y\!P* Y08A&AR*UFD386=E'1$QG,'#2)+MO,L):WH1N;0_5N2%2Y* MIKRIC\@E)2TU8/RNQ@;6RD 9C&0V9B[E^!(AB[;C-XCBU;B)C[FS',\/=W;' M,_E\SJO/B81+=>.DA$IH;WRE*C,Q$S2ISALK$U*DS'-:M,",2A/14Q$1TXB- M=R_:"N/>ST#"L-Y,5.%QZ#?F+:*K6]T,:ML@QK)G(U!!/XO.RR MTAIJ./IZF;NY]Q4KD_=T[6(;:M5+/Z]6S9KV@-%BQ7;W4YZ#89I:P"8LC,@( M9*9F0/J-F:&U]LW*,S3N5GHU*' M8M4LA6P0 3& M8$8BU3AAMAAFV'JO\0[/#8-I$MLVV&7F67W-SE.5Y==Y+E&9[=9",GN[NZR^ M[O;6QFVPZ]YISMI@^ZG!;D)CN?X_'R*HK\*=RJ!%?D MSX:X60XO)CVU#;1)=9+A38\NNGL-O-J9D(0ZCW(TA#T5YYEQII%W].29/SU1ZN;*B5W[UK9XJD MO+Z<$L?5C<=1ZLGI\W#;S[5EBSVW#]#)9?=95 =F;KRGY2@VTM#,GWW M&T%Q,QN0DI2$>/M_ATTT_=Q@"/-686@!2$;'R90"AA803]N.8^8$(&(EQM:; M9XY8;&$?,F4S'^U6&_P?A6N,W-+>>+@F-*6&4*W/5!4$9S)3"P6 +B9GH( ( M\0,1&QMOCM)MMOEM9F&V>[>&TN>8+D=3,9N,2'8LEES\6OFZ9WO5O1Q@W6R?:SC_O'NUM5MXWD%C';Q+%- MR\VB5#:9%HI$AUMEZ]D+;EOI0D/3D.)FNE(*Y"E?.FFO?I?$;UW=&,NC%S&Q M6IVXQ]J(L4HM0TEQ9BHWNC[CUQ >[U^SI$#VZQQK9^IV9I8_;62IS-3(E:NU M"OU9FO=FK%;VQ6FTKH^:\-_4A,L]?L_/KV^=;K'";:; =SO2(I,0W%I9&0;D#*KW(KVWS*^GV^0S)%U=Y)8VTC))5LF355;L2Q%LB77FMKTP'HR M(<9+>GIQTSO<6EY,XYQ>HMT-U<=V"R+=9B@N=LL;W1W QVAG4]C:0V;."MRD MR.!9M-6C;[Z;54>>T[9A]XSW)!=<*FFMGQ41/N>9JSR)U=%K(7$UVS+$IMKL MY %VE*/D%V0 '@,-$1$1*(&(A-\LB**7A=Z(A+["L?3L.5$+:^HRMC&,JN M8'!MK&PS,T')*(S(B&2*9G8O]$#$J#:WEWZ@^V.!P54&"4^01&:['D3;"Q8C M-XWE-Q5T@$JVE3[%Q4"!/EQD./3'''4/$R%.K2A2:_\ U7"[:>J#O-,G29C\ MBFVXP''ZM0FRVFX-,O'L5M%P([#+S;"&G+"0]+<5[9=<><4I;BAT TTD8%[V M^6,S88YK+#MFTB<\V&;FD>+PL&3&E,F9%$1!213)1$1//&M_* "_$V#2L!6E >.^;ZTI 8%2EAE(CF=?_9 end XML 11 R1.htm IDEA: XBRL DOCUMENT v3.4.0.3
Document and Entity Information - shares
6 Months Ended
Mar. 31, 2016
Apr. 26, 2016
Document and Entity Information    
Entity Registrant Name NUTRACEUTICAL INTERNATIONAL CORP  
Entity Central Index Key 0001050007  
Current Fiscal Year End Date --09-30  
Entity Filer Category Accelerated Filer  
Document Type 10-Q  
Document Period End Date Mar. 31, 2016  
Document Fiscal Year Focus 2016  
Document Fiscal Period Focus Q2  
Amendment Flag false  
Entity Common Stock, Shares Outstanding   9,339,532
XML 12 R2.htm IDEA: XBRL DOCUMENT v3.4.0.3
CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($)
$ in Thousands
Mar. 31, 2016
Sep. 30, 2015
[1]
Current assets:    
Cash $ 4,162 $ 4,615
Accounts receivable, net 19,277 16,798
Inventories 61,491 59,440
Prepaid expenses and other current assets 3,715 4,195
Deferred income taxes 1,169 1,167
Total current assets 89,814 86,215
Property, plant and equipment, net 83,460 77,645
Goodwill 30,925 24,384
Intangible assets, net 24,148 17,605
Deferred income taxes 4,555 4,932
Other non-current assets 1,613 1,668
Total assets 234,515 212,449
Current liabilities:    
Accounts payable 13,915 14,023
Accrued expenses 6,797 6,505
Total current liabilities 20,712 20,528
Long-term debt 47,500 31,500
Other non-current liabilities 184 174
Total liabilities 68,396 52,202
Stockholders' equity:    
Common stock 94 95
Additional paid-in capital 4,026 6,961
Retained earnings 162,477 153,618
Accumulated other comprehensive income (396) (379)
Treasury stock (82) (48)
Total stockholders' equity 166,119 160,247
Total liabilities and stockholders' equity $ 234,515 $ 212,449
[1] The condensed consolidated balance sheet as of September 30, 2015 has been prepared using information from the audited financial statements at that date.
XML 13 R3.htm IDEA: XBRL DOCUMENT v3.4.0.3
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Unaudited) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Mar. 31, 2016
Mar. 31, 2015
Mar. 31, 2016
Mar. 31, 2015
Income Statement [Abstract]        
Net sales $ 59,492 $ 55,404 $ 115,451 $ 108,448
Cost of sales 29,163 28,149 57,014 55,338
Gross profit 30,329 27,255 58,437 53,110
Operating expenses        
Selling, general and administrative 21,779 19,789 42,121 39,343
Amortization of intangible assets 999 728 1,980 1,460
Income from operations 7,551 6,738 14,336 12,307
Interest and other expense, net 322 273 596 570
Income before provision for income taxes 7,229 6,465 13,740 11,737
Provision for income taxes 2,611 2,369 4,881 4,290
Net income 4,618 4,096 8,859 7,447
Other comprehensive income (loss):        
Foreign currency translation adjustment, net of tax 62 (109) (17) (330)
Comprehensive income $ 4,680 $ 3,987 $ 8,842 $ 7,117
Net income per common share        
Basic (in dollars per share) $ 0.49 $ 0.43 $ 0.94 $ 0.77
Diluted (in dollars per share) $ 0.49 $ 0.43 $ 0.94 $ 0.77
Weighted average common shares outstanding        
Basic (in shares) 9,401,972 9,622,051 9,430,878 9,637,753
Dilutive effect of stock options (in shares) 0 4,874 0 5,884
Diluted (in shares) 9,401,972 9,626,925 9,430,878 9,643,637
XML 14 R4.htm IDEA: XBRL DOCUMENT v3.4.0.3
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($)
$ in Thousands
6 Months Ended
Mar. 31, 2016
Mar. 31, 2015
Cash flows from operating activities:    
Net income $ 8,859 $ 7,447
Adjustments to reconcile net income to net cash provided by operating activities:    
Depreciation and amortization 7,020 6,507
Amortization of deferred financing fees 63 67
Losses on disposals of property, plant and equipment 4 7
Tax benefit from stock option exercises 0 (1)
Deferred income taxes 375 (77)
Changes in assets and liabilities, net of effects of acquisitions:    
Accounts receivable, net (1,139) (1,706)
Inventories 771 1,137
Prepaid expenses and other current assets 894 517
Other non-current assets (61) 81
Accounts payable (296) (1,136)
Accrued expenses 804 (1,685)
Other non-current liabilities 10 10
Net cash provided by operating activities 17,304 11,168
Cash flows from investing activities:    
Purchases of property, plant and equipment (4,023) (4,217)
Acquisitions of businesses (26,235) (81)
Net cash used in investing activities (30,258) (4,298)
Cash flows from financing activities:    
Proceeds from debt 25,500 2,000
Payments on debt (9,500) (7,000)
Payments of deferred financing fees 0 (420)
Proceeds from issuances of common stock 40 64
Purchases of common stock for treasury (3,566) (2,352)
Tax benefit from stock option exercises 0 1
Net cash provided by (used in) financing activities 12,474 (7,707)
Effect of exchange rate changes on cash 27 (179)
Net decrease in cash (453) (1,016)
Cash at beginning of period 4,615 [1] 6,232
Cash at end of period $ 4,162 $ 5,216
[1] The condensed consolidated balance sheet as of September 30, 2015 has been prepared using information from the audited financial statements at that date.
XML 15 R5.htm IDEA: XBRL DOCUMENT v3.4.0.3
BASIS OF PRESENTATION
6 Months Ended
Mar. 31, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Basis of Presentation
BASIS OF PRESENTATION
Nutraceutical International Corporation and its subsidiaries (the "Company") is an integrated manufacturer, marketer, distributor and retailer of branded nutritional supplements and other natural products sold primarily to and through domestic health and natural food stores. Internationally, the Company markets and distributes branded nutritional supplements and other natural products to and through health and natural product distributors and retailers. The Company's core business strategy is to acquire, integrate and operate businesses in the natural products industry that manufacture, market and distribute branded nutritional supplements. The Company believes that the consolidation and integration of these acquired businesses provide ongoing financial synergies through increased scale and market penetration, as well as strengthened customer relationships.
The Company manufactures and sells nutritional supplements and other natural products under numerous brands, including Solaray®, KAL®, Dynamic Health™, Nature's Life®, LifeTime®, Natural Balance®, NaturalCare®, Health from the Sun®, Pioneer®, Nutra BioGenesis™, Life-flo®, Organix South®, Heritage Store® and Monarch Nutraceuticals™.
The Company owns neighborhood natural food markets, which operate under the trade names The Real Food Company™, Thom's Natural Foods™, Cornucopia Community Market™ and Granola's™. The Company also owns health food stores, which operate under various trade names, including Fresh Vitamins™ and Peachtree Natural Foods®.
In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all necessary adjustments, consisting of normal recurring adjustments, to state fairly the consolidated financial position of the Company as of March 31, 2016, the results of its operations for the three and six months ended March 31, 2016 and 2015 and its cash flows for the six months ended March 31, 2016 and 2015, in conformity with accounting principles generally accepted in the United States of America ("US GAAP") for interim financial information applied on a consistent basis. Results for the three and six months ended March 31, 2016 are not necessarily indicative of the results to be expected for the full fiscal year.
Certain information and footnote disclosures normally included in the annual financial statements prepared in accordance with US GAAP have been omitted. Accordingly, these financial statements should be read in conjunction with the Company's Form 10-K for the fiscal year ended September 30, 2015, which was filed with the Securities and Exchange Commission on November 19, 2015.
Use of Estimates
The preparation of these financial statements in conformity with US GAAP required management to make estimates and assumptions that affected the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements and the reported amounts of net sales and expenses during the reported periods. Significant estimates included values and lives assigned to acquired intangible assets, reserves for customer returns and allowances, uncollectible accounts receivable, valuation adjustments for slow-moving, obsolete and/or damaged inventory and valuation and recoverability of long-lived assets. Actual results may differ from these estimates.
New Accounting Standards
In February 2016, the Financial Accounting Standards Board ("FASB") issued authoritative guidance, which is included in Accounting Standards Codification ("ASC") 842, "Leases." This guidance requires lessees to recognize most leases on the balance sheet by recording a right-of-use asset and a lease liability. This guidance is effective for the Company as of October 1, 2019. The Company is currently evaluating the impact this standard may have on its consolidated financial statements.
In November 2015, the FASB issued authoritative guidance, which is included in ASC 740, "Income Taxes." This guidance simplifies the presentation of deferred income taxes and requires that deferred tax assets and liabilities be classified as noncurrent in the classified statement of financial position. This guidance is effective for the Company as of October 1, 2017 and is not expected to have a material impact on the consolidated financial statements as the guidance only changes the classification of deferred income taxes.
In September 2015, the FASB issued authoritative guidance, which is included in ASC 805, "Business Combinations." This guidance simplifies the accounting for measurement-period adjustments and is effective for the Company as of October 1, 2016. The Company does not expect this guidance to have a material impact on its consolidated financial statements.
In July 2015, the FASB issued authoritative guidance, which is included in ASC 330, "Inventory." This guidance simplifies the accounting for measuring inventory at the lower of cost and net realizable value and is effective for the Company as of October 1, 2017. The Company does not expect this guidance to have a material impact on its consolidated financial statements.
In May 2014, the FASB issued authoritative guidance, which is included in ASC 606, "Revenue from Contracts with Customers." This guidance provides a single, comprehensive revenue recognition model for all contracts with customers and requires that a company recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. In July 2015, the FASB delayed the effective date of this guidance by one year. As a result, this guidance is effective for the Company as of October 1, 2018 and shall be applied either retrospectively to each period presented or as a cumulative-effect adjustment as of the date of adoption. The Company is currently evaluating the impact this standard may have on its consolidated financial statements.
The Company periodically reviews new accounting standards that are issued. Although some of these accounting standards may be applicable to the Company, the Company has not identified any other new standards that it believes merit further discussion, and the Company expects that none would have a significant impact on its consolidated financial statements.
XML 16 R6.htm IDEA: XBRL DOCUMENT v3.4.0.3
ACCOUNTS RECEIVABLE
6 Months Ended
Mar. 31, 2016
Receivables [Abstract]  
Accounts Receivable
ACCOUNTS RECEIVABLE
Accounts receivable, net of allowances for sales returns and doubtful accounts, consisted of the following:
 
March 31,
2016
 
September 30,
2015
Accounts receivable
$
20,344

 
$
17,882

Less allowances
(1,067
)
 
(1,084
)
 
$
19,277

 
$
16,798

XML 17 R7.htm IDEA: XBRL DOCUMENT v3.4.0.3
INVENTORIES
6 Months Ended
Mar. 31, 2016
Inventory Disclosure [Abstract]  
Inventories
INVENTORIES
Inventories were comprised of the following:
 
March 31,
2016
 
September 30,
2015
Raw materials
$
26,508

 
$
23,106

Work-in-process
11,576

 
9,755

Finished goods
23,407

 
26,579

 
$
61,491

 
$
59,440

XML 18 R8.htm IDEA: XBRL DOCUMENT v3.4.0.3
ACQUISITIONS
6 Months Ended
Mar. 31, 2016
Business Combinations [Abstract]  
Acquisitions
ACQUISITIONS
During the six months ended March 31, 2016, the Company made two acquisitions of businesses. On October 6, 2015, the Company acquired certain operating assets of Dynamic Health Laboratories, Inc. ("Dynamic Health"). On February 18, 2016, the Company acquired certain operating assets of Aubrey Organics, Inc. ("Aubrey Organics"). The aggregate purchase price of these acquisitions was $26,235 in cash.
During the six months ended March 31, 2015, the Company made one acquisition of a business. On November 18, 2014, the Company acquired certain operating assets of Agape Health Products for $81 in cash.
These acquisitions are in keeping with the Company's business strategy of consolidating the fragmented industry in which it competes. These acquisitions were accounted for using the acquisition method of accounting. Accordingly, the purchase price was assigned to the assets acquired based on their fair values at their respective dates of acquisition. The excess of purchase price over the fair values of the assets acquired was classified as goodwill. The goodwill relates to expected synergies from these acquisitions. The following reflects the preliminary allocation of the purchase prices for the fiscal 2016 acquisitions and the final allocation of the purchase price for the fiscal 2015 acquisition to the assets acquired:
 
Fiscal 2016 Acquisition - Dynamic Health
 
Fiscal 2016 Acquisition - Aubrey Organics
 
Fiscal 2015 Acquisition
Assets acquired:
 

 
 

 
 

Current assets
$
3,821

 
$
755

 
$
41

Property, plant and equipment
644

 
6,004

 

Goodwill
6,541

 

 

Intangible assets
8,020

 
450

 
40

 
$
19,026

 
$
7,209

 
$
81


The fiscal 2016 and fiscal 2015 acquired intangible assets totaling $8,470 and $40, respectively, related to trademarks, tradenames and customer relationships, and are being amortized over periods of six to fifteen years for financial statement purposes. The fiscal 2016 and fiscal 2015 acquired intangible assets are expected to be deductible for tax purposes over fifteen years. Goodwill of $6,541 for fiscal 2016 is not subject to amortization for financial statement purposes and is expected to be deductible for tax purposes over fifteen years.
The Condensed Consolidated Statements of Comprehensive Income and the Condensed Consolidated Statements of Cash Flows presented herein include the activities of these acquired businesses from their respective dates of acquisition. The expected long-term sales and expense synergies of acquired businesses generally are not realized immediately following acquisition, as certain transition and integration matters must be completed.
Since the date of acquisition (October 6, 2015), net sales of $8,355 and gross profit of $3,207 for Dynamic Health were included in the Condensed Consolidated Statements of Comprehensive Income for the six months ended March 31, 2016. The Company tracks selling, general and administrative expenses on a consolidated basis, not on a brand-by-brand basis. As a result, the disclosure of any results after gross profit is impracticable. The following table provides unaudited pro forma information for the three and six months ended March 31, 2015, as if the acquisition of Dynamic Health had been completed on October 1, 2014. Pro forma information was not provided for the three and six months ended March 31, 2016 since the acquisition was completed near the beginning of these periods and the pro forma results are not materially different than actual results. The information has been provided for illustrative purposes only and is not necessarily indicative of the actual results that would have been achieved by the Company for the periods presented or that will be achieved in the future. The pro forma information has been adjusted to give effect to items directly attributable to the Dynamic Health acquisition. These adjustments include acquisition costs, amortization expense associated with acquired intangible assets, interest expense associated with borrowings on the Company's revolving credit facility to fund the acquisition, application of the Company's depreciable lives policy for property, plant and equipment, elimination of intercompany transactions and any consequential tax effects.
 
Three Months Ended
March 31, 2015
 
Six Months Ended
March 31, 2015
Net sales
$
59,970

 
$
117,591

Net income
$
4,161

 
$
7,580


This information has not been adjusted to reflect any changes in the operations of the business subsequent to acquisition. Changes in the operations of the acquired business may include, but are not limited to, discontinuation of certain customers and/or products, application of the Company's pricing and credit policies, integration of systems and personnel, changes in manufacturing processes, relocation of facilities, potential cost synergies and changes in marketing and sales programs. Due to these changes, future results could be materially different than the pro forma information provided.
The actual and pro forma net sales and earnings related to the Aubrey Organics acquisition were not material.
XML 19 R9.htm IDEA: XBRL DOCUMENT v3.4.0.3
GOODWILL AND INTANGIBLE ASSETS
6 Months Ended
Mar. 31, 2016
Goodwill and Intangible Assets Disclosure [Abstract]  
Goodwill and Intangible Assets
GOODWILL AND INTANGIBLE ASSETS
The change in the carrying amount of goodwill from September 30, 2015 to March 31, 2016 was as follows:
 
Goodwill
 
Accumulated
Impairment
 
Net
Balance as of September 30, 2015
$
64,778

 
$
(40,394
)
 
$
24,384

Goodwill attributable to fiscal 2016 acquisitions
6,541

 

 
6,541

Balance as of March 31, 2016
$
71,319

 
$
(40,394
)
 
$
30,925


The carrying amounts of intangible assets at March 31, 2016 and September 30, 2015 were as follows:
 
March 31, 2016
 
September 30, 2015
 
Weighted-
Average
Amortization
Period
(Years)
 
Gross
Carrying
Amount (1)
 
Accumulated
Amortization (1)
 
Net
Carrying
Amount
 
Gross
Carrying
Amount (1)
 
Accumulated
Amortization (1)
 
Net
Carrying
Amount
 
Intangible assets subject to amortization:
 

 
 

 
 

 
 

 
 

 
 

 
 
Trademarks/tradenames/licenses
$
13,893

 
$
(2,587
)
 
$
11,306

 
$
12,470

 
$
(1,966
)
 
$
10,504

 
11
Customer relationships/non-compete agreements
23,975

 
(11,133
)
 
12,842

 
16,836

 
(9,773
)
 
7,063

 
7
Developed software and technology
772

 
(772
)
 

 
772

 
(772
)
 

 
5
 
38,640

 
(14,492
)
 
24,148

 
30,078

 
(12,511
)
 
17,567

 
 
Intangible assets not subject to amortization:
 

 
 

 
 

 
 

 
 

 
 

 
 
Trademarks/tradenames/licenses

 

 

 
38

 

 
38

 
 
 
$
38,640

 
$
(14,492
)
 
$
24,148

 
$
30,116

 
$
(12,511
)
 
$
17,605

 
 
(1) Amounts include the impact of foreign currency translation adjustments.
Estimated future amortization expense related to the March 31, 2016 net carrying amount of $24,148 for intangible assets subject to amortization is as follows:
Year Ending September 30,
Estimated
Amortization
Expense
2016(1)
$
1,944

2017
3,582

2018
3,391

2019
2,964

2020
2,875

Thereafter
9,392

 
$
24,148


(1)
Estimated amortization expense for the year ending September 30, 2016 includes only amortization to be recorded after March 31, 2016.
General and economic conditions may impact retail and consumer demand, as well as the market price of the Company's common stock, and could negatively impact the Company's future operating performance, cash flow and/or stock price and could result in goodwill and/or intangible asset impairment charges being recorded in future periods. Also, the Company periodically reviews its brands to achieve marketing, sales and operational synergies. These reviews could result in brands being consolidated or discontinued and could result in intangible asset impairment charges being recorded in future periods. Goodwill and/or intangible asset impairment charges could materially impact the Company's consolidated financial statements. The valuation of goodwill and intangible assets is subject to a high degree of judgment, uncertainty and complexity.
XML 20 R10.htm IDEA: XBRL DOCUMENT v3.4.0.3
DEBT
6 Months Ended
Mar. 31, 2016
Debt Disclosure [Abstract]  
Debt
DEBT
Debt was comprised of the following:
 
March 31,
2016
 
September 30,
2015
Long-term debt—revolving credit facility
$
47,500

 
$
31,500


The carrying value of the Company's debt approximates fair value at March 31, 2016 and September 30, 2015. Estimated fair values for debt have been determined based on borrowing rates currently available to the Company for bank loans with similar terms and maturities and are classified as Level 2 (significant observable inputs other than quoted prices) in the FASB's fair value hierarchy.
On November 4, 2014, the Company amended its revolving credit facility (the "Credit Agreement"). The Credit Agreement extends the term of the credit facility to November 2019, increases the available credit borrowings to $100,000 with no automatic reductions and provides an accordion feature that can increase the available credit borrowings to $130,000, subject to approval by the lenders and compliance with certain covenants and conditions. The lenders under the Credit Agreement continue to be Rabobank International and Wells Fargo. To date, the Company has not experienced any difficulties in accessing the available funds under the Credit Agreement. Deferred financing fees of $420 related to the Credit Agreement are being amortized over the term of the Credit Agreement.
At March 31, 2016, the Company had outstanding revolving credit borrowings of $47,500 under the Credit Agreement. Borrowings under the Credit Agreement are collateralized by substantially all assets of the Company. At the Company's election, borrowings bear interest at the applicable Eurodollar Rate plus a variable margin or at a Base Rate plus a variable margin. Base Rate is the higher of: (i) the Prime Lending Rate, (ii) the Federal Funds Rate plus 0.5% or (iii) the one-month Eurodollar Rate multiplied by the Statutory Reserve Rate plus 1.0% (capitalized terms are defined in the Credit Agreement, a copy of which was filed with the Securities and Exchange Commission on November 5, 2014). At March 31, 2016, the applicable weighted-average interest rate for outstanding borrowings was 2.12%. The Company is also required to pay a variable quarterly fee on the unused balance under the Credit Agreement. At March 31, 2016, the applicable rate was 0.25%. Accrued interest on Eurodollar Rate borrowings is payable based on elected intervals of one, two or three months. Accrued interest on Base Rate borrowings is payable quarterly. The Credit Agreement matures on November 4, 2019, and the Company is required to repay all principal and interest outstanding under the Credit Agreement on such date.
The Credit Agreement contains restrictive covenants, including limitations on incurring other indebtedness and requirements that the Company maintain certain financial ratios. As of March 31, 2016, the Company was in compliance with the restrictive covenants. Upon the occurrence of a default, the lender has various remedies or rights, which may include proceeding against the collateral or requiring the Company to repay all amounts outstanding under the Credit Agreement.
XML 21 R11.htm IDEA: XBRL DOCUMENT v3.4.0.3
SHARE PURCHASES
6 Months Ended
Mar. 31, 2016
Stockholders' Equity Note [Abstract]  
Share Purchases
SHARE PURCHASES
During the three and six months ended March 31, 2016, the Company purchased 80,529 and 145,940 shares of common stock for an aggregate price of $1,962 and $3,566, respectively. During the three and six months ended March 31, 2015, the Company purchased 68,463 and 117,025 shares of common stock for an aggregate price of $1,278 and $2,352, respectively. All of these shares of common stock held in treasury were retired prior to March 31 in the respective quarter of purchase, except at March 31, 2016 and 2015, the Company held 3,354 and 2,000 shares of common stock in treasury. As of March 31, 2016, the Company was permitted to purchase up to 335,321 additional shares under its approved purchase plan, with no expiration date or restrictions. The Company accounts for treasury shares using the cost method.
XML 22 R12.htm IDEA: XBRL DOCUMENT v3.4.0.3
STOCK OPTIONS AND OTHER EQUITY AWARDS
6 Months Ended
Mar. 31, 2016
Equity [Abstract]  
Stock Options and Other Equity Awards
STOCK OPTIONS AND OTHER EQUITY AWARDS
As of March 31, 2016, the Company had no outstanding options to purchase shares of common stock, as all previously issued options were exercised or expired prior to September 30, 2015.
During the six months ended March 31, 2015, the Company received proceeds of $9 related to the exercise of stock options. During this same period, the Company recorded a tax benefit of $1and optionees realized an aggregate pre-tax gain of $3 from these stock option exercises.
No options to purchase shares of common stock for the three and six months ended March 31, 2015 were excluded from the computation of diluted earnings per share because none of the stock options were anti-dilutive.
On January 28, 2013, stockholders approved the Nutraceutical International Corporation 2013 Long-Term Equity Incentive Plan (the "2013 Plan") and the reservation of 800,000 shares of the Company's common stock for issuance under the 2013 Plan. Equity awards available under the 2013 Plan include stock options, stock appreciation rights and stock awards. In conjunction with the Company's fiscal 2015 and fiscal 2014 incentive compensation (bonus) payments, 22,664 and 24,827 shares of the Company's common stock were issued, respectively. These non-cash stock awards were granted on December 11, 2015 and December 11, 2014 at an aggregate fair value of $556 and $504, respectively, with fair value being determined by the closing price of the Company's common stock on the grant date. These stock awards were registered, unrestricted and fully vested on the grant date. As of March 31, 2016, 720,721 shares of the Company's common stock were available for issuance under the 2013 Plan.
XML 23 R13.htm IDEA: XBRL DOCUMENT v3.4.0.3
SEGMENTS
6 Months Ended
Mar. 31, 2016
Segment Reporting [Abstract]  
Segments
SEGMENTS
Segment identification and selection is consistent with the management structure used by the Company's chief operating decision maker to evaluate performance and make decisions regarding resource allocation, as well as the materiality of financial results consistent with that structure. Based on the Company's management structure and method of internal reporting, the Company has one operating segment. The Company's chief operating decision maker does not review operating results on a disaggregated basis; rather, the chief operating decision maker reviews operating results on an aggregate basis.
Net sales attributed to customers in the United States and foreign countries for the three and six months ended March 31, 2016 and 2015 were as follows:
 
Three Months Ended
March 31,
 
Six Months Ended
March 31,
 
2016
 
2015
 
2016
 
2015
United States
$
52,350

 
$
48,807

 
$
102,400

 
$
95,532

Foreign countries
7,142

 
6,597

 
13,051

 
12,916

 
$
59,492

 
$
55,404

 
$
115,451

 
$
108,448


Certain net sales attributed to customers in the United States are sold to customers who in turn may sell such products to customers in foreign countries, while certain net sales attributed to customers in foreign countries are sold to customers who in turn may sell such products to customers in the United States.
The Company's net sales by product group for the three and six months ended March 31, 2016 and 2015 were as follows:
 
Three Months Ended
March 31,
 
Six Months Ended
March 31,
 
2016
 
2015
 
2016
 
2015
Branded nutritional supplements and other natural products
$
53,687

 
$
49,102

 
$
104,186

 
$
96,190

Other(1)
5,805

 
6,302

 
11,265

 
12,258

 
$
59,492

 
$
55,404

 
$
115,451

 
$
108,448


(1)
Net sales for any other product or group of similar products are less than 10% of consolidated net sales.
In October 2015, the Company made a decision to classify certain net sales in the other product group that were previously included in the branded nutritional supplements and other natural products group. As a result of this decision, the other product group net sales amount for the three and six months ended March 31, 2015 has been increased by $781 and $1,570, respectively, from the prior year's presentation.
XML 24 R14.htm IDEA: XBRL DOCUMENT v3.4.0.3
BASIS OF PRESENTATION (Policies)
6 Months Ended
Mar. 31, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Basis of Presentation
In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all necessary adjustments, consisting of normal recurring adjustments, to state fairly the consolidated financial position of the Company as of March 31, 2016, the results of its operations for the three and six months ended March 31, 2016 and 2015 and its cash flows for the six months ended March 31, 2016 and 2015, in conformity with accounting principles generally accepted in the United States of America ("US GAAP") for interim financial information applied on a consistent basis. Results for the three and six months ended March 31, 2016 are not necessarily indicative of the results to be expected for the full fiscal year.
Certain information and footnote disclosures normally included in the annual financial statements prepared in accordance with US GAAP have been omitted. Accordingly, these financial statements should be read in conjunction with the Company's Form 10-K for the fiscal year ended September 30, 2015, which was filed with the Securities and Exchange Commission on November 19, 2015.
Use of Estimates
Use of Estimates
The preparation of these financial statements in conformity with US GAAP required management to make estimates and assumptions that affected the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements and the reported amounts of net sales and expenses during the reported periods. Significant estimates included values and lives assigned to acquired intangible assets, reserves for customer returns and allowances, uncollectible accounts receivable, valuation adjustments for slow-moving, obsolete and/or damaged inventory and valuation and recoverability of long-lived assets. Actual results may differ from these estimates.
New Accounting Standards
New Accounting Standards
In February 2016, the Financial Accounting Standards Board ("FASB") issued authoritative guidance, which is included in Accounting Standards Codification ("ASC") 842, "Leases." This guidance requires lessees to recognize most leases on the balance sheet by recording a right-of-use asset and a lease liability. This guidance is effective for the Company as of October 1, 2019. The Company is currently evaluating the impact this standard may have on its consolidated financial statements.
In November 2015, the FASB issued authoritative guidance, which is included in ASC 740, "Income Taxes." This guidance simplifies the presentation of deferred income taxes and requires that deferred tax assets and liabilities be classified as noncurrent in the classified statement of financial position. This guidance is effective for the Company as of October 1, 2017 and is not expected to have a material impact on the consolidated financial statements as the guidance only changes the classification of deferred income taxes.
In September 2015, the FASB issued authoritative guidance, which is included in ASC 805, "Business Combinations." This guidance simplifies the accounting for measurement-period adjustments and is effective for the Company as of October 1, 2016. The Company does not expect this guidance to have a material impact on its consolidated financial statements.
In July 2015, the FASB issued authoritative guidance, which is included in ASC 330, "Inventory." This guidance simplifies the accounting for measuring inventory at the lower of cost and net realizable value and is effective for the Company as of October 1, 2017. The Company does not expect this guidance to have a material impact on its consolidated financial statements.
In May 2014, the FASB issued authoritative guidance, which is included in ASC 606, "Revenue from Contracts with Customers." This guidance provides a single, comprehensive revenue recognition model for all contracts with customers and requires that a company recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. In July 2015, the FASB delayed the effective date of this guidance by one year. As a result, this guidance is effective for the Company as of October 1, 2018 and shall be applied either retrospectively to each period presented or as a cumulative-effect adjustment as of the date of adoption. The Company is currently evaluating the impact this standard may have on its consolidated financial statements.
The Company periodically reviews new accounting standards that are issued. Although some of these accounting standards may be applicable to the Company, the Company has not identified any other new standards that it believes merit further discussion, and the Company expects that none would have a significant impact on its consolidated financial statements.
XML 25 R15.htm IDEA: XBRL DOCUMENT v3.4.0.3
ACCOUNTS RECEIVABLE (Tables)
6 Months Ended
Mar. 31, 2016
Receivables [Abstract]  
Schedule of accounts receivable, net of allowances for sales returns and doubtful accounts
Accounts receivable, net of allowances for sales returns and doubtful accounts, consisted of the following:
 
March 31,
2016
 
September 30,
2015
Accounts receivable
$
20,344

 
$
17,882

Less allowances
(1,067
)
 
(1,084
)
 
$
19,277

 
$
16,798

XML 26 R16.htm IDEA: XBRL DOCUMENT v3.4.0.3
INVENTORIES (Tables)
6 Months Ended
Mar. 31, 2016
Inventory Disclosure [Abstract]  
Schedule of inventories
Inventories were comprised of the following:
 
March 31,
2016
 
September 30,
2015
Raw materials
$
26,508

 
$
23,106

Work-in-process
11,576

 
9,755

Finished goods
23,407

 
26,579

 
$
61,491

 
$
59,440

XML 27 R17.htm IDEA: XBRL DOCUMENT v3.4.0.3
ACQUISITIONS (Tables)
6 Months Ended
Mar. 31, 2016
Business Combinations [Abstract]  
Schedule of preliminary allocation of the aggregate purchase price for the acquisitions to the aggregate assets acquired
The following reflects the preliminary allocation of the purchase prices for the fiscal 2016 acquisitions and the final allocation of the purchase price for the fiscal 2015 acquisition to the assets acquired:
 
Fiscal 2016 Acquisition - Dynamic Health
 
Fiscal 2016 Acquisition - Aubrey Organics
 
Fiscal 2015 Acquisition
Assets acquired:
 

 
 

 
 

Current assets
$
3,821

 
$
755

 
$
41

Property, plant and equipment
644

 
6,004

 

Goodwill
6,541

 

 

Intangible assets
8,020

 
450

 
40

 
$
19,026

 
$
7,209

 
$
81

Schedule of unaudited pro forma information
 
Three Months Ended
March 31, 2015
 
Six Months Ended
March 31, 2015
Net sales
$
59,970

 
$
117,591

Net income
$
4,161

 
$
7,580

XML 28 R18.htm IDEA: XBRL DOCUMENT v3.4.0.3
GOODWILL AND INTANGIBLE ASSETS (Tables)
6 Months Ended
Mar. 31, 2016
Goodwill and Intangible Assets Disclosure [Abstract]  
Schedule of changes in the carrying amount of goodwill
The change in the carrying amount of goodwill from September 30, 2015 to March 31, 2016 was as follows:
 
Goodwill
 
Accumulated
Impairment
 
Net
Balance as of September 30, 2015
$
64,778

 
$
(40,394
)
 
$
24,384

Goodwill attributable to fiscal 2016 acquisitions
6,541

 

 
6,541

Balance as of March 31, 2016
$
71,319

 
$
(40,394
)
 
$
30,925

Schedule of carrying amounts of intangible assets
The carrying amounts of intangible assets at March 31, 2016 and September 30, 2015 were as follows:
 
March 31, 2016
 
September 30, 2015
 
Weighted-
Average
Amortization
Period
(Years)
 
Gross
Carrying
Amount (1)
 
Accumulated
Amortization (1)
 
Net
Carrying
Amount
 
Gross
Carrying
Amount (1)
 
Accumulated
Amortization (1)
 
Net
Carrying
Amount
 
Intangible assets subject to amortization:
 

 
 

 
 

 
 

 
 

 
 

 
 
Trademarks/tradenames/licenses
$
13,893

 
$
(2,587
)
 
$
11,306

 
$
12,470

 
$
(1,966
)
 
$
10,504

 
11
Customer relationships/non-compete agreements
23,975

 
(11,133
)
 
12,842

 
16,836

 
(9,773
)
 
7,063

 
7
Developed software and technology
772

 
(772
)
 

 
772

 
(772
)
 

 
5
 
38,640

 
(14,492
)
 
24,148

 
30,078

 
(12,511
)
 
17,567

 
 
Intangible assets not subject to amortization:
 

 
 

 
 

 
 

 
 

 
 

 
 
Trademarks/tradenames/licenses

 

 

 
38

 

 
38

 
 
 
$
38,640

 
$
(14,492
)
 
$
24,148

 
$
30,116

 
$
(12,511
)
 
$
17,605

 
 
(1) Amounts include the impact of foreign currency translation adjustments.
Schedule of estimated amortization expense related to intangible assets subject to amortization
Estimated future amortization expense related to the March 31, 2016 net carrying amount of $24,148 for intangible assets subject to amortization is as follows:
Year Ending September 30,
Estimated
Amortization
Expense
2016(1)
$
1,944

2017
3,582

2018
3,391

2019
2,964

2020
2,875

Thereafter
9,392

 
$
24,148


(1)
Estimated amortization expense for the year ending September 30, 2016 includes only amortization to be recorded after March 31, 2016.
XML 29 R19.htm IDEA: XBRL DOCUMENT v3.4.0.3
DEBT (Tables)
6 Months Ended
Mar. 31, 2016
Debt Disclosure [Abstract]  
Schedule of debt
Debt was comprised of the following:
 
March 31,
2016
 
September 30,
2015
Long-term debt—revolving credit facility
$
47,500

 
$
31,500

XML 30 R20.htm IDEA: XBRL DOCUMENT v3.4.0.3
SEGMENTS (Tables)
6 Months Ended
Mar. 31, 2016
Segment Reporting [Abstract]  
Schedule of net sales attributed to customers in the United States and foreign countries
Net sales attributed to customers in the United States and foreign countries for the three and six months ended March 31, 2016 and 2015 were as follows:
 
Three Months Ended
March 31,
 
Six Months Ended
March 31,
 
2016
 
2015
 
2016
 
2015
United States
$
52,350

 
$
48,807

 
$
102,400

 
$
95,532

Foreign countries
7,142

 
6,597

 
13,051

 
12,916

 
$
59,492

 
$
55,404

 
$
115,451

 
$
108,448

Schedule of net sales by product group
The Company's net sales by product group for the three and six months ended March 31, 2016 and 2015 were as follows:
 
Three Months Ended
March 31,
 
Six Months Ended
March 31,
 
2016
 
2015
 
2016
 
2015
Branded nutritional supplements and other natural products
$
53,687

 
$
49,102

 
$
104,186

 
$
96,190

Other(1)
5,805

 
6,302

 
11,265

 
12,258

 
$
59,492

 
$
55,404

 
$
115,451

 
$
108,448


(1)
Net sales for any other product or group of similar products are less than 10% of consolidated net sales.
XML 31 R21.htm IDEA: XBRL DOCUMENT v3.4.0.3
ACCOUNTS RECEIVABLE (Details) - USD ($)
$ in Thousands
Mar. 31, 2016
Sep. 30, 2015
Receivables [Abstract]    
Accounts receivable $ 20,344 $ 17,882
Less allowances (1,067) (1,084)
Accounts receivable, net $ 19,277 $ 16,798 [1]
[1] The condensed consolidated balance sheet as of September 30, 2015 has been prepared using information from the audited financial statements at that date.
XML 32 R22.htm IDEA: XBRL DOCUMENT v3.4.0.3
INVENTORIES (Details) - USD ($)
$ in Thousands
Mar. 31, 2016
Sep. 30, 2015
Inventory Disclosure [Abstract]    
Raw materials $ 26,508 $ 23,106
Work-in-process 11,576 9,755
Finished goods 23,407 26,579
Inventories $ 61,491 $ 59,440 [1]
[1] The condensed consolidated balance sheet as of September 30, 2015 has been prepared using information from the audited financial statements at that date.
XML 33 R23.htm IDEA: XBRL DOCUMENT v3.4.0.3
ACQUISITIONS (Details)
$ in Thousands
3 Months Ended 6 Months Ended 12 Months Ended
Nov. 18, 2014
USD ($)
Mar. 31, 2016
USD ($)
Mar. 31, 2015
USD ($)
Mar. 31, 2016
USD ($)
acquisition
Mar. 31, 2015
USD ($)
acquisition
Sep. 30, 2015
USD ($)
ACQUISITIONS            
Number of business acquisitions | acquisition       2 1  
Expected period for deduction of acquired intangible assets for tax purposes       15 years 15 years  
Business acquisition goodwill amount   $ 6,541   $ 6,541    
Expected period for deduction of acquired goodwill for tax purposes (years)       15 years    
Net sales   59,492 $ 55,404 $ 115,451 $ 108,448  
Gross profit   30,329 27,255 58,437 53,110  
Assets acquired:            
Goodwill   30,925   $ 30,925   $ 24,384 [1]
Minimum            
ACQUISITIONS            
Amortization period       6 years   6 years
Maximum            
ACQUISITIONS            
Amortization period       15 years   15 years
Acquisitions            
ACQUISITIONS            
Aggregate purchase price in cash $ 81     $ 26,235    
Assets acquired:            
Current assets           $ 41
Property, plant and equipment           0
Goodwill           0
Intangible assets   8,470   8,470   40
Aggregate purchase price           $ 81
Dynamic Health Laboratories Inc.            
ACQUISITIONS            
Net sales       8,355    
Gross profit       3,207    
Assets acquired:            
Current assets   3,821   3,821    
Property, plant and equipment   644   644    
Goodwill   6,541   6,541    
Intangible assets   8,020   8,020    
Aggregate purchase price   19,026   19,026    
Unaudited pro forma information            
Net sales     59,970   117,591  
Net income     $ 4,161   $ 7,580  
Aubrey Organics            
Assets acquired:            
Current assets   755   755    
Property, plant and equipment   6,004   6,004    
Goodwill   0   0    
Intangible assets   450   450    
Aggregate purchase price   $ 7,209   $ 7,209    
[1] The condensed consolidated balance sheet as of September 30, 2015 has been prepared using information from the audited financial statements at that date.
XML 34 R24.htm IDEA: XBRL DOCUMENT v3.4.0.3
GOODWILL AND INTANGIBLE ASSETS (Schedule of Goodwill) (Details)
$ in Thousands
6 Months Ended
Mar. 31, 2016
USD ($)
Goodwill [Roll Forward]  
Goodwill, Balance as of September 30, 2015 $ 64,778
Accumulated Impairment, Balance as of September 30, 2015 (40,394)
Goodwill, net, Balance as of September 30, 2015 24,384 [1]
Goodwill attributable to fiscal 2016 acquisitions 6,541
Goodwill, Accumulated Impairment 0
Goodwill, Balance as of March 1, 2016 71,319
Accumulated Impairment, Balance as of March 31, 2016 (40,394)
Goodwill, net, Balance as of March 31, 2016 $ 30,925
[1] The condensed consolidated balance sheet as of September 30, 2015 has been prepared using information from the audited financial statements at that date.
XML 35 R25.htm IDEA: XBRL DOCUMENT v3.4.0.3
GOODWILL AND INTANGIBLE ASSETS (Carrying Amounts of Intangible Assets) (Details) - USD ($)
$ in Thousands
6 Months Ended
Mar. 31, 2016
Sep. 30, 2015
Intangible assets subject to amortization:    
Gross Carrying Amount $ 38,640 $ 30,078
Accumulated Amortization (14,492) (12,511)
Net Carrying Amount 24,148 17,567
Total intangible assets    
Gross Carrying Amount 38,640 30,116
Accumulated Amortization (14,492) (12,511)
Net Carrying Amount 24,148 17,605 [1]
Trademarks/tradenames/licenses    
Intangible assets not subject to amortization:    
Carrying Amount 0 38
Trademarks/tradenames/licenses    
Intangible assets subject to amortization:    
Gross Carrying Amount 13,893 12,470
Accumulated Amortization (2,587) (1,966)
Net Carrying Amount $ 11,306 10,504
Weighted- Average Amortization Period (Years) 11 years  
Total intangible assets    
Accumulated Amortization $ (2,587) (1,966)
Customer relationships/non-compete agreements    
Intangible assets subject to amortization:    
Gross Carrying Amount 23,975 16,836
Accumulated Amortization (11,133) (9,773)
Net Carrying Amount $ 12,842 7,063
Weighted- Average Amortization Period (Years) 7 years  
Total intangible assets    
Accumulated Amortization $ (11,133) (9,773)
Developed software and technology    
Intangible assets subject to amortization:    
Gross Carrying Amount 772 772
Accumulated Amortization (772) (772)
Net Carrying Amount $ 0 0
Weighted- Average Amortization Period (Years) 5 years  
Total intangible assets    
Accumulated Amortization $ (772) $ (772)
[1] The condensed consolidated balance sheet as of September 30, 2015 has been prepared using information from the audited financial statements at that date.
XML 36 R26.htm IDEA: XBRL DOCUMENT v3.4.0.3
GOODWILL AND INTANGIBLE ASSETS (Schedule of Estimated Future Amortization Expense) (Details) - USD ($)
$ in Thousands
Mar. 31, 2016
Sep. 30, 2015
Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]    
2016 $ 1,944  
2017 3,582  
2018 3,391  
2019 2,964  
2020 2,875  
Thereafter 9,392  
Net Carrying Amount $ 24,148 $ 17,567
XML 37 R27.htm IDEA: XBRL DOCUMENT v3.4.0.3
DEBT (Details) - USD ($)
6 Months Ended
Mar. 31, 2016
Sep. 30, 2015
[1]
Nov. 04, 2014
Debt Instruments [Line Items]      
Long-term debt—revolving credit facility $ 47,500,000 $ 31,500,000  
Statutory Reserve Rate      
Debt Instruments [Line Items]      
Reference rate one-month Eurodollar Rate    
Margin over reference rate (as a percent) 1.00%    
Restated Credit Agreement      
Debt Instruments [Line Items]      
Available credit borrowings     $ 100,000,000
Deferred financing cost     420,000
Outstanding revolving credit borrowings $ 47,500,000    
Weighted-average interest rate (as a percent) 2.12%    
Quarterly fee on the unused balance (as a percent) 0.25%    
Restated Credit Agreement | Eurodollar Rate      
Debt Instruments [Line Items]      
Reference rate Eurodollar Rate    
Interval for payment of accrued interest under option one 1 month    
Interval for payment of accrued interest under option two 2 months    
Interval for payment of accrued interest under option three 3 months    
Restated Credit Agreement | Prime Lending Rate      
Debt Instruments [Line Items]      
Reference rate Prime Lending Rate    
Restated Credit Agreement | Federal Funds Rate      
Debt Instruments [Line Items]      
Reference rate Federal Funds Rate    
Margin over reference rate (as a percent) 0.50%    
Credit Agreement, accordion feature      
Debt Instruments [Line Items]      
Available credit borrowings     $ 130,000,000
[1] The condensed consolidated balance sheet as of September 30, 2015 has been prepared using information from the audited financial statements at that date.
XML 38 R28.htm IDEA: XBRL DOCUMENT v3.4.0.3
SHARE PURCHASES (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Mar. 31, 2016
Mar. 31, 2015
Mar. 31, 2016
Mar. 31, 2015
Share purchases        
Additional number of shares authorized to be repurchased (in shares) 335,321   335,321  
Common Stock        
Share purchases        
Shares of common stock purchased (in shares) 80,529 68,463 145,940 117,025
Aggregate price at which shares of common stock purchased $ 1,962 $ 1,278 $ 3,566 $ 2,352
Treasury stock (in shares) 3,354 2,000 3,354 2,000
XML 39 R29.htm IDEA: XBRL DOCUMENT v3.4.0.3
STOCK OPTIONS AND OTHER EQUITY AWARDS (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2015
Mar. 31, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Proceeds from Stock Options exercised $ 9  
Tax benefit realized from exercise of stock options 1  
Gain on exercise of stock options by optionees $ 3  
Stock options    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Options outstanding (in shares)   0
XML 40 R30.htm IDEA: XBRL DOCUMENT v3.4.0.3
STOCK OPTIONS AND OTHER EQUITY AWARDS (Details 2) - shares
3 Months Ended 6 Months Ended
Mar. 31, 2015
Mar. 31, 2015
Stock options    
Antidilutive securities    
Anti-dilutive stock options (in shares) 0 0
XML 41 R31.htm IDEA: XBRL DOCUMENT v3.4.0.3
STOCK OPTIONS AND OTHER EQUITY AWARDS (Details 3) - 2013 Plan - USD ($)
$ in Thousands
12 Months Ended
Dec. 11, 2015
Dec. 11, 2014
Sep. 30, 2015
Sep. 30, 2014
Mar. 31, 2016
Jan. 28, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
Shares of common stock reserved for issuance (in shares)           800,000
Equity compensation payments (in shares)     22,664 24,827    
Equity compensation payments $ 556 $ 504        
Shares of common stock available for issuance (in shares)         720,721  
XML 42 R32.htm IDEA: XBRL DOCUMENT v3.4.0.3
SEGMENTS (Details)
$ in Thousands
3 Months Ended 6 Months Ended
Mar. 31, 2016
USD ($)
Mar. 31, 2015
USD ($)
Mar. 31, 2016
USD ($)
segment
Mar. 31, 2015
USD ($)
Segment Reporting [Abstract]        
Number of operating segments | segment     1  
SEGMENTS        
Net sales $ 59,492 $ 55,404 $ 115,451 $ 108,448
Branded nutritional supplements and other natural products        
SEGMENTS        
Net sales 53,687 49,102 104,186 96,190
Other        
SEGMENTS        
Net sales 5,805 6,302 11,265 12,258
Increase in product group net sales from prior year due to classify certain net sales   781   1,570
United States        
SEGMENTS        
Net sales 52,350 48,807 102,400 95,532
Foreign countries        
SEGMENTS        
Net sales $ 7,142 $ 6,597 $ 13,051 $ 12,916
EXCEL 43 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( /QLG$AFZG*XK@$ 'D5 3 6T-O;G1E;G1?5'EP97-= M+GAM;,V8RV[",!!%?P5E6Q%CIZ4/ 9O2;8O4_H";3(A%'%NV"?#WM0-4;916 MT!)I-GEPQW-O,LY9,'G;:;"#K2PK.XT*Y_0#(38M0'(;*PV55W)E)'?^UBR) MYNF*+X&PT6A,4E4YJ-S0A1[1;/)2@S$B@\'C7@B]IQ'7NA0I=T)5I*ZR5M>A MRG.10J;2M?1+8N>MXM2[% *P( L !?.0Q(OW[CMB PD.MQ-*O>X^NO ZIK XTHO8<4M?'5$Q^#*G* M_=ITJK$"2+8CCVG!D4*>-BP>-9?20D0[8$NP+,L5R*V.V:SGVL7.U49V[M,4 M1Y26M#;3"&>6X9MY6&3I//B)]!=C;IK>TI;MR5/0!_ZS#0//>997'L=V+YRO M+0O]C^AY%.!)T:'B1?4C9@,2[2F]@OIZ (4QOCLEFI2"(S>C@KN_V/P"4$L# M!!0 ( /QLG$@L!2\7>@$ %T4 : >&PO7W)E;',O=V]R:V)O;VLN M>&UL+G)E;'/%V$MJPS 0QO&K!!^@\HSR)LFJFVS;7D X$]LD?B"IM+E]72^* M^]#01>#;V-B"T7]A?@COVI!OG^3J8MVUH:K[,'MOKFW8#N_W615COS4F%)4T M+CQTO;3#ZKGSC8O#HR]-[XJ+*\5PGB^-G\[)#KN?LV?'TS[SQQ-ELQ?G2XG[ M[*WSEU")Q&#&&ST,&PS+MU[^LWUW/M>%/';%:R-M_*/"?&V0F700IX,8$F33 M0182-$\'S2%!BW30 A*T3 MC-&;%;T9=-;6#ML8O5G1FS%ZLZ(W8_1F16_&Z,V*WHS1FQ6]&:,W*WHS1F]6 M]&:,WE;1VV+TMHK>%J.W5?2VH'\E$[U#Y;R(MZO< M/V6&ULO59-<]HP$/TK&D[IH3&!-#-E MB&>,K09/B>TB0Z9'Q1:@B9$\DL(D_?5=VX$:8DS"H5Q8K=[;C[>+S5#H[B!2 M,F?*<*;1RSH3>@#.V\[*F'Q@63I9L375EP 1<+N0:DT-'-72DHL%3Y@GD^Q[GBBIY<(@_)*P;&@= DH& M1"8L>5;T$RS"O7/66)+6JTX2+)SW+8^E1 MP^JL_8LJ^HHJED+2O>@[9XD9OT*?6<%U5U0L65K'OK_<:C%G2A>=7O4NN_#9 M2;#U5[$93;E81I0K;0\W9K!AB9'J;4P;<^Z44ID40]?S&.K3'?1(-2O,V\Z& M*DZ%Z2#-_\"QUZG25M[2SG)ME/T@U9->,6;TT-HY2[..K=O\VN[W2@18^TAK MUYG])MM>WX4GYB9C.EQ$5)G_)$79TU:(_IL25:/;$(B*%&%A8!V1+ZI4,+RZ M)#O+#0,/!P1[""P23GS/B>$PL>!V=PKALY(X?X!(4_4#3% M! < ]S/G=$$-^+\8 YQPJF/R9$XOV8^\8L\S8"[,/0> M_,D$.8&'?"@IN/,A&7((P7$SQ<.CN/&"C)TI1M%LZHX=XRG"4&?\NWD\!-_!%(Y4TZ@INH@D/.3@J?A1==%%3!]A];^[ M'=DN?+,0A?+M4;=2G:JRH7^/&F1>K6 M\@_6_12Z;?%[WS_/Z7?/X%R=V)JF%MZ]-@Y>$M;^GQO[+U!+ P04 " #\ M;)Q(=W3!ES\! !I P $0 &1O8U!R;W!S+V-O&ULS9--3\,P#(;_ M"NJ]2[M. Z*N!T"+MU=80)3J &!1H]R4^?'F*&)%WESLN^JFF: M45/$NC!P3M[G3R_Q;%*I/3+-(:B\I-A:F"7'SF_%_3Z8S_9F;_!L.J&^+>.CP;C=E%B#1?N-FI$7&[\C" !GCMI41I]$2YB M3L01YK>?7\#Q621A'^_1S80 MRY8-[9)-NIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X8-DOV]:[MR_>X%#BVR]*+41B1%G\@MNN01.+5)#3(3/PB=AIAJ M4!P"I DQEJ&&^+3&K!'@$WVWO@C(WXV(]ZMOFCU7H5A)VH3X$$8:XIQSYG/1 M;/L'I4;1]E6\W*.76!4!EQC?-*HU+,76>)7 \:V@S&L%&KQMUAVC2/'K^!?F< M-0HACA*FNVB<5@$_9Y> MPTG!Z(++9OVX?H;5,VPLCO='U!=*Y \FIS_I,C0'HYI9";V$5FJ?JH M,@H%\;D>/N5Z> HWEL:\4*Z">P'_T=HWPJOX@L Y?RY]SZ7ON?0]H=*W-R-] M9\'3BUO>1FY;Q/NN,=K7-"XH8U=RSTS0LS0[=R2^JVE+ZU)CA*]+',<$X>RPP[9SR2';9W MH!TU^_9==N0CI3!3ET.X&D*^ VVZG=PZ.)Z8D;D*TU*0;\/YZ<5X&N(YV02Y M?9A7;>?8T='[Y\%1L*/O/)8=QXCRHB'NH8:8S\-#AWE[7YAGE<90-!1M;*PD M+$:W8+C7\2P4X&1@+: '@Z]1 O)256 Q6\8#*Y"B?$R,1>APYY=<7^/1DN/; MIF6U;J\I=QEM(E(YPFF8$V>KRMYEL<%5'<]56_*POFH]M!5.S_Y9KF4Q9Z;RWRT,"2Q;B%D2XDU=[=7GFYRN>B)V^I=WP6#R_7#)1P_E.^=?]%U# MKG[VW>/Z;I,[2$R<><41 71% B.5' 86%S+D4.Z2D 83 >LX=SFWJXPD6L_UC6'ODRWSEPVSK> U[F$RQ#I'[!?8J*@!&K8KZZ MKT_Y)9P[M'OQ@2";_-;;I/;=X Q\U*M:I60K$3]+!WP?D@9CC%OT-%^/%&*M MIK&MQMHQ#'F 6/,,H68XWX=%FAHSU8NL.8T*;T'50.4_V]0-:/8--!R1!5XQ MF;8VH^1."CS<_N\-L,+$CN'MB[\!4$L#!!0 ( /QLG$@=4#PK,P( .<( M - >&PO\!=F6;8$NKBQOO?GZZN+KPI)M>LN^:'0T<^;,6#MVU*@#Q?<5Q@ITC/(F MAI52]4?/:[(*,]2L18VY/BF$9$CIK2R]II88Y8T)8M3;^'[H,40X3"+>LBU3 M#?F^%NGD#W+IZMUKYCY)<2'8+-U2S +CIO*F2. MY9@Y@ .41!072@=(4E9F5:(VTH52@FDC)Z@4'%%#.43TAJ;-,*7WYC(_% ON MK@#.QSQC'P*C8C!U(WISN@:VJ=Z$3)25GV&EU MT%;TN^?H@Q/T280&5E )29ZTO[D'F0:PA&"/I2+9'/DA4;W#G>HOL-<5IQ2^ MM.2_J>G/=VU2HV_@OV[/?TT^?S;V7PB/])SQ*.Y:EF*YM:/YUX6]__!:E9E7 MSZN5%OZF-*\?<;,YNIBB(PK2EE!%^* !F??>G=%-%Q-NFJ":,^^FX6E/%4KU M5\&PO=V]R:V)O;VLN>&ULE99= M;],P%$#_BI4G>*&-^P&K*%+:F"VB)*7)AGCT$I=:.'$5NVSPZ['3E=VL5Q4\ M)79\CZ_M4_>^-[,'W?ZXU_H'>:Q58V;M/-A9NY\-!J;OR4(O&#NAP.!VT0G$K=6-V$K=41 M5G/9!!_>F]E6*G$G6N/ A._W*:_%/'A4 5'<6%9)*ZIY,'9-_2!Z'>UAOSA( MY1N3X208>-AIJ>N6E+H21UBQD^;KTX> 5&++#\H6+MG3O/,@I&-*IT>&'W8G MQ8.!0-]!>&GE3U'P^WDP# @_6/U1*BO:F%MQW>K#7C;?'2L@6]D:F_OE=B-K MVJB_(P,MO]_XDY@' MTZ$#_I1&WDLE[:]YT+TKX5+&4;ON?WTC3;<[IB EO*L(:ZR@D:8Z'Y[;& MY^ &)U4W<3N3[J5-JO"X51"TS-*8I3F+B7O+LU421X5K+*)5E"X9 2 *0/2? M07GA'I]9"D C !K]+V@,0&, &I^#%E&>Y"3[2-8;EK/4Q2<9S&,"PB?GX=%R MF=VF14XV;,F2NVBQ8B!X"H*GY\%)>N=FS#8)RT'06Q#T%IOQRVV2)SY-&/4. M1+T[C[K.LOAKLEJ1*(U)XI:97BE":%V(:)>S M:V=7;YTA%"Q$#$/%(*_66LE2"@-14+$0<0R1A+QR%X$2YC7D0-="1#;@"QH/ M=0L1WZ Z* "J%R+N7;:H=R30QQ 1THN$Y@ %#!$#3V>)!5.H(T5T1$\B%I9+ MU0=!.2DB9^\H,$#O(D24[)\%1H""4D30BX=!X15(H: 4$?0R:@)1T%&*.'H9 M-84HJ"M%=#TJ@FT-])0BGKZX=7 (-)0BAEZ\?^@51$%G*>;L)=1H"/_VH,$C M[$*]B HA"CH\PB[8O[\D9'M&4. 1?2HZGNL,5VK)1E2^"C,=V94QI2_-W.-X M)X\G_K?LVY]=N38/?$WERJ>#4DO7ES4KS;O*XT@^%6,?_@!02P,$% @ M_&R<2)G4GAI' @ C0< !@ !X;"]W;W)K>>N%45X?_VM&3MUH=^/_!17'.I M!X(L#0;?N:AH+0I6>YQ>MOX.;@X0:XE1_"YH*YRVIY,_,O:I.S_/6Q_H'&A) M3U*'(.IUIP=:ECJ2(O_M@CZ8VNBV^^BO9KHJ_2,1],#*/\59YBI;X'MG>B&W M4GZP]HUV1+_LN:O-N[9<0=K9Y ^H,:#!@_*T! M=P8\&&!H9FHS,_/Z023)4LY:3S1$KS;<*#G7051D3YAHW)9+S4RHT7L&TN"N MPW0*9!1[5P$'1:!BSP*0/[8CQX[F =7@9P\7$6R#%A- "MW M'X!9PDCRQ%Y93Q!KUX]F$2/)$[LEF2 2UQ_.(D:2:!D!P82A3X]'A'AVS3N- M770$X!,;"\(I9_1K3O96U'%&FO43%#2EN/\G3&9+-M(@\ 0%3RGN;XS@7,T. MG<;6+,$XB3":H +G]*LHOYI;07@G=JNE/?R&T>'FV2%S>C[D6=J0*_U%^+6H MA7=D4IW!YL"\,":IR@2\J.KFZFX<.B6]2-U&PO=V]R:W-H965T&ULC9C;M>7[8?(.L$*-D M5/QU,M>.7 >#^<>F^3G<_'%XV$2#!U.9IWYHHK1_;R8W536T9'O^9V[TO<^A M(KV^M?[;&*ZU_UAV)F^JOT^'_FC=1IO@8)[+UZK_T5Q_-W,,:FCPJ:FZ\3=X M>NWZIKY5V01U^6OZ/YW'_^OT)+Y5XRO@7 'O%9+HPPIBKB#N%4!^6$'.%>2] MPJ@/ITC&/!1E7^ZV;7,-NDLYC [(K+H=VK -!]W86#NEUV:BLZ5O.\1M^#:T M,TMPE.P=":?('87@)(4CD7=):"VR/O'F4TP^D=97I(NA_^GA,) _;%/QVXF>G$C2":08LZK<4>DX M33[WHCPOBGI)6"^*]*)!IL!ZH2J52AE][D5[7C3UDK)>-.E%Q*!8*]IYC>F* M-Q1[3F+B1$2LDYCF'C1K-_=$\>=.$L])0IVPF=\GI),D34"R5AR5QC7C-O6\ MI-0+LEY2VHN0FLU=3E5QK.4*+Q!Y9@;(O[L1K)M9,P^7*$5^O#@RE")902P MWP]EGF#?P7[6W#H"R4ZXW)%!K*,U^4'?#WX^A@'I3%%J(3V.*B5O?MF-#U^@ M]!5L/WL0#LZ ?:>YI](KF <^@($26&C>#84K"JD68./J *5,5SBZ8WA>\(!R M6%#:CWV\P_7C9GVB D6JX/$.%)<@TJ4X'9F,R,J_[,?G*CA@Y1$/%)IV4>.7 M/E>E5DT1GZU X2H7I@CE)D8QL-S+/9G"-]D#9*6,5\81U9 *H M;'D3YB,6*6(E#WRD[(2$7WM<4;QF0^CC%2E>)8][I-S4B4C9F9T[,H48K0 : M_F^'2O$JI3=A<>4>%7U.(N6DY#F)E(#I0L8=S8K)@3XCD3)2\HQ$RCZ+A(5\ M4Y5.-:QPXV]3D?)1\GMFI%M0NWN7"[MF5Z>$AA63%7VT(D4KOY#OD3+SR^)X M=%7QBO4#?; B!:ODP8H4F5\2'F2N2*[)C(]5I%A5/%8Q<=Z5!N WT)XN0KEB M#XT^6)&"57E@G;_]D!*36^_GSS]7MW*]%Q-:Q\_0:!T:A$] L?!1331[1Z-\ MKH7DL* V[%^4YGG?KB,[74[G3A. M-WUSN1V@WD]Q=_\!4$L#!!0 ( /QLG$@:X88U800 #84 8 >&PO M=V]R:W-H965T&ULC9C;;N,V$(9?1?!](YY$4H9C8"VI:"\* M+/:B>ZW8] $K6:ZDQ-NWKPZT,V3':^8BMIAOAOPY%'^&JVO3_NB.QO31S[HZ M=Z^+8]]?EG'<;8^F+KN7YF+.PU_V35N7_?#8'N+NTIIR-P755]U7;;_;DS57%\7='%K^'8Z'/NQ(5ZOXGO<[E2; M"? >*7 <(&B- >$AN0>#W$L_9IYO*R+]>KMKE&W:4*P[CY?-X<8L7<[R \H$MZNB34A8YE(T$OG'"&4AFDF&+^$K:Z()5HP16JRZ$X MI>2Y+N6M9 5TR8!X[.LHU024YD BI%"6>I-$L/S6A;]W&,G; MB;]16%4.)17'=3D4%9Q+5)F+,4Y4@#;J:X.^(]%=8&,9NRP86M3,@9A"9REW MH"1]H(NZ>U. *N:K@CXET9UB8YG;$GNPZSB4%'BNW*$H5P)?BRY&%0^I&/>U M00^5Z!1N+&.+(>F#U>A07.([AT,)K?&=PZ58&E(UW]PI='>)[MP;"KU62(J^ M09E+$7RAY0ZE->Y.A4,I(4)J=C=W:Q84NKL,<%'JVRB%/HI7:D.AK>%[;^8P MOU'RH.8NA9NH"W$>4G+ERX(VJKRWQA[H+',KN;_/VP.=0_%4HX?#W*&T%NCA ML' H16E(R;5?<&VAMY\0][VLZ-1W&,RCTJY:GS M@\447HP*F"GFVRN#]NH;A]7)2(A.G\)U>E203B\F2"?U5@2#5JM$0 ;?UABT M-87;&H,>DPHR' GQG< %)6,$/[3D7D9.M$)WW<++R)5* @Z0S#K;)GR:'OKG<;NGN5X7K_P!02P,$% @ _&R<2,5Q! 514 !@ M !X;"]W;W)K/;M5QQ,6IHFUDULR-_2WY+ZDZS-K6Y^M">E M.N]7653MR^K4=9>U[[>[DRKS]KF^J$K_YU W9=[IQ^;HMY=&Y?LAJ"Q\8"SR MR_Q;?Z_I'__#7_F7%>@^J4+NN M;R+7'Q_J315%WY+N^>?4Z&>??2#^?F_]CR%=;?\];]5;7?Q[WGB^U[?_E13#F'?X*XNVN&OM[NV75W>0U9>F?\:/\_5\'D;_Q.S*8P.@"D M7 /$%"#F@.!+?3#I@UG/AP!_S&08ARSO\NVFJ6]>>\G[U<'76M[TC>B6O79H MK1F'5X]$J]]^;&6\\3_Z=B8)#)(42_BL\'7C9 ^P,L,!A0/508858?BX!W'O M08PY")Q#\C@^N,>/CZ\!BH^D:5&.28R2:I#$<9A0H@R+9!#(QTY"*Y,0.8G9 MX_C(RB3"\=PT&8V91-@D T:),BR*0N:0B;2<2.P$2"<2=R)('X;$P45LN8BQ M"[*+-$9=!*0)K'#PD%@>$NR!["%-4 _TA&#%DT,1$I-=FRC'_8K8P2])P M$SD5E U*CDD9T+SF&(2>)-FFL2 ;T?6C)PJ4FPX0D8GC&]\L"@(D1 UVYF MZESJ$FQV F9G0N],@+'X)!B$Y#!FIBZ Q&7& WO&,3\3EY1LZ@&F7D)7$V"@ M01@RNJ!,&6,.)04V^0"3+Z&/06 P+5FT8\BDFQ\;?8#11^\]*6"J+7B1YF2[ M6+&Y!YA[";T_@7%$7/""-5'@X,3F'F#NT1M/"L8Q4(01O3^9,EVZ\-B/L ^, MPN >/4F"/9PD0^)02\*FI\#T3.BCGL!8Y!!(>C\P9/KHZO*[1MCT%)B>"4US M@:E('T\S89T['7ZW"AN=PD G37)A(C&D-Q93Q1EW.-((^^ I,#@Y39!4X$-E M$'&KYL:FWHRF8&$Z<4MZAW)9Y3:I16A8MLZ>TX]_@1D<\ @H56:H0G :P9'4 M@Y%/L'X=8L-4R"]&*I@2P)K?:."C&Z-2-N,4^]A_4;I==+K3"=.1 AYOT#T/RUM-Y?\J/[.F^.Y:KWWNNOJN_RKU]V:\]1L?NOIRO\2<;U*W_P-02P,$% M @ _&R<2)3$5P>A 0 L0, !@ !X;"]W;W)K6B?O3" %=M#;;.D?U]?@"Q1 MI+S@F>&<,V=\*21=>[4&!5 MR59>(Q1H*U 3 ^V)WN^.YR(@(N"W@,G>Q"1XOR"^A.1GZ/65Z_5+LM+=@U",R91SAO,BF!>_<,6.=W2\QMZ M_CE]O]#WR>%^XW#_N4"Q"!1)H-@(%-L1$^:\Q1S>-6$W>ZK =/'J6%+CJ%W: MTK6ZWL[[/)[)&[PJ!][!+VXZH2VYH/,G&X^A173@361W!TIZ_W[61$+K0OC5 MQR9=J90X')8'LK[2ZC]02P,$% @ _&R<2%0-/BND 0 L0, !@ !X M;"]W;W)K<.>-+,:)YLQV (^]*:GN@G7/] MGC%;=:"XO<(>M/_3H%'<^=2TS/8&>!U)2K(\RVZ8XD+3LHBU)U,6.#@I-#P9 M8@>EN/EW!(GC@6[H7'@6;>="@94%6WBU4*"M0$T,- ?ZL-D?=P$1 2\"1GL1 MD^#]A/@6DM_U@6;! DBH7%#@?CG#(T@9A'SCOY/F9\M O(QG]9]Q6N_^Q"T\ MHGP5M>N\V8R2&AH^2/>,XR^81K@.@A5*&[^D&JQ#-5,H4?P]K4+'=4Q_\NU$ M^YJ03X1\(=QET7AJ%&W^X(Z7A<&1V)Z'L]OL/=P$$:],;%0S:7IOU/KJN=QD M-P4[!Z$)DRC'%69!,*_^98N/N]P&X6V"6!W4K@ M;CUBPAS7F/O_FK"+/55@VGAU+*EPT"YMZ5)=;N=#'L_D$UX6/6_A#S>MT):< MT/F3C!I"3+DN0+4USTM"Q"[4F7!8Y6BAZ>-#&C4ES_.8/$Z413NA2>1=M97V!E MP59>+13T1F!/-#0G>I\>S[E'!, O 9/9Q,1[OR"^^.1'?:*)MP 2*NL5N%NN M\ !2>B'7^'76?&_IB=MX4?\6IG7N+]S \K?HK:=,YM04D/#1VF?&P6;C]SRLM X M$3-P?W;IT<&U%W'*Q 0U':=W1HVK7LLT30IV]4(S)E+..\R*8$[]TQ89W=.S M#3W[-_VPT _1X6'G\#_ZYXM '@7R;?^[_801SOMPANP=7A8#;^$GUZWH#;F@=0<;3J%!M.!,)#>WE'3N^:R)A,;Z M\*N+=;Q1,;$X+.]C?:3E7U!+ P04 " #\;)Q(9:R*X*,! "Q P & M 'AL+W=O&<\Z<\:6<4;^8'L"25R4'.1,5/WH+BYPQ$&]Z=%K;AUJ>Z8&37P)I"49%F2W#/%Q4"K,M2>=%7B9*48 MX$D3,RG%];\S2)Q/-*5KX5ETO?4%5I5LXS5"P6 $#D1#>Z(/Z?%<>$0 _!8P MFYN8>.\7Q!>?_&Q.-/$60$)MO0)WRQ4>04HOY!K_733?6GKB;;RJ?P_3.O<7 M;N 1Y1_1V-Z932AIH.63M,\X_X!EA(,7K%&:\"7U9"RJE4*)XJ]Q%4-8Y_@G MSQ?:QX1L(60;X6L2C,=&P>8W;GE5:IR)&;D_N_3HX-J+.&5B@IJ.TSNCQE6O M59KF);MZH043*><=9D,PI_YABXSNZ=D-/?N\S]NR;L9D\5Z"Y<'4-JG 8;MW2K;K?S(0MG\@:ORI%W\(OK3@R& M7-"ZDPW'T"):<":2NP,EO7L_6R*AM3[\XF(=KU1,+([K ]E>:?4?4$L#!!0 M ( /QLG$BM#U'HI0$ +$# 8 >&PO=V]R:W-H965T&ULA5/;;J,P$/T5RQ]0 TEZB0A2TU6U^[!2U8?VV8$!K-H,:YO0_?OZ C14 ME?J"9X9SSISQ)1]1OYD6P))W)3MSH*VU_9XQ4[:@N+G"'CKWIT:MN'6I;ICI M-? JD)1D69)<,\5%1XL\U)YTD>-@I>C@21,S*,7U_R-(' \TI7/A632M]056 MY&SA54)!9P1V1$-]H/?I_KCUB !X$3":BYAX[R?$-Y_\J0XT\19 0FF] G?+ M&1Y 2B_D&O^;-#];>N)E/*L_AFF=^Q,W\(#R552V=6832BJH^2#M,XZ_81IA MYP5+E"9\23D8BVJF4*+X>UQ%%]8Q_MEM)MKWA&PB9 OA-@G&8Z-@\Q>WO,@U MCL3TW)]=NG=P[46<,C%!3%FY?#V9X'M++"- MN5P-UZQ(@YKC!9\J4)N]A3!;H)5\>0 M$H?.QBU=JLOMO,_"F7S"B[SG#?SENA&=(2>T[F3#,=2(%IR)Y&I'2>O>SY)( MJ*T/;URLXY6*B<5^?B#+*RT^ %!+ P04 " #\;)Q(PC'[+Z,! "Q P M&0 'AL+W=OZ !*WX0VPS9OU\_@ Q1I.2"NYNJZFH_RDF;%]L#./0F MA;('W#LW[ FQ=0^2V2L]@/)_6FTD#+*CE,S\.X+0TP'G>"D\\ZYWH4"JDJR\ADM0EFN%#+0'?)OOCT5 M1, ?#I.]B%'P?M+Z)22_F@/.@@404+N@P/QRACL0(@CYQJ^SYGO+0+R,%_6' M.*UW?V(6[K3XRQO7>[,91@VT;!3N64^/,(]P'01K+6S\HGJT3LN%@I%D;VGE M*JY3^D-O9MKG!#H3Z$KXF47CJ5&T><\&=FH9M+T MWJCUU7.5T[PDYR T8Q+EN,&L".+5/VU!\99.+^CT:_INH>^2P]W&X3<$BD6@ M2 +%1F"W'3%ACEM,\:$)N=A3"::+5\>B6H_*I2U=J^OMO*7Q3-[A53FP#GXS MTW%ET4D[?[+Q&%JM'7@3V=4U1KU_/VLBH'4AO/&Q25 :4! "Q P &0 'AL+W=O#;MS\.X/$\40W="Z\ MB+9SH<#*@BV\6BC05J F!IH3?=P;,9)34T?)#N M!<W.7JX"2)>F=BH9M+TWJCUU6NYR?<%NP:A"9,HYQ5F03"O M_FF+G*[I^0T]_YJ^G>G;Y'"[,6'.:\S#AR;L9D\5 MF#9>'4LJ'+1+6[I4E]OYF,8>71<];^,5-*[0E%W3^9.,Q-(@.O(GL;D]) MY]_/DDAH7 @//C;I2J7$83\_D.65EO\!4$L#!!0 ( /QLG$A)&U>+I $ M +$# 9 >&PO=V]R:W-H965TVF MI\?SP2,"X+> R6QBXKU?$%]\\K,^T<1; F5]0K<+5=X "F]D&O\.FN^M_3$ M;;RH/X9IG?L+-_" \H^H;>?,)I34T/!1VF>RS3[5K"K%YHQD7+>858$<^H?MLCHGIYMZ-GG]'RAY]%AONV> M)Y\+'!:!0Q0X[ 32_8@1<]YC_G?)-GNJ0+?AZAA2X=C;N*5K=;V=]UDXDW=X M60R\A5]!I"1+D^26*2YZ6A:A]J3+ D\$*I0E?4HW&HEHHE"C^&E?1AW6*?]+O,^US0CH3TI7P M+0G&8Z-@\P>WO"PT3L0,W)_=[N#@VHLX96*"FH[3.Z/&52_E+LL*=O%",R92 M3AO,BF!._=,6*=W2TRMZ^C4]6^A9=)AM'.9?"^2+0!X%\HW ?CMBQ)RVF-O_ MFK"K/56@VW!U#*EP[&WMZ TYHW4G&XZA0;3@ M3"0W>THZ]W[61$)C?7CG8AVO5$PL#LL#65]I^0Y02P,$% @ _&R<2.A& M!;:^ 0 >P0 !D !X;"]W;W)K&ULA53;;IPP M$/T5BP^(N>TF7;%(V415^U IRD/[[(4!K/A";;.D?U]?@,!JI7W!GN%<9F#L M8I3J0W< !GUR)O0QZHSI#QCKJ@-.](/L0=@WC52<&!NJ%NM> :D]B3. M4@-)4" M*6B.T7-R..T=P@-^4QCU:H]<[6$7 P\F6^$D/*0LD1Z9ZX?Y<<+%PY M$:N,M%=3H7M;J+;92YEDCP6^.*$)$RBG#69!8*M^TR*-MO1T14_OT[.9GH4* ML[5[G-T7R&>!/ CD&X%\VV+ G#:8[.F^R>[*9+<1^';39(/)X_LF^RN3_48@ MN6FRQ5Q_;[R:#@ZJ]8= HTH.PH3A6+++.7M._71]P&UL MA5/+;J0P$/P5RQ\0,PRSB48,4B:KU>YAI2B'Y.R!!JS8-&N;(?OW\0,(1)%R MP=U-576U'_F(^M6T ):\*=F9$VVM[8^,F;(%QNXUG]5YC6N;]P P\H7T1E6V[HX-J+.&5B@IJ.TSNCQE6OQ2[;Y^SJA29,I)PWF 7!G/J7+5*ZI:OH] M?3_3]]'A?MT]N?U>()L%LBB0;4;,MB-&S'F+.7QJPE9[JD WX>H84N+0V;BE M2W6YG?=I.),/>)'WO(&_7#>B,^2"UIUL.(8:T8(SD=P<*&G=^UD2";7UX:V+ M=;Q2,;'8SP]D>:7%.U!+ P04 " #\;)Q(]$G_(*0! "Q P &0 'AL M+W=O<.>-+,:%^-1V )6]*]N9$.VN' M(V.FZD!QED6H/>NRP-%*T<.S M)F94BNL_9Y XG6A*E\*+:#OK"ZPLV,JKA8+>".R)AN9$']/C.?>( /@I8#*; MF'CO%\17GWRO3S3Q%D!"9;T"=\L5GD!*+^0:_YXUWUMZXC9>U+^&:9W["S?P MA/*7J&WGS":4U-#P4=H7G+[!/,*M%ZQ0FO EU6@LJH5"B>)O<15]6*?XYY#- MM,\)V4S(5L)#$HS'1L'F%VYY66B_H?_?-%((\"^6[$ M^_V($7/>8QX^-&&;/56@VW!U#*EP[&WMZ VY MH'4G&XZA0;3@3"0WMY1T[OVLB83&^O#>Q3I>J9A8')8'LK[2\B]02P,$% M @ _&R<2(F>!1RP 0 %@0 !D !X;"]W;W)K&ULC53;;IPP$/T5RQ\0 \NF[8I%RJ:*VH=*41[:9R\,8,47:ILE_?OZ @16 M*R4OV#,^Y\P9C4TQ*OUJ.@"+W@27YH@[:_L#(:;J0%!SIWJ0[J116E#K0MT2 MTVN@=2 )3K(DN2>",HG+(N2>=5FHP7(FX5DC,PA!];\3<#4><8KGQ MK.^L3 MI"S(PJN9 &F8DDA#<\0/Z>&T]X@ ^,U@-*L]\M[/2KWZX&=]Q(FW !PJZQ6H M6R[P")Q[(5?X[Z3Y7M(3U_M9_2ETZ]R?J8%'Q?^PVG;.;()1#0T=N'U1XP^8 M6@@.*\5-^*)J,%:)F8*1H&]Q93*L8SSYFDRTVX1L(F17!!(+!9O?J:5EH=6( M3$_][-*#@VLOXI21"6HZ=N^,&I>]E&G^K2 7+S1A(N6TP2P(XM1OELCPEIZM MZ-G']-U,WT6'NW7U-/]8()\%\BB0KP7VR;;%B#EM,9]HZ!!P:Z[=?W%['>QL#J_KY%2Z_@O(_4$L#!!0 ( /QLG$B/ M2E0%OP$ 'L$ 9 >&PO=V]R:W-H965TU#I=4^M,\.#!>M+]0V8?OW]058B"*E+]@S/I<9 M,78^2O6N6P"#/C@3^HA;8_H#(;IL@5/]('L0]J26BE-C0]40W2N@E2=Q1I(H MR@BGG<8SGQ%O7M,8E2)&3A5=U'(3N MI$ *ZB-^C@^GS"$\X%<'HU[MD:O]+.6["WY41QRY$H!!:9P"MW*?O9OHN M5+A;N\=/]P7VL\ ^".PW+:;;%@/FM,5D]TW2*Y-T(_!XTV2+^8].LBN3;"/P MY:;)!I-%5R9D-1T<5.,O@4:E'(0)P[%DEWOVG/CI^H07>4\;^$E5TPF-SM+8 M&?4#54MIP!81/=A66_L2+ &#VKCMH]VK<#E"8&0_7_7EO2G^ 5!+ P04 M" #\;)Q(@;@OXZ0! "Q P &0 'AL+W=OP1=\[U!T)LU8%D]DKWH/R?1AO)G$]-2VQO M@-61) 6A679#).,*ET6L/9FRT(,37,&307:0DID_)Q!Z/.(:([_/#:1\0$?#"8;2K& 7O9ZW?0O*K/N(L6 !E0L*S"\7 M> A@I!O_#YI?K4,Q'4\JS_&:;W[,[/PH,4KKUWGS688U="P0;AG/?Z$:83K M(%AI8>,758-U6LX4C"3[2"M7<1W3'WH[T;XGT(E %\)=%HVG1M'F#^9861@] M(MNS<';YP<--$/'*R$8UDZ;W1JVO7LK\)B_()0A-F$0Y;3 +@GCU;UM0O*73 M%9W^F[Z;Z;OD<+?N3O]#8#\+[)/ ?C,BW8Z8,*&ULA53+;J,P%/T5RQ]0$T+2*B)( M34=59S%2U<7,VH$+6/6#L4WH_/WX 12B2-G$]N6\KJZ=?%#ZT[0 %GT)+LT1 MM]9V!T),V8*@YD%U(-V76FE!K3OJAIA. ZT"27"2)LF>",HD+O)0>]=%KGK+ MF81WC4PO!-7_3L#5<,0;/!4^6--:7R!%3F9>Q01(PY1$&NHC?MX<3CN/"(#? M# :SV".?_:S4IS_\K(XX\1& 0VF] G7+!5Z 8&PA)"P5-^$7E;VQ2DP4C 3]BBN381WB MEZ=DI-TFI",AO2*0:!1B_J"6%KE6 S(=];/;'!Q<>Q&GC$Q0T[%[%]2XZJ78 M[+.<7+S0B(F4TPHS(XA3OVF1XC4]7=#3^_3M1-_&A-NE^S:[+Y!- ED4R%8M M[M8M1LQIC=G?-]E=F>Q6 H\W3=:8IRL3LAB< -V$^VE0J7IIX]SFZOP$GM,P M^&]XD7>T@5]4-TP:=%;679\PZUHI"RY$\N!2M.Z1S@<.M?7;1[?7\=[&@U7= M] KGOX+B/U!+ P04 " #\;)Q(H]_];"," >!@ &0 'AL+W=O]?!S_/6#[0%3/!):@6DECLN,2%:2!7^VVM^EM1$=S^H?S?=*O=')'#) MR)_Z+"ME-O"],[Z@&Y%OK/N!^Q92+7AB1)A?[W03DM&!XGL4?=BU;LS:V2?I M0%LF1#TA&@FKX"$A[@GQ2 B3AX2D)R0CP>"![<235&VW&%2 M[@MV,V-7&\U&_8<$..L/+A=T('L7DL[?)W#N"\7\:N:.\$[LUDC[G8U9.]I* M-=K,))KE=]GFD"WD][ ?A>!3OLA;=,6_$+_6C?".3*I+;J[DA3&)E>?@11UD MI8;U&!!\D7H+U9[;^64#R=IA&H]_"<5_4$L#!!0 ( /QLG$CCM1&//0( M *H& 9 >&PO=V]R:W-H965T^Z:L36+Z1L-T$@3@6MB7AC+6W4G0OC-9%JRZ^!:#DE9V.JJR *PR2H M2=GX66IB[SQ+V4U694/?N2=N=4WXOSVM6+?U@3\$/LIK(74@R-)@])W+FC:B M9(W'Z67K[\#FL-(*(_A3TDXX:T^S'QG[U)M?YZT?:@1:T9/4&8BZW&E.JTHG M4H6_^IR/DMKHKH?L/TRWBOY(!,U9];<\RT+!AKYWIA=RJ^0'ZW[2O@6D$YY8 M)K!XGLU^;;7LC'7SMZ!N+$(V&5?C4$/>&>#0 ^-0 >P-\ M()F3L9V8[B21OQ%!+;-JRFL9 ) M"E=+JGRBBD&8O(:!,Q@X@8'3,HF%@4X9 !!.EE2YJUICA%ZSH!D+FK"@118T M:1F&>)$%38\/KU_#)#.8Q'U-%H]_GSA5$@#78/$AN2JTAC"PK!Z/>H\K;X5%WUN_GDKRCRMF\?R/:PNI4X/G5&> MA8R0*,S3TWFQ6G;OOI>K9?%19Z>S_EX&U4>>I^5_3SHKKH\+NAA?_#B]'^OV M1;A:AI/=X93K;K:%Y/WK?=>$V]%_22J^+[)_3H3XV M;,DB..BW]".K?Q379SW$(%N'KT56=;_!ZT=5%_EHL@CR]%=_/9V[Z[7_1ZG! M##=@@P&;#&)RTX /!GPR8/2F@1@,A*^!' SD9,#938-H,(A\#=1@H'PIQ8-! M/!F(KG?[WNCZ@NJ3M"*)APLHJ'2VHE(HJ=32U(2@ MI0M % /MG2 W&2BMU-+$Q&.*H1*F1,Y."10S&OFDQ"5G5DIF:QZ%HD>5%8^/ MBQBF))Z=D@2RL"HYX5CE/ V@OG+@&F(L0A/#(L8] F($!,3(7%UAL/B857P) M.@/L!U!/UF=:9 PV8Q5H@LKQ?@#US7BH+(,US/A=D=PS/K,16)O,KLT(E>(! M- P!H0@Z_WBA]A9*^%"&"R1F:4&B\$Z6^*AU-P/U@MEZX3,<%1S1:FZ),KB& M8-8B IW2M\R6<$76_'0Z+G,\N<@Z+G-\L\F'( M@+D)1; 8;(GQ6"MR MN)#@][=/&V[OGQ)B5\]$I84D3@7GIDXT2Y MZ4#%$AZ*)?!5CD5EYD)(?#G_\=$J82U>I(.*"^0F Y5*>"QQUL*4(,5(@J&V M;I2;3J]3'9%HLKYM G5)F+K$T,WVDX61<%L8&L>SN2[?NZ/Z*G@M/LYU?X8X MO>T_!^SIPW-W' S>-T$\/#>!?/VG83!^00A_-[%:7M)W_5=:OI_.5?!2U'61 M=Z? ;T51ZX8X^=;D]*C3P_20Z;>ZO57-?=D?^_&ULE97+CILP%(9?!;'O8&RN$4%*4E7MHM)H%NW:29R !C"UG63Z]O4% MB(W0)-T$VYS__\XAMD]QH^R=5X0([Z-M.K[V*R'Z51#P0T5:S%]H3SKYYD19 MBX6T;P48O:)H )$&+Z\XO"[WVRLJ"7D13=^25>?S2MIC]W9*&WM9^ MZ(\+;_6Y$FHA*(M@TAWKEG2\IIW'R&GM;\+5+D0J1$?\JLF-6V-/);^G]%U- M?AS7/E YD(8QQ;<;,UY*% M<;EZ+2$(B^"JC(88J&.V=LP](I#NBPCHNW)HR]/LL0$:#(?(;( M'42VB,@M1!JB,'^,"<&,H^X5"Y0O@H:@_]LD83A'.4<[!(N[?@@R* 1R&#]! M,@=<,^ D_UR"YLFAY9UGQ6R=F'A^[ /KGFL).^OKGWL'>NF$.9K3ZM1B-E#= MD[/UK6H]2^MPM5N*ET5+P;(3&KM8<$^I+'I\)C\Q.]<=]_94R M=7[\G2@61 MA8(7>2E4LM%.DX:&PO=V]R:W-H965TJS. M7GVM1'KLC(K< T)"KTBSTMUMN[5OU6XK;TV>E>);Y=2WHDBK?]]$+N\O+G7' MA>_9^=*T"]YNZTUVQZP099W)TJG$Z<5]I9L]BUM(A_@K$_=Z]MUIR;]+^:-] M^./XXI*6@\C%H6E=I.KC0R0BSUM/*O(_@]//F*WA_/OH_;=NNXK^>UJ+1.9_ M9\?FHM@2USF*4WK+F^_R_KL8]A"T#@\RK[N_SN%6-[(835RG2'_VGUG9?=[[ M-Q$9S,P&,!B K0$;#-AD0/U5 W\P\">##N_U.^G.89\VZ6Y;R;M37].V.NA& MH:O6AW+LU)VSJC]>=1*U6OW8 :5;[Z-U-&"@P[S-,7.$>I?T[]H::M<\%=$8 M%ES=)@ ]2K8&HSPDR%L?I8RS$+7H-A\=&QV)N:JTB#,A@G6,NH_?1X!/H_@64&E6#5H:-%H M5%,$%L5&6*+#P.?$@A#'A+A%LPV@H8T@B+B9D :C<6C1^Q0K$8W6FFWXT:%S ME:&4D=!,2(.1@-@T$E8CJLD1$%._OB&0A2.9P=4*MD MZC"[9 )@0IJ"@$7' !YBX.DI!G#KP^H<,]0XS$<48#$WRGRBP6@8,9MCP:,, MV,PRH$\IJLK-,J#C8LXM)D7 N@2KX\Q8.;K@1+[Y-U>#<1+:\,&R!-RBZ1#( M)DZ$JRMZNNFP/L#JN#(>76R9S/CY9#(\KS!-26RF!T;1N3#Z;-2N;_C_F:76ZA7J%]F8$K2=TLZ>F==CL M37BUZ;?S7-XKQ>-'E?5+:;:_I6?R95N>LK)UWV32RZ"Y<3E(V0FV4?%5% M=1'I<7K(Q:EIOW+UO>IOI_J'1E['R[;IQF_W'U!+ P04 " #\;)Q(_Z(^ M^ 8" ((&VH5NU%I=5>M-=., &MP:SMA.W;UP=(,4)E;V*/^>?_9HQQ M\I&R=]Y@+)S/CO3\Z#9"# < ^*7!'>)/=,"]?%)3UB$A0W8%?& 853JI(P!Z M7@PZU/9ND>NU5U;D]"9(V^-7YO!;UR'VYX0)'8^N[\X+;^VU$6H!%#EXY%5M MAWO>TMYAN#ZZS_ZAS)1""WZU>.2+N:-J/U/ZKH(?U='U5 F8X(M0#D@.=UQB M0I21!'],GO^0*G$YG]U?=+>R^C/BN*3D=UN)1A;KN4Z%:W0CXHV.W_'40J0, M+Y1P_>M<;ES0;DYQG0Y]FK'M]3B:)ZDWI6TGP"D!/A+\\+\)P900K!* J4SW M]0T)5.2,C@X?D'K9_D'*F3*1S@[7;LQLE^R,R]5[ 6&<@[LRFC10:TZ69DM1 M6HK@(0&R@,TJX%R%"9^A546R;Q#,!K$Q"+1!;PP\?]5'8OI8BOPL#/VY\Z9"GDGZ ^XIE1@Z>4]RVK_5FK6]M>;ZHKW70W*JJJ/]_5J6^/RU@\3!\.Q]/K36$FW4X^NW/ ME;HT9WT):G5X6GR$[$4("^D0_Y[5O9E\#VSQKUI_MQ?_[)\6D:U!E6K7VA"% M^7A36U66-I+)_&,(^CNG=9Q^?T3_U+5KRG\M&K75Y7_G?7LRU4:+8*\.Q:UL MO^G[9S7T$-N .UTVW?]@=VM:73U<%D%5_.P_SY?N\]Z?)-'@QCO@X("CPW+> M00P.8G0 .>L@!PM[N^'H:XQUK<-XFH=OME P8[S/,4 Q.$.=OV9_:AL[;09&33XL(-B=.T M7-*M@Q <)'<@DH.\N%&B$?-NH>)1J.CY$4X VKWPZUX^@LH^J'2"DO[3GB$Y MAG[;R#2.[!\'W$Z! @CPW9)B4E+LE"1(G[%?GPDA+YDE+_$+FI)*4RT] MYMG%Q"1QZI=X21(OG: )F]C%I"3QTB_QBB1>.4&7).C*+RA$Y.98$9VY.\/Q MW^,"J18<21$K&M=5C,F3_#(Y,D(3#7]_?Y8!:0FN,D2T!/RSA&0H :=CAY[Y M! MD@,)3>Z(CDQH7$_5@92.2SH_+IZB E158.FA9RY(4ET!3V$!JBS@2(M<\LE= MT!\#[2E &)'DZ A0'+')"8C2CIXJA52ET%&IF!\0 J(#@K[+#]4G=/0IEC0N M>L:ERPK.;ROHJ29(U02EQS/J@F(ZT.BI)DC5!!VAB.E HZ=0(%U.<'X[04^A M0+J?H,^"XH)B.M#HJ29(U01]EA07%-.% CW5!*F:H",4,14*]!0*03<5,;^I M"$\-$%0#Q/RF(M[?5(2SJ0CO347T2M E]QQR09<+X2X7[!UV,!-QZ[.$DY^( ME:J/W6_S)MCIVZ4=$H[F\07 1[2_,8E]"UD.G%UDN>#L,LLE9X^S/.;L298G MG#W-\I2S+[-\R=E76;YBZX], Q%[8EMC>P,T)SP;IFU@^P;3.+"=@VD=V-[! M- ]L]V#:![9_, 0 RP 8"H#E T'R'* A@-D.4## ;(% MO^=KL[X61_6EJ(_G2Q.\ZK;55?<:YJ!UJ\S41A_,Q)]4L1\O2G5H[=?42D'_ MDJN_:/7U\&ULE59=DYHP%/TK##]@@4#X<)"9%>RT M#YW9V8?V.6H49H'0),KVWS)B24\.ZRA&AX'4U YPW=!I4-7:63K$WFB6 MDC.OJQ:_48N=FP;1OQM_8U\%Z=2BX#3I8Z$^]0-;AE%6DMBH]K^]5; M;1.)& "_*MPS[=V2WG>$?,C%C\/:=J4%7.,]EPI(/"XXQW4MA43B/Z/F+:4D MZN]7]6]#M<+]#C&"E,.O:U@$?T;GF[Z3_CL<2H!3E;M\.S5-V$RTLP$,!+ 1)CRF G^2/!OA.!+0C 2@F0%, M<$V\Y@7N2")PY+O"@MGI6V M.+*1*BW6\R3+ Z% ^0P$HM@$*G20#\/0!-KJ(.!#\+BH9%%4,BLJ-.Y7,C^9 MQDW-=9 87<9M*)Y1VMY54D4YVGW88'H:)A&S]N3< M*O<,\4(,1S7+;O)9VJ$3_HGHJ6J9M2-&PO=V]R:W-H965T)P.SJGW:%( M-<( ?E;0BZ=C/C'WHP_?KT?%T"$#@(K4"5LL#"B!$"RGCW[WFTU(3I_M! M_:O)5D5_Q@(*1GY55UFJ8#T'7>&&6R+?6?<-^A0B+7AA1)@ONK1",CI0'$3Q MIUVKVJR=_9.D/6V=X/<$?R2,/NN$H"<$3T)H,K61F;R^8(GSC+,.B0;K8N\. M"LZUB%)&PJAQ^UPJ,Z%N'[D?)YG[T$(]QC>8URDF"D>(J^17/7QGSO>G_&C- MHIA"_&V'8'"PQU,PRV*_+1 . J$5"&<"Z3S&Q*9A,;7!I-L6T<(BFEHDWMPB MMA;1Q&*W;1$O+.*9Q6XUBWAB$6Q;) N+9&;Q#Z7:+TJU_]]2I8L(TED$P=H[ M%NDD26]AX4X:A *_F\$AT(6UM;3],=Z.L^GDFP9[PO.LP7?X@?F]J@4Z,ZG: MU/34C3$)*@3O1=6R5--S/!"X2;U-U)[;@6(/DC7#>!QG=/X74$L#!!0 ( M /QLG$A[^Z1MQP$ (H$ 9 >&PO=V]R:W-H965T MEI[$&8FCZ$@X;07.4I][4EDJ>\-: 4\*Z9YSJOX^ )/#&>_PE'ANZ\:X!,E2 M,O/*EH/0K11(077&E]TI3QS" WZW,.C%'#GO5RE?7/"S/./(60 &A7$*U XW MR($Q)V0+OXZ:[R4=<3F?U!]]M];]E6K()?O3EJ:Q9B.,2JAHS\RS''[ V()W M6$BF_1<5O3:23Q2,.'T+8RO\.(0_R;>1MDV(1T(\$^8ZVX3]2-A_()#@S/?U MG1J:I4H.2'?4;?;N9.'*B5AEI+V:"LME.],V>\OB^T-*;DYHQ,0>\[#$))N0 M? G9S0AB#6RZB/&Z0KRLD&Q6^ 3R:8G]5.(0&MVO&HV_%CA, B&\'%8"_^$@ M^> @60DPT($C/"8: N1;R."";+8>PZJ]G="HT+VPH2MG[/SM;O$_NR\ MP[.THS7\HJINA497:>P)],>EDM* M1#=60^-?1CF@$%EW/3>SE6X*R$PLIMN M_OS\9/\ 4$L#!!0 ( /QLG$AW\^C?# ( & & 9 >&PO=V]R:W-H M965TK%=NTD M3D UF-I.Z-Y^_H ,(VM)+N(/?N?\#S:&HF?\0U2$R."KH:U8A964W1( <:A( M@\43ZTBKKIP8;[!40WX&HN,$'XVHH0!&$0(-KMNP+,S<&R\+=I&T;LD;#\2E M:3#_LR:4]:MP$8X3[_6YDGH"E 6XZ8YU0UI1LS;@Y+0*OR^6+T@3!OA5DUY, M^H'.OF?L0P]^'%=AI",02@Y2.V#57,F&4*J-5.'/P?-?22V<]D?WG;E;E7Z/ M!=DP^KL^RDJ%C<+@2$[X0N4[ZU_)< NI-CPP*LQ_<+@(R9I1$@8-_K)MW9JV MMU?R:)#Y!7 0P)M@D?Q7$ ^"^%%!,@B21P7I($@?%:!!@!X59(,@FPF 75VS M-ULL<5EPU@>BP_J!72P5SK6)<@Z$<>-VR]7N"#5[+6&6%>"JC08&&F;M,KF/ MV;C,-Q^S=9C8ASP[2![YF)W#^(@7UV5Q8X!:$.^JP'%58KLJ<&J \OL&\6B0 M6(/823!+B6Q*R[2&R2/]NU\GF=5)G#JQK\XVF=2!$*'$1ST[5)+#['Z8=!8F M=<+,REC).IV425/D8S8.$R7W@Z!9$.0$27WWNT.3(AF,,CA_3,#D('7X3'YB M?JY;$>R95&?2'* 38Y(HL^A)1:[4Z_XVH.0D=3=3?6[?@'8@63>^SV\?E?(O M4$L#!!0 ( /QLG$A9,S,[#@, #$, 9 >&PO=V]R:W-H965T^ M9XUZLN%M74@U;+>1V+>L6'=!=15AA)*H+LHFG(Z[N==V.N8'694->VT#<:CK MHOTW8Q4_3D((3Q-OY78G]40T'4?GN'59LT:4O E:MIF$+S!:0JXA'>)WR8[" MN ^T^'?./_3@YWH2(JV!56PE-46A+I]LSJI*,ZF5_PZDES5UH'E_8O_>I:OD MOQ>"S7GUIUS+G5*+PF#--L6ADF_\^(,-.5!-N.*5Z'Z#U4%(7I]"PJ NOOIK MV7378_\D0T.8/P / ?@<@.%F0#P$Q(\&D"& 7 *RFP%T"*#."E&?>^?9F1A*?)"% M"8$S(E("O"IP:*^ S? T\RTQMS&Y5P:VLDE]F.4UGJMBXY/8N+-90Z&JFE,;Y/D#@:$W//'2/3?M,20R+-28Y]J+F% MH@01'VIAH@ HH>"#+2T8R@C)[F>6.IFEEOL/['_F>)L]ZVWN*,AO>-MO_RPW M78L3]U7N47,317) V/LJY99I!-ROO(0([N)P;(R4Q7YHNY#U& XR[ ML_8"=E7@^P8/F,'A#%&OP18JB:\8;*$ <.(E6]HPC.D#+R_$;FZQY3#X9+IF@5NTX%;5&DX$,&M( M"L1_(EBHA.9>KH6%@AA=.1%LF/H@$B>WR.B':M9NNTY4!"M^:&1_MI]GS]WN M"];]E#,_@]$%?CK>%UOVJVBW92."=RY5%]>U7!O.)5.ZT3=E M\T[U[^=!Q392WZ;:_[ZC[0>2[T\-^OE?PO0_4$L#!!0 ( /QLG$B?5]V! M^R4 -6K 4 >&POY8\M2\&-WFHU"5596OC,K^_L\+T291'\LY6E:)L6OWO1. M!F_$ET6/*39PB_@SVSV-E]FT@_SN93% M(G[;ZW1&;Q=^E+SYX?L\^N'[XH>S-"@7,BF$GX3B/"FB8B4N$YXA2A-Q*/*Y MG\G\^[?%#]^_Q7?XO9'XF";%/(=W0ADVGW[TLR/1[WJBU^F.F@\G2WC8&[4_ MW )/<[@:<2MG45YD/KQWY2]D<]35I_O;R>GYI_O+T\D'<7EU?WY[-;F_O+Z" MOTZO;V_6S'H*<&1^#.N'\HOXC5PUQYV668:P7D1Y .-^)_T,\2'._,*!X?"P MGUU=GYU=WX&A'%U=_WA\FQR#W^\ MFWR87)V>B[L?S\_O[\3^I\0OPPC.XP XY-/=F=C?.Q![(DK$_3PM8.5;*"O.;<6>M MU!SX(4UFAX7,%B*4TQVVNV$J7G/# .*K>1J',LN_I6,J5BZI,@_F.-;9=0AL M!((=ED&Z.P0."OQE!,LV1][* A07(LC/$N!I2*,)TM@G[,RVS5#AXC(&_9Y594$>'N].9< J2@8^#40_R4IW$4TC:F/K! M( 7I;Z ]D3X(D".%7$QE]I?_TM)$S.'15,I$+)%]D0O+'% $6ZXT^4.6+@2@ M12C))1ZB!":/:'^P&K(7 %W &/@?KG^THW"\NX=_/IY?@6"\OH!''V]NSW^$ M<9>_/0=E"W^?OTA@]GLDRZ$[O2_Q^,D7[("@<,7L%B,W]V"7MTQ0L M+\!WZ\/W69H#)V?I0^1RV!)5-:)_'2O?R3B&YYZ8R42BA8&DXH>+*"$KI@!J M=35@FA71G_@H :JH*=O6H(!./66(@+):1*0$C5A88EX!O49QT*13"60EXO0IKS$$L"B(A.AQC<(V%)*+(D6; M*@5Q"0R75 <.W^-? 8K:6.8M.#([*G,RG5LAV[:;B@(V[29+ RE#]4J;97CCKYC8D5@V M/M^9^NJ+1GE>HCE#,P0;C,(:YNV!I#X*9;'M1!W["K$'K5ARG$8CX>27@,A7 MH-SD W8"S!3PUU,9;7D,<0'U? ?EM#MP*AJ&6=X*L63E;X0GA:B@7,S MS5$Q M>"3!I24FD8EP\P[(41*"3@9OC9P4ZYCU*3?PLPT]-?"!-^-(@OSEV0OVRQHL MHT%7' .#@.?5QD)["TH*@72) T *4%D&Y\+F;3Z/EHW-6^,WD _U[MDK\!3#!CT1E M?_V/_Q:>N,*9)5#-A^A!TBC\&+ "UK2=\B> MN#BB!%Q2'Y1377[1A'5LIT^@^A,TRJ=I-DP>!> /XTI'*!V!T(T*8-T&?D4 RT3C(9^I&5Q M .[E/1P##GE+>@Y(*EJ!J!_H19!]2@P6X31(7\.)<_!8P"EYNKB&X MD7XP!T*6]1T LE$:$B)@!XGB-:!@. ]VV2B0$00,+BY0:J]@72RE-=S! ,)4 MP%2)!-,D]T&X5+XA[ $GB=@D Q@2C*?$Z R 4TG&A#T69!Q-+A[\*$--4!,A M-2# %H\L(5)AGA3J1R(RG4$1O%] 81FS_84JL?+JV2Q"JIDC+HFY@987'#Z1 M) ;,^(8"AUI!1M81J6:;>F0%&;%W'^4'$%,X00!XB,QH:%P?,H2 377 M.GT.3C>8/U/T<_J;"2H40A7L3Y#09$Z'% MSA-PR /8'F$U]QUR8Q5T/=>V.PH^<#J(RQ)QE3[RE-T3GO)(?,KIX,Z!O1=$ M=B@#&5\-#;]&>CA4KQ&:26415$(+:6+A?P:J,,N1TP]>T4)%4LCN\,D)D:&B M)S"%*:ZSX.P!^LBMWK2V?!2QL.M$_%?E--QWV,P)-<_Q:;3%A9/U\"0ZA,I> ML/8=Y#A=@ MY&$D-YV"D)=LT+Z%AZ&_@&,/R9_'5-N*UK8F(R,Z2#%:1Z>Q0DS&F+K!#8=J M0\B&14D*A^7* LRJ, (*R8S)DUL4=22NY).85*+W#J-^?@8Z%?3IA9QF)2HX M%&BL4RJ/K_6E=RG\ Q+X8G+WCARM'%-4/MA(*5I')/EF940213-HE-?$4^N\ MIVE(IT^XV'\SN3N%V8\'/4^\$1\DN?Y';X ;82X]O6:I7,1H8$L3E -"^I,$ MT9T7\,17T2[<6SU[,EW1:!)IH!HRC)<>I@^'9:ZHAZF#YS!,LCIJ0 &?.5R% M6]<"K*Z\KX,B)3E#8N:D;EG!^RKQ!F)<*H)0;!+!D Y,D+[GG%%)T[B&79% MBGJ;44.FDQ%V*.C44<,9ONP$[T[%>-#!LU$)@'L,W;LGE,,&8CA7\FQ(D-:B M"V%;BEAQ@CI:SCWI<3!@G> "=1/$*!0>(F(6S&CJA*;2B=9S@QP$P[7!?O$9 MC]F,RLE ,$H?Z),.SA?(FQE9*GS"BD"WVZ<^8]) EB9 -3H:96\RV(QEHHE* MJ7XEHCCN#)$HWFEW'U TC1)EDVZC#LL^1!0O**A'VSYD+5$3N J_SSN649WU MPE3:)\1\9L#;>%J[,]ZORWCUM?#;[RNFTSKD13CE1+!10ZSQ07=QV"M(5?8/ MM3A8<''T)U1\K(%?AO;QWP#M'WW"^N K8'W4&2'6;R6@K%09U-,TH1!HSE;> MJ3(L6JA"*:)$*F]K@N?"MI37&/=L,C]FMW&.1P:;TXZGC"AJ!B9GEN9+ MGH^#PACL4!:PUHWHJ&8X.QPD%Z_ Z$.5:*WDGUI?F^KD!(2;D%$]/KS]A-OSV_/3\\K>3=Q_.W0HI[;9L M2MJ8.K1J^ YKB76UA42+QJ5BQXA\0=OG"M-R6CR4L7&Q3%A-AL;M3'$6.//O MK,A+/0[0 H/8 U;T^H,!?.B.O>/C'O@/8(I8(.UWO2-3XZ=.I>KWYY?W5_?7I[?K:N=7(FSRM=>CVUK)F&570K0OBPE,Q+$ MN^/@UG\RFC+'W8^\8><8/_2];FQ%X0UKPPRN#SIBF&)_ %*.N-SCIPH?AB3<8.+7*D].?/EW>76+^SD%+NPVX MB0JK%/FF=<19%478%J%K)LQ"$!%/::VDH)Z-/Q+7B1'J7) ^K$]B0@V!"M-9 MU0;LF,"$]=2&^.!/,7M)Y^RAQW0$'FY]S)L#6MKXX]UCS_+)G[7XI)QFH+\&* M65K65[.$AVD.3#W$%AJ>#9I[5-DN>VXE"IO0(,1UCW^FRKYY$?T7IT#9DC6> M>)5QM8)F-KYY#B-^ZW8NV&IQM "AANX3C CLV'!C3WDSJ,VY@QJ!*2,"U7Z\ M=<*6^88U F@_O>_T10M:WY*VXK IK]8/;,@0:^2P-G+27+M^=P$42M\[[J%B M026T)P9=L;'*7XQ GX^\3F<@_OKO_RET?3]\-817\2O\SRGO%\=>I]<1@R'\ MUV$EW^F-<%6OUT']!IQ_WSP93+4T,=L:6P9$%SZ6[8($\0;C#KVZ!PMY%A<@ MNS$!,EMA,A1SO9@;Q,^\.TUV)-(DDMTUQJ,G_9_A$J.[8%QCA(_%(%SXE,_2]F*0:X!MY1 M=9*P@3T^30:Y D@%T?)R^@<*%J2UJLBM.S01BU\&*/LX.H]\:EOK5F44[*)> M(*S"HY6;L,L,F'B]H,1KY12"XR$I*%J=C<&W&2 M.98 U5,T5K7RNBI/RK$DI*3%0H81K \/*PEKP4%U+5J94YPB:BVW ;.WP+#$ M EB' L" >\RYA)A.HEB2[1];\FF_8>,=>%;."DGQV.L/.14^LPK[Z5$?9,>8 MB*8A-DE#-_.P+Z>979/N=?\;C>O/.97R;+E04.7E3&;5.#!%*$^ MO](@-\1LPTD&D $HP5PY);GL>E*6"EI+:#%48="/(VB>(]M(07"5@,6EA)4@V5U#45^;0BA55H47]8(ZA&JKPM5T# MC6N-@5J4C6>*5+1.SZ 8]Z'$4K0C50#0=K!FQQR68]4RL^Y%P)] L(L<4)G! MW[CG@LL0[6A5@]::XAB%NI7V,/5)%B%@Q!X-!5LM:CD-JCK%&P6Z.F)3JCS2 M=W_6O0QN;$;,:3*JE0^4R<QT2@I%>75A3Q'[EJ*GF"^ M4-V%0 YX[\$\13PD6XLOO>$LLZMJU$R"RH!F>1^4%G>^"4*/W@?(X- :6@, MJ!L(> 3(I?;%,] M7^I?F"MC'"DY&9.QV1U[PY.NL&X#@:'K=4=D]GK#XPXG M"IHDA0SAD)5R/QC8ZAH%U\.9JB^%Q,H=+:=J6Z9*0E/6Z;9)')U.\59%?AY\ M6QBA@=AF.*F@FHM,2H-^KS;*JJI7+D2CH)BD0A';[U+42VLLTT)1!N7&*M.'(+*G MQF)*#2H3!"P X"UR#))HEL_-_0%/B1DCW )=.K5>$!=K!9*6O"JPPV*3,&&& M-RISU,79FH<"KS;=O)K6D0U5X02FWU]?G_U\^>&#F%R=86^%R=7[2PH8W]V= MWSMQ0N,!($"6!Z=!Y\A#N5B=)U WZ6K93S57+)@ DND''=4IP& MF&PH<8ZP* ,G_ZYR?>QKRI= ]%%&#@S*#5WHW+CH6RVS!YZQ-QYCN'=_T/'Z M)QS-[@V\_O&@6J*I=]:&(BJ'FC_5 6CL",18U^MW3QJ+ W GO2'CL8ZYO/6B M*@:/6@I)6W;+,3 +AXW76E[1UR /Q43=@ZS=FU-=)_:Q3T5^(/@6[ZF&>L+G MO=\]J!U2;09\B$?5?.DK3N7&-=8XP]^)>Q-?>%N%%]Z"L&1+'[12WSL^Z>.) M]4 %C3GW :?8P>/L]BB.L8>)D9/1B!]VO&%G &-,CKL>H'A+G0,XNQU1GTQ%F=@?,6@AD!P MI@_%$^H6,E=E,$_2.)VMQ'C<$_OXOP,BT,:?0]$_]D:##JPX\ 8G^#5P07=P MC+30 0[9!P"&L(T#3 L-1^,6M&Z(,VQ%K0Y"X7_]8_W/GH9JSX)K3T-&O-(E M3JJ@H[35J#-D6E%\8_O].G'X@#)]E_O,H'QT06NH%4ZKL=A0 PWNXGNMCBC< M4YM1E=B[42K=T+(867?*H:+ &A=7D-=XY5R!C) AH@!KWLE@P+57?2#M'F?D M^R"6NE1U)WI TSB@UX&/QV.24)EDS_0$AO6J@\$9JX5;<:4]"UVC[$+.T2L^ M..WSV#-Q((I+$'$5 L1Q[M];#CQ>.$[15\ ;#4IBDU7&%,%WL-@J@4=X'4<@ MR29A[:(00JWO$EF9GMJ=K>J&I:?F0[LDP4015R^8V@'[/45;5?H%/I#=0?4U MYD*!MO_X!B?#4"W"IA#JWIFEUM^V4!;[(Q+8S>8>5B>=99I0QGNVK7-IYT_,U-Z?F9GAKP9M=R)QAD%3:'#,\_- MY]>[]8 >6>]9@S\)JJR#V@7FP0\UHXLK]EH\:X ./*XL_:*J[*MLV^ZV6$VG M6-DZE(NT0A6<"?&N[8):]9@4H@DET'UJNTC)?P0AUE+.0S-/_>2SB%,_4:5P M.;B>,0:^8(%P58=_9M#7<@(C+$W:J>M!ZTYJP7'.F+BDVA$W6OF;^=:.-* MI^Z;WX-N D#GWCFOJFJ&C5'H-ZT C_P[EZW R854!L= M09)B166*/F@ 6Z&TBHZM5+6/^J81A6HE7?/D^%M %[755?F=%N_SXEY-'" Y MPRGH^%^,V%4%DL3_477%R<0C 4@F H]2JM41JZ>H;J!Z:!;BVBER6_]:4KT M6;^\CI/_3#=K+T""IC![2CF)]O(T-"^R"(PY59^&SG\4@-2/5.., .,5)N]O M<(41MDW 'HFS]@X-9,(-P"9J&'_.;M?F()O4YBX]<81*<_.AW9#&90@[\(C@ MLM3;M-MWU1L;3I"D [;2*=#&HBT! 6'8#$ I6+_Y<6R5D5A@T[[JHE72U2&, M;5H03]%"-+%556YM52V>EUG*_7R A+ .)RXQL8+W9^DYV!PS+&K)!-7WOD-& MV3#PR!H1,3^CJJ1"W^_$?G1 7]UD>*GZ@S)<:; '#]73"QF2T7E!5%4MUCD: M?H. P$ U,DWD(:4NG&TLD&BY E8Q)2:]2JJ4N^5+6=;,W:/.-V)?=7JC@U B M/<-<[0,I#YU2:YRB1]FK)17=?*T;@4.6V0?K:=XE$U'\(*,(]* M\\BI0HN.TV'M2U;TW;Z80!54)8)Z@ZS;^Q5 M!9]UTALD#[I7)6"?VNJU@XGJ!?04KH_=*SAM;Y26?9>> O Z?$_J5-U%9R,F M2M @DR%%\:TK ZJ3E6YM417E10DK2*4H*_N=W!S._*Z[DZYG0;J)$D?YXI#6 M_1R)3TM%Q6F@ AJ<1D;^]TV.F?4RZ4O=80!W$E(I0L:W^$Q' BMEP:%^R9?] M9HA7W=!#BW]ZG3"CU:M)JMOG;D*9.QVTXW+<_3BY/1Z.O4YO M^"*0>V.^[['7\_K#G@/RA(N:.-VS9OZYC%FKZ9:C%.#.9$'2!A9#<5@E$K0" MM*IXE*BS2RD]*J]<%FM,6(*(4&_><;] )LY4BE +O;)*A%C[/FJ M6%A=&; [AYDUC65-F3XNI759^/[Z]#?B^H;KT3&+='W_X_FM./_IT^7][\3D MY\GMF4_XILS MJEO'\C*[(KF]K^(1*(1GG,X+2J/4::E2-M-*"95Y:5W?5KT\31K9=",%1 0^ MWJ.G*U#*;:KW".5<'CA9AZ%J)TI1DU_["3[1354,=0GV14)"] :DB0JUT%#\^\V!U>&"8D-ZU\WWPG),BJLNA M926898XT-#ZQM^70MPPVIDP-DPI#A!K3/)3-(#YK?DKST_W)+=U8:L6_M6+@ M 0*@<$89OR17B-1DJ=#+SCWG@W='$))4F.IC[E:#HE M&S&/8.^*7YOAKSVPDW$&S,_W131!(R#-;P?D3]O,:,7RD!6'0U:9>Y@ ;19U M$^:L%S@T8HG.,U5RZ-MJ1;MQ=%.*L_ R %[MQG]P 5\"C'@K=6=RA9@ M4Z&5P+ZAYKY&;=(U^F#WU"$& M,;=!9?)85RNJN86>3%_Z#*I>*[F.U= 5V:HME.$(JT\/+%]2GSSNREJO,43$ MS"/Y8*6]0N##G N4/TO2;>KFK;0S8BI<_5F:\:@D9GZF8F!Y"G)=6O=!6K)X MG(51S6(L/\V4$S7WY5N[X4A1Z-;RM6Z=H#5WBR*6MK'JY$,9L68\DV2_04K. M9^'TA]R,.],K@/-HUD#3_ P+E,,H-VRLZI/_!;W5.3;Y)#;AK3W4X M]\00W1K,+ V.O>,.W8SM]+P!)9M.AMZPWQ,7SD;&7G?0P]*ADS%6FG2&72S[ M.*$*![Q"2CGVX1"FH>NY8+0-AEV:&GRRP;'I?9:\$+N "VJ]6AOZ-$]I>)DE M%!# VG@.OMB-3VM3.T=$ 05,23P'0/>@OQJ SMZ;;%4!"-)*=VV=92EX7?\? MJ.W=RYO4 @'UO=$Q4N3@Q .B)/H9>-UCI+*3D=<]Z;#KA%4<0R#>(5!D'\:! MWN^-ADB1O>'QCA2I:[(8EQP0T%T#-%K33&&6;F%Q0M* BT>._:DXE=CM?%._ M&RK#ZJC(.M.W"ER7AB[+^I7D0IK@S.:JA2YU86\-4@:3Z]XE_6!#Y:\U+J[\ M@C;"M$KM>HAIPJ&!]]8"9W$6EQ@]WWLQA?E5%UU@@KWQ,;MD>W@!WKVE9[P< M=DBQKN=;U@^MK!]+6#Z?]B!].FR&DV M--WV_+7AZ?RUX>G?=<-3][FJ(Z ;J[8"[#,I96][ROU-]TUU]F_T?O MGKH3ZJ/U/T?_C]0R=2=<;.XUN+9[IY;#M=O]NC.@>:G1([#MA\A?6R#^H[= MW$1]6[IN-5X57Q;Q=SF(:_FK-TL5AWKSP_]F"YUG]O;8A>$:[74V-/]H8Y?7 MSB&_N'/(QL/9I:%(Z[F\=B)Y[43RVHGD;]Z)9!-SR\T=-ZS2[9W[C#A5^*]] M4/X^^Z"T]EG819VW_7#]WZP_P]I"U5UV\M*BN+:2P[8?K'\M9_S*Y8R['6:S M/J_->GFMZ_N[KNO;*21U1MV;P/0[%)_NSL3^'@ISX+K[>5KFV"MHAQ!21-D<)#& ;0;G*GT\,C\0HG;0'/,10]F:_'<8 M,WS&/)8WM,N4&X:#OCDR?L,:"*Y*4DAI]>LU=7?LW\2&!;4^I\[HA\?6D)!CK>)OXNP0DML8PMB^ M_4WQ$4=D;H;X67$Y1]MUVZ7]LR)4S9?'[7-NC4LU7UBCB9\C,"OG_X+C)6W! MAY=0-!J A3S\0)6>#H]X:)M[K8MY.N-"H9*/W.UO4U^%*KK1'D-P06^U+#NJ MC5]K+.$RP7N2[.+\_@/8.>(2V] [L.P>.W"[0[3USG)_\),ZQ0?.(H?6=_URL.\WL ML!ZK.>QZMZ9R:T5">T.OS3B@?E[-+W_:H5O7YFFI!]?.J 7[?\L9;WE\J?IS M\<]M\+U^5151[\?%=[U5BPJ@,(8OGE('W2K"\946P+A'M:F49"#%*O)CFFH0Q.L[>3CF#_4:2=9_P(5/NJV M/:X>WC"U!M_NHO35SDWT\.1X*H?HDB+2;71$;JZ.M0T[K,;5-OWUX.PCG%73 MFEVI[4P&1Z9ARZ:'C@EFQ\N^MR.L:UJP;#I.DW3:,0;2%NU4W3S6AR6=QA\8DUSSULNS!@X'XBC7%%#M MI:-D[65SDB'5S6\1@$ M %T4 : " &UL4$L! A0#% @ _&R<2'=TP9<_ 0 M:0, !$ ( !*@< &1O8U!R;W!S+V-O&UL4$L! A0# M% @ _&R<2)E&PO&D<" "-!P & @ &T% M>&PO=V]R:W-H965T&UL4$L! A0#% @ _&R<2"/$MHO% M! T14 !@ ( !,1< 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ _&R<2)3$5P>A 0 L0, !@ M ( !:B4 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0# M% @ _&R<2&6LBN"C 0 L0, !@ ( !]"H 'AL+W=O M&PO=V]R:W-H965T&UL4$L! A0#% @ _&R<2$D;5XND 0 L0, !D M ( !7C( 'AL+W=O&PO=V]R:W-H965T M&UL4$L! A0# M% @ _&R<2+_(:OZB 0 L0, !D ( !"3@ 'AL+W=O M&PO=V]R:W-H965T&UL4$L! A0#% @ _&R<2(]* M5 6_ 0 >P0 !D ( !I#T 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ _&R<2*/?_6PC @ '@8 !D M ( !6D, 'AL+W=O&PO M=V]R:W-H965T&UL4$L! A0#% @ _&R<2*4&AI9A @ V@< !D ( ! M)TT 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% M @ _&R<2*@VE3\L! 1!0 !D ( !,E8 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ _&R<2)]7W8'[)0 U:L !0 M ( !\&8 'AL+W-H87)E9%-T&UL4$L%!@ I "D *$0L !V- $! end XML 44 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 45 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 47 FilingSummary.xml IDEA: XBRL DOCUMENT 3.4.0.3 html 72 157 1 true 22 0 false 6 false false R1.htm 0001000 - Document - Document and Entity Information Sheet http://www.nutraceutical.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 1001000 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) Sheet http://www.nutraceutical.com/role/CondensedConsolidatedBalanceSheetsUnaudited CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) Statements 2 false false R3.htm 1002000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Unaudited) Sheet http://www.nutraceutical.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Unaudited) Statements 3 false false R4.htm 1003000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) Sheet http://www.nutraceutical.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) Statements 4 false false R5.htm 2101100 - Disclosure - BASIS OF PRESENTATION Sheet http://www.nutraceutical.com/role/BasisOfPresentation BASIS OF PRESENTATION Notes 5 false false R6.htm 2102100 - Disclosure - ACCOUNTS RECEIVABLE Sheet http://www.nutraceutical.com/role/AccountsReceivable ACCOUNTS RECEIVABLE Notes 6 false false R7.htm 2103100 - Disclosure - INVENTORIES Sheet http://www.nutraceutical.com/role/Inventories INVENTORIES Notes 7 false false R8.htm 2104100 - Disclosure - ACQUISITIONS Sheet http://www.nutraceutical.com/role/Acquisitions ACQUISITIONS Notes 8 false false R9.htm 2105100 - Disclosure - GOODWILL AND INTANGIBLE ASSETS Sheet http://www.nutraceutical.com/role/GoodwillAndIntangibleAssets GOODWILL AND INTANGIBLE ASSETS Notes 9 false false R10.htm 2106100 - Disclosure - DEBT Sheet http://www.nutraceutical.com/role/Debt DEBT Notes 10 false false R11.htm 2107100 - Disclosure - SHARE PURCHASES Sheet http://www.nutraceutical.com/role/SharePurchases SHARE PURCHASES Notes 11 false false R12.htm 2108100 - Disclosure - STOCK OPTIONS AND OTHER EQUITY AWARDS Sheet http://www.nutraceutical.com/role/StockOptionsAndOtherEquityAwards STOCK OPTIONS AND OTHER EQUITY AWARDS Notes 12 false false R13.htm 2109100 - Disclosure - SEGMENTS Sheet http://www.nutraceutical.com/role/Segments SEGMENTS Notes 13 false false R14.htm 2201201 - Disclosure - BASIS OF PRESENTATION (Policies) Sheet http://www.nutraceutical.com/role/BasisOfPresentationPolicies BASIS OF PRESENTATION (Policies) Policies 14 false false R15.htm 2302301 - Disclosure - ACCOUNTS RECEIVABLE (Tables) Sheet http://www.nutraceutical.com/role/AccountsReceivableTables ACCOUNTS RECEIVABLE (Tables) Tables http://www.nutraceutical.com/role/AccountsReceivable 15 false false R16.htm 2303301 - Disclosure - INVENTORIES (Tables) Sheet http://www.nutraceutical.com/role/InventoriesTables INVENTORIES (Tables) Tables http://www.nutraceutical.com/role/Inventories 16 false false R17.htm 2304301 - Disclosure - ACQUISITIONS (Tables) Sheet http://www.nutraceutical.com/role/AcquisitionsTables ACQUISITIONS (Tables) Tables http://www.nutraceutical.com/role/Acquisitions 17 false false R18.htm 2305301 - Disclosure - GOODWILL AND INTANGIBLE ASSETS (Tables) Sheet http://www.nutraceutical.com/role/GoodwillAndIntangibleAssetsTables GOODWILL AND INTANGIBLE ASSETS (Tables) Tables http://www.nutraceutical.com/role/GoodwillAndIntangibleAssets 18 false false R19.htm 2306301 - Disclosure - DEBT (Tables) Sheet http://www.nutraceutical.com/role/DebtTables DEBT (Tables) Tables http://www.nutraceutical.com/role/Debt 19 false false R20.htm 2309301 - Disclosure - SEGMENTS (Tables) Sheet http://www.nutraceutical.com/role/SegmentsTables SEGMENTS (Tables) Tables http://www.nutraceutical.com/role/Segments 20 false false R21.htm 2402402 - Disclosure - ACCOUNTS RECEIVABLE (Details) Sheet http://www.nutraceutical.com/role/AccountsReceivableDetails ACCOUNTS RECEIVABLE (Details) Details http://www.nutraceutical.com/role/AccountsReceivableTables 21 false false R22.htm 2403402 - Disclosure - INVENTORIES (Details) Sheet http://www.nutraceutical.com/role/InventoriesDetails INVENTORIES (Details) Details http://www.nutraceutical.com/role/InventoriesTables 22 false false R23.htm 2404402 - Disclosure - ACQUISITIONS (Details) Sheet http://www.nutraceutical.com/role/AcquisitionsDetails ACQUISITIONS (Details) Details http://www.nutraceutical.com/role/AcquisitionsTables 23 false false R24.htm 2405402 - Disclosure - GOODWILL AND INTANGIBLE ASSETS (Schedule of Goodwill) (Details) Sheet http://www.nutraceutical.com/role/GoodwillAndIntangibleAssetsScheduleOfGoodwillDetails GOODWILL AND INTANGIBLE ASSETS (Schedule of Goodwill) (Details) Details http://www.nutraceutical.com/role/GoodwillAndIntangibleAssetsTables 24 false false R25.htm 2405403 - Disclosure - GOODWILL AND INTANGIBLE ASSETS (Carrying Amounts of Intangible Assets) (Details) Sheet http://www.nutraceutical.com/role/GoodwillAndIntangibleAssetsCarryingAmountsOfIntangibleAssetsDetails GOODWILL AND INTANGIBLE ASSETS (Carrying Amounts of Intangible Assets) (Details) Details http://www.nutraceutical.com/role/GoodwillAndIntangibleAssetsTables 25 false false R26.htm 2405404 - Disclosure - GOODWILL AND INTANGIBLE ASSETS (Schedule of Estimated Future Amortization Expense) (Details) Sheet http://www.nutraceutical.com/role/GoodwillAndIntangibleAssetsScheduleOfEstimatedFutureAmortizationExpenseDetails GOODWILL AND INTANGIBLE ASSETS (Schedule of Estimated Future Amortization Expense) (Details) Details http://www.nutraceutical.com/role/GoodwillAndIntangibleAssetsTables 26 false false R27.htm 2406402 - Disclosure - DEBT (Details) Sheet http://www.nutraceutical.com/role/DebtDetails DEBT (Details) Details http://www.nutraceutical.com/role/DebtTables 27 false false R28.htm 2407401 - Disclosure - SHARE PURCHASES (Details) Sheet http://www.nutraceutical.com/role/SharePurchasesDetails SHARE PURCHASES (Details) Details http://www.nutraceutical.com/role/SharePurchases 28 false false R29.htm 2408401 - Disclosure - STOCK OPTIONS AND OTHER EQUITY AWARDS (Details) Sheet http://www.nutraceutical.com/role/StockOptionsAndOtherEquityAwardsDetails STOCK OPTIONS AND OTHER EQUITY AWARDS (Details) Details http://www.nutraceutical.com/role/StockOptionsAndOtherEquityAwards 29 false false R30.htm 2408402 - Disclosure - STOCK OPTIONS AND OTHER EQUITY AWARDS (Details 2) Sheet http://www.nutraceutical.com/role/StockOptionsAndOtherEquityAwardsDetails2 STOCK OPTIONS AND OTHER EQUITY AWARDS (Details 2) Details http://www.nutraceutical.com/role/StockOptionsAndOtherEquityAwards 30 false false R31.htm 2408403 - Disclosure - STOCK OPTIONS AND OTHER EQUITY AWARDS (Details 3) Sheet http://www.nutraceutical.com/role/StockOptionsAndOtherEquityAwardsDetails3 STOCK OPTIONS AND OTHER EQUITY AWARDS (Details 3) Details http://www.nutraceutical.com/role/StockOptionsAndOtherEquityAwards 31 false false R32.htm 2409402 - Disclosure - SEGMENTS (Details) Sheet http://www.nutraceutical.com/role/SegmentsDetails SEGMENTS (Details) Details http://www.nutraceutical.com/role/SegmentsTables 32 false false All Reports Book All Reports nutr-20160331.xml nutr-20160331.xsd nutr-20160331_cal.xml nutr-20160331_def.xml nutr-20160331_lab.xml nutr-20160331_pre.xml true true ZIP 49 0001050007-16-000004-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001050007-16-000004-xbrl.zip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

$CJVI.4IV M1YL$15:40XR7O1*]/S]MY(,;O8N'1HNQ$1NAU>@H&O[74JYE&8#I1S#], !W M9 M)IKJ2O@FE\KCR(I?D'Z.Y_333]?:!8Z7(T"^&S7G>L(FUT.&RU -%BJ"D M)FBAREL(/8MC3/1J@;(YP(OAL%7/Y@F'>+0WQ#< *5 7ORPMNUQ^GU(NOX1E M^0IIASXHY1G/>Z"=Y,LNQ!HIA9C3^6)W!F[/L+Z4.2KAQ (Y:9L[.P8BY0,$SN\E.DE=E^!W++!FIU8+E(2R\KQ) MOZ^S9F>8W](RS)W5LU'WOM>\L_JE*FC675>Q*;9I<.0%N?P^)G%N/F/LY@7E)6/8\^3UMG@SZ=([,'=P M9_>0_>>],_@/LKY:O5:I9L\++BXTGW:4F3W#?D^;8;N@]S;OGO?YV6L >?8R MDML%6BXDT=D;EEMN;[P&EHV7L=SZB2,GEHW_4RP_UC;>YUMTK+WU9][Y6WS< M ^&AT%C)JXKD(50,^!J^OZUPR&'N\C&FQ!.?83H$7C$O+UY5GKE'@D 7W+$H M$2K91(9ZW%O.PME5Q7PPXY)(F%90]+Y4]&&/2Y]-,:&.NJ&-J:"(< :<,']@ M"/V0+W[5KNUNQ#7'U >_H]K&FSCHA[-9Q+4,P0Z62G;0Y

D?[_Q)/@#_+3H MU4?0YL?"I9]^P$!%W!GUQ+[Z@?[T^SUESI2[P[P(&S@(V!XBB+;Y* M%DCK9N:@/SYC;\ 'M3S>A-07/2QAW;1G[QZA(;HH@S9Y -_\&KLHTQ8])NNJ M>@WTN&)I7CZ>GS[U;I7CVDP(_0 )<(\(8*-DG WG[JAIA-Q@CP1FW9# ']2L93RJ,XAG MND#(+IYK_@A[ET+LG?W%'$']MX\1@XDJ)@[AC5C0_[H_'ME!O&'$'&'MVF9T M/ ^C8XX5')0U"KI=]6LU!]+6E\%=R4^OD71[(#3-\_IMX[/A!X\L.!!K9[K M$:@_(\%])>P&] 9_HV[)RW1\9J^>#LPL4E*?.HN]L*>,W9SBR\N),I-[X= 4 M2J]2^.@7UT+]&<@>J$+E ;8KU4R*GW_68TJN'LR6QP-LS/'4\OW%P54GU*JZ M(_-;H[!".5$;I7_ '[!K6+'Y*VL/)6Z/FM;(SO),1F7W;-P/./9ABODW85KF M$\8J9-O$TT\I;^2P78F/;WH_HWE712W=S-0[TO[\(!_H"CODBOK-J-^#4#=,VJZ#@^^J+?IU_^"U!+ P04 " #\;)Q(!8$: M[2T6 "3Y %0 &YU='(M,C Q-C S,S%?8V%L+GAM;.U=67,;-[9^GU^A MZWE&C'U))3/E= MO7KUZ.]_^\M/_X70OYZ^?7WRO/'+_.=G#RJ:M_[/P9G-O7C;>+5;=GB\7%CX\?7UY> M_O#)M;,?FO;#8XHQ>_REUKTE\M_0=3&4?X4(18S\\*D+CT[2X.9=C_;7)7_\ ME'_Q5?E+MBI-C#&/5__ZI6A7;RJ8FB6/__7+ZW>K(:)ZWBWLW,.CO_WEY.2G MMIG!6X@G^<]?W[[ZJOY\N6BMA^6B]G;V@V_.'^=2CY]XWRSGB^XM>$B@NEF6 M-='N5H:-I&870WZK_?76'R^@)\?=?7Y1?[=X_%$>@X+6\^ZATMV MJ^)D K[/_QL@W]?U1A/O_Y9U5V?J]Q#I;MD)Q.@]@?=6F4"HOI-V7XV11'IJ MN[H[C6]:Z)+66VFL73)MJ3*=4&^:6>WKW8#UJ#J2D,^:>8!Y!R']T*4N0C87 M3^TL*\1W9P"+[M>Y788Z_7:7T .:FG(0[Q)ND(U@ O*9[SIK+/0?3K\EB M@VK.+UHX2V7JC_ J.03G,.+P>C0^TD"?@UOLDO=FF1&[[:E3-Q0=48A^.O1N MR;%$6/N*3^;AQ7Q1+SZ_FL>F/>^E1/O4'4G,?S1-N*QGL]35JZ02YQ_JA,63 MKDMJ99>4/:I.+^0SV[:?D\?^Y'SEOYS&VP5Z24%P7&G/ ][0Y_;#Z*:_>#8PD M\*OYQZ25FK:'J[6AZ/A"])SJ^VN,+U*_B;NWPD@"O8,/*X=CEQRWRXW2ZH]6R_64&.,%DO4/]U_>OJKC#_A,6S9=LF+7PMS\PZ MF/W\* E0]:E6!:JUXM$B+CA#0G&)O"$6"6&"LHZKJ-378YWE!?FF7>-;<+#_ M:)NN&S+F]A7>)QMSR_"EI1O8#SZ_IYIV2JR6PFABV- M;'*.S&;-95[<>]FTSYNE6\3E[.XX>E#F(>U4Q'!'-'$(L*3(.!X1L]0A"]@Z M+)CTB@]B$/V#0>B;I-#$,/[!J)\>WU+KDZCZ38[MV.;EOHV;Z?HYH %[NNSJ M.22ETIR[>KX:3$*[^3"O_PWA54BLJ&-MOP3F*ZE;"#=B]]?IG^M9&@ATJZ(>*\JDL9()Y+@)R"FND!94("T#<$QB (L/8C8'#GCC0-=?ZM?K ME..!O+O/2D3J#148A<@=DI@$Q(TA2!&FG='* ?%';*R/@GW-\4Y6 1=AS.&^ M:9L+:!>?W\SLU89#*GMQOMVU*-)_Y0"K$'!$/%B/*"1JF( M,LKC- ^."Q_W M=4G^_$Z.8N(*?#/7N&ZA]761*BC*L&: HK(,R: -,H9*Q*B-UF*"@[:#F,?^ M8YFW![;?F$*]O1.S6DYZ?V;G/1A85(X*8^<527%0Y)SD&-BA2!5. 9*A+CH7 M%16#:,[_8VE^[!,X=;2Y_4#:N/'?SJ-FDW>W^?#8N-T./OY5:/EV5QRU]J.Q M=@ :&P14 >+:,Q0L#4@$00W7X+@Z3&RY/N.Q>SGM9KDJN#2<& V*@2 <]_M<"5ITR)>,SA_![SV)2!J\2:^W%N M0ATR?!V/%R.C5( .U\=S/F]?A[U9K+(B-<:P0-[)I$8)B.25@4JJ57!LHA.! M'7/,.-YT[XE*@>E-+MR%K?=@KPA@9GC_7F(]L?H][2?CVZELBW8M/?K;,U\-[ MS'.?ZA55C@B6ALNTM"@:S9 GZ:^*D2 #\RRZ8AR2^Z,4(M[H%%=+C%04(> 43V&L#[*#ZX/FY?YZ'(U-PG?R-_=SS$/K&"A5- M_S%C*6(A)%L /")N@2!'B)?841/,-S+M@Z;KG@7RO4$JPX!V">%!W_V]=2HA ME8O!1J2L(@A;[1&P% @Z$Y7CV$C-V2 >E%GD&)\'H^%40O\>^&RM53@JM%3!$M!0)M41JKRVDST=I[%V,!F 0 Z3+>,@ Y)@$CY6 K8)'3?PNF$9!W#?*;I]$JX?B&LCG;:V1M;AU?S9_:B7MC9#>&W^8 [*U4> #S,%973"R)R8!+ "+'F;;V+.(;RP[;R>?^B24[L\SW,"X3G$VF_U M$7=7KJ(2!E0R@B8FK\AP H@0IA$WSG,>98J.ABT7E7$81F;))("5"2.OY5RY M/AOR(KYNNKS*>QK?VT_;@\N'M%19< 13;).7IBU*D11!D7&/G(W)W9;I2_+' MO.=>KLC=PE5@,D3O-7*2VNQF:Y0TJT+4!:6D$ 0/ M/+HGRN0^&)D3HR T[463O=/(EKD??^WR':>7 M]=S.?4ZOZ1?UQUT;1_T;J;"6A$?LD6>6)D/*DX L!!& Z @[;YP<,L28 M;M*;@I"6.7SG 4+W,D&8U\^Z'FN1]]:I)&AA PU)TPF&HC4*F: (X@QC#)9* M&H?MNI=AS523>?=HWFCX%8E)+NSGM67H2Y%[ZU0Z8BJ9QLA8)A!7"3BK11JG MHM$1EN^W['VQ8TIWH1!'Q@2PA!KY(NP7()XUW=:KC?=5J9R0AL<4: 4?*2+. M2Q1E&B]VRDOGP3NY=XSZ'3!D1/P*VYE77;?,%W!7"?U[K'[MK%N%R!0+1N1[ M< $)D;QV1H5 6@C&>4X?%L(@RI0)2P]@=\;"L:!N>=FT22NN\^?VYL[.RE7T MU%NA0OI>9$83)'+4%@\5>8\:F$--36V!6AW#V+Y?F>WV#-@W]!(9424BN54:RR?F@F<(& N M^88\W^8A!H@8MC);9O_GT '[.) 6M(;OFW7ZF^ND.7"USKP"?W6,B),#T$N8;D-^S? M2&5,OKH,-'D(42&")4%1Q 2"M-X;$HF2>RNM[Y%88R)Z.%MXFL9@][6%&QJI MC!*61>N0BCS9!Y*<4>J=2&(Y1[@RAI%AN2_+['(?VA:. VD97OVQR_KDHZUG MJQS=S8V89+VQE]./^>WD>DA+%2%6>2$X<@Q8\CN91U830,*+&+7Q5(#Y]A:Z M]Y[XN_R:&-4B]Q8O6O#U"M;T\PQ6,S8/-]]OV\*L/M4KAX,$C1VB^80Z=RQD MI!62P GWTA+*CMEY+T2GB: L<6#GAH0/6"+?5JTREO+(A4<$3,)/)CA5%!1I M 8%YKJ@CPVX!E3%RA3@S,H0ETF#8>I[UY>G\>=U=-%<)04_CSE216^M5T0KK ML/'(8,F05-8@&26D_BW5)#@GU#"7B!_4TQZ;+F.#6/!>_96E?6\_K=-%K=?- MMIJFK34KD_0FEZE3HTU(8P:-",/Y2@:-.=D(PV;81ER9] K%K-+8*!;)S_)U M&/%J?O\C:AOSL^RN7L4(Q!"CD20I '4@;?J)))M,H^1"8R[QL%L*\KM2.1-A M>1 2;7BWMA=[;M2KG,VYJ1BD,#8PQ$GZ"4<*R%IK0OH?-V'88J/ZSFFS'X@' MX&U"MV8Z/!!1.K38 7&1 N$(XLC0X;EE'LX[U5ZXWCPZ7."8;Z0_LX9 M-A&Z!Z'>2N0_+HH.X-K&%BKEM540! )&.8H\$ 1X=0X'(E>8"#+0:3+?.;G& M@O-0WM.MY ,/]9YN5:\\**H!\G7E%&N MOG"B.2(A.0SIK@T:#DPR0?^GKSO MB; \!I4TE$SW-U.!I9'XC$%^G$4"<$2U3/&LUXPK&;R)PRZ.D^]JW7IB3 N0 MZ][3,T]OGYYYV";<7NU6V ENC97(.J^3:R!%SL:B$=="218=MG'@KLEA]WO' MYE]IE ^ZX+#.VS1HM6%=MQ*8)5<@N9OYC@3"2:TC+X5 ,D@;(_8B3<0P8GU7 MB^%3 %E"F<4(?G$:TV=Q9N2 M8%0CK[#6D4=HBP@H M8QXKP$+N,MU%(;DS@ETG0![43@6:$RNT19%02.8U>,1D2#]18RQGBAA[S.<_ M)IW]IBRP!0S0QB''7/&OX/S;A*("S!P@R'JD=UE2ZU*2F8E)QXY@ADB0-8G4Q.L&KRR.#F4 M!U'H?Q[J&^KSC37;W^,IOC]&D(/IY.^EL&J9/OQUB)7\OZ<0FQ:^[.)#]TL] M;]IZ\?G5? %)6^1SUE^W7A88_QK"%Q1M*5QKCX%S> M9N:I!\#6(\_,[9.(>T%38(;?V1ET;^$C MS)>P_:6^6R6KJ,")D!QZJ3%%%@1! :1#*<#CD5-.L#[FW%*#9^9VIN*]82D2 M>'3)A" 41<4D4L89))G2*=0# M8P:^75%H!VBLR1\5HA)?.\QF^54YF";C]6N(4KVRM6 M7"A-O>'($!I1=!SR^E!$Q!A@(C)/U;#=OD()HL;FR.AP%8G'K[SF-8&?@]O^ M5OR=TI4SCF+F%(K).*+\UFG2D#G?>T)+DE"KAHQS-E^@5(CI9]S1D H )E0./294[IE)X[60,#$NL<]R3I?ME M^L[J#_.K!Z/\Y_>MG7?6KZ^7KOZVGLHOVP37*ZMOLNI-_[!8M+5;+JYP?F/[ M/.E32HY*> P0F4 RG^P@>4=#0O1(Z\"H"MI?&+_-$YU0KR4YG"YQ,\_E7=_^GZ/?Z$>^5 MH=_L/A?N]IEMV\]YP_1\=6[LKKNY?<[_?'1^JL&_3%'A EXG+79GSFX\4]$S M:<7#&ZN"T<2;%+$0EY5BWK3NN-CSWYS $S+1&Y? M";]:$=OG.]O<0$6Y4=Y'C%)T$A/"FB>G%/L,/3"OF4^309C 0YM M^1:V;R5LKU@IK"AW0)"/FB(0."#L?0I3K22&1Z7=SE+/%A7WGSR L9W :7W2+^CP/Y>5RL6SAYH"^K'8=S)O]4T?>8-W=F7D2%]#^ M#]CV9:HPT)7=T6H%2AO)$THZ4);,9C1(4'!(<$^]UL+:@9M1W[-FG0#5PWHD M&P8T.N^^@!,B)T+F%["9H5?",ITF17H>0M#6*#+,F)?Q>H^&IQL:Y;M MN&Q+#58V2"D(SP\V $=YXP8QAC$*7"@K J=$#GN[L-BVS! CY)M[U/W MXRJW58L5P7Z5JPH))P IT"1-AG<(!P+!$&J2WSB(;V5N51X5WX8B>IR$NVS& MI=ME4S'IF"."YB>,7$Z*<@-#2(!>P3CZOB2B*P!"-X#RU3E@)@VA8YN6? MHZ'A6.@>P;K#=:$"^Z-;Y)E^VW1#.LB)NSGH[N.5%)^WK\[<+%99D1IC6"#O M)$/)9 L4.2@$5'!LHDM,/LQSTU^D?&LO?[$I>J_M[.H1F[?00?MQ1TJJ796K M:*@ E[Y3+(E%8#1'E&*6?K+*>Z&9&?@<6JGK0D,G\K$Z:'^=P?CJ^/R32]N&@_9]!,-?BT"/0 :V18:?'N=_R4_"_NTO_P]02P,$ M% @ _&R<2#D;B_BP&P YSD! !4 !N=71R+3(P,38P,S,Q7V1E9BYX M;6SM75F3VT:2?I]?H=4\RUWWX;!GHDZO(F1)H6,\;PB(1'=C31(] -E2SZ_? M DFP#_$ 00!$:R:LL"BRCLPOLPJ965F)7_[^;3IY<9OD19K-?GT)?P(O7R2S M439.9U>_OOS\\97Z:%Z_?OGWO_WEE_]Y]>J?^L.;%S8;+:;);/["Y$D\3\8O MOJ;SZQ=_C)/BSQ>7>39]\4>6_YG>QJ]>K3J]6'Z8I+,_O\1%\N);D?YG;EWSR4Y9?72 \,6FU\X6Y;]>5E5^] M@N@5AC]]*\8O7P3F9D6-\=K'S=-R[Z/AOZ*EVVAE/)B M^>NF:9%N:Q@&A1?__/W-QR4:K])9,8]GH^3EW_[RXL4O>39)/B27+\J_/W]X M_:C_;#'/XU&RF*>C>/+3*)M>E*TNU&B4+6;SXD,R2@+^7R8E6R4=/U_GR>6O M+\MN 2'( %[A\]?=/>9W-\FO+XMT>E-^=]$>23:9Q^FD.)ZR)QT[(_!3^;\& M]#WNUQIY_UJD15JNDAHD?=^V S)J"W!GEPZ(JBNT73U:(DG'15J\NWR?)T78 M()>;VR&:]G3ICJCWV20=I8"6E,_+ *2)BVL_R;Z>R$R](7MC*IO>Y,EU M:)/>)J^#[3!-6F2OQN M,6J3+_-#]#YLT^*T-??4+4U;)*+>'OI]R[9(6)N5 M:C9VLWDZOWL]N\SR::U-M$[?ELC\+3HM-QF_F"_R M))"8S]-_+Q7%?;LIMZ+3^3]AMCZAJ!JUR?".,;MGJ][F57N E@A^/;L-NU*6 MUS"UMC1MGXB:HM[=HWV2Z@EN9X>6"/J87"T-CD-T/&W7\O0UY;.C>0Q=3M"NU6TMHP(TR71#WJV2$_X7/JFV>S5.+F,%Y-Y M0^IVCM,-K=DT3F>GD_IHF#8I70[\:II,OR1Y4S*WC=$BC==AJ'RT^)*\V@#2 MD-(](VVC-RA(.EL&,=^$)NN&)4FGG1&LIDJ^S9/9N(RM=#+9UFVYXSFW628M M3[DK\-[9-/MQ+.<*LTVRT3:%7"KC95Q\66KDHGAU%<>[5;:"_TW8-_?7JXD+8P?^Q0 MD6*(.<^@#,!PR20G2JT!$1):=0"0>SU3^>A%EH^3_->7L.JTWL&.>MB6![M= M"#3K%:C 6/ABN?W^/)ID13+^]>4\7R3W7V:S>5A&;K*,/X>==^7==*UJ6YA5 MW](CEU/9(\+*,T 8$$X1BH5S M$*#^*UZT=Q]CS1OE>D[F2>=8'94H?Z5X?R M8YXD]I')55,Q'O6-H%.&\,"M9U)C'% D&W:-9RC::H%VI2H[#=]:.\YQ\JNA M#VU ]<-K2.^:\8BEYZ 8O2O$QZ2,C99'+>/T-ATOPJ/[[O6T/'O(TWBR;6/] M_9%CM,UH:3AD9#@*&S*V0 GA2@N (E.!@S'N2WVV^7_U=*>AK)_:,OW@MU>Y MOH_=E-]$]FX63]/1_R;Q9'[])OZ2Y?$JN/YZ-MJI%S5[1@P:XRE F 2HK ;> M:EZ1;\,:;")^]'S$WPU,3:2L%E_RY.Y=?A7/TM'N];ZS;02)]91P![@@AE+ M@A&_(3',U422^)E)L@5@>MC^/\2SJ^2 R[!I$TF.M9(8"A3H1=!(*#:J)[#J M:84.TTEHBE)?0C[XV'[0*@*:*>1@>&HX!ITE2DJ[T5,L^6!-_092V";'DV!X MEA(=FFG>KR![%^#O K/*1L3>,]T;_E6;'/,#[4-=)<(T"5%(A(YIQ&A)"*V; "AK72.]&$EB'J M01\J3?4E],F;]#;Y+N7SCR2]NIXG8W6;Y/%5\KE(+A>3-^GEOI.\4X:-#$;! M G(L//G"PC'$!1]ELV@LH4/WIT_7HQ[A:Q(QV<)SE;WW/D]'B9I,UG=6GU+] M/LG3;.RSW 8W=52V>'=9IGB/ B>?XF_K;\OFRZ3X76&8W@B(!"5 *DDU!4Q@ MPAB^!Q-IV<@&)<]"%P<-]'G.CG:P7J7+'Z?(G! M$3'81%_IL]#7(>#9[69:T=O[)MIPX@@*%1Q7;Q'@P?DA.#R+< 6>IU@W44;V M+)1QD #W<;X:3Y+B0W*;S!;)VV3?MO>D911 Q8Q)QSVTCECCC-P@C#!H%&SG MST)7VD&D!^$N79CW>7:9[A/L@U:1 !Y!CG#8."51F+C 0,4"90 T$:IX5D)M MCD:/)H[)IE_2V7(G^I",LJM9^N_@<(R#)YM>IO'&I*N\D@?7 ]^$G]-)P"HI M0IO%-!D'S55?BC(SMX[1T]',D>4<"@:90A8*H["RC&YBI\8W,MOELU*\82$\ M7&7>RJA9Y'EY3_[1I?/VU/CPG!'T4A#EL=?"6.^]D[PZ!E+$>CO(J.K9=:V= M-="Z>)Z9]H?'U4V2S^_>3^)5K8C0]F:5W]W+2M@Y?P0XH@%W&UPR +FE+EB] M&]@%)TU61><1YA]Y5;0EJCZLUS6N^TS7=9/(& S#4U99IQW@5FF!JV,;!60S M/>L\ CTT/6N(YC/;+)_&/9>W?#]=Q[,:^M8K'9$E4EM.G16865CF>IOJ[$DI MY1HI=>>A[*$I]9!%-MR5U% [(O!1;Z!(.:F,(5893:QET'-8Y2 %G\,U.LZ! MH&LU[?P\IS7$SJ,Z1<7 .MI[G+X\[1WAL$ZTQT)B:)GF%#NXMJ\DL+19AEV? M&5BMB/.PUIR(VYE5)6R+J[J>;_9G:=4>(X+>"^0$8IY0 B@SC+"*?<[=%_$X6(>YZ]FV%U9N==;&E9&[I^*8DL8] M4U.[ G&K='U?:;CUX<]81*:<_O4L[&G+LKT;6VK/]K^C1T0U( @ASR3QP% + MI/00,*FI(U;20S9"'^P=J@ZSI77D*,<,*1 V8:](:5X:5[%%=+-+M"T7@#E9 M(EG;, RUO(L)KF$Z]_&H= CO#ES3_+YQ) 'U'C(#I%>20 NP4QM$.>SIOM!1 M]S5/$F;6,B(]6+B/:3Q8@V-;\T@@ZX#4S.GPB2-G-8$54\@+/=C;FJ<(:*^L M3P+F!Y%Z[](^<*/SW,+N7'C@!3==&X^-O5\@S2[\=A:1:$78G8/4P\+_1YPO8_P?@C-XP&A[VC32 M%C/#&/'* *2TTTR(C1ISUNCR:,<< M-\ C!8.E@G#%"M"L48IQ9]96BS(]#8+/+B9T]R=M6B5:Q MZ7G/J+DG1- CH8'U1E,MO1/,,K+19$$:77ON['G?Y9H_$HD>Q/F86YL4HSR] M615:>&CX+!./:N;KM J4KVK MRY+(CS=Y$H_?S1Y2#VNKRNXA(BV%=Y89+10R.G@C5FUB3Y UNY_36;64;M6D M-91Z4I$GQ=A>S^9)GA3SDN(#FK&G9V2DML8!%!PNA(4/B\)O5@-%S0(TG95$ MZ4(AV@/G3,[%Y]FB3)E<6[@FFT[3>0F/3Y+W23XJ^L\DH?;D<7L#4)+&VC;:G8M_'$9_FJ E0ZJG1]75%T M]1;9=[-MRM+&L%%90TI:02T,^RJ@V&J]@5I8V.A->IT53&E+7\Z 7-\J\^EK MUH7*A&$C#SVUC&$OI- 8$<20W*P5X9J]?+&SNVF#T9GCH>M=9\+(G6PTRX$C M(!QV"!'CK-&P3&12FQP9HFVSL\3!1TK/ EZ7UXY*8#J_;F2ST1+WLK3(;+Y$ M:W/9J\-I'UQ0?GI)_SRSFCC/[]+9U:KNX_)M:8\;-+JDLNNX\K[J])*4-5/K M;Y;3;=;!SD/,(\:(C YVO-)<:A,6#R$<"NZ07D,2/MI7-00@J9M<&#H9[*-=O0GFE0QEFYX%OJ)=>]I1X MUW>_Q_^7Y682%\6!Q,HC1HD0HA!3YPV6&$F!K,65I) ;UC69'I4DZPO0'D(1 M>XB_)_UM/#V=?7J1;!_(_6 MKZ$EF#Y'M3K=^?R4Q^-D&N=_%LM/Y=Q%V+#?Q_/RKOC^-*HZ?2.%(/5>> (U M!JX\$D"P8H'H9B?HG7F0G39/\0S)9^FC%=7I3V#2XS^F7 MQ;(\5!G1+RE[FY4U FZ2>:*N@F-;FEK[%:.%H2,!C,)6BH MPM&;_E'MY4CN-IED-\GX4S*ZGF63[.INQ<;!'.D#/2/ #*#**>.# MNV/*BW<*;%:0PHU@-$&$M)D/#0E6^ U-A#X"K>- M\J9;5YKNCT8Z1>V\ZG+H'=.'ND9>^3+1QC,$.=2"$,M0Q:RW=%COQ6E;@/7U MHPE8Y]4,-1HMIHM)6592K2Z(/#KD/TY7=@P6*2&D$= I8(6V@!)%3 6(50-[ M?\SYM*<=^,[^8&K\0(H80<@P@YC X6',$-->58QB2)]-F*=C/3D>JK/J1*TW MU]?I'@EK>' (M#&8!_./:&4JIK7 ME'9T)U-/QH#=GZ7V7T;31;C=':U MRFF0J(\)W*SXCQN=N_\7 YX"R(_4<>.A+,7W?IN*V^V:=4?)@K[=IGF MC('%AEL C!65/Z$9M8VJ];5N%O6Y476&W1D4:.DR'K5YGT9868.OR6LB>2PSWA\FNF*?3,KS@%V5EVX=!AG4AD/WW&3J^ M;7%/:-7HK.1T?LOF]>PVF85UU.UK=1[,TCV<#R;K'+Z/JYL"?4QQQG?1K$GX MD-R4BW5V]> FUIL]MX&.Z1Y9*8&TV@8#S#+LK2 <$U*@.]0[2YCU>OR7951[? M7)>;SX',MYU](H"M(9ACA95"5CHI %E+*/R$>SKZ/ZJF^YF5XZFJM@1M#R[! M>LD^)/1@?M'./A%20IGR?9R2:LH =DBSBCU!%!MLUEH+$GNJ RV#],/IPM R MRH:D @U%7R2CGZZRVXM1><<\OUM)?OV/IT)??QU]_KA%NO<_1H*5_FC8_CSA M#&&+I.)K4J%R9ECY&BT@GIV(0 _K]&TV^WSX)L2#5I& $$O O=;08 :"W47E MF@4LA6^T%CM+FVA/B*=#T8,TU];'NWQM>QPPV[8UCZ"CUFO@J$,6:L:UPK9B M"C@[I%L)P[386D"U/U5YR/;!!_3./I'%SH9EI(/;!3!!UOCP><4>,4RXP1IK MIPEKN^1;P^>'4X.AV6D#D?X14M^1Q*_SN SZO0V?E_C%DX^+FYM5Y* DZ-W\ M.LG?EF^.BR<5G?LS^YN/&"'!N9?:2^ EQ()1)WW%+G7B4 6??LV\%J26G0.V M)EJRG+R>^+UM$VQD!/[^<[CUQ/QZ,/ISN>),7: MVMF?\OJD9<0DAX9.0:;(J7\]&>1(7P6)= MZ]=O>;:X"7,O2;&+Y%.VO&^47MZ9))\'A*K?=BW>YB-&FDIKH=0<6^"0(3KX M116[&,I&3_"NO;MV%:%?!+L\?:_.";L_\[R.\^3](A]=!\CZF^B,YY]+X;^[ M_#C/1G_6.?#?FN0$(I@M08MRY?;PE1CAY8;%V?<"ZIU7=+VNN? M4W[7*W*42(Z5-XQ*;#W R+"*38ME3V= >T\;3Y3/SN/%4\$8_"'A0^#J'A(^ M[1-1:!3R4!N*)#?*0V],A0DU9-B'A">(>-=1WXD ]6!I/J3P8+S@^\:1)0$= M!#R3CCG$)2=5Y6)+C$%PL/&B%F24=83.#R#VH<6'!B'M_J6<3:?9;$GBP9.A M[]I&WCOD#-!4:TV-5R(2S6IW!"=ED=\M9UT: MQX4:_6N1YLG89,7\]V1^G8UW>8FU.D=>*,P<((8#@36F"N '-A!OE(/=BSB; MFW&=H=/#VGU$]C_BR2*II1#'=(^T-(9[X3BRRGL E!:H8AK"IR^S/W.,H%W+ MO@-\^E:*E2[7U8%5ZXA8@7F@W3$N+<+&>Q0>=Y(!7L91FZ7Q=783HT.1-X*C MR$CA)U5EE$2]C^ +97*D I4CG2CV@B=W7UO\>EP'OPZ#1:6'*U>+K,YIW)A M:YO?J:]Q/NXTJG=@ZG/>Z"E4\1@?>X(XB$.BUTL'A%O/&V.2""N MRXMR1'I%.'/<&51!** 80G2R3T79'>A!C[5;)Z.TTG8PFZ3C\EH49[R M)^O[NLFX3#$KT5G,X]5;C5VU5OG80UVCLDJ4$9A"0#4M[T,3+RMF MD<5ZL('@06A +:T\&>T?7,6&%G3^(37K=(_836\FV5V2K-X^4?WKH>^P/Z.M M;O^(,,DHDI@R*;U4UCEH*U8XLSV]B:^F3]N>8++NL>HC!:ZIJ;SFZ]UB7LSC M65E/8^7#=^&_[9HK@H)KJY'B6")@%:=&X0I.2T+6H_$L"[3V0I%RWAGFAN;&-;N)UE^9W/D5K M&\D>%&>S6Z^RGK>#]RG^II-9D.+\0Q)/RLCDZG;4BJMUC'3-ZQY%:WVN2!%6 MUHUE3#LL.*1 01K@M$!@2P1MY(UV=M!P1L4\-_)-++C? J9OLJ(HZSJM2,@> MD?#EKOI^IQ%WQ!"1H#!PH(1SSGHJK0$&$@* 1]HHTNRB:F=G$V=0I8X!/>=A MQ?K$X,F5F7Z.#$YTW^H<'+0U100@%H1S(U3X@)B#P8S'A$%%A-),'[K1T_7Q MP8E\UC]#:&.BB"NG&*!*"0$9\XQ;Y"LPL74]&>][#Q+Z5YR=QPEG@/R_9PI] MA9D#A>.D\LRCO@Z"8/5H%,0@ MD/-EK0]4,>O=@%\^/P@-.#;\VPSM'US%_I,.%LZF6<_H8('3X)49 :1SIH1' M:JHK5I0=6%V$]@33Z&#A.*S.MI'47CQJ6A8!Z\X<6XT?$1FL;Z/"4L1 06\U MYV*S#%UO!5A.4;$>O9%S8#Z L,B34-Y_,RF790*#^) M9Z4Y<:A&X8-F$4""AS]"2.\H D)*!BK.&5$]A=C.E*M86^Q/SS";(]C'.?>: MNL-5YQXUC P$@ =$$/#*(D.E!;)B!'!#!^O?-Q/'#IF>!,8SEN[07.MS"/5T MS_=--KOZE.33E8WX>C8*&TXPA4LZ0F.\W^VMU3GBDG-IH5>.:&05@=#"B@DH MV+"2Z9H*(.L8EB'GS>VZZ=:%M;YKKL@#ZS2V5F$J*1?.6;E9<9;W%HGK[:B_ ML0UZ9N3[4.32!WY=%(MD;(-#/[L*WGJ:C5>$;^=_GZH>/UHDD26<&EW&/;5P M&!!10>(,DZ"),@XYMZZQ,G:.[9#WS>KY4 1?;&G\+Z,UGZ[CV3J \X^DF)7N\[ M<)_B&?*Z>?(DNHW32>D=^RS_+?3=6_.VHRDC3T%YQ(\*U371)I M R,@4 %0 &YU='(M,C Q-C S,S%?;&%B+GAM;.R]:W/D.'8M^OW\"MQQ MQ)V>"-4TWX^YMD^ !-BN.-4EN4KM.1,=-S*H3$BB)T7*)%-5FE]_ ;XR]'+7@B9945^;_\P?RS\0= \G6QR?*[ M?_G#;U\_P*_QQX]_^)__^C_^^?_Z\.%_1U\^ 52L=P\DKT%D^CNX+8L'\->B_'OVE'[XT/X1:'[89OG?_\+^WTU:$?"]ROY2K>_)0_JI M6*=U8_N^KA__\O//W[Y]^_/WFW+[YZ*\^]DR#/OGX:^.?H/]ZT/_M0_LHP^F M]<$V__R]VOP!4 _SJK'-8:3_^O^^+]+'FS__[ MUT]?&S\_9'E5I_F:_.%?_P< +1UEL25?R"U@__WMR\>CZ,*?V3=^SLD=X_N* ME%FQ^5JG9?TIO2%;"J-YVGU);M]_Q+8L7SR!,10RADR/,?1/9QYTZY+U")^^TC%F-L7#><; M'>_OZ\(WX\TCCV+>LF]]HC]U7V1//R&_C?%.5 \>3+[7 M)-^032.:+QX-LLV__('^M,IW=;GJ8Q+,:?O76?W\,;\MRH$C#T6F$X1VB&S3\!S+-2+#0?"*Y!]^^]K#:#Y2;>@/(IR\9;LD M5;$KUVVHH@A9I&Y!_^L0F]-\ UJ X #A/_^\=VH21C?=4YH_6QBS+[#Q,MR^ MX@-OQ?I%UV*.T*YC>H;=)A__Q.W::UJ*M09:6N^V+.4JRM>^,,.P7(.BW)"2 MIH+]'Z7E^@R=W3=^7AU" H>*3%GG"3FOS)%R)2;$@3:^4I$/2H*C(^L]WQ=//U$F*QG38 M#TQEG ^&V0UR_ND8 >_(RFBNYE61\? +1>^,J$;$5)S*=/N1)C3?_Q=Y7F'' MBUW',?TPB#T?)2APD]Y.')FVF$B(/GT:E>A0@086H+A$=4*8-%ZAT,F7E%+P M4Z5,*UYQ<%(L9/E:BEI(XW\C%^.8X-&+>%>6U$B25>MT^S>2EG10B^@ ;.7B MR ]LQ(0(QK&=&,BR>U,XM&)>R9 VH%DU.ER@!088,CJ,V0"&C5\YY.D[+QZ3 M,">F'U*D*="08U0_@ M +N!DSB!;Z#>BA$&H5CV(?;L:7*/!A/H08DF'H)L\:8=^HB22CHX.5*6<;QP M_V2^(4?4_!HQ"OV;7&,,"SS*T$^:7-._6'EN:*'$]-PH\ +/"K&/G?[Q@6\& MO)(@]%#-6C#,B#(P_!H@QLOYSJ^-$LGYX9-L*.CMA_X>Z>92E,S?O^5@%R-? M!?$>/:R&-3E%0-7!O!Q$,! MQ 9V M?O9T$C,PBYIQIDGS^59AR.FAMDXJHA3!V_;NAD35(Y^ E3J!VO>#BC M'K*L+4<_I#UX1T'&L2&N(:UBM;:<$!H^]!W;-VEV8[B^A8W>5H)=2141L3"Q MCG1Q=922"!$HJB6ZN!NG)ERT*=>3 RZX%$6&NZ5IBI0/1U5%GA$>78'4T*8Q MMDWO5JX=^8GMVU%H6!C'=, 4>GWN8_HXX=42L:=JUH\!#&!H^!5#D)KS*J&/ M%3%EX"1$@1:\\/A(_Y=C9?X^+XF[&/L^".^)*!X>BOQK7:S__O4^I:_%Y:YF M^^39^8-5&+BA'QF^YUDPQBXT$79[HV&2<,]'*C UT6Z)!B)H,%Z %B4X@"F\ M>6(4N[Q+&I,1*[7"(5"!;'S:Y%*9]YNQE#'T3G5VE4?[M+T M<87_:T<-#UM*#0LFT+9"RT0!=AT?A[[EV(D1A1CZ5@#/]"/)IVKL-PT0\'L/ MY?^5Z2&W:773H.C<8]W$^YELZZK_I-DG?=!?WN?AG?XQDK!Y^\-8\(62ET;L M?6<'V#:[+;F\;7I8E%9D0[O=(\FK=G-U6=+WA[!]]^Y2I^;_=C?TG)S MG=YLR2JP?)I&!+$3)M#Q/>SC>, 7F+2K< 3TZ5%ICOV](Z"X;QH?'@1,#9/C+AH3CR" MWUN02F*%",%C!%\3MTI4FY?6"=5[3Y>P!$LPO60=E7&'2PRE>3JG:,W9>?SP MN"V>"8'YYG.1]_]J9E4O'YGH5K^2AQM2KAPO]%PKM%TO#),0(HQ--,PP>8AK M/X=:B[IG9Q@B4+20!.IGJ&/TM([-1Z;@K'('"E",@(($PP5-#OE/1OJKK, MU@T7%R %^8[QP2;#JG81KGL8:=?ITII^IWHDZ^PVHT8?Z9]2"VD%-N0VR^DG MW=?3NY(TCOR9-_(=JHRQC-3.OQZ&6)JKK5'C"Z<'>Q% M^=QD/RLS\",46="W0\M T'=C:/,21INXA!RT0_^+@[WY5V UK,?)*8<:Q@=(6;T M2_"#1YSQ_JL*0(I:@C<>797%FI!-Q59$#H=-^#LIUQG%MG)]&NR0Q?X3&E&2 M&*'#1DZQEP21'R,D,D 9;TWS^*,'V):=?SF/1'J08A%# <-\$6!:2L$=U?U4$"F?LC5Y7XZOT^\1RF'FEN!:&O\ES?)/1545>6^S>&'S MYKG_O%P%KDGMP0!CC!(W1+$1FXYC&(D5Q=!)/.[5<95&-0<3!A70T?[1T,'& M_NV/A(BLH"LEGF,1?2[.Q52_H?LGAO-/C/6C^LU8'_#.Q;K >OI<[,LMJ:MM M!;[U:@&&CBU9ZR!Y :O66MPJ-+^<@BL1] 5M9J(N;^.TND^VQ;=J./9GF;&- M8B? =FP&CNLARV\WA$$KI('O7)TZ)38TSB_WL%CO8L! @VRV ZJG:#HUVZN" MW65DD&I<>3T'JXX?WD[UF=3,U%59/&4;LHF>?Z.YY\?\\I&4*=O,!-=U]M3L MOHR+G'ZPHY]UOZ2=?@"'_=@.L!7#V$]<[!HABIP>G&M'CLA$32^] M;7II,\HL>O@@'?#_16Q*8:JVXI/*!3:3F*A2!UHM[5U@F/=65S6RR'UJCYS( M\Q(O[J%B)^&Z:W-6@)JE^,"G[BA'ZQ7(!XUFG[-_K5E&^'B0$2I(W.=I!@T6*L32_]GR?!V-="+>S/I.+",HS4O!Z^.P\[<';WA# MY)&J:]:,1>C/6]+L(LPW\*$HZ^P?[2H(]B R3#_"08 ]VT%&$*'>=)B$ADBX M4F)0<_@YQ-B<#DP/P(F%$C7\\H6&R:D5D_I#>!=@ -@0#'D(UB+5/*2=D%ZE MG"]#2M6Z5&A\1P4S^0,3E[=)EJ=4EO.[N*CJ:H40C&P8QI:/?"OP?:JI26\2 M(5^LM-880[HSZP-L;'%J0VY)6;*M53U,<,N]YT$-LYQY[U2D"N:OK_A$Y(;F MK56UH_ (:-!-G'J>X.E4"JF"WF7HEQI77J=TZOCAU:M^!?\R1UGU6%19:QM6 M%:$V;0-9@1OXL1$$OF?0_[$&C702RUCEY"ZMR89/LL;9XNI>8=N]#F%Q]S(& MC0[G:!?;-/#2;<4Z&QWVTX2Y?KX C_3K=9-)D/_:98\L]1:3L)%D\VG8!"RK MV*!U (ZQ?-6Q#*X:DG%/\ 5HJYTU:VO9MF'_E[3:?Y]]<)TU%33ZSZ;5PI-\ MGQ!#->VT##54Y$NAXTT6/''Q?4WHP'G86]N<^'AW_^T[P^B5Z6/+=*, >J87 MQ1Z.3!3TF.S8]'J]O!8X9*$5D(2H7H\[5]'L>SCZ;MZ%&)]Z8^)SX+,8;K4^<>)FG#90CU1+Z^/L\P(&@G005Y;O0,M!!@J\!(66[QNN.>RL,V(D5I!BK#41)9 J+]$# M'!:^TN^B@CR:4=X)R.FH%)U[[#CLEI28NG;@P$\=O..%.C1-/)XDZ^2[:+62D*E$Y'VOP=K.G'ZF-7I=EC0L7W?LU&4Q);EV1B[ MG@D' +Z'39$I1X5F=>^SO6<%*II*BFDS6FB&B=LLO0]R;@U\2YN0^HU@ M?:FZ-\:ELXHWFB]YK?N8/Y&<4LV&V7Y@F"BB1@S;\$RJJ8YE#<-LA/%8D1.Q MI5W=#L",%30A#F653#EY*B6,A\R)I.L BI!FR?"[5+&2\N6L2LDS)"]/5R5Y M3+--/\CNQM8PWURR0OK=.E 26F8( \-S_0A!Y,>>:PQ::;IPK&XI :%=T#J4 M@+3PJH/[!M8[BILM7#=0Q\J=FC:1U<'I&D.E0/:-TT\&LK9I -XNDTF4DT> M5H7D5&DS+55GU3IY5H U<#IBOI'9_$R9:[6E7Y(W71QYH1&:(8Z3*(C=KK@K MM6XEACE6BN6L:M?>MBNS:V+42JTDR=(3B/K853I[V+"]Q[D0#7V7/;%9PU'\ M+U4E1WIU?KY0 6OC)PNOTN=FX&Y9(30"$T,'AQ$V CN)AH%[8'IPW'*+J#7= MV[S[J:O'%H^JJ4%N,L?."^K@4>VDX-499B>>$>S@2$T'BI*]5$&3]H=[(E". MJ5$B5NYHTK-?'EUYU)@=&+YC1(Z9Q(8-S:%." X#H=)-2@SJES*&:!@^*Y R M84I'J)E.-E4)6L/O <@%:-HKVD1E39;U!2N;M$L\XC:.+V6#U4,(T+5"PS8L M#QI.$(1N8(1#.0\WMH*1VV/D#6O6N[=#UBU'SYR ;T6#5UU4ZQG!+D@5C_,X M9BPKTQQ+54D5KHF.:N7Y4U_RU46=;ODT M4Z%9(<4<$'+WY<^\98!TE>\\SSN?=LY$N9AR2I3A7&J1S1.ZJ:$IEJ&:.AR3 M+H@IR-U(Q63KY)5 14[H.RCTH.\YT$:)94:.X0YR;EA"96\F@J1[\_:K(LE9 M#U]YD63E;35*@>=L)J7J/#CRXQ5)%FP#<6W7U #SS5#S8!7;-$Y!TZ>!RS5\TS8C-!QMMP(4BJVC*S2L M?QL3_?P^;))Y180TLL0VUU./;ZXE-=W$FK9K2KLIRP2CU4[=LK4;K?;%86PI89H\B. MS=!B&Y^L9#@I'@7V6-T<8UJ[M%4 M$^ZO8NKASJR7)X@444P5[;%0S53BVCG55,>?^MF)5>R$7ABX81!;H6% [(?Q M/MU-0DO!?*Z,V:GFU.GN3PK^!0[3D2S>0Q1 D,<8!P/LR"^@82NMI.WHEG5>V"M MIF_(C>ALK#Q]G!,*DS G.'OP@K0&53-;T.":>)K@&#VGY@1&4[H,65/@Q^O1 MOB)F>,7G"WGLYA\'?W+1/U, M'"O6+BP_(PCDDQ_-S$G)SQX34YU9Y>#>.K'J,Y$5F#-;?A42E;W]O[RH,S,0U$+)#QXD- MT[5M>]CW&2!':&OE>&N3CLFR#F+3P=;MW=?-I0OR S5)CL4';/KI'3-P&Z[= M8LG3P:7B\XW@WN6+:^/0] ;#(;3DDJT1!J?=&G@H:>"V*$'-#D[MRN-W/VDC6BP'T\WP MN&R,,;F'-[/$G66,(T=30/="1$ZA0T?R-F5 M9066%:/$MEPS2,+(P,,*L&G%,EF=6@2:,STMMVEI:@NQ[&^^9I#,")NMT8)7 M:@>+4O*U[U)9ZAX4)?M,N)MB M&8JJPS'I_2*"W''?'-O<)'5Y2T6\N7WJ"QWB7N;-5N]\P_[#CLH\I5N6:J\\ MS[.]T'$]-_10Q,[*!'#8]!U9B4@2J]2PYMRUQ=I*I MQ[775[3JXX]70-\W=D7*K-B\KI"TBJ%CQ1XV;,^&%G:-,, #A, )/9'T4ZGA M"1+038>%G5H15TNU-/.IY6P,BZGE44F\ "U6\$Y%MVGE4H3)$W*II4&6(9=Z M7"LF>*%5R"6D67!9/M.$]S_2[8ZLD&$E 7V7D L]SZ<8XFC8@NA@+UP]-IB_ MUFE9CU%+4;LBG?@U1,'^7(,;LJH2S=-4:*8PUV/$4B?!RE0R9:/T M%B5H8"Y!'%\Q)ZR*LLPO60ZE?>+2P7&,J15 V[1=WXW#) HM;$'7P,%P8! [ MT.@$$.><2^5JK(K+7P]06/P(NPCLK.S]P/V1E^L?J3]R^R35'\48X^V/?9&# MN'BXR?)7Y[ ,%YL!"J'KX@";&+(<"%MN&%HQE0"7M_K]*!OZ0F(/"QSBFNT\ MY"F23O0V)=PNHY.I<:70\.Z)=:FOZWNRV6W)Y>T7LB[N\NP?9/-Q0[MT=IN1 M37O745](A';[@S+1]'>[![*Y9A>)7)/O=;1E^SB\YG*X!&-HX\@,O"CVHAZE M%2 L,NT\-3;-,].].VWA.;+-'F@;E\\@W38O,]M:07]3WQ.0WMV5S08V,&R4 M>BRS-6GWH;$O')9BJHM7?]3>#==^Z52!H&6\$'RRO.1W04S)#U^#O2]@[TQW MW=Q0X*D9"1TX!#J/P.^-3X Y!1JO)HX"BMOD1."8J_67$6MF\[Y81A^42Q(/ MRM5=E452E _IQ_R6_8=]M$=A6V9L^Q$V<)0$B85CWQQ0)'8H=!&5:ML31J1= MGNXV64UEY;$L0(,59'O,8D%$>1N(Y>YST"^9SA] O6!;3T"#%AS G5WF!5GE MR/]5M\\R9%J;=T=&"7I8Y)79R_(NI1&@L173-+389IOF'U3YK^B;3\-"\\_A MK%ZZ_4H_(VCO0=-]G?HP\&!UG0+]F[,-AF@A/P3JC%MXRY#2R;VN9BS.PFF=VF559>W MW4VF67YW1=&MG]O_OQ<]WS!I3FD[* E,C$T862:%$1N.:YM18EI"69T:DYJ3 MN08E$X?#%A),VQ1QRYFM34^K8)+6,[J'2'.T!A[XO?OO?%D9%WNGDC&U]"]# M-U4[]3KUTL$9K_+]QL[,X:K.:()'JI7O1)%CV+%C)TX2N0DV([.75]^/A11. M\-&:E>RW]F#H@$=,Q$1IXA,KC0R)B=)K9;MMW2T?!'.L[*[[*;+6F7/U!6K;=%M2O), QVL(\MPXD3UXE= M$^+0]T-LN8;E(FS$">+LX&J-ZNO=/AF6W^XQ:./<2WHGJ.+:A2%/\#+D M38DG1W='C&5'7+I>JR<5U '$RST7V+$\&]E&:+BNX7M!X(5VC\0W J':1CKL M3REU+[6MF>G-]@E+NXM.5N44MHBH^LW3&/*J^#9)9*GC K62FU@N#57?3$O3 M5@T>'M5<76R*:G'!ED2SFGS*GLB;I#;9U2RA?2C*NEM=Q=]9P27R"J)KQ:%A M6SZ*<>)[H@A!K;8--RDP"94;]+-G6Z8? ^P 6EQ@Y)LFU_6Q5M-!]7N MYC]9T0KZR\,_EM/Z:5I<+ @LKK'EHT/KR(?&D[>AX@*TWH!#=T#GSV)"AXKF MX(@ID[;ZLH+-M*X?B4(S\,\=GEB-O_MB2YNC8L?VZF<:()L/(U;X;[A.>+]I MT(EA A&.3)BX,+&0[?FFZ\#8"ZTX]H3*1RDWKCO,--5.+Q_;XS4L&;VL[TD) M6NP ?A-?%E+//V= F)-Z0=$_@/K'GFM&_F&9TZ&.]._SB;H@I:>$6U?K+$2< MM;GW6H#U\LA_;=J:9$],SO>;()W09[58J(D0NF: 8L?T^\W7,+!M[ON^Q!^M MKZL>H)EM%><=1D[TM#'\+:,SC?+@S85>8]G@[1+=] &(6F9;F!C_T8A2'NC1HALD6RC)&F-.<4/3HZ,.WAB6408YGDTYD)2123 MG(&_/;(+T&"[ !VZ:?7G-%,GI$@1Q0T&MVFZ+;^P"GJ0H4;&[ MJ6]WV[= >@PN]FTC,9T@Q!%T;)QX-)_H,/AA(G@7H5K;7-UPS$TYG]C1Q;3' M+#@64LPSI[!-3["JI'>9.;CAQ&Q13/, M.'!]A^:8.#+CT(:V:7AAY":V8WE"I:RT M$\=#VW M=TU/?6WRY DE7K= O^ M1M(2_)I2/]F<+L>,T0R-R2>@BVE',8&=H0FU*/,8^D\H]R2MN@QEG\;58H9> MHRPRO /F"WE(LYPV#:MXP/H#ZPXK([ \F 2.!1T7N\B(:8/TR+S01HH"A#(\ MFN,$Z[/*%%U=(XP6]EGX5ZOO[TO[X$6[SV;0^<5H.B_S87 M>DULZ]%[!N3Z6[$RL&^&=N*%KAOZANWZV$IZ+#!"H3Z%YT6@7]-]G9K.3;0. M%=?!\12ZW>3B%/B2=;KC5IDRB[;5CZC%PCZ.4E\Y1C7J+7U9RI]-=!GWQRLM JM5>H1;[ M8=57S,OQ^BO!JCX%3FAW64'?IJ;#,/(3&WN&96/3'\ 8ME!9,4T0].MOJ%M_ M^:C6);_*69Y,?1GRI8LOPZA4>X6:ZT>57C$G1RNO!*<:A9=^=X5#+\8VC06V M8QF>[T<>W.?A,=(MO#P0M NO96@77BZJM0FO:I:G$U[Z-XL77OI=M<(KTEP_ MK/ *.3E>>,4YU2.\\)9*U( HL)W8,Z/ B@UH8IO^TPE[1);E"YU$T(E#LP1? MWY.2I R13B$6I%Z'&NMC?0I);EKHQQ#F%T0K4V>YYOL1)5K2TU$Z/89=!6+] MF; C'B@R L=,(#N>:87("*+&J&?8IAEBD;W#(TUIWCU,(>RO-(=-*2IEVLO% MY&AY54VB\KUMB]%'BD5. D4H7KS*"3G#+V3B''%7SR!W[ #Y%_+(I#*_&_:F MN38RL.O8D>^[MA78D6,%3;$.S_#LV.3=?"3]?'V]JH,$!DRS[?D\1LZ)CC2: MSV5TH?%NO*Z3H(87V6ZSK^F[K\3@F%84)$:,O=C&C@=MY.'>LN%!L7J4"NQI M'E]U$$6KQZ@@4DZ*=',X5I4.ZXG/5Q+F/&D":C6&\F4*URB/SFC8>+9XY0R1 MF_J]LN0H9HL%K@L-%[M>B&W#:PMVXDH^VX9&&88N;&- L> 3FQ8INOTU@P4&B*Q7M:&YOC.8(G% M=FFR9&1%#T\C=66VL'V$&VYI$6=SB=HBX<5)<9%E1>GM.WL0*/(0"B+LQ@FR M/118CMW=&H)=FTJ?B.@H-JU9BT[?Q".F4JI)YQ.O&?D6TS2!2X]F4SLQ,D^( MH*96688VZG).YN8C60[%[P_I2S-\+FI2?2K2G-7/[^[VSN_V!1OVB&('1M@/ M? MA#P8P03"*VB&6Y]J)(WDUDGH9VM8DG2/.'1,([(\$UDX M<8W QT[4C0!BWPN1*1XIK MTHK4;>LO6/<.R\:0&5X$T1BS['= /@9U?@&F5J#W# RN ?CBI>B\ X-[X.89 M[!T$S,,%A2GEC<85QN9[5986YF9DXF@8G+MUQ,,DSNNL?OYKMB$?R_8=N2 Y M-^3M[2\=]@6%,<6- MP17$YGH!EA;"9N/A: ";MV6XPQ<;)K"-$ZS64C/&3+=7194QL/OE8->-L.$F M%DIH'S!@Z$21Z0:!%T2QX<;<,T$J;&E,MWMXW?6"+4#0(YQOHR,';:>T0B7K M"^GV2EUZW8/5\\5=-;T]>-$;L0/#L7S3,=W8L2$V?<>#O1'7]".A6W#$'JTY M:X-?O^+KKX)UT 7)X=,DC;R(J4^W)#B7R+SDX82<2!*V#.&0!?^Z8OD8#L3$ MH*N#/MCRW22,(L^/'!1X86Q!;'N]+129$IH@:D&S-'1PNBN9_R*C$<*5Q24(B[<.[>C*.$5Y9B=/JGHXOV'_8E9A/Z9:= M.X!U?]3P/]+MCJP0=/T@2:#-KL.,/1R%CM7;=GPLM#M*C47=LD/13=MMN&@Y MT8W4TKJ,;J78IT+GBZCP0B04.2[$D6D'GNLB#T5^A(8$(H1",[VC#.E.^T4O M1/IAKO'A)789W4R-*R+7^(CQP]NI/N9/].%%^9"# M7BAX4\2Z_U5)'M-LTQ7]3TI7R33*P<;H>%@,_!\WT*A'X>ATUE&T'"$ MZC>IL*=9+#J(@+08VZ6R@L$$ZQ<#:S$I4<(TG\),3;*8\/3\=O :>AN X-5H M?%I-XB#MA%2II'P9"J;4HT+?"RIZ?O*6T.=OKM/OK;E/67J3;;.:I@8'N9:- M[=AT3-]Q;-)@8W M61'\0X2) ? M8]/WP]YDE"2)V"AOA"'MP[L6VP5X9.B:X0?I\4G<+3^.5-X!W41\BH[D>BJO M!BKQGLK)IY5.T71R[*: W65HD1I7WHS6E/$C6HAB90;8LCTWMJ'A0\/$B9=T M*TFQ%9E0Z*)X[H=J5J >AUR9B/.4\&F*%C;$].,L$5J+-9Q0!&%NEM'[Q6$? M*9T@Z#?_6M.;JK+X^WJ[VV3YW6 :8A-AB",Z K*08Z'(<^W>=!#:4&P-2H%! M[6M30TF3M$O5A7,0-<3R+E]-S*GHLM9[5:K!3P-&T(/\T]1K7N=Y.[D6II#V M9K)TIYTO1'/-GRDXWS$O<(#(#9-L>=F$463! 9F_?]4RA,90]O45/.>UCRL\X2S"]#_#3X)3;W+,TK.D=V(I0 M &$8>UMQ8@L-Z.0L:):W=BD[+_(/8Z:D)^B0W/00B9D8^L! [291FQ*[ZJ M=?:1DRQGR2]CG:=$9/U**1LR"U=SK%>=7:CB9F49O5P4]+M+4X(^\_;C@Z2$ M'=FOB_7?[XLM):1BT\SU\_Z$8&(BP[94/,/KXZ>/U1_P5P,\(?+V^C/_7OUU^0OC+US\"_.^_?;S^FYA&J*.;3T5F M85I,9PX@#BM8]?-L1P%Y&3LA4LI)7X:,J7>KT/RR2DOAZW.,263'@0.CP J1 M%WNQ8<9);] S;*&)HA%F-,M=?PIWNT'AY#(7"@J:3/6D)F_\L\W&&^"1+ MEM;%B92T(\=E:1PWH@+( MP=-1G C(2[DCF[>RMO)L)S%A9":6A4TKWG.Y&KS/CNG!65M7))-5J]P8#J!'1O8Q-!8$I=!>'E '=\] 4TP?Z=P]@(WP)IQQAG.JAFRM!_1AH8H!8"=P6 MTGQKVN\1=$I1QO"Y$$T9Y<)K51G/A]!NF<,=.@<+Z$X0(H1=TX0)E3+7#[RH M-^C%KM#*UP@SD^^;D4Y7QG#))SP3T2@F/RV#+Y*86??2O,O/N0TUXTA=A@:I M<.2]K34JN)$8*JW\P XCT[3\) [].,*A':,ADW(\1W*,=/:YDPR.5 R*SC,D M/!I22H[T,&BVT0_?L(>;I&7H@A3RXP,=0>_YK[,XNNYMAJ85N%'@02-V71C: M#O2&U,5XR5RWD::_::RY M8J@NP%4ZZ_*TU(X:!6PO0X)4./+FL@]%W'"7WRX>'HJ\,=N6&\8TW\%N$!HH MMJ$%'T],@P=4#)"8!HG3Q*<\6AD2TYN.G ;+!6C0 M7("/5;4CFXD+D;_BY(242-.W# &1A_^ZDO@X'K@7FS>;YMJA='N59IN/>9P^ M9C3M/["^,J 9)[&7F-#%R$X<^O.@4F'DAT*KSN/-Z5Y^'A "5H/Q0Y:#=0M2 M<"%: ;&<*]+3'7M"ZG3+"<;G)9YEM]5<+W>/>RV:4TVB-QFZZQ>^1"ZT YLA\T(>2@P MHW!OV(^$-@TK,*=9UWJ$@'00Q>1,!9]\ #'<")2V>< M9^R$FBFD>QEJIM*A0MNK*;PEL#?4S'13_7PLR3W)J^R)?&SJ1'PJ*G9L_?+V M.OV^BC'R[=B++3=R8Q\E5&/Q,//E&F(IFV+;^KATEFYDR&,#[%T\64E*@-%!W.GTTK6&_Y.*%)(\A; MANR,<:!0]B*-70U<^5%D1#'$%G2] %+!"HUX4"G;BT6V T@\?I)= =4[:X!C MEP#/$R>[]*>4,VU+?G.O\PFM[W%3N@QI&>/ V?4\02Y4E?Y883NPJ(9YOAG$ M,4S,)-RO" 0)#B7W'93Y0FY5=,HMXO\+&LJAY\^YW& M,;L,I5+GCF#U#D&>Y!.DST5-ABT0R AL%#JF'[B(#N&\",8!MJ(H@3#$)@RD M8[Z0E8GC/\.VH T^AU0))0%2'"^CFZERYFQR,(*C<5T,9=5Z6]!!$+DFW^MH MR];: NA9M@U=VXU\,*6B@+D+AWJ%06.S&-,.2=6^47UP2.)XY[EN\Z*OZ.7T@ M\'M6K0PK\.G_!4&88-TL2,F3=S$Z+EAZX"$$^(BQ=4R]$,.^NL;L^3]%U4!5#RD6;Z*3

O!.7JT*D)K MG$,3!!E;EBJ(@C^B"U(7PXGU-C'Y2)W+Z^R),,.T >U?R<,-*5=^ MZ/LA,A.(GG[1W5%\# MX_-& AT.%=K>3L'Y-3:!%*45V; -2B2OFC<.EB5]+0E[@:/G_5>NTF?V$?R6 MEIO/.X;J\K;Y;05W]7U19O\@FU5B(!S9"$';#5T_P!B%0\Z+?"14*G9Z=%/, MUU5L@^#ZX' ?8)V^?"(;0/L\R*IJE]*7 /R4T=\W?W!\T_52&I5S G#1[2DX M4QNZ]V+OV,2SBJK;Y=3LXVSO MP#+&$S/Z_WHV<^:6$%H#:H_VHEU)LZ K4F;%IK7^OA.KT$*.[\81]$TK"K!M M.$&/!,=>: BO!BFVKSG.= GA^E"7'ML6K$;$%1T-(;!T-&,;2"PB=:?108L7 MM( O.JF_ ,?BQW"$("G*6Y+5NW+J6CP27)];;=+4<@M1=)T>OK<"I95-[2.' M?IA3U64S1*Z:\Q'7]VE^^<@>4?T'J6JR^9BWKC6[XY(T*]NMSF%@V$G,=O%8 MCI^$""5>W#OC6:[0;/="79@Q-DPTSM#\"F@>C"RG]2NH5$U(63I&H@-66;3CTC^)1F6W8( MA*:QO]"_95>-&YZ7>!8V(\-A%\K@$/=PD\@T5T^DO"FFGAH4ABFBSX<>C9TC M3'ND"YLD%&_G:><*M3;P J8,7[P6C8<_2(0]TTX33"%*OQH_>)141H.F"<61 M[<(=Z=;W9+/;DLM;F-?9)MONV++;5[*F VMVE 1_7V]W&[))*//,H5V[FGMY MV]=(H5&Y07S-P*[8+D_/<"$, I.A9==DVXYG0B> -L)"^S$GAJ9[U:OSALG6 MH3]@[Q#H/0+L/0<'/K$_&BH24;=:X0._-YX);@B;NL4Y(]UR&ULPOLW0SGIB MFM(6.17)YFGZA<2OF9Q_';7F; /N*EGCH'W*&/;S($ZL,.!DHS?'IA595@R."A;0F:R&^J++(QA&+)\IB"',&--Y,'$A4 M-<*)$#)Y.R\C>$SO]NL"7_/P/E' @ _L4NB5$U($,?0I1@.:"8I\/^BQ^3C M$T8+3D03A(H/^UC1S,P5[5RM_%3<1&TU2=S0T$RS!(T+T'KR0\6+%K*^8"'8 MN/\M(H6HSVK#A!3CO#$BVE4T"E4517"3Y0V"]\XR^Y;M6[Z''60YANO:@1E$ MV'+#T(K#. R$=G0K,JE;Y=?_MS\<0S0S>(_- +?0=" M-_ \(PZ"T$1B5]ZI-C[AE/W0B0\A7["%RH,/QD[(JVH3T2GW&9I#?E)=34MH MGC+G8Y1K4EQQXRQ#8_6Y=W1B6PN/HEGF@;FF.(8-$\]P/"/ T*$:CW%@N;TU M)XF$YA9D;6A6T??ZJU15&VD.Q?)(G?1))HX"S&G-$U]1PY$8RI*Y#)4:[<61 MU&\<*V,TA_U8DKX AXEA[/C4;.*%D6U3R7,&NW'B66/51\S:##IT 7J,DM5U M%' LKT[ZZ!VO4R+,3J99+P@35"\YLI>K8Y+^<"C:&*:XQ[&DS$AU>?LQWV1/ MV6:7;K?/'Q\>4JH+6;I]+]7K*DC$OD7S.1L9, BP';F6:\4]'-NVA21/&XC% MSNSIHYUSR+H$Q@6'K@UD-G ]! WVJ-\?T)ZO*:1G!"M)\*F1K.XV6X;&ZG?S M].VU]& V@H8UZ;>=KP+;>>[>B3VJ65] [365WA1ZWDV! M@ %W-R5YOBSOTCQ;]X')=%#B.CXV_,")7=?PG&@8*B#Z5G"'"*FGZTZZ&TR@ M!R4@5G)<<:B^=IK$=/X50S*Z+D>5@))KITQ.NX6IX]/>][P]IK:CF%F OH[# M7ZAZ1\2F0;ZP0X7-%'+HVQ$,;3.PZ ,M,P[-8-#HP(9=SI^GI4FLP0O0(]'8-S$CU]UF63PX8.-?G!7E:4*\7 M1?Y>OY?RGK?G_TH'W0^[A]Y&@A.,@@2RY %[AD]UIK,1AI!O?"3W9,V]OP,C MUNT%N>'K^/IH$>OZ'8Z95@%>L'"B^\NQM0P!D,1>J'A?!$4@_7Y@(\&.Y<5) M@,S826+?"PRCWY\6&@$4NN)1[,FZ1: %(R@"8MQPBH V6@1%H,4QEP@O3<'K6<8.(W8?!%O,\VT6.3_6G,^G$=CAR'Q>_ M(=USJ/&___;QZ\?KCY>?OX[>IR5 'Y]L3,:('8MH0(K M(\QHEJ-]'<*;OH^ETENKQK#)IT\3$2FF3GL.][#ZK:,37P!SG)\3NJ2 U&6H MD@I'"N4OG."EL%T%]^NB,[2W_$M95-4J\B/+<&$86$[H81Q9CN/T9FG*)C1X M&FU,=[)T=U>2N[0FX)%^XSZMZ ]EMF8[.\ ZK>X%KY$=32V?2$W*JIA4]=#8 M'I@.W(%H78 &W\2WSYYAZX1P*2-Z&?*ESIW7=]:JY8F[=%&GE$F69S7YE#VQ M"N@U?1VSFRV!U'I=_95D=_*W.ZVG[);LHIM"X8V]A+H486- M'>Q9WJ"NR!&Z'T0K$-T2^%"4=?:/81-;5AQ/*69H!3Y%7$P#B*EE#QNTN#]L M&7"P1PY:Z!>@!P\Z]*"%#QC^B0L/C6#ZA-).TH#+4.%I7'U=76@Z?KGV-KXS M%+_J,K KEH#!;=-,]./7,-L;+I*B1&2S6W?%D+X_DC6%?IU^[SYE7V\K(@6N M8X0P="/7\%@I),_>@[>BD'_#Y'(@:XX(/;0N&C3W!6QZY&P4FO:RE>V5*FT\ M;;Y;I]]9.OU85+RE41?&+\^^T.6@G796] +T;H+&3[!W].)MY.JN=6I>"W3X M"@WO&/48[%T^5TMOT6^-P!;9Y: 6>7N4G)GH1*6@409\N\_6]\VG:8/VC+BP M07F1YZ1]B[YE]3U(]].*ZX/*85D%2/^&T9'H#>D%;+@6)Z=?)R^D:NPAC,G: M])TT:J$OU0*V+"^0E&+10C!ZR?4(_E^*8O,MVVY/80Q]F&#LT)PR22S+]FW+ MQP-&RQ.Z&65:9)I3LNB=M1-PU^'NQ'/T8J_.AI->'5Y(FZE(G'K,%[+9SU1K MS?*7OR5I \:1 #U T")H!=+&7(,OP8R=Q[-C!=@\Z M<>U(PV2 +JB+F008PM#KL3_XZ9FD)6^-^X70JG;LOX3&USSFWT>U!8WUM;T= M6L;X2WA+IAW;#YKQWV5(+]F$XX?RNM^='VH(KYT,N:'[-&W$718NW9+J"WDB M^8Y\)O7*=I'M>2'V$Q-A!\4X#H>-CY9M")V*%GVV[LV'I 85@R18P4V4(;[1 MK4YRQ()\!^("4!@3UTY[R<&)\:(L6\L8\4FC?UW ;!0+O)+0;-*Y*HO;K%X% M1F*9OF73(5WH0-O!]/F]!=Z_O#(@U![8>V 5X9- :Y2,]N/GBW(@6GC[F3=.XBXA_^]>E<;8= M N*S[\OBX^'1)IPH-HY_A?[[Q4D%G&B,F:I:;([X^7J#]F5]3\KK^W18_ETA M)XR0[V(4V!XRV3V&<7\*&D*(9XNCXY%KCJ'V=8?-[:>;=*)8JRZ5^N_7ZQ5R(W&F*NZ!6=>>ER9"&(4!\AU MO0 G9N"X23_23B(4!JNZJ-/MK$N.9S$*Q=/!'?ZEQB-ECQ:QY'B^ 6==:E3: M=@M<8OPA0N*Y1II^/9'[M?BAPYPZ%J99/Q1LE3&G7LLB87?:QUA&G- [??\G2WR9IC1&4!&GB'ER:./[(Z MAG6Q,#(#X9+1X>7)'4V$%HF\B+?-?&9E<(-320*W:=@PI[RSRUH(1):4W42J):(>P0 MSJY\KRD3DSMIPA>KG1>VD6RI4#/:K3\V1Q0_L8JH9I($%@XL+W%/4;4RQ\AN@8*?&-3CY_ G%[P7 M%$K*GEPS+%_\)/T2D, QS/$*(2(WU C-')M#Y==LY+["KF][%C2HH00Z[*Z- M&)N&%T8N=IP("QTTE7F^9G'[NKXGF]V6L(/NGXK\[@-]Q@-@0,$>:05^;\ * M7M\I12>?U.EF4DS4%)&H1='>8>J$=HWA=1DJ-.&RX26)ZL1$F,'1,9-@8]H:0;PH=0I-XO.Y=] TBT$.2N@I=', MEYBZ"%*E147>$G)"1$:PMPP-&>- H>Q-&J,@[BNU3EM^]M-E=B.H9 1V 063#R$]<,PS]R.UMQD$B-!TTSI)FG?E" MJCIE"X)=_X%W)2'BQR)&LLFG.-,1*28] R[P1H1FN07Y)$\GU$@-O\N0)46^ M%#K>0($2K$<,PO6:,I@5>4+2>E>2_B[W&&&:??ETX!8D.(H3.T;[_,OFOUM% MK=EI4J5!N2Y VN,$MRU0@:*6BAD_K6PSDZU*Y@:HH,-Z7OBT$R]0&72^!AA= MY?-@\PZK]EG3?(DU4%VTE3Y?]X.FZ"4X"8\."$8Z\(!C"HN\)7:PM M_'#-L:?' Q@@J:D^<;KXDF6M3(D%#B&2M&3$K\DXD01+\[:,O%<>?J'H_9%7 MBVZ\'P"$?DAQP:L@>%<6FV*[3CU$=.)JS)[:-2HLX+,T LPQGYL)!8T(\>T[-Z*$7E")0%%GZU9)1HX MX!/)-VR0+RX4PE3QZ81.EL1DHB6H32MFD8E75)Q0"5G2EB$2TN@+-:^.P%1[ M0B@7Z3;9Y9OJP%($#=-V+1SYD-V[[AE!$O>6DL3C6@D<\WS-4M&A @TL :D8 M11G'I/@$;(E)QENB9":Y91D3F,V>@#DEEU-E.7U=256#DG&9UMT-51OR6%09 MU:QG^HVJSNI=LUD:I.LZ>R+;9U"7Z8: FY0^>TTJ<$^V&_;7[)%]&WVA9LHG M<@'6Z79+-N"V^_R6<7+17FM%4FJL8+4U+L"NVM$O/C<79>79W7U] 8H+ZQ5V%V^R_=MFFJS?'JH;5X#8K'RKPL*,QY+Z@ M42#+6R%CRY\E85-.H"JV3Z2K^)K6;'D4/*9EG=%@\%@6=7?/87J7LE@#4E#M M;JHZS9LO9/D3#4\,-]@6%7<=[".B?YSJ8\*OH'$6(/XJO"C4OK)CCDY]RG+R ML28/UR+!I]&/80H#(5V^RLUK#F^PZTCH=S;$0 M#=3BVFMMU,VY)R"1J+)M\*C@AD6*Z=P"L MJQ?100,=MFE5[C1/)W1-$<'+4#)5SA1:7D+Y#&]E)E80&2B)(S<*$QQXR',& M00P<0S:#._M@S4ITN:O9?&2SC^/-&$A%MG:>.?%L3"EI@MG6,'A\F7?-EU)Q MIDS*J2589K)W0FY'S0!?@ .D3)E> M;F]OT,XY,7R:1^[98D7-L0R9T^/:R7EEI?S)R61CZ>MC2=+-97X(P5Q%89!@ MY,51 *TXLFT3P>$0D.F)79FFS*AF>?PU+>_8TO(3*6D.=BB5X*>T BD[>+NF M'APOZ*F91F5W%881B;%A1&%EVD%!E3@9)=BVQ@P1C;6F6 MPA[:A[3%]FH3YU@Y',4ROPI.1;"X^%V 'AOHP($>W4R2=X*K,TJG@N7E")P2 M;][1-74LC5D9_2W?5633+R_$Q<-#UFQ\2PBY:GLSQ;;RC3@V \-R(/9<#(W$ M"X9-MF84"1W,UH="LP3^^RXMZ9]MG\$M(2PG81O/=PWR?E/Z*!W4V#SRZZK3 MMXRB1=86^+"R>@'VV $%#_;HYU]TY2)9< 56;<,M0XXG\)-C;58'LUSG$MX# MTX2-IW2;%"4UGA6;;-U'DJOTF<&Z;&<4O;L G0-&&Z M8=<>\_5%]J1M]W*\V@]Z\::[7K!S(7^\RO^6_YJCZ_S?Z'^^_K&]^Y*.MYA! M\CU]>-S2+_[QROR;^ZMIHS^"\B5N^L^B9,,R:J=!1A\,GDE:TB=D3P0\%'E] M7[4W^=;W&?TJR<$F?1Y]5G#D&_!.NC#IB[6 RB3N5K,T'$GRANNOQ6KQ$Q< MY'EV$H1!9%N.Y5GAD,H$>)J\@0?((O.&^ELQ40SB:BO->8/J9IHG;[A>5IM- ME#>H;KL?,F^@W?7_W+R!O@$Z\@:1%^L'SQN$7%65-XCSJS]OH.\H61D!MK%E M.3%&<62R*OEPN,##B1!_67K]4):9.S#H4T4BOA;3G3\H;ZR9,HCEM=Q4683R M%OPQ\PA&P__!F01S7TLN(?1Z_>C9A)BSRO()"8[Y*BMUE\I>WB99GM7D$WU_ M-S#??*0]YW;_"05%>W)VLR6P*?K2WE(:)2'&9FBZIH=0$OENXH;8@AC[CHG\ M,.:OO:03A>8\XO!:WA8]:, VO7_O0/?AW@70^B!VZ?$$;<:13BRFN<0RB?]N M+2527&HI+2:7.1RV7%MUZH+&Z?5VUQS&ZDZ&TORAJTC%VO.N*#;?LNWV FS3 M]=_9UQ[OGZML3;_5%99:D[;Z8 JZ=M]FMZ2+V07-/YJZ5N1[1E.-K+G1YY'4 M.P4W\XQIBV/Q>Y+V74#HGL;/8NJ>([9K+#EN-GK^-?W/HHRWM"_N?TX?^QA3D0L.R3)1X MMADBP_ I:2\14;+JO;&4"FM,NTPM;Z^ M1ZB?Q:SH#XHKL0HGF7FYF4 MQX[YYF8(FOJSU1/Z 9M% 0<-EI8$E.SP%;M;XK]V&:OW5=^7Q>[N'I3D+JOH M<]LUG *P^N" +0VU-:"*+;OLJNY2Y1OZ[YS0(,B 7(#J^>&FV+*_:>Z8 M !OR1+L9^W=5/[.5GA>H>:&\M70>'3-/V!\>4,,,[K^U)7?IM@4 [LHT9ZM, M'6]WS948S7)8=Z=T\2UO*ZR3[X_;(F.EU9M*Z7D+L&0'G\IBS?#=MO\:EMQJ M=NE2]4C6V6W6FMBFW\;.;/&\N\=FL)2^]PN8J5+K3Z%+(01B>+RKZN*!E%_( MMND!U7WV6"'6(;*;YF*8+TVWH5 ^4WZ*AT=2$WA7$L)>V0Y68,301F% &UGD!'QSB!ZT#38JQ=P$,/LCD&Y,TGD ZLK1&')VMK-_M=1=@<]BP?0) M&_;][OAN0O-NASY81JK #:F_L;T@^[]J;&0'N%YM0J& *(0:;+.'C.4"=4'3 M%3I8H&\7CP/EBXR"?NN.Y.S.)G;!%LM?^L=N=FU6<\&RB>%)I$T@-CNVRZ7L M?Z1/*6XIAF;UC-WKTF81:_KL@J8LC_?T1VHXK9H,:_?X2(VM[],\)]N6TH%& MMJ[6WC3&-M"PRV">VU]6C<\4RN.NK'8,1D6!LIMDVU2-_EW;)EGC;;N,E[?9 M7?<8ZOG[33;+@0PSB)#"M.7#.$QI#609MKQXTJ6YK3HP$>J*CBW?/<'5B7E@5R\N8!U;FS9N:-BI9XI6P M,QLCWJSNQ8X;VYYK17;H!]"R79CT*%P+0J$+/U3;UGX$H8?[87MLSYG$U@3E M+< G?7.2+R:%XWG7HH>"!)[01UU-L0R]U.9=,!2VMHT1OM3>,:LU=S/X%"6+EM7A4,_T0 M>CS.0S%-5L#FF/T,G[KE^V$1QK*18\/ -SQLQM0F#'K#IB-0ID.-N1]\1X,H MN?);&C3RJFQ/0X]1X:8&48+'[VK02+36;0W]2_W_[VMXNZ]AX&9O\=6RP]M% MA_:<;IK3OREI<[2+ S^]6 BA&"JRW7O[+:-V=W6VS?YQN)&A7Z/HL+*]#Q0* MQ9X>?(F*6YFQ>\O_I&G'P\OW6G#+@V2G6,"$OF*'.#8]C.***]*?//73)AV? MANNGX\BP(ACY811C!SDTN0CZ10'/=SV+.^ KM:I[M/7Y&G[^Y6/T"0/X]2N^ M_BH0B=2RRQ'Q9R-6+/"?/Y[:SU-]XKC*7C?O HG ;/Q+Y0.OU($O)HBX>"PT M:*%I 1%"CU^%[A=,VVXT5V8AJX-Q[[EM ] MF8I,:I^7&Z9\NI/:U>[F/UDZ2;.[[MK2IG_^1=G!(2'"^>;=9N!:)G@YS+.1MT0)[\R'\_G:)E33Z5:@6OP M+4;7&C1RBB9&].*U3- =?A63X4F!?L$U'5/LMBF[,^H@>UG!( CCP,300$&$ M#->!3MP#0=!W5CFY8W\T6M-D 7!US;#MFH=8N7OH 3!PB$R9U$E3/UK\M'*N M10Z%&V-JA3Q"J9QFCFV?Q:OH: ?Y=54-E^.5]K>*W.ZVG[);L@I0[+NQ'<6Q M[=NNZT0PAIWI*+!1H"9;%#"H.6,,#5/A7C]Y$)-/+++S8VHF%_4U#)]R+J)-Q-3T M8*_?L3)P/PVX00_\3[--2LI2++_K;WRK+4.-];LIMO]/%:^Z5'MEF:Y%+4.V M)=%T8.([X1 \$CM4N3-;W+AFE1XU[:F>:3WRJY3D261WV5JK4&.YF^;'U%9^ M]T9JJB"/_%KZ9FGJN)S3M-L(P\0VD!W[R#!B%/1SO9'GHD1,1Q4:UKW)NJC3 M+;L#Y66^*ZJE*IGFU=&92!;5T'>7RQ>6KO)3>5(^-;3(4J13AVMO9%,;?[*2 MV:R#O=5K%P<8!QZ.XC!Q[9 5GX\'O?99R UM'"V)*\ MA)22ASL!)1Q)_C(U<*Q39]1/"6+/E)2/S$6Z.E]D'Q[DDD7\(\L7;_SZG]:XD ME[>7CZ0]PE6M_-!%GN];K@!&,36VX86G%H6(ZW>B+E3<&;94@8$.E= MAUBX^U>45EG%SJ]=M4<$)3:TR/#&ES]H)DPL5VC!,*KV<,#OU^1[#2+:/?X^ M\7CI+3*M%XSHI6%^4SRJKUMJBHU6'DA!/#2@SLV!"& MMNU[(<;>8-&'O)W7VC8*I](M?)H.N!8B9E8A@5-E#@F.R;;&D8N%+H4 M3H$YS7,!%!AXZ)&)S@&,YU)0GJ:A45*E+@ C<\#7SHW2,-]CG$FOCG+&(UOC M"5^8>BEPZ)B(J>)*6,O^6I1__YA?M04=7EJ&AAD$] VQX\0,Z2 GA&BOHC$6 MNI=-A3W=^T$IL@]9_J$K;B&I9V/X%!2TB:B45C2&CQ4(Z1 N1=..T\8C:@I( M7YBJJ?#HF*PI8TM8U]B&T^J>;-A\S2O+9H3<,/"<")F.'6(K1&'26TZP$4GI MV@A[FG6M1]9+#F598>2S9;'Z(D\'06 M$:X6UBN$H!][_<7]YWW/^\65+\5VFQ3EM[3TX0FF[@ M^;[I4R9S]%!PG\SD"!#I5@K60IWOC"LF[*Q,*P*%M:].(=2D[( MQA@"EZ$>HSPHU+U.."Q"E]!=KMH>5I:9?:2,W91R!;5P ^E:[LS+2B2OT7+WH<,Z&'N8NF1( M0?.(2=1$C3%2OGJ4+\N2[(&"3[/)VUD".:1/72,L2Q85^G5$,E4S)RJG*RNT M;6S[@06].+!-/XG=H'\\-JU$/ODZ^^B)\ZZ:UL6MFV(_<&&&WK=< 'G@EK#]W3Q$4,/9/0\[:^4KWM@-J,$ M[T>8B.3EQOW[PU P?T^HRCE&UQ.Q:;8"',$D5I4Y01+)X1& M!;?+T!XEGA3JWSQ!A:II$L"B?V.ILPN_9S03,&-H)684NU;HQS QDSCN[;FQ M(Z9/TE8TJU/;?X8>]3O#)"I(\@QRRM$DY(F)D1AO>O3G&"VGU&1<^BA:US:P3"!!M2,J<= #&?V M(4[D0O1DG \G*BJG\E]7VQ624! MM#UL.+%O!'9DN]"P#PS[7/<+*C0WA>(T'6G=QN2JZ4^]!&W 3QG]K/D2Y^6" M*JD^K4TSL2PF5#V^3J@ZOH>MD PC:$%.3^^F6.\>^D*F2Z/Y!3A^NN\)R'?- M/G;Z3E>OW^XTWX!'JOZD9.2W[WI]G];@&Z&!MR3[]W[3[E&MZ?/:-<8_@R]D MS:1U W95_ZLU:[Z'QOD_\\8=QF<330R[BR7\#+\36#0TS[Q11H=#A;9762RO M?6'[/]+MCKQC.@KCV$\"[%L()HEAP"BP>M.F:?HB::X2@YIC$+R[*YLM-;1K M9FP5GG;'^VQ]_[;[O@I.8OFQ&N[YTN7):1\3E"Y @W"_0?^"*RQI2:=YB#N1 M72OE?1G)MEJ7"HWOZ0@I;&5XY:# ]NDCL>>'R++C)+%BTP@]P_9%B@VM@ MWSS^RY"\7Y7%79D^P,VF.:J7;C\W X++VR[9VU%5*[-_D,UU$9']GVU6EHT1 M1)[KT)S/L)$;PMCIAQG1DD]5)NLZV%!^IV)5$S8U$ M*S>*7>0;MI6X+H1&Y$>N@2VW.4CANK90%7EU5G7/_A_L4]Z0&\%CPPK)Y1N< MS,.K8-@]H+19E*3_;7&"/=!N%SB8[48L;B9/;=!4WAK+& !I\.OHUG&US(FK MXE L-]Z5)?VI>2WWYOT@,B(/V[&71+%I1Y&1P,:\"RFQD="&"V5&)]3$C*/6 MLV:&195Q0G+EA?&@3'T')I!+D%4U A+TT-5;AV50Z6\\5>M7Q@&-H1F$,:Q8R=&!*TP@@%O62;9Q^OKB2TB,$":\;[!=ZDY MT<7&DKF,'C7:BSH&/YB=B>;FDSFC.$9G&4S82F6^$]FB.XXY.;B6@34YR>L096 MLPFG!P88LJEW?A]CZ-2VS?&T+D-[5#CR9E.X(FZX2U2PFC9797&;U2MDN(Z/ MS=#U#=\)4>C8*.DM4+T+1*Z9$7FND,:(WS+30 &/#9:)*U#L23C1'V2H6D8' MD$+^NA2%M/>\KWAWXW9^A[\_DKPBU1#4+<=,S(25@8TM![4;)G]47I.2,IX2IY:G$TJF[Y *CA/J(AISEG"Z4D6G"/L^?WE@-^7('MM MFWAVD(NY4W.#:JE?AM*I=NKUO* .SG@U$#X499W]H]F7P28F:_J>9C=; JN* MU-4*1=0:"G 4Q+X5N:;M1+@WZGD(B6C?2%.Z-X$=H&O71'I\(&T BBG>6%[Y ME&Y"2L44[C6;>V@ GF93BZZ=YNF$GBDB>!DZILJ90LM+*#EP;">%FT*A9HB, MR'6C!"74IN-ZCNWUEHPH\$7F2&2>KWFNI%O/8.T*BA:>\ 4=4K0)#A4U,28[ M2.QH^XD!.KY-5^_P<$\)S\!0@L!E",PH#XX-!J79X%\8I>D"J>HNT4+DIEXE M'C8Q=)#A0G9_N!];=C@D6SBT1/(>F>=K3G9Z2,W HZCO2=E/0#65@L4T18H_ MWD5EO=2)+BAWK.&>*W1J,Z&FM>0WC)Q<1Y;G;QF2,LJ#-^O'8]D0VVO!-"NA M'L5%3H5L1[7L<@C;$;DM2M)^[SK]3JI?L[PHL_JY!TG'@2^?@O]K1W_=GE5D M&TBJFBV"5RL7NR9RW 0&B8V].#+C8!@7NJ$9BV0]2\(]339UT_C#5J">LHH- M5N@_Z=BO^5W-_!/5PN40*+1Q9QF0M6\&:K/ -H?>NPKVOO8O1.M!=S8<'/AP MT2>4#1,7X#/5,?H@"FG;9ILM)7/L,)JD#<_N6EK6F[24*+9 9M[=7;4PC!)1 MER+K GQ$O!3AVKBR8(CW)S56WDVEZ2-([QX5\?&LL*K.9])O9<\^)1F MVV8O=W%00?2^V%(*JRBMLO4J#DW+C1P?0^PE#HH=RQ_&&X'+KECAS]95V]:< M<5.XG3)-V[$$:3K1X701OHR.J,V[8IK75KA2]V-)[JE"9$]=3D.!7=Y2X1BV MG;BAYV+?#VB:@GW3]2,3#AO+[< 76OU484_W;K1F(G!]"+1/)7[:LG'37X1K M?(^GF"^QF)I=L23C!;J7"Q)T $F:/>,4Z06 KVYEOTK+.0^N<+!Z0BU5MLDR M%%*I1V]+CBMFBWLIE77[=\PG=+"7W>7M&;7U\W69YA5%00<9=)S7_&O;C OA MYC]W[<"N!WS%%H3I+P[>YNNB?9=7T(,PL'P+!B%"?N!%T7X-QT)BFKHLY)K5 MN7,*K#NO0+UW!*2#)\T"#A,4.OH37!M>%)N\J\Z+ JUQ/;N)S2<#2?^"]#Z# M Z>;A;X#MP$\>&$.(U#G_9%(-/'R^91M>VIA?I'OV#)"XD*Y>;V98)DH50U8 M5IYKF(;O^U[@V#9T##9>&BP&-A*951AC1_,,0OS.T$39D.0\B:.'(DKYFW0( MLIAQA]QX@YOX98BJ$D_XQQ>"[/ *%D[+/,OOJBM2-E71AF$,1E:,0C?RH>4X MR#>0YPWF$M<6.E C;41SMKZ?[&3W*@R%W1E$,<629Y%/KB8A4$RK>DB 8FKK M=#<*Q2_:./5IYY+].'(,FIW9V/G_JCNWW3AU* S? M]REX@*UNP)Q\4PFPJ2*UZ=9.HE[D8D1FR!3M"43 1,W;;S"'(9/,C(] I:I- MFQ3__A=\RS8>+Q^YMHTC; \?U ^1$'KH6E#,'2*"'$R\R7>[N"@)?@AW&$]? MYS20CSKRO1-%SE\:T30O;BZ]D!*S<9F@8>S#!LB& M;HA1:+BZ[R'='?:41J$N AG:-A1CII.A!#34-O*A1H6#XK#I5,V+FTX$ W!8 MS5PF+6X%OYF)E5I^4,P&+?E!H*/9K/ZS M86ZPOM/ZO@C#2.] P-FF>JS.GJ&DLB M Y_JNI=/=+.K 6X[UM0MU[ \B!T= M0\,,]!#JYJ#!0535==2T/-G4DZO:EV27Y>)4OL%*63K#U)7)20GL9(O(GP5. MQKYQ4I/'02%D=AG^/;Z'MZLK.P*Z8T46]I"E1V'#\\-A$:;/M#M(E88IIM;- M2[KD\3%9MR?PD@)%^7/["36YA)41% '63AP/.=3MAZKOT3O:5[, _%XVEQ7$ M$L.U8"3+["4-G*6[*CBR/:5GI8< &$"W#!N&H0<=:#O#@H9C(:9])K+;5KSW M9+SB*7-\R^^UT AW$ING6"]8 &9/N\D^SA6.RX*Q*J-W=&-=22[28O1;'F?E M=5XEY6T1;Q(_VY -A_\FZR1]:392E2@MU[N\W!>C,B^U#MTT#&09.K*QZ45( M#]JB5[YG(+9S9=4H4#S2]=?K?)]5I7:0R8941;[3@75^R]GP2O0VYU54S;$5 M1#/9%=[N+!_)U@ZZM?O9"E5QV7N&MVK#M0SJ*NYC/N4#P'KT0U=1ZZ,FH1W9 MNJU[OF'I'C;]T YLTJ0+/#ORFG*NS,AI/E#?3!$-Q0=SK&\2;;MX3>&&7B6[0((8.!%N,9A M/:?'&!L0X-!RF2J;\+>B>O_S,'?+AY-8RTX;&YP$C*0CTS0>LF'I8-_A(-N; M2_:I.3WCE#MG<"3NZ#)8)*$?QV=?2'*&O00RSJJT>OV9;I*K[#$OGLCGVOY- M:B[N$W)4U^_Z*<_B7;@OJ_RI.7SC]9\BW^S7U;C:&:E4NJKGRB$*_,"H?QD^ M\HW YW6R+=TMHHHLRA43+].=7O.8*];&X1K#Z]:+_UMF<"V//#I0<>2@DQ' MU^7'EXW,RD*KN-RS1/?/D'_>:"\C:\SLP.?_3LN5#E!H 1?XP/=-!#'T=*MMSZJ_!7RFC,/=BN*L,=:CW3>*6!,!OW^4 M,)_$.C8@L[BFAK&G3#G'26$C%\(Z\7X<\TJ2,_1% +?'K:'\*4ZSE>E[?@B\ M>D!N![:C VP&3M^>9_E,\W3^5B9E3JN)E3K\#E)29Q+S1*ASR3=%Q?I.V'*. M.\)6+H0[XOUX5X5/CC.7N$->>1:OJ[N;E>=XH1G5XZ>HGM^; )G0=[L+&SX. MJ38[,EQ.,4GNLI3LB6OX3;G$Q^+%>50HLH&-"7?75[<8:3>W_BV^X6%!F:P_ M;_.7O[O>M"CH_G),@4.//WC<.>R8][GF$9QSAYYQ)3_/[LKO2;-PM_(, T#= MC8+ "(&C(P?8L&L!0"]B6[MGN*[B9W8P+L/GS9_: M?2MDXOP^LN#<6CN'4D8018,<#6@F %]QT66\P-K-.A# J)YN!);MZ< R41C57[?M6:'C80[$<+0R#V>X MEB$$K&3"C6(7I3!GEO6(D_Y<1H^ IXOBCT@_/H:0L#.72)3MJV(5%/7]DVRN MZZ_3YJU0O+O9/S_OR#ILV6_LO(ZK?1'O>F'=J,OT7#>"003U"!K 9!(8@ FES\4N4JU-6Q)J$TP M(HF%RR>&C*':+RFIH .[MBWR_7,'_>I7G GD"-&L\(%OIW O8O$"."XD/Y=T MJW'MZZCOHJ921[8=[7G[EF;)594\E2L$H0Y1@ S/10Z(D&>YH&_: ]CCV.(A MUJ!B0M_@K]_Q]>WIEY,*K:1;9)G<13:8=_*T09\V$JC=-Q(UHG&>O2!G;;N\ M+42.Z\M8D9';I8\WB\CTBVI$>96MBR0NDZNL8^C7)AM>)]5-W'S<=M]44=W% M99D^OH9)4<5IUG]O%=@0(0,&+D Z-D,KP&:_:F0# ^+52U(\Y%1#3X4J6)[< ML6#J![C7KJ79T9"B*9M7-B+;K?W/19H7VFL2%]IF3RKAK+L^:>NV4X?_P3"6 M4QE!BJ'Q0D+'!MUQS#K9&M%-"A<1=1IJ8]2+USKUAY]82(P8AN4+B17?Z-U_ M:K:2:,5A$)^.HM@_._^X\0[ MOK/J-/[?ET_]O]2_/=1:OGSZ'U!+ P04 " #\;)Q(D"8C7FTY "^M0( M%0 &YU='(M,C Q-C S,S%?<')E+GAM;.U]69,;.9+F^_R*VIKGZL)]C$W/ M&,Y:V:I*,DDU/?L$H\C(3&XQ&3E!4J6<7[\ R6">)(/!N)(UW6VM5 I P#__ M +@##L>__OOWV]D/W[)B,3Z?SZ[S_^_ODG]=F\>_?C MO__;/_WK__KII__4G][_8//QZC:;+W\P139:9I,?_IPN;W[XQR1;_/'#59'? M_O"/O/AC^FWTTT^;2C^L?YA-YW]\'2VR'[XOIO^R&-]DMZ/W^7BT7'_V9KF\ M^Y>??_[SSS__]OUK,?M;7ES_C # /^]J[2V1_O936>RG]*N?(/H)P[]]7TQ^ M_"$*-U]4:'];\E^^IU\\*?\G7I>&4LJ?U_^Z*[J8OE8P-@M__L]?WW]>B_C3 M=+Y8CN;C[,=_^ZKCT6VB+/>>L8ZUJ<#5=KKU,=\ M-AU/CP-6H6I#G33Y?)+-%]DD_K"(GYBDY4*/9FE"_'R39;0ER6;ZL+65E3SB9LOI\O[=_.K MO+BM-(E6J=M0-W_)\\F?T]DL?NI=G!+GU].(A5HLXK1RK)<5JK;?23,JBOMH ML:O;M?WRX>IY@8I<;/ 3[0N=+.S):I9]N'*+Y?0V33)^M5P56>QBL9S^]YHH M[OM=FHK.E_^,KW4)15FH28'WM-F^6-4FK\H---3A=_-O<5;*BPJFUBM%F^]$ M157OK]%\EZHI;F^%ACKT.;M>&QS'^O&\7,.?KZB?/<4;[DPUS;Q>NJFNW(R* M[..J&-^,%A6Z\FKI5KI255&'*C75L64^_N/#W=JIC?/:A^5-5KCHYR[OU9^C M8G*\CQ7K=]3=JLB>UDRWG4<-]1[UTWW<4/=QW>X_WGB5FZ[/L^MD1[T??WA< M[7>/-D/?QT+;HJG)\PYI-A_+OB^S^22;K$^!XN=F^?@UD=;B7(T67]F1_VWT\5XEB^B,_XE(JUC-_XX('BM]@+$ " (+8' 4H>$MT"7T$!+ M^1%H'A-,%>,?\F*2%7__,2(:_^4J*XKMPG7@K'+-M.6+:6%4C%_0]&G%;8F? M[Z+=.E_^-+Z9SG;;K.G MD%>Y-U#':4K1_'/SX=Q.V/[53/TK0QQ(KEPBGAD MI:)06$,@C^!*B8Q4 N->AOA+C'\I\L7"K(K$V ,2'JX8)"=*:0D1HH([;JR4 MKA062'M,V+<]:"MK.F\1TX?1V1YY9K/\SW0.Z//"YJNORZO5[*4,%;AT2CN! M.HZ!AT1(IQ7!SC-E2QBX]+(>M5!E:AUPH09-KA9![H)K+[H:W;@ZT]1#M>"X M]D98"!41%.#X$V:ED#J"68])^.1)ZH4%/V@>-8=H]P;$:]NJ;\5^X,1!*3B# MT$&&L3,&TXUQQJA'M!\7X>&LJ@1[;72NS<]H=/KI/$XYT_GU(Q54,#_E"U("4TVD$JB<0ZNH#.F=VLZJDX1NG.!#UM-Z!: X$CS!%GCEA$ M *580*%+X8T4Y&+&A=0$F%YI*M?=P2$ GM,4 N M9'A7IL7>=;L5N#OPZU[IM_H^75087\]J!*P\ X2!Y-7$&)^3+@)_TFV/OYZ'8Z M_M_9:+:\B?#FQ6@3D?EN/M[+J8HU X/&^.B"8Q*ALAIXJWG9?1O';]M[Y&^8 M.NU 7(C^72\?Y[96S9 8CTEW $NB*$4,*)WHEMP],2QL?WM MM\J"!D#M8,GZ-)I?9T=LYEV9(#G62F(H4.PO@D9"L:.MP'7// 8X,W1F)=?% MMBMJ'#50'I4*0#.%'(QKG&/06:*DM#MV8WE!P3:G:^TUO=>"K0/-_SJ=3V]7 MMT=U_Z1< -YY9X57:5)S#/ (RE8,*57=!6.HVC]5=WEST'7!@-'W:@QX7"YX M1Q S7EAHB#><"0#*25 "H6J>G@UP>6B$ 6= U\^NR/OXBW?+[/;$_;5=M4#B MXJB15>NF$97;WF_;J8S?Z6&SO.64.Z 1A]' M]YMKCOFVCP^=7H<\'B#3L:I!6V;OI]^R%[?1_Y%-KV^6V41]RXK1=?;[(KM:S=Y/KPZ=9)[3;# 8 M19?"L6@.QD%GB(N+PV[ 64(O9IELA8,=0E]G7^X5F[VY#Y<"<*-M,4XE/ERES!7C=(]K]'W[VU1\G>MCWV9?9QT(@A(@E:2: B8P M80P_@(FTK.D0D@OG\:"5U(_CL4?T,H/(:8.@E>\$R95WCL0YPGN$,,>(NQV, MB!V+K]W#=7KA7!^"+MJ=Q,O^=CYYU_QP@$+1N/Y9!+@AGN"X!I;!1-)3K.L1 MF5TXD0>IG"XB'D:S;/$I^Y;-5^DFQZ% AJG=/ M]S[^\W06LZ/R:3[3YH; \6\&Z*4@RF.OA;'>>R=Y>2ZNB/7V8@Z#!\/3 M9L9/XZI]8R,G+I-W6;&\_S@;;5(8Q[)WMX>OB7?R_0 XHA%W&UU; +FE+GH M.]@%KWF5;< G$Y<\HII252H@*S+ MT0&?7 R-HS4U\<8FZ>=[WNOL5%]N1O,*7.VT'\$2J2VGS@K,+$PW8$QYWJF4 MD LLA]>L/DT5,F)VPP56LH*">5,<0JHXFU#'H.RT#2Z&.Y MFD>($/P5M\1;A;X?#BY* ;8[_:<1[WGM@.. TQX+B:%EFE/LX-9 E,#2NK': M#<5.=DFV1GAQG'YG*J!GSL6)>O/@U_O#\965VPC0>X&<0,P32@!EAA%6BL^9 M:ST1XU^6?^>HH6?8=K7*,L;1?ZMM>U MHP\+=[.P;9(1;-X\?'CD-;%K/GGC?QP]>$N*S:4/G1E[47AP"6UC'-$F=).]A+GC]'>__F1,>V "-4=1$73%(,6: M4BHA51X*ASWTQ^R]E@R+C2:W28^G\^NU'N\W_U_)GJC40. 1DL*$^L%= XJ MC6"$P0!",=0>7DXJKXZY\MS$:$,;'=BWOR\>O6Y\:%EZ6C!PHC4!V!#LB=?4 M.ZAAB1/GIB:M!AA0TB^MSD*]BTOYV9^/*%_D\_CC>"/[J?/9J4T%A2SA6@A@ MD&8\>@2/,,6L[B;T .-%^J5@RWIIVV**@$W2^^R3!^2RB1[-TGLTGV^R;+GX M?3Y:3:;+ASP275I0.T4]4M['?)M([KB!5*5Z()1&7Y9Z9'VZC*9DG$4@%8() M;0 U_23QW^X-'1?Q:<& !2"(0Q)738*5@YPP50I#(:]YQ6R ]DRSJGU^S_T< M4+O(K+#N7QDZ7)4DS\H'3KW4<0[2Q HF#5(.LU(LJ^'E<*6N.E]EQ7DH=D . M,UK?O@=I+*I?E'WJPF5"5W3S!*+;.::[L;AE)=3M!]LPQJ M$-,.B/-N_BWV*R_N#T3 M$J=9VC0/;0=LLEN-?!E]W_3TT=%YI96I6@,!.VRBH<@)P10"9DR<7DO!J00U M-U$&F'JF64ZU@F[7?E55?RH XYGA7+,TR7J,@?.N%$- 4'.].CVM2^OA\PT; M,F> V,F"M><:X6%+YE"U8(Q@RG)AG/"6F^AZ4%]A%ORXNC\@29#6CN!1:R*./4[XUT_9LMK0 :O]&[6_Y?'RN M7?O01O!4:"@LQLQ1I352Z77XK?B4P9IKT6!-V[,YU1:R'1#KD4=7B42OE@_1 M#E-*1@.-$V\4F^30 4:L MM5!SB[S:41P!4W/W__0,@QVY/ T='9T(6P?Z?GSC8#[YO,S'?]SDLZB,13*U ME_<5SA:K-A&PAQ9PI)6A%*?+_,;PK?#82GDY,5&M'DVW!'>W7*M^3'T7TZ^ZI^!OFT0O"$ M>A.]1P(Q\LQBZ.A.,*GK9H\9-GMJ*W?/$>19D';#E6*535XB<)@NK]<)#!,/ ME88>(0>13D^)@:UXA&-?,UQF@.M7.XQI!-5>EJF3EJ=@4++NHD%G%1#6<,9( M"1%Q5M2DR>D[>ZV;QBW0Y&PXN^!'/K_^DA6W[Z?S[,.5B?HXF'G[M>+!"4@$ M-L APJU$V%JI2J&$@#73T0Q[*FG)=#D?WJXV8![O%U7>A7FU4M!$2&L=A5#Y M."PH%TR7 C)#:[I2 SP]:)T_C8'<[QL;O)D[#. M4B1VN1:U[B*=B&H'Q*BU;W, )"@A$E0+ID"$24E,%-O-GQ36/&X:X-% Z[1I M#.0NXL;SV]M\ON[QT1#Q9T6#BS.CHT(":[!"BA#.RU-9 CSKXWWRA[,!U!9] MFM#N\_CP\Y#MPJF>3-8[F:/9Q]%T\FYN1G?3.+T_ZO@A[_IHY0!4=!8,BTXA M=39=Y#1LAYS4O(_D96^&/8W#VP&?/F7+433>)VY4S*?SZX4:CU>WJUFZAVBS MJ^GXH'=UO'+@2E&%!2;)?F-60"T?!.:ZYC;Q &WE%OC4.+S=;/J5?5P;]Y'\ M45,WV7PQ_98]9.?[+5M^N/HR^GYX*_"4EH)QEF/##**:&FY]'&IN9Q=24'/F M&F"43ALS5ZM8=T"[+T4V6JR*^TKVT\O"P:\C:(416@J>XNRMW.US:5'W/**Z MS2TWY)EGUTD';XT^9P/:BY=VDG<6N-9 &^60HDRHR'X)S([RF)FNXF]:=^9; MX,?9< X@%N.,&(S@L$"1_HQ#88SRT,L'+R*EN[T8[G2Y$=0$U+WD]WA(?_+A M*MU$]K/\S\'D^=AUZ+3\'B^JA92ETD;,TR4C02BSB$N"/= *28'ML4WR=@1- MMY]B3S\6^;=I1%7?_[Y(CY]L,^K-K]5X.?VV.0#+4TJ95?S=0[J]"I T\X'@ MN,'"(:,,]S095%:3$CR*]>6$1S1#H1=)@7I00B?YK![E-U??1M/9.C]Q_FB# M83L9IH1OX\,T/:6E8(W6T %,(PHT:ED2JDLH3/SUQ?"Q:^J\9&Z+>NED>_+_ MK1;+]>+V)4]9M^?CZ3I%PH-849IJ"%?)K-/"YP+W4"+#D:6,6Z(9\\R4H#IR M-"/GV]D"[9GL U!>)]>*HMK'TS5F\>=9MLV-IV[S8KG-FW> X56J!\>4!9!K M)X1C.&6;T+846GI9\TWY 4[/_5+FQ96DQE73Q0S]J'>["/GYM'*@6 MK%4:*VD0MQP)SB-NOA326E[S_'& ,^:@^->@2KJXGCV:SA,^'^9VNKC;WL?X M<'7TRM/!>@$#BP05W A. /Q/V@WO(A'-6>^ZL=+'>[;#HI[36JE _*Y[^,L MPC/ZKK-Y=C5=^HCNYYL(>S2CT^;,;;_\M6;/+E77X>WU#911K&U&J:UT!RW,@S4#XD2A M:+A8P;R5B'- X6X7!IB:^75.#D?KXGV/01&T6;UTDHICG,X!,YMM_GP$RS82 MIH)'7[V1@#EGV&IO$&+8.9[$S9?5 M@Q686B>PP1QK"I1F@N]L'X):WRKMT")M@PI'V78VY+WPK,P.>MB"T,[FL*[U?(G6KV R MRK55EAM&P6ZL05KSY>2-B"$OHQ_5)W'ZYSU:#CJRT$#*G33 ()I3-> M"T,5+D5''M0T^NKZS)?'OR90[]62VV9%J&7&;>L&A*0" CI%G-0.".SUSJ 0 MD%W.#:Q>+;AZ:/=%KF<)%$[EU[/J@44QL0"< $V@-P!'-'?NEQ0U(WP&Z+SV M1;'S !_"FEF7;?N;"8HB&2U:Q!0@0D@J@-S%BU"#CCU W%CBN,MD76/ =Q-+ M5G''J)%HQZ <\,0Y+X'WEGA$J=P-/\]IS?#Y >9EZ3^"K!V5],?)Y)Z 74/G0<8[M!E=&Z[2NB O=&:.T@)W#5_GC^*T):& M^J"H7BVF\RSZ^)NKG>OG\3;_,CF%I >:"(^>UEYPJQQBRQ.Y.JXRE-3?%!YEDHSN#M%TE=+':%_DX MRR:+%-GV/BT$%?)E[JT3D"$DO2CFE/5*.N&/KK5B 8Z MR1UTMS4Y/EQ5)=C>.@&J:',-\M%JO8 MV935N%)JO:-U@Q304V MEH08 "G&>+?=*BRIN6LXP/Q4??.M84UT.,OYO(AS M\ZH8WXP6U9EWM'(@T5Y@B'I/F)2,8BP$RA 1"QGJ,*!1>:N!VSC]$G>77^JM,CVUJ9U!;,XUL MOP2LL/?466.MBT@;$,'> >#J!E\/\,F]GNG9FDJZN&5Z=96-EQ^NXKBZ&TDQ@C&$F"654,JO3$9-0NWU\C6KF MUQV@5=G*UE^+4'? M]?[^3&++N7D>732 ;Z=TDPPBB##', ,*Y3B4H3;@2"( MK'EG^?30V [28+; MQ:A[HUO*D[817$?Y^:C[Q94J1\L0%[$'EBJ&.-1?/.0 M,84XUE6RS+NU4B(+BN6E\.P\I"^&8!ABRJF17DN4\L\")W;'C(ZHFALQ)YMR M&X*Y>=O9GGNCUVDX/]"KKU2L+W.>]YJ4==.%70^KW9U_K4:(JX=$W&&@J,!* M02'-[JJW5N*8:]V.>)\C:1:?LF_9?)6NLA\0ZUG)P)1A$B/IF;:>:TH]W>T; M2Z)K)J08X$GDV?I\GH;[+""[F/_S19RG?LGS]?;$YZSX-AUGB\_Y[% TVOY* M 1B*M69*4F]3BA:.Q2ZTGR!>TSD:8*!NTTQI#-,N$HL5^6+QL<@/9[EY5"K: M/91P!R7E@!-IXY)G_<,.K*EY"V: H5]-TZ(^B!WP8'?%87MGNDK\U=XZ 1'H MH7>8"TVL=2J2W3Z81J;UW%QO=NIH"M(.&/,YF\4VKW_)YK'+LY2Y MHH?"68BWP@Y7A=J!2D8=YR).R8Y#RC54.VBQX'4/ M5,#E3US-H]N%8[GGA6-[[\4H_DB"K!YU&;]M]E&Q[MTU*6L M'Y-G'?]AN2RF7U?+S0#[N-;((9>URWX$Q902B",ETOLG@FG]X+\A6YODP^-X MHYQ\[A@/6&7]3L7UIN# *(" <\ZB78,5 6GI>4@1@CO;SVM]66^3EHAV@%9_A&-M9O8,_4M*T;7 MV6^KVZ]9\>%JW>G%A]5RL1S-)^FRS?&UZ=2F F>>>:TE<5@*8BAGZB$/K_,U M8[+@ /G5])K5,M0#XMVQ->ZD=@(@'!(A'0-.0J2!D6!W%BHAC[<8J,> $4]<2CO@3=+'0] !4I<3SM$O-1O7 M1']SY3Y13I\M][44@,$88D @C0N3D$Q2MC-7&*D;8S3 \-B^Y\N&--#VS9G' MD25=7H!)W[73Q7B6+U:5]DE>KQ"(-1@"3*D"U%$FH^7%'*( 4:)^]" MN"\143T[G.=E3XT@ )2:&FQ%]$B) 0A24HH'[/,7YM^P>7.N>E^\K]H$GET, M/ILM1]/9XBV/01<=&\(41PC'Y55)J;6&@$6@'1&('0NG;T^X=_/8PU4R ;X< M>3;JE=+!48ZC=0!\"F@A&EEE7"D6T:[F39*W,_8JJ_65L7<>EEV<]JQS(OK1 M.#WBRH?U6O$@D'5 :N9T_(DC9S6!I5#(BYJQ8F>1XR$5)6J+*>=H]R!1 M:J': 54^9=_RV;>4\O))=W_-D@=P@#,'ZP4&!/-$6:PT]Q1*R34MQ33"M_[T M1W>Q#&/BNI<;IS<2 M'4GKXM#BC]).,R%V0X"SR[DNWZ3!S.4>1SX,#S@.Q T9\+*:W:TF/$N)9R6"A9,(YQPWP2,&XS")< MB@(TNYQCK ;YQ/GTW2)7J_FD\6!]5\H'30"D!,D=/1Y,%(1:O9F[*; MWM?-SC? IX8:4'5S.-91=PH\647P[S]%R(MOAT?VD1J!2$R$1<@IH4T2UCQX MZ8K FL^5GY4.I8.7,YKB0&/ =K */+6-WT_GV;ME=GO(C]A3(RYP@""$(IF) M!X9:(*7?^4:2UDRA,\"IHDEWHADP.^#)^WQ^_24KUF]457CWZ;7B 5C$G;;" M*\^UISB.A1WY,2 U&7*R'?DM*[[FG7*DAE[SQO'L@B2/>K?;;QM]G]ZN;G5> M%/F?:9]E=!?_97E_B#PG-!.H<@9P3[CS#&KD!*>[,RDM9>L/SO8T[31 J?90 M[H!JO\]'FP0_V60-S/;EG^-)O Y7#(!Q0"7 " B+%> 2JIU=SKBOZ>L.?A4[ MGTZ-XMKQ7%5Q+@K0(Z&!]493+;T3S#*R&P7B@M[T:G.N.1'%SFU@FRW&Q?1N MDS?LL4N0PINK&\:'FPF6 @V )II;HY@T2%OVX%B FO/,ZGFSK39*I.6![ M.DV>M#[*K=9N# &"@ (LHQZA3P3.PV M3J'6-4\C!YADJPOWK@W(Z^Q5O]:W]:#X-IKYO-@\D#0=E^-D^\KFA\TR/W^- M:$TT&[Q%0%I!+8SS.:#8:KV#6EC86=*M-\.U'E#OFFY?_LS;H%ML-GCHJ64, M>R&%QH@@AN1NG E7DVY#S,,U&+Z=#GOG?(LMMS+!K1L.0#CL$"(I-X&&*0A2 MP8=S"ELWE&. L1S#X5P-X+NX9K0^N'K3MXPX$))1AKQ*"3:T51[0]=4M!KFP M[EA0?3O"?1[?9)/5+-+E%=),LT65NW^5VXALCA3F "-/J5) "-O-&,:V\#7(:)4P4MQC-WL5Q\_W_9*\=4>\M&QQAAA("N12&<>NC M1^-+ >**__;O7G1!BO- ;9P5FP2G2Q_7G='L_V:CPLTG]O5]U$/% W6:BQ0Y MII R!GM@$2[%'IXPG)0/26 '/ MB1.."N*)X,"6G0=2U Q<&=!AC/,H$E@RAQ$W MJ!2 */'V7V?JA@SG@-H:*QY6+A]_\UH,R8'2P0%E*5.>6:$<<$107IK&.F63 M?/-'K]TPXSQ86^;&AK;5V?&H?"!2 :XXP1S&B0]0CAPH!?&.UN3'@(Y(N^1' M?6 ;9XB*O9JL>S8;O9;P[T690+'F'G.L)4#.F;@22E9.=Y"[FC>Z!W2 V2X3 MS@&SK1V)AV>+JN2 K%8QI)>-N :@W.:J@=;0437I?-X_5@$X>.]FL: [B MMK>-?\GSR9_3V6S];-_KCQ-W>0!TH#LGG0N=U$[0U%,"L)-4:F>X\EBZ;:8_ M:C ]%KW=(Q15SHQ.:RA8S6RD?I3<6QQ-($0B&ELP,,#TS>]AM\R1O$/T>YP= MS*@H[E-.W-M\-5\N7CZDW6.RRGYF$6\H)@:F1\@A40Q9195#RCE.('7V6-1. MQ6.XA_-)/YU/E]G[Z;=LLN[@)+MZ^,WS_NY+:GEVFT'[.!"@A!1&YGK-XSB1 MI=B6UW5"W_Q\49D->3^*Z"!>V._OL;[_=?3_\L+,1HO%D>Q4)[024#2B,'7> M8(F1%,A:S+<0('<)F38[9$G>E1KZ9>)#U]-I\]&T6">V%"Q5 "%H/<-06A#M M?%O"C3P[&M0P?$:VRH_J'&P _#H!G5^*T22['15_+-8_I6\OXDC\.(IF3NS4 MP2PK5>H&A2"-3J$G4&/@TK4B!$L1B*Y[Z_AM\><\W>;M0EZ'-6:U6.:W6?$I MV[R&NKB9WB4;8O/T:?S%IW0K*/7LMSR]'767+3-U763KYZ,.DZJ!IH, 1N'T M5)EG!*]OX)+=\,06U+Q9,Z" E4XYU[U&.KE.^"V;Y7?9Y$LVOIGGL_SZ?B/& MT91Q1VH&P R(EK(R7@-D4@)>!7:C3^&W'Q'3%?G: ;P#;ATQ8T]P'4YL*1A" M#684:2RY4 A3Y4LH*%+J[6>,Z<]]:%<5_;/R1#>B1FO! TH)\&E=.XV0#2FC0I7@_':=T.?5\BJ>5HX4;K0:"E>" .6AB_Y4H MA8"D]OW"-\>D\S1:G60,!82H*$ATY@PC3V$+A2<,/1 MVW_RKD4N5-];JX]XOU3[I<@7-4\6UE6#5S[E'O ,00ZU(,0R5 KK+:V9VF9 M]&I+^=6Y50?H?EFEQN/5[6HV2EE[-GD-G]RQ/(UG>QH+2@AI!'0*6*$MH$01 M4P)B%:]Y;%#=$Y4;YLVSZ]2U"^5>,^#WOIS67D8#(P@99A 3.)JF##'MRS-J MAF'=^. !/O#<'\=.A[E7/OV^R*Y6L_?3JT,YNZI4#\(:'MUR;0SFT9$B6IE2 M:"VPK1E).J!+;+USJS;8_>^6N>_CV2I%P^YB:HZ[!'6;#-*R.(EC @D00BC. M.=(E.-( V/9:>D%.0DI-E]69"7"]2KBL,+#;< F"L*+TOS:BM>3EH:'MX'4V0 MK>'> _G6SOEI4V&5!@)UPCG!G#8R/4Z2]D'-;M0Q6G-%'N0$V 8=CG"N$="? ML.TM;2=T ODE;"I4 >K,%28@K>,*BY7E7A@4O5ZI:(DOM[BF$SC #89>!GH# MD/=X@>CA3,TMEM/;-&#\*KVH_7C8;!^)^SM9]QKF3_5%[:F M=='S*ZU1L/0"!F/*"($6HHQ:8R(P2,B;Q7^*$ ML4%BG6"FM:.AP9$ZR?!ZIOJSV@O <2BQ9Y)2R0&FT3OV)2Q*V[V&)A @ H+*0" 2R2 )K:$!@I_.4\0OQ6ZUM#*( GK\U5S-D+9 M8% <1QBD3'F&' ,(.\AWP !<,ZKR;1V>#HFN-90R3+;&LLVR-98-3C+CKI3!L55=174V3MDGK0:!B6%0"V2 @@[' MOY*=DXP0KWFW>D")5=\0;\_1S!N.P)/<:B (]$IY9)&T0&Q>3V< 0RAK;E^= MGL&USPB\7BAX.OB#V"HO"_WE-L0IU"!E4-)000FE L8<9[ND1EL.99*22MD*08RN*M$,'?K+,B?EZ-BV0E?:FER M#ROJ -DA'][=WHVF40^/(@@VOUH_4UB-*T?;"$9( 02UTJ0@.ZV@!:P4GW%7 M<\:I&PKR\0W3J6FL.Z1:!28%)#%VF NDF!$8$02 "89TXH2_AN0J5*U9Q1!KA9V09% M&D"T\R7JY/7H84),616X9\AZI+ 5BDE<"I8>ZFQ[I[##.,3V5IR:: [6LH4> M8&&B(<8H1LAAK!S?B4%ES;.YD[?A[LKW@=X<+>K >'%V+64 00_?G0MW!3/_0V1='BO/) MKO]IW)_&LLJM!4<0PQ9'WXQ2P)D0T>8N(>% M+Y]=K'L:TL%';(ROZISRGDR M79OX3*#(2( 1M]&)Y"PMY78WM 56EQ,0V2V/>]!-VQ;6N_FW6#LOIOW84N7G M[T^RG [4"IA(9RG SELEK&31E;%K>#D6 *%CN;4Z$[/*G'"H6C3U/044")72 M*#B46\Y-:(ME]SJ:I6BB#U>?HA*+;]GAA/3'*@>F;$KH#ST" M2$'K"4PY@C="6WI4Z,L8M)4UOV_0-H5O)_?PMWW^1U[\\6[^L)T1NVO M'12 0L2O8^.A],)(91_0-*[U9)*70:G& .Z24\D:7433-%G!IW-J?^T M:52 M,*(M7+]0*JWTI 7TQ_D.KG&H,X"XY=3C@^7&Q0(0'&BGKE<9:<^FM=:40 M@OF:,\_IH0$=Y/]HD26G(]FAQ=G?+GOS!B([>]Y;KMN5D4B9:V-SD--!"XTT,QAP[PV,!(-I$RU&P UG\-C[$R"P[L M93:(QG"VV]_RN[2GMC\NL+XW5KH=KC+D^3(Q8AXJ*!RU2<:E5Z)0<+2EQZ*P=++D$_R^UOJ_14TX>K#W=9 M,4K=?3X_OB+AWCHAT8=0CJ-$D4<. "3L5D1G"+^C[CT4^68W7YYV?H^8%U;YT L#4$,[5AA32 M!=\VX_1Q1X^^J[JW3D!**(-%',I44P:P0YJ5X@E2-^!AB'P[7\.O&\IG@UJ9 M,XML_+?K_-O/XWPU7Q;W&\IL__*<+=M?A]\_OT*+AW\,@J5TN'&L^&@B(&R1 M5'S;5:B_''YM_5"H("+$$W&L-#6; ,DSE5@0L M:Z> &ZY]TP !SH>Q R9LE\@/Q7:!/&*1O%8\0$>MU\!1ARS4C.OHZ)=" 7=! MV2R'98PTH(ON"/98[*-VR-XZP6)GX^#3A J ";+&QY\WXA'#Q.4DK#Y/N:\S MY6P\#])ESYO:NABE?;7?XL_3!/MH]GEU=S=;VUBI0Q^6-UGQVVBY*D:SLI^' M7VFOWV) @G,OHW,*O(18,.JD+\6E3M3,M3=<^IRC\;P/R.LP;/WQ:M1YI6A@ MD#D25V&$"+<\10I$PW[30ET *[SIYI^8N9/RWHI@M"CF;98HO4X5"@9R4# MD\QAP*$$2&+A"%*R=!VH!:B/9[_NBFD>%X3[]737S7;S>5I^3J&S(*ZS5KV; MCXMLM,C6H9!I//Q2Y*N[^.UU5^PJ^Y*;V6BQF%[=FZQ8QLFY_+=]2UK]%H.F MTEHH-4]'P,@0'3W:4EQ<.WWFR2O?MZSXFK_"*?BF.-6M,KHZ*^\O/JW)HW*G M/60^*A0K +36D(CMG4<3E4N/F7AMGWL>6CC5,IK<7U?+;/(E]WF13:_G9KVQ M.,WBHOJP2Z4B[TX+9FO\JT$2"#1BT"+G*1#<$4U*F)FTE_,PY?E$VWL&VK=6 MWN*!_TFT;_B;@0E"M78*:$,)A90H;4MX$7[^,N4;=A];)'V_.FE]+;V)^'Y< M%>.;:!GTLY8N(RHW^2Q2:^'^:Q6Q_BU?5@GW/EPQ6""PC?,+%]0Z"IA61D2S M17NEI(.JIXCO5_M\8NAHU3:"4 QAK"BFFF*N7+H?5T( I+FD@_%FJ/ BHJ(= MI+L=U'V&E+8TMH'U$G/&K=&20N$]I]M')"S1GA^+,&K;=%CW7M^OO:GJ$7\O M:@5'B>18><.HQ-8#C PKQ;187E @54/JWKN(GXMMES%XZTYNNUPU!N]YG4"A M4]_#HT?7+PL&2B X"GLET M&UF[ HT]2;?+'\-5O>O/I:0/7*P0N% MF0/$\.AU:4P5P(^$X#5/G <^:=308=XRLAU,)$^Z_1^CV2JK1*93J@%> M.(ZL\AX I04JA8807L[=I6;HU"*V71-J,PZJ\F=3.A K,(]]=XQ+B[#Q'D5C M3C+ 4P11W;M' XQW:9$NM:"LLQJMO_8IN]ON5'TLTB'1K9I,MG%\Y471[8RX MBJ0MIO^=3IAT]E!M[WK54/,!86>5993$>1=@2Z4RI 25(WTYK^ TN*+U@WWK M&ZM)J@]WJ?8NLG2S7Z52!OY>]EBWWS^^I_JT8'!.4..X-,@ZR3WVPJQ/HTQ* M2VN/OJK1TB98HL.3CIF=C M,>-;0) QK&:L[0 -U[I$>+Y+UB[ ?8_E'H]-Z@YI@"*^&$D$K8B>*8_J1 1[ MH*53'(G>CT5VW##Y;A?#-3@*5J;/_B*53Y#MP1M1\.9U,9W'>^)9]SL:K=+LD6[CO MX]DJS@ I]",)NMHH^\.5&Q7SZ?QZ\3$K-F+>O][ D2.=%K\:I*$"P[2IS3A@ MRFO$30DQP+TD(.XB2KM[BN9#U6EOP^:WT6UV]'SJ6-6 $$-&8 H!U=1C8(F7 MI;#1G*B9FG: L_,@&%.)Q;6U4V?#P-W>S?+[+(OVVF_YO/S;8TON\!6[JO4# M89)1)#%E4GH9;58'[6XY9/9R4N\UI]2\?9R[B,(XMD3L6R&J'*2=WW@0CGNN ML6:& TT-8VDH;P$CINX,.,#M\/Y7[S@M<'V M?=\*4'!M-5(<2P2LXM0H7,(I">DJ6&7?G3#2VECHD(E-#8*&E-A-$I!QEDT6 MR:IZO$2Y[UDQGKY^OE"Y;J \HFM1^D,"[3V0)*UPAGFAN;$UDU,-<<+NCZ1- M:Z$#TNULHLW]D-?!^S+ZKK-Y=C5=?LI&LW0\LKEPLI%J>U"SE?70+F'3WPJ* ML&@6,L:TPX)#"A2D$'K^<-.% M_$D7OMZ7O]_KHIW01! 4IO,#X9RSGDIK@(&$ ."1-HK4S?LVP(/9'FC8LC(& M&6,1L5 [XZ 6!!,&%1%*F:-/[K1]O'/FGE7U,YXF/A32 M)2T&J%)"0,8\XQ;Y$DQLW>4$OM9OIR4H!>QC)>5W'#9[VZ3?FZ>:,TRO9:^!K+O\VRO<]C[/D)#9*52%*0W7IQ0 M-H5C>!-=>*NDZ/OMVK<0UFNU$5IC+I%"0G*KM'0EA-)>4":5NM1I+:SW-.2[ M..Z=C>;)\CWVF,BC8@$@P>/_A)#>402$E R40C"B+F>SL >]/S_+K8][A^0Y M_DK(DX+!0 !X1 0!KRPR5%H@2T$ -Y>32:.>^O9PH!9X=78.:*1501""TLAH&"7LQM;5WEYRY . M.;JNRH9" V? UAD=]F[#;;O M^U;PP#J-H]F+J:1<.&?E;C&R_().%;JD7E.L;TAKG:1IS,=_O%LL5MG$KHKI M_/IC5DSSS;WGQ>OR'Z+YZ:T%B2SAU.ATC*.%PX"($A)GF 27,XOW2.36]3+D M^;HTNQ;+8K5>(]?;:%]N1O/MSMI_9(ME-GDWWZ#R)5^.9GXT+=9YAMJ8U,_J M4) "8&^$,0H1[J6UGIE2,0S1FL[794:K=C[S=ZG:(8^Y9RO@M]%TE@Q0GQ>_ MQ+H'N\AC5WO4X.KWUZW>9_1DX[ZCM\,/.O M/Z>B7V,7_NV?_C]02P$"% ,4 " #\;)Q()TLBC7R) #>)P@ $0 M @ $ ;G5T ME ;G5T&UL4$L! A0#% @ _&R<2#D;B_BP M&P YSD! !4 ( !?JH &YU='(M,C Q-C S,S%?9&5F+GAM M;%!+ 0(4 Q0 ( /QLG$AXK5-=$FD #(R!0 5 " 6'& M !N=71R+3(P,38P,S,Q7VQA8BYX;6Q02P$"% ,4 " #\;)Q(D"8C7FTY M "^M0( %0 @ &F+P$ ;G5T&UL 64$L%!@ & 8 B@$ $9I 0 $! end